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 1.1 The Skin
1.1.1 Anatomy and function1
The skin is the body’s largest and heaviest organ, with a mass of 4-5 kg, and a total surface 
area of about 1.2-2.2 m2. The skin is composed of two layers, the epidermis and the 
dermis. The epidermis is the outermost layer, which principally functions as a protective 
barrier, while the dermis is the vascularized, innermost layer. Additional functions of the 
skin comprise regulation of body temperature and vitamin D synthesis. Beneath the skin, 
there is a layer of loose connective tissue known as the hypodermis, or subcutis. This 
layer is not part of the skin itself, but instead it functions to loosely attach the skin to the 
subadjacent tissue. As a fatty layer, the hypodermis also functions as a shock absorber 
and as an insulator. 
The normal epidermis is a terminally diﬀ erentiating stratiﬁ ed squamous epithelium, 
which is supplied of nutrients by diﬀ usion through the underlying dermis. It is mainly 
composed of keratinocytes and its diﬀ erentiation product, the corneocytes, which form 
the outermost layer of the epidermis, also known as the stratum corneum, corniﬁ ed or 
horny layer. Corneocytes are ﬂ attened keratinocytes which have lost their nuclei and 
organelles. These cells have a specialized protective barrier structure on their periphery 
termed the corniﬁ ed envelope, which is composed of numerous structural proteins 
that become cross-linked by several transglutaminase enzymes into an insoluble 
macromolecular assembly. Corneocytes are continuously shed from the skin surface and 
replaced by cells from the deeper layers. 
Originating from a pool of cells with a limited proliferative potential, called transient 
amplifying cells, newly formed keratinocytes move from the epidermal basement 
membrane towards the skin surface in two weeks. Microscopically 4 layers (strata) can be 
distinguished respectively. The stratum basale consists of large cuboidal cells which are 
attached to the basement membrane by hemi-desmosomes and integrins. Immediately 
above the basal cell layer, diﬀ erentiating keratinocytes enlarge to form a layer of spinous 
(multiple desmosome containing) cells, called the stratum spinosum. Together these 
layers are also called the stratum germinativum. Above this layer, microscopically visible 
keratohyalin granules containing cells can be seen forming the stratum granulosum. 
Sometimes in the lower part of the stratum corneum an additional  homogeneous 
eosinophilic layer can be seen called the stratum lucidum. 
The skin is constantly renewed by migration of keratinocytes from the inner layer to 
the outer layers of the epidermis, ultimately leading to desquamation of corneocytes. 
Normally, these processes are in perfect balance so that desquamation cannot be seen 
with the naked eye. In pathological skin conditions, such as psoriasis, the percentage of 
active cycling cells may be increased, which results in an increased amount of immature 
cells in the outer epidermal layers and a thickened corniﬁ ed layer (hyperkeratosis) 
consequently. White scaling may be seen as the clinical substrate of these processes.   
1.1.2 Epidermal barrier function
Probably the most important function of the skin is its barrier function. Its corniﬁ ed 
layer is composed of corneocytes and extracellular lipids which are arranged in a ‘brick-
and-mortar’ structure.2 Consequently, it is highly impermeable to water and serves as 
a protection against loss of ﬂ uids and nutrients from inside the body. The extracellular 
lipids are primarily generated from exocytosis of lipid-containing granules called 
lamellar or Odland bodies. At the ﬁ nal stage of keratinocyte diﬀ erentiation, the lamellar 
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body lipids are secreted into the stratum granulosum and form a bilayer structure. If the 
lipid composition is quantitatively or qualitatively disturbed by exogenous inﬂ uences or 
disease, barrier function will be hampered. This means that exogenous factors or skin 
diseases that inﬂ uence epidermal growth and keratinization may change the structure 
and function of the stratum corneum and may therefore induce barrier abnormalities.
 1.2 History of photodynamic therapy and
 fl uorescence diagnosis in dermatology3
The importance of sunlight and the roots of the therapeutic use of light can be 
already found in ancient Egypt medical reports (1.300 B.C.), but the ﬁ rst observations 
with the combination of photosensitizing drugs (possibly psoralens) and consecutive 
irradiation with sunlight were reported by Abn Mohamed Abdullah Ben Ahmed (1.200 
A.C.). However, it was not until the 19th century that Downes and Blunt discovered the 
bactericidal eﬀ ects of ultraviolet irradiation (UVR). Niels Rydberg Finsen was the ﬁ rst 
physician that actually treated patients with smallpox and tuberculosis of the skin (lupus 
vulgaris) with artiﬁ cial light. For this work he received the Nobel price in 1903.
In 1897, Oscar Raab, a student, and Hermann von Tappeiner, a professor of Experimental 
Pharmacology, were performing experiments with various dyes to kill certain protozoa 
in order to ﬁ nd a treatment against malaria. However, their results were inconsistent and 
not reproducible. After numerous repeated experiments they discovered that the only 
parameter that varied during their experiments was the time of the day they took place. 
Von Tappeiner concluded that light was an important factor in their experiments and 
Raab speculated that the toxic eﬀ ects of the dyes in the presence of light were mediated 
by ﬂ uorescence. In 1904 Von Tappeiner coined the term ‘photodynamic reaction’ for this, 
in his eyes, ﬂ uorescence-based eﬀ ects. After some more experiments Von Tappeiner 
started together with Albert Jesionek, a young assistant professor at the Department of 
Dermatology at the University of Munich, with experiments in man. In 1903 they reported 
the treatment of syphilitic and tuberculous skin lesions with topical injection of eosin 
followed by irradiation with light. This treatment also had some interesting eﬀ ects on 
superﬁ cial basal cell carcinomas (BCC). The treatment of other skin diseases followed, such 
as other forms of skin cancer, pityriasis versicolor, psoriasis and molluscum contagiosum. 
Because of the promising results they extended their experiments on patients with 
superﬁ cial BCCs, but they later discovered that the eﬀ ect was only temporary on the 
superﬁ cial parts of the lesions. However, at that time still little was known on the exact 
mechanism of action. After that time a lot of experiments followed describing the eﬀ ects 
of intravenous/-muscular injection of haematoporphyrin derivatives (HpD) following 
irradiation with light. Friedrich Meyer Betz experienced the eﬀ ects of the long-lasting 
photosensitivity caused by systemic administration of haematoporphyrin (Hp). One 
day after the injection with 0.2 grams of Hp he reported enormous swellings of the 
sun-exposed sites. In 1911, Henry Silver, a dermatologist from Chicago, ﬁ rst described 
the successful treatment of plaque type psoriasis with Hp following irradiation with UV 
light. The retention of Hp (red ﬂ uorescence) in rat tumors was ﬁ rstly described by Albert 
Policard, a French physician.4  This was conﬁ rmed in humans by Auler and Banzer who 
observed red ﬂ uorescence in human tumors, metastases and lymphatic vessels after 
systemic administration of Hp.5 This ﬁ nding prompted Figge and Weiland to further 
investigate the tumor-localizing properties of porphyrins in an attempt to develop this 
application in the diagnosis and treatment of tumors.6 In 1948 they administered a range 
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of porphyrins, including hematoporphyrin, coproporphyrin, protoporphyrin and zinc 
hematoporphyrin, to 240 mice with experimentally-induced and transplanted tumors 
and 50 non-tumor-bearing mice. Porphyrin localization was found in each tumor type 
and with each porphyrin. The ﬂ uorescence appeared within 24-48 h of administration 
and persisted for 10-14 days. The ﬂ uorescence was not seen in normal tissues, other than 
lymph nodes, omentum, fetal and placental tissue and healing wounds. This diagnostic 
procedure by using the tumor-localizing properties of photoactive substances was 
later referred to as: photo(dynamic) diagnosis (PDD) or more accurately: ﬂ uorescence 
diagnosis (FD). A more detailed exposition on FD can be found in the next paragraph.
In 1978, Thomas Dougherty ﬁ rstly reported the successful eﬀ ects of 2.5-5 mg/kg 
dihematoporphyrin-eter (DHE), a HpD, following irradiation with a Xenon-Arc lamp (600-
700 nm) on cutaneous cancers. From the 113 tumors, 111 showed partial or complete 
response. Despite these promising results the use of HpDs was somewhat hampered by 
the long-lasting photosensitivity caused by HpDs and it was not until 1990 that James 
Kennedy reported the use of a new topical porphyrin precursor: 5-aminolevulinic acid 
(ALA).7 Long-lasting photosensitivity was no longer a problem and from this time on lots 
of studies on treatment with ALA following irradiation with light followed and are still 
being published on a regular base. 
 1.3 Topical photodynamic therapy nowadays
The events above led to the development of topical ‘photodynamic therapy’ (PDT), as we 
know it today. After 1990, numerous clinical studies were published proving PDT using 
ALA (ALA-PDT) to be an eﬀ ective treatment with minimal side eﬀ ects. This eventually led 
to the approval of blue light ALA-PDT for the treatment of non-hyperkeratotic actinic 
keratoses (AK) (Levulan®; DUSA pharmaceuticals, Wilmington, MA, U.S.A.) by the American 
Food and Drug Administration (FDA). Research on new topical photosensitizers continued 
which led to the development of ester-derivatives of ALA, methyl-aminolevulinate (MAL) 
in particular. Some years and clinical studies later, the commercial form of MAL (Metvix®; 
Galderma, Paris, France) was approved in most European countries for the treatment 
of superﬁ cial basal cell carcinoma (sBCC) and Bowen’s disease (BD). Nowadays, PDT 
using MAL (MAL-PDT) is used in an increasing number of dermatological clinics for the 
treatment of BD, BCC and AK and has proved to be a valuable addition to the current 
treatment arsenal of non-melanoma skin cancers (NMSC). Although Metvix®-PDT is 
approved only for the treatment of BD, AK and BCC, several non-oncological indications 
are also being evaluated.      
 1.4 Principles of PDT
Basically, PDT requires three components: (1) a substance which increases photosensitivity 
(photosensitizer), (2) tissue oxygen and (3) light of the appropriate wavelength to activate 
the photosensitizer (ﬁ gure 1). The photosensitizer, or a metabolic precursor, is applied to 
the target tissue and is activated upon irradiation by light. The activated photosensitizer 
then reacts with oxygen to form reactive oxygen species that are cytotoxic, resulting in 
tissue destruction. In this way photosensitizer-accumulating tissues can be destroyed 
without the need of surgical intervention and its potential hazards. Other advantages 
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of PDT include: the possibility to treat actinically damaged skin (ﬁ eld-cancerization) / 
multiple lesions at a time (repeatedly) and its superior cosmetic results.
In cutaneous PDT nowadays, ALA or MAL (which are porphyrin precursors) are 
applied topically to the skin under an occlusive dressing after the removal of crusts or 
hyperkeratosis in the treatment area, which could potentially hamper penetration of the 
photosensitizer. This can be done by gentle curettage or pretreatment with keratolytic 
drugs. After 3-4 hours the cream is removed and the treatment area is illuminated 
with a special light source, which is capable of activating the porphyrins induced by 
the photosensitizer. The treatment can be performed in a day-care setting and may be 
repeated, dependent on the indication or the treatment results. For a more detailed 
exposition on PDT the reader is referred to paragraph 1.6.
Figure 1: The basics of PDT.
1.5 Fluorescence diagnosis in dermatology
1.5.1 Introduction
Fluorescence diagnosis with aminolevulinic acid-induced porphyrins (FDAP) oﬀ ers 
the opportunity to study various tissue-types based on diﬀ erences in the ability to 
accumulate the endogenous photosensitizer protoporphyrin-IX (PpIX) after incubation 
of the skin with ALA. As PpIX has characteristic ﬂ uorescence properties, its preferential 
accumulation in certain tissue-types can be used as a diagnostic tool. Since PpIX emits 
red ﬂ uorescence when excited by blue light (408 nm), PpIX accumulating cells can 
be visualised after irradiation with blue light (ﬁ gure 2). In a clinical setting FDAP may 
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provide additional information in a non-invasive way, e.g. the detection and demarcation 
of (sub)clinical (pre)malignant lesions, e.g. during surgery and the evaluation of the 
treatment eﬀ ect during and after PDT. Information on PpIX ﬂ uorescence may also help 
to understand the variable therapeutic eﬃ  cacy of PDT in various skin diseases. Because 
many factors inﬂ uence PpIX accumulation and detection, the clinical procedure has to 
be well standardized to obtain reliable and reproducible results. Once these ﬂ uorescence 
data are obtained these have to be adequately interpreted before clinical conclusions can 
be drawn. For an adequate interpretation of ﬂ uorescence data one has to know the exact 
diﬀ erences in the mechanisms leading to diﬀ erences in PpIX accumulation in various 
tissue types, taking into account any disturbing factors that may inﬂ uence ﬂ uorescence 
intensity during the procedure. Since the exact mechanisms of PpIX accumulation in 
diﬀ erent skin conditions are poorly understood, interpretation of ﬂ uorescence data is 
still problematic. Studying the mechanisms involved in PpIX accumulation after topical 
sensitization of the skin with ALA and the factors inﬂ uencing this process, may help to 
understand diﬀ erent ﬂ uorescence intensities in diﬀ erent tissues, so that ﬂ uorescence 
data can be better interpreted and ﬂ uorescence diagnosis will become a more reliable 
tool in dermatology.
Figure 2: Fluorescence diagnosis with aminolevulinic acid induced porphyrins.
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1.5.2 Tissue sensitization: penetration and uptake of ALA and its esters and
 interference in the heme-biosynthetic pathway
1.5.2.1 Interference in the heme-biosynthetic pathway
In FDAP, ALA is applied topically to the skin area of interest. ALA is not a photosensitizer 
per se but an indirect photosensitizer, which induces formation of PpIX, which is the 
actual photosensitizer. ALA and PpIX are both endogenous compounds that are part 
of the heme-biosynthetic pathway, which takes place in every nucleated cell (ﬁ gure 
3). The enzymatic condensation of glycine and succinyl-CoA to ALA by ALA-synthase 
(ALAS) is the initial and rate-determining step of heme-synthesis, controlled by heme 
via a negative feedback mechanism. The formation of porphobilinogen (PBG), the next 
pathway intermediate, is followed by conversion of 4 PBG molecules to uroporphyrinogen, 
catalyzed by PBG-deaminase (PBGD). The subsequent steps lead to the build-up of PpIX. 
The ﬁ nal step in the heme synthesis is the incorporation of iron into PpIX, catalyzed by 
ferrochelatase. As ALAS has the lowest enzymatic activity of all enzymes in the heme-
cycle, exogenous application of ALA will therefore lead to excess PpIX formation by 
bypassing this initial rate-limiting step of the heme-biosynthetic pathway.8   
Enzyme defects in the heme-biosynthetic pathway, acquired or inherited, can give rise 
to accumulation of certain heme intermediates causing skin, hematological and/or 
neurological problems. These conditions are referred to as porphyrias. Various types of 
porphyrias with their own speciﬁ c enzyme defects have been described up till now. For 
more information on this, the reader is referred to some excellent reviews.9;10 
Figure 3: The Heme-biosynthetic pathway.
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1.5.2.2 Penetration through the stratum corneum
Before ALA can exert its eﬀ ects intracellularly, it ﬁ rst needs to reach the target cell. When 
ALA is applied topically on the skin this means that it ﬁ rst has to penetrate through the 
stratum corneum. As ALA is a hydrophilic zwitterion at physiological pH, its capabilities to 
cross (lipophilic) biological barriers such as cell membranes or the stratum corneum are 
limited.11 Although it has been shown in vitro that ALA penetrates the stratum corneum 
when applied topically12;13, it seems likely that its limited penetration depth into normal 
skin as well as in nodular tumors in vivo, is one of the major limitations op topical ALA-
PDT. This hypothesis can be supported by numerous reports. Firstly, the addition of 
penetration enhancers prior to ALA application or combined in ALA formulations has 
been shown to increase PpIX ﬂ uorescence13-16, or to improve the clinical outcome in PDT.17 
Secondly, treatments aimed at the removal of the (hyperkeratotic) stratum corneum 
by means of keratolytics, tape-stripping or curettage have also shown to increase PpIX 
ﬂ uorescence18-23, or to improve the clinical outcome in PDT24;25. This is in accordance with 
various studies that have reported signiﬁ cantly lower cure rates and higher recurrence 
rates in thicker (>3 mm) nodular BCCs26-29, as well as in hyperkeratotic AKs.30 Furthermore, 
Von Beckerath et al. showed PpIX ﬂ uorescence to be increased in chronically UV 
(ultraviolet) exposed skin compared to UV-exposed skin which was shortly irradiated 
with UV light and hypothesized structural abnormalities in the stratum corneum of 
actinically damaged skin to enhance ALA penetration.31 To increase penetration of the 
hydrophilic ALA molecule through the lipophilic stratum corneum furthermore, eﬀ orts 
have been made to increase lipophilicity of ALA by esteriﬁ cation.32 
To achieve an optimal concentration of PpIX in the target tissue, the precursor drug 
must not only be able to penetrate through the skin and reach the target cells but 
also have suﬃ  cient intrinsic capacity to trigger PpIX synthesis. The skin distribution of 
topically applied ALA depends on many parameters, such as drug permeability through 
the stratum corneum (which is in general often the rate-limiting step in epidermal drug 
delivery) and diﬀ usion through the epidermis and dermis, which are, in turn dependent 
on drug structure, formulation, release from the vehicle, local drug clearance and 
potential de-esteriﬁ cation of ALA-esters.33;34 But not only does ALA or its ester have to 
enter the stratum corneum eﬃ  ciently, it must also be able to partition out. The octanol/
water partition coeﬃ  cient (P) is commonly used to describe a chemical’s lipophilicity. 
Typically, compounds with logP < 0, such as ALA (logP = -1.5) and MAL (logP = -0.9), are 
very water-soluble and have low membrane permeability. On the other hand, molecules 
having logP > 1.5-3, such as HAL (logP = 1.8) are more likely to be relatively good skin 
penetrants.34;35 As already mentioned, good skin penetration alone does not guarantee 
therapeutic success since the drug has to be able to leave the stratum corneum and 
enter the deeper tissues. Therefore, a successful drug has a balanced lipophilicity and 
possesses some aqueous solubility.
Figure 4: ALA and some of its esters. 
With ALA, the ‘R’ is replaced by a H+ atom. When ALA is estiﬁ ed, ‘R’ can be replaced by CnH2n+1 with n = 1 for the methyl-
ester, n=2 for the propyl-ester etcetera… 
20
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1.5.2.3 Cellular uptake of ALA and its esters
Once ALA has passed the stratum corneum it has to be taken up intracellularly to be 
able to interfere in the heme-biosynthetic pathway. Although data on the cellular 
uptake mechanisms of ALA are scarce, a few studies have identiﬁ ed transmembrane 
transport systems, which may play a role in the cellular uptake of ALA. Rud et al.36 studied 
transmembrane transport of ALA and its esters in adenocarcinoma (WiDr) cells and 
found ALA to compete with β-amino acids and γ-aminobutyric acid (GABA) indicating 
a similar uptake mechanism by system BETA-transporters. ALA uptake was Na+ and 
Cl- dependent. Uptake of MAL however, was unaﬀ ected by substrates for the BETA-
transporters indicating another active transport mechanism (involving transporters of 
non-polar amino acids) and/or simply passive diﬀ usion across the cell membrane to be 
the potential mechanisms involved in the transmembrane uptake of MAL. In the same 
human colon carcinoma cells lines, MAL uptake was found to be partly Na+ but not Cl- 
dependent and was partly inhibited by the non-polar amino acids alanine, methionine, 
tryptophan and glycine. Transmembrane transport of ALA has also been shown to 
occur through the intestinal dipeptide transporter PEPT1 and the renal form PEPT2 
expressed in oocytes and yeast cells. ALA, but not ALA-esters, enters pancreatic tumor 
cells through the PEPT1-transporter.37 Bermudez Moretti et al. found that ALA and GABA 
share the UGA4-transporter in the yeast S. cerevisiae.38 They also found in a mammary 
adenocarcinoma cell line that ALA was incorporated by two mechanisms: passive 
diﬀ usion, which is important in short incubation times, and active transport, mediated by 
a BETA-transporter, probably the GABA-transporter GAT-2.39 Long-chain ALA-esters have 
also been extensively studied. The hexy ester of ALA (HAL) was found not to be inhibited 
by the above amino acids indicating passive diﬀ usion across the plasma membrane or 
endocytosis to be the main uptake mechanism.40
Thus it appears that lipophilic ALA-esters enter the intracellular space without signiﬁ cant 
resistance as compared to ALA or short-chain ALA alkyl-esters, rapidly providing a pool 
of precursors suﬃ  cient to maintain PpIX synthesis over a long period of time. 
Kloek et al. have studied PpIX accumulation with ALA and ALA-derivatives in intact and 
lysed cells at various incubation times.11  The intact cells were exposed to ALA or ALA-
derivatives for 5 minutes and PpIX accumulation was measured at 2, 4 and 6 hours. The 
lysed cells were exposed to ALA or ALA-derivatives for 2, 4 and 6 hours. In the intact cells 
PpIX accumulation by ALA (and MAL) was signiﬁ cantly lower compared with long-chain 
ALA-derivatives, indicating a faster diﬀ usion across the cell membrane by the long-chain 
ALA-derivatives. In the lysed cells PpIX concentrations were signiﬁ cantly higher for ALA 
compared with ALA-derivatives, especially at short incubation times. This phenomenon 
can be explained by the fact that ALA-derivatives ﬁ rst have to be converted (de-
esteriﬁ ed) into ALA before they can interact in the heme-biosynthetic pathway. This 
study clearly illustrates the direct consequences on a cellular level of modiﬁ cations of the 
ALA molecule by esteriﬁ cation, excluding the eﬀ ects of penetration through the stratum 
corneum.
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1.5.3 Selective porphyrin accumulation in lesional tissue compared with
 non-lesional tissue by ALA and its esters and factors infl uencing 
 PpIX accumulation
1.5.3.1 Introduction
The process of PpIX accumulation is a complex and multistep process, which generally 
includes 3 phases the photosensitizer has to go through: (1) penetration through the 
stratum corneum, (2) cellular uptake and (3) metabolic conversion into porphyrins. 
Diﬀ erences in these phases between diﬀ erent tissue types account for the diﬀ erent 
pharmacokinetics and –dynamics of PpIX accumulation. These are intrinsic factors 
(properties of the tissue) but there are also extrinsic factors that inﬂ uence PpIX 
accumulation, such as the speciﬁ c properties of the drug used (e.g. vehicle, concentration, 
application time). 
These intrinsic as well as extrinsic factors, may not only have consequences on the total 
amount of PpIX that is being accumulated but also on the diﬀ erences in the amount of 
and distribution of PpIX between diﬀ erent tissue types (preferential accumulation). In 
general, diﬀ erences in any of these variables between normal and diseased tissue may 
account for diﬀ erent aﬃ  nities of these tissues to accumulate PpIX.
1.5.3.2 Proposed mechanisms for preferential accumulation of PpIX
An optimal contrast between the tumor and its normal looking surrounding skin is not 
only crucial in FDAP to be able to discriminate between high and low PpIX accumulating 
tissues, but also in PDT since the cytotoxic eﬀ ects of PDT have to be maximum at the 
tumor site, leaving the normal skin unharmed. 
On the preferential accumulation of PpIX much has been published but nonetheless, 
this remains a controversial subject. However, knowledge on the exact mechanisms 
of preferential PpIX accumulation is important to better understand false positive 
and negative outcomes in FDAP and the variable treatment eﬃ  cacy observed in PDT. 
Generally, diﬀ erences between lesional and non-lesional tissues have been reported 
Figure 5: Uptake of ALA, MAL and HAL in WiDR adenomacarcinoma cell lines.
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with respect to (1) penetration of the photosensitizer or (2) metabolic conversion into 
porphyrins. 
The important role of the stratum corneum in the penetration of the photosensitizer 
has already been addressed previously. The relatively limited aﬃ  nity for ALA (-esters) in 
normal skin can be explained by the limited penetration of the photosensitizer through 
an intact stratum corneum. Disruptions in the stratum corneum, as may happen through 
underlying neoplastic growth invading through epidermal structures or disturbances 
in epidermal growth and keratinization, are expected to interrupt the lamellar integrity 
of these lipids, oﬀ ering ALA a facilitated path through aqueous ﬁ ssures. This leads to 
relatively increased ALA uptake and PpIX formation consequently in these tissues.41;42 In 
psoriasis, increased permeability of the stratum corneum has been found to correlate with 
psoriatic phenotype, providing a possible explanation for increased PpIX ﬂ uorescence 
seen in psoriatic plaques following application of ALA.43;44   
Figure 6: Proposed model for increased ALA penetration through a normal (A) and 
disorganized stratum corneum (B). 
The stratum corneum has been described using the classic brick and mortar model, where corneocytes are visualized as 
bricks suspended within a lipid mortar. The movement of ALA through the ordered lipid structures is labyrinthine and 
tortuous (A), an observation manifest as the poor penetration of ALA through intact skin. Disruptions in the stratum 
corneum, as may happen through underlying neoplastic growth (B) are expected to interrupt the lamellar integrity of 
these lipids, oﬀ ering ALA a facilitated path through aqueous ﬁ ssures. Therefore it is conceivable that in these circumstances 
the permeability of ALA rises sharply and exceeds that found in normal skin. Adopted from Donnelly et al.42
Another explanation could be a thinner stratum corneum in neoplastic tissue compared 
with normal skin but this seems unlikely since hyperkeratosis is frequently seen in 
epithelial neoplasias. However, thickness of the stratum corneum does play an important 
role since removal of the stratum corneum results in increased PpIX ﬂ uorescence.18-23 
The rate of ALA-induced porphyrin synthesis has been shown to be higher in (pre)
malignant cells and tissues compared with their normal counterparts.19;45-47 Studies in 
various cell lines have shown malignant cells to have increased porphyrin synthesis with 
elevated enzymatic activity of certain heme-pathway enzymes accordingly. In human 
breast cancer tissues signiﬁ cantly more porphyrins (a 20-fold on average) in conjunction 
with increased enzymatic activity of ALA dehydratase, PBGD and uroporphyrinogen 
decarboxylase, were found compared with normal breast tissue.48 Malignant urothelial 
cells were found to accumulate more PpIX, being more sensitive to photoinactivation 
than cells from normal urothelium.49;50 Similar results have been reported in cervical cells, 
explants from BCC and keratoacanthoma and amelanotic melanoma.46;51;52 In contrast, 
photochemical treatment with ALA induced similar cell killing eﬀ ects on normal human 
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keratinocytes, spontaneously transformed human keratinocytes and on squamous 
carcinoma cells.53 Moreover, Washbrook et al. found accumulation of PpIX in ALA treated 
mammalian epithelial cells not to be dependent on transcriptional and translational 
activation of involved enzymes.54 
Under normal conditions, ferrochelatase activity may be suﬃ  ciently high enough to 
convert PpIX into heme under conditions of high intracellular concentrations of ALA. 
In most cases, ferrochelatase activity is estimated 10-fold higher compared with PBGD, 
the enzyme in the heme-cycle with lowest intracellular activity. Therefore it seems more 
likely that PBGD may be a rate-limiting enzyme by exposure to excess ALA. However, 
in tissue samples from Barret’s oesophagus and adenocarcinoma, Hinnen et al. reported 
a weak inverse relationship between ferrochelatase activity and PpIX accumulation.55 
This was conﬁ rmed by Ohgari et al. who studied PpIX accumulation in ﬁ broblasts 
after transfection with ferrochelatase cDNA. In addition, Krieg et al. found signiﬁ cant 
diﬀ erences in PBGD and ferrochelatase activity between malignant colonic cells and 
normal ﬁ broblasts.56 Furthermore, by the same author in malignant urothelial cells 
signiﬁ cant diﬀ erences in iron and ferrochelatase, but not PBGD, were found compared 
with their normal counterparts.50 
It has been proposed that changes in PBGD activity are closely related to growth and 
diﬀ erentiation.57;58 Induction of diﬀ erentiation via hexamethylene (HMBA) in B16 
melanoma cells resulted in an increase in PpIX production which was accompanied by an 
increase in PBGD. However, induction of diﬀ erentiation via butyrate resulted in decreased 
levels of cellular PBGD and a proportional decrease in PpIX synthesis.59 The association 
between diﬀ erentiation and increased PpIX accumulation was already reported in 
1998 by Ortel et al.58 They induced terminal diﬀ erentiation in cultured primary mouse 
keratinocytes by means of increasing the Ca2+ content in the medium and measured 
PpIX after pre-treatment with ALA. The increase in PpIX present in diﬀ erentiated cells 
could be attributed to several factors including: (a) an increased uptake of ALA, (b) 
decreased eﬄ  ux of PpIX into the cultured media and (c) an increase in mRNA for at 
least one late heme synthetic enzyme, coproporphyrinogen oxidase (CPO). The increase 
in PpIX accumulation proved to be dependent on Ca2+-induced diﬀ erentiation since 
other inducers of diﬀ erentiation were not able to increase PpIX. In addition, Sato et al. 
found induction of terminal diﬀ erentiation by vitamin D (1α,25-dihydroxyvitamin D3) 
also to increase intracellular PpIX content in 3-D organotypic cultures of rat epidermal 
keratinocytes.60 Subsequent irradiation with blue light led to a signiﬁ cantly increased 
phototoxicity compared with the cells that were not treated with vitamin D. Similar 
ﬁ ndings were reported in prostate cells after induction of diﬀ erentiation with R1881 
(a diﬀ erentiation promoting androgen), vitamin D and methotrexate.61;62 However, 
terminal diﬀ erentiation induced by vitamin D as described by Sato et al. did not appear 
to be mediated by CPO, thus pointing at another mechanism for diﬀ erentiation induced 
enhancement of PpIX levels as described by Ortel et al.
These results are in contrast to prior reports in which increased ALA-induced PpIX 
formation was attributed to high rates of proliferation63;64 but it seems that PpIX 
accumulation is independent of cell-cycle distribution but a correlation has been found 
with cell density and cell size.65 The reason for this ﬁ nding remains unknown. In this 
study, Moan et al. measured PpIX content in human colon adenocarcinoma cells (WiDr) 
and Chinese hamster lung ﬁ broblasts cells (V79) after incubation with ALA and reported 
the PpIX production rate in G2M cells to be 1.9 times higher compared with cells in the 
G1-phase but this appeared to be related to a higher cell volume of the proliferating cells. 
This is in accordance with a study of Fukuda et al. who reported heme enzyme synthesis 
to increase proportionally with cell volume.66 PpIX accumulation (per mg of cellular 
protein) proved to be linear with the amount of mg protein per dish in exponentially 
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growing cells.65 In contrast, Washbrook et al. showed ALA uptake and porphyrin synthesis 
to be more rapid in less dense cell cultures than in nearly conﬂ uent cultures.54 Steinbach 
et al. found diﬀ erent aﬃ  nities in diﬀ erent cell lines with respect to PpIX accumulation in 
changing from a two to a three dimensional cell-cell interaction.67 However, in normal 
cells the cell density dependency of PpIX accumulation does not seem to occur.50;54;67   
In conclusion, the regulation of the heme synthesis pathway in cells treated with ALA 
(-derivatives) has been extensively studied. However, the rate-limiting steps in the 
formation of PpIX have still not been fully revealed. The conﬂ icting results from studies 
using diﬀ erent cell lines therefore suggest diﬀ erent regulatory mechanisms for porphyrin 
metabolism in various cell types.
1.5.3.3 Factors in uencing PpIX accumulation
1.5.3.3.1 Application time of the photosensitizer
The application time of the photosensitizer seems to be an important variable, not only in 
the amount of PpIX that is formed in the tissue of interest, but also on the ratio between 
the amount of PpIX in diﬀ erent tissue types (e.g. lesional skin versus non-lesional skin). 
This can be explained by diﬀ erent pharmacokinetics of PpIX build-up in diﬀ erent tissue 
types. Fritsch et al. studied porphyrin levels (measured with spectroﬂ uorometry) in 
diﬀ erent tissue types after incubation with topical ALA (20% cream) and found diﬀ erent 
tissue types (normal skin, psoriasis, SCC, BCC and non-lesional surrounding skin) to have 
diﬀ erent incubation times at which the ratio between lesional and (surrounding) non-
lesional skin reaches its maximum.23 Lesional psoriatic skin showed highest porphyrin 
levels at 6 hours44 whereas SCC and BCC had their maximum porphyrin concentration at 
4 hours. After these time points the porphyrin content slowly decayed (due to increased 
clearance of PpIX in the skin). Non-lesional and normal skin did not show much diﬀ erences 
in porphyrin content up to 6 hours incubation with ALA but hereafter porphyrin content 
in non-lesional surrounding skin in psoriasis, SCC and BCC was signiﬁ cantly higher 
compared to normal skin. Consequently, because of the decreasing porphyrin content in 
lesional skin and the increasing porphyrin content in non-lesional skin, the ﬂ uorescence 
(selectivity) ratio slowly decreases with increasing application times. This was conﬁ rmed 
in a recent study by Angell-Peterson et al. in which porphyrin ﬂ uorescence was studied in 
AK and BCC after 3 and 18 hours application with MAL.68 The depth in the skin at which 
PpIX was located was also measured and not surprisingly PpIX ﬂ uorescence was found 
to decrease with increasing skin depth. Surprisingly, a more superﬁ cial distribution 
of porphyrins was seen at 18 hours incubation with MAL compared with the 3 hours 
application time, but no signiﬁ cant diﬀ erences were seen in the total average porphyrin 
ﬂ uorescence between the two time points. Thus, the application time not only aﬀ ects 
the total porphyrin content in the skin but also the biodistribution of the porphyrins 
within the skin. In the same study, the authors expected application times above 3 
hours not to be more beneﬁ cial in the treatment of BCC and AK with MAL-PDT, but that 
these will rather lead to more side eﬀ ects since the selectivity ratio decreases with time. 
Extensive studies using longer application times are lacking, though. Application times 
shorter than 1 hour with MAL in AK however, are thought to be less clinically eﬀ ective.69 
Considering this and the relatively high initial response rates (93%) seen with MAL-PDT 
for BD an application time of 3 hours (using MAL) in daily practice seems feasible.70 
However, in ALA-PDT for sBCC an application time of 6 hours proved to be more eﬀ ective 
than 4 hours.28 
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1.5.3.3.2 Skin temperature
PpIX accumulation has been shown to be temperature dependent.71-74 Juzeniene et al. 
studied PpIX accumulation following application of ALA and ALA-derivatives in murine 
skin at diﬀ erent temperatures and found signiﬁ cantly more PpIX ﬂ uorescence (2-3 fold) 
at 37 °C compared with 28-32 °C. At around 30 °C PpIX ﬂ uorescence appeared later after 
application of ALA-ester derivatives (14-20 min) than after application of ALA (8 min), 
indicating diﬀ erences in their bioavailability (delayed penetration through the stratum 
corneum, cellular uptake, conversion to ALA, PpIX production) in mouse skin in vivo.72 
These diﬀ erences in lag time in the PpIX formation after application of ALA and ALA-esters 
may be partly related to deesteriﬁ cation of the ALA-ester molecules. Interestingly, PpIX-
accumulation was unaﬀ ected when the skin temperature was increased during short-
term ALA incubation (10-15 min) but higher when the skin temperature was increased 
after short-term ALA incubation, suggesting diﬀ erent temperature independent (ALA 
penetration) and dependent (PpIX-synthesis) processes to occur subsequently. Van den 
Akker et al. also found increased PpIX accumulation in murine skin at 37 °C compared 
with 32 °C during long-term incubation with ALA, but in contrast to Moan and Juzenas, 
this was associated with increased uptake and penetration of ALA into the epidermis at 
higher temperatures.74 According to them increasing the temperature during long-term 
incubation with ALA enhances (1) ALA penetration into the skin, (2) ALA uptake into the 
epidermal cells and (3) PpIX-synthesis by the enzymes in the heme-cycle. 
The temperature dependency of ALA-induced PpIX formation in the skin is relevant 
for the patient undergoing PDT since a low skin temperature during incubation of the 
photosensitizer, i.e. when the patient goes outside during the incubation period, may 
impair therapeutical eﬃ  cacy. However, increasing the skin temperature during ALA 
incubation may help to enhance PpIX accumulation furthermore, which might enhance 
clinical outcome in PDT.
1.5.3.3.3 Formulation of ALA and its esters 
The uptake of the photosensitizer into the skin is a multistep process, in which the 
drug has to run through various compartments. These steps subsequently comprise 
penetration into the stratum corneum, release from the vehicle into the stratum 
corneum / underlying skin and from the stratum corneum into the underlying skin. The 
molecular properties (electromagnetic charge, polarity) of the drug play an important 
role herein as already described previously, but the precise formulation of the topical 
drug (concentration and vehicle) is almost equally as important to ensure an adequate 
release into the skin. 
Casas et al. studied ALA-induced porphyrin accumulation by diﬀ erent vehicles.15 In this 
study ALA was applied (for 3 hours) in a cream, liposomes, vaselin, lotion and lotion + 
dimethylsulfoxide (DMSO, a penetration enhancer). The lotion + DMSO was found to 
induce the highest amount of porphyrins, subsequently followed by the lotion, vaselin, 
liposomes and cream at the tumor site as well as in normal surrounding skin. When the 
selectivity ratio (porphyrin content at the tumor site:normal skin) was calculated, the 
cream vehicle proved to be the most selective vehicle (selectivity ratio: 3.2), followed by 
the lotion (+DMSO), liposomes and vaselin subsequently. Donnely et al. have incorporated 
ALA in a bioadhesive patch for the treatment of onychomycosis and neoplastic vulvar 
lesions with promising results.75;76 This new vehicle, according to them, prevents variations 
in the concentration of ALA (10-200 mg/g/cm2) that may occur when for example ALA 
cream is applied under an occlusive dressing. It is also easier to apply on sites that are 
moist, e.g. mucosa. Moreover, a greater selectivity ratio has also been reported using 
the bioadhesive patch by inducing less porphyrins in normal skin and at distant sites 
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compared with the cream formulation. Lesional porphyrin content was comparable 
between the cream and bioadhesive patch.42 Thus, assuming a disorganized stratum 
corneum in neoplastic tissue to be an important factor in preferential accumulation of 
porphyrins, bioadhesive patch systems increase the selectivity ratio even more.        
In most clinical studies a 20% ALA cream and 16% MAL formulation is used, but according 
to a study of Juzeniene et al. in mice, the same amounts of PpIX can be achieved using 
lower concentrations.34 Similar ﬁ ndings were reported by Van de Akker et al.22 This points 
at saturation of the enzymes in the heme-biosynthetic pathway at already relatively low 
concentrations of topically applied ALA (-esters). For the ALA-derivatives the diﬀ erences 
between low and high concentrations (0.5-20%) with respect to PpIX formation were 
more pronounced compared with ALA, especially at increasing application times (up to 
24 hours). These pharmacokinetic diﬀ erences may be related to the fact that the esters 
are more lipophilic than ALA, and a signiﬁ cant fraction of the ALA-esters may be bound 
in the stratum corneum and other lipophilic cellular compartments, thus slowing down 
their penetration and production of PpIX. The question remains however to what extent 
these data may be extrapolated to certain skin diseases in man and despite several dose 
ﬁ nding studies on ALA, there is currently little consensus as to the optimum amount of 
cream required for a successful photodynamic treatment.
1.5.3.3.4 Methods and pre-treatments to enhance PpIX accumulation
Since accumulation of PpIX in the target tissue is a prerequisite for PDT and FDAP, eﬀ orts 
have been made to optimize preferential accumulation of PpIX. Most of these eﬀ orts 
have concentrated on increasing the penetration of ALA through the stratum corneum. 
Modiﬁ cation of the (indirect) photosensitizer molecule by esteriﬁ cation (ALA-derivatives) 
is one example of this, but less sophisticated measures have also been tried with 
favorable results, such as the addition of penetration enhancers to the ALA formulation.13-
16 Another approach that has been tried to increase PpIX formation is the introduction 
of additives that interact in the heme-biosynthetic pathway, e.g. by removing ferrous 
iron. These iron-chelating substances, such as ethylene diamine tetraacetic acid (EDTA), 
desferrioxamine (DFO) and 3-hydroxypyridin-4-ones (HPOs), prevent breakdown of 
PpIX by inhibition of ferrochelatase (an iron requiring enzyme which degrades PpIX to 
heme). These iron-chelators were able to signiﬁ cantly increase PpIX formation compared 
with ALA alone.13;77;78 Moreover, a positive therapeutic outcome in nodular BCCs has 
been found but the future role of iron-chelating agents in PDT remains a subject for 
discussion.79;80 
By iontophoresis, which is a method to facilitate transport of ionic species by application 
of electric current, a signiﬁ cant increase in ALA delivery at physiological pH has been 
reported.81-84 Transport of ALA across the skin and the amount delivered into the skin 
were ~4-fold greater with iontophoresis relative to the passive application of a DMSO 
formulation.84 A more than 50-fold enhancement of the methyl-ester compared to the 
zwitterionic parent 5-ALA was observed by in vitro iontophoresis, an eﬀ ect that gradually 
decreased with increasing chain-length (long-chain esters). However, when in vivo 
iontophoresis of ALA, butyl-ester and hexyl-ester were compared, no diﬀ erences were 
seen in PpIX formation.85 The discrepancies between the in vivo and in vitro results could 
probably be explained by diﬀ erent formulations (and the pH of the solutions) that were 
used.  
Other methods to increase ALA uptake and PpIX ﬂ uorescence consequently are the 
application of pre-treatments aimed at removal of the stratum corneum, such as 
treatment with keratolytics23, curettage/debulking25 or tape-stripping.20;22 These pre-
treatments enhance PpIX build-up by facilitating ALA penetration into the skin, but as 
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a consequence, selectivity may be decreased because uptake of ALA in normal skin is 
also increased. These pre-treatments may further increase the clinical eﬃ  cacy of PDT 
in NMSC, as reported by Soler et al., who reported the combination of a debulking 
procedure before PDT in addition to application of DMSO to increase cure rates up to 
about 85–90% in nBCC.86 
1.5.3.3.5 ALA versus ALA-derivatives
Several reports have studied the diﬀ erences between ALA and its esters with respect 
to their ability to induce PpIX.21;22 However, there are some inconsistencies between in 
vitro and in vivo studies which may be attributed to the role of the stratum corneum and 
interactions between the drug and the topically applied vehicle. ALA-derivatives (ALA-
esters) have been proposed to as new PDT drugs under the assumption that they should 
penetrate deeper than ALA. 32;34;87 ALA-derivatives were found to induce PpIX up to 100-
fold more eﬀ ectively than ALA in cell cultures in vitro.11;88 So the assumption is certainly 
fulﬁ lled for layers as thin as a cell membrane. However, in animal models ALA-derivatives 
do not induce widely diﬀ erent amounts of PpIX.34;89 In most cases ALA-esters induced 
similar or slightly higher PpIX levels compared with ALA32 in normal mouse skin34;90;91 
while in humans the opposite result was found.45;92 These diﬀ erences will probably 
have to do with diﬀ erences in penetration (stratum corneum properties) of ALA and its 
derivatives in mice and men. 
ALA-derivatives, especially MAL, have been reported to be more selective than ALA 
with respect to PpIX accumulation in vivo.45 Fritsch et al. studied PpIX accumulation in 
AK and normal surrounding skin using ALA and MAL (1 and 6 hours application times). 
With respect to the selectivity ratios (assessed by porphyrin content), MAL was found to 
have a signiﬁ cantly higher selectivity ratio compared with ALA (8.8 vs. 5.1 at 6 hours). 
When total porphyrin content was compared between ALA and MAL, ALA was found to 
induce signiﬁ cantly more porphyrins compared with MAL (in lesional as well as normal 
surrounding skin). However, since the eﬀ ects of ALA on normal skin were relatively 
higher compared with MAL this resulted in a lower selectivity ratio for ALA. In addition, 
Moan et al. studied PpIX accumulation in normal murine skin and found higher PpIX 
content at distant sites (opposite ﬂ ank on which the photosensitizer was applied) by 
ALA compared to MAL.41 In accordance with Fritsch et al. they also found an increased 
selectivity ratio (although not signiﬁ cant) in favour of MAL compared with ALA as well as 
less porphyrin induction by MAL compared with ALA. They contributed these diﬀ erences 
to the transport of ALA, but not MAL, to distant sites by the circulation. The diﬀ erent 
octanol/water coeﬃ  cients between MAL and ALA may be responsible for this (see 
paragraph 1.5.2.2). This indicates that MAL does not reach the microcirculation because 
of its increased lipophilicity compared with ALA. However, systemic eﬀ ects of topical ALA 
are believed to be negligible.93;94 
Histologically, selective accumulation of PpIX in BCC with MAL was reported by Peng et 
al.95 They studied application times of 3 and 18 hours and found the former to be more 
eﬀ ective regarding the depth of ﬂ uorescence (up to 2 mm). However, 16 hours application 
time proved to be more eﬀ ective with respect to the total amount of porphyrins formed. 
Martin et al. performed an analogous study using ALA instead of MAL and found a 
disappointing correlation between ﬂ uorescence and various types of BCCs, histologically 
as well as clinically.96 They did not use any kind of lesional pre-treatment and included 
sBCC as well as nBCCs. Not surprisingly, in sBCC higher ﬂ uorescence was found compared 
with nBCC. 
The increased selectivity of MAL compared with ALA is also demonstrated by the 
fact that MAL has been associated with less pain during PDT compared with ALA.92 
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Decreased induction of porphyrins by MAL in normal skin compared with ALA is one 
explanation, however ALA, but not MAL, has been reported to be taken up by receptors 
for γ-aminobutyric acid (GABA) in the peripheral nerve endings, due to its molecular 
similarities with GABA.97;98 Since MAL-PDT can also be very painful, neurogenic uptake of 
ALA cannot exclusively be held responsible for PDT induced pain.
1.5.3.3.6 Other parameters and studies in cell culture systems
Most studies on PpIX accumulation have been conducted in cell cultures. As certain 
environmental conditions in cell cultured systems may inﬂ uence PpIX accumulation, 
to interpret these studies adequately and to learn more on the possible mechanisms 
involved in preferential accumulation of PpIX, it is important to know the eﬀ ects of these 
factors on PpIX accumulation. 
In cell cultured systems, serum is usually added to the medium to enhance cell growth 
and survival. However, serum proteins such as albumin have been shown to extract 
porphyrins from the intracellular to the extracellular space.46;99 This could lead to an 
underestimation of intracellular PpIX content when leakage of PpIX into the medium is 
not accounted for. 
PpIX accumulation is also strongly dependent on pH. Bech et al. showed that PpIX 
synthesis in Chinese hamster cells (V79) and human adenocarcinoma (WiDr) cells 
increased with pH in the range 6.0-7.5 and decreased above 7.5.100 This is most likely 
related to enzymatic activity of PBGD, the rate-limiting enzyme in the heme-cycle. Since 
the acid-dissociation (pKa) values of ALA are 4 (carboxylic groups) and 8.9 (amino group) 
it is unlikely that its lipophilicity and rate of penetration into cells change signiﬁ cantly in 
the pH-range 6.0-7.9. Tumor tissues are generally more acidic than surrounding normal 
tissues, which is most probably due to an overproduction of lactic acid and hydrolysis 
of adenosine triphosphate (ATP). To study whether this could be a signiﬁ cant factor in 
preferential accumulation of PpIX, Uehlinger et al. incubated three diﬀ erent malignant 
cell lines with ALA at various pH values. 35 At pH 7.5 the highest PpIX formation rates 
were found, which makes a pH dependency in the preferential accumulation of PpIX in 
malignant cells unlikely.
1.5.4 Activation of the photosensitizer3;101
1.5.4.1 General aspects of light and photosensitization
When a suﬃ  cient amount of the photosensitizer has been accumulated in the target 
tissue, it needs to be activated by light to exert its eﬀ ects. These reactions can be best 
explained using modern quantum physics in which the relations between energy 
and light are described. Light corresponds to a small region of the electromagnetic 
spectrum. For the description of some of its properties, it is adequate to treat light as 
electromagnetic waves, while for the description of other phenomena such as absorption 
and emission, light is best described as a particle. This is referred to as the wave-particle 
dualism. In the particle model, light can be seen as an electromagnetic wave, which 
consists of discrete packets of energy, called photons. These photons can be emitted and 
absorbed by molecules acting as energy transporters. The relation between the amount 
of photon energy (Ephoton ) and wavelength (λ) can be described using Planck’s equation:
 Ephoton = h ∙ f = h ∙ c / λ
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where h = Planck’s constant (6.63 ∙ 10-34 Js), c = speed of light in vacuum (3 ∙ 108 ms-1) and 
f = frequency.
When a photon is absorbed by an atom, it excites an electron, elevating it to a higher 
energy level. If the energy is great enough, so that the electron jumps to an energy level 
that is high enough, it may escape the positive pull of the nucleus and be liberated from 
the atom in a process called photoionisation. Conversely, an electron that descends to 
a lower energy level in an atom emits a photon of light equal to the energy diﬀ erence. 
This is called the photoelectric eﬀ ect. Since the energy levels of electrons in atoms are 
discrete, each element emits and absorbs its own characteristic frequencies. Together, 
these eﬀ ects explain the absorption spectra of light. The dark bands in the spectrum are 
due to the atoms in the intervening medium absorbing diﬀ erent frequencies of the light. 
The composition of the medium through which the light travels determines the nature 
of the absorption spectrum. An organic molecule can be visualized as a set of relatively 
slow-moving nuclei (which constitute the framework of the molecular structure) and 
of highly mobile electrons (which occupy speciﬁ c volumes – orbitals – surrounding 
the nuclei). These orbitals can hold a maximum of two electrons. During an electronic 
transition, one of the electrons is promoted from an initially occupied orbital of low 
energy to a previously unoccupied orbital of high energy. This process transforms the 
molecule from its ground state into an excited state. 
Figure 7: The light spectrum.
Classiﬁ cation of the diﬀ erent forms of light and their wavelengths (nm). The human eye is only capable of viewing 
wavelengths from 400 to 780 nm also known as ‘visible light’. Below 400 nm there is UV radiation which is highly-
energetic, capable of modifying molecules and is mainly responsible for the photobiologic eﬀ ects on human skin. 
1.5.4.2 Excitation of the photosensitizer:  uorescence and photodynamic e ects
After absorption of light by the sensitizer the energy of the light is stored in the singlet 
state of the sensitizer molecule, which brings the photosensitizer to a higher energy 
level. As this singlet state is a very unstable condition, a couple of reactions may take 
place. The photosensitizer may return to a lower energy level by emission of ﬂ uorescence 
(a radiation process) and/or by a radiation less process called internal conversion. During 
internal conversion the excess energy of the singlet state is released as heat and during 
ﬂ uorescence a photon is emitted with an energy equal to the energy gap between the 
ground state and the excited state. Intersystem crossing is an isoenergetic non-radiative 
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transition between two electronic states having diﬀ erent electron movements or 
orientations, a.k.a. spin-multiplicities, which gives rise to the triplet state. These triplet 
states are far more stable (have a longer half-life) than the singlet states and thus have 
a greater chance to interact with other molecules. This explains their dominant role in 
photosensitization processes.    
The ﬂ uorescence emitted during return of the excited singlet state to the ground state 
can be used for diagnostic purposes, i.e. FD. For FD in dermatology, porphyrins are mostly 
used after topical sensitization with ALA. Porphyrins emit a speciﬁ c red ﬂ uorescence 
once excited. From their absorption (excitation) spectra their predilection for blue light 
appears. This maximum absorption peak at around 408 nm is referred to as the Soret 
band. The little maxima further on are called Q-bands. For FDAP the Soret band, but not 
the Q-bands, are used because for a good discrimination between excited and emitted 
radiation, it is not desirable excitation and emission wavelengths to overlap.
In photodynamic therapy, it is the triplet-excited photosensitizer that initiates the 
photodynamic cascade. It may act as a mediator in two types of reactions. In the type 
I reaction, the photosensitizer directly reacts with substrate molecules which are in its 
proximity by exchanging electrons and hydrogen atoms. This results in the formation 
of radical forms of the photosensitizer or substrate, which in turn may react with 
surrounding substrates causing direct tissue damage. These radical forms may also 
react with oxygen molecules to form reactive oxygen species (ROS) such as peroxides, 
superoxide ions and hydroxyl radicals, which initiate free radical chain reactions. In the 
type II reaction the activated photosensitizer directly reacts with molecular oxygen to 
form singlet oxygen (1O2). Singlet oxygen plays a key role in photodynamic cytotoxicity 
since it is highly eﬃ  cient at causing damage to various biomolecules in its proximity. 
Figure 8: Excitation of the photosensitizer in FDAP and PDT. 
0PS represents the photosensitizer in the ground-state. 1PS** and 1PS* are unstable singlet states. 3PS* represents the 
triplet excited state which is more stable. 
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Once the triplet-excited photosensitizer has transferred its energy with singlet oxygen, it 
returns to its ground state. When this does not occur, the triplet-excited photosensitizer 
may also return to its ground state by alternative routes. The excess energy may then be 
transferred to heat (thermal deactivation) or a radiation process called phosphorescence. 
In the triplet-excited state, energy can become trapped with only quantum mechanically 
‘forbidden’ transitions available to return to the lower energy state. These transitions, 
although ‘forbidden’, will still occur but are kinetically unfavored and thus progress at 
signiﬁ cantly slower time scales. This results in the emission of light at lower intensities 
compared with ﬂ uorescence over a longer period of time.  
Both type I and II reactions can occur in parallel, but the extent to which one reaction 
occurs rather than the other depends on the availability of the photosensitizer, its 
subcellular localization and the substrate and oxygen supply around the activated 
photosensitizer. For example, under hypoxic conditions type I reactions will predominate. 
In general, chemical reactions between an excited photosensitizer and oxygen are called 
photodynamic reactions. Hence, the term ‘photodynamic diagnosis’, which is sometimes 
used as a synonym for FD, is not completely correct as for FD no oxygen is required. In 
fact, oxygen is believed to be responsible for consumption of the photosensitizer during 
FD.102;103 This is also referred to as ‘photodegradation’ or ‘photobleaching’.  
Figure 9: The photodynamic reaction. 
0PS represents the photosensitizer in the ground-state. 1PS* represents the unstable singlet excited state, which is 
converted to the more stable triplet excited state (3PS*). ISC = intersystem crossing.
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1.5.4.3 Which wavelength to use?
When light enters the skin, a part of it is absorbed and another part is reﬂ ected or 
scattered. Consequently, due to these phenomena, light intensity - which is deﬁ ned as 
the light dose (ﬂ uence, J/cm2) per unit time (s) - decreases with penetration depth into 
the skin. Light intensity is also referred to as ‘irradiance’ or ‘ﬂ uence-rate’ (mW/cm2). The 
part that is absorbed is only capable of excitation of the photosensitizer. Despite the fact 
that the skin is irregularly shaped, consists of hairfollicles and glands, is inhomogeneous 
and multilayered, wavelength dependent coeﬃ  cients of scattering and absorption can 
be determined for epidermis and dermis. To estimate the ﬂ uence-rate at a certain depth 
in the skin, the formula depicted below can be used, which shows that the ﬂ uence-
rate Φ at a certain depth z is dependent on the ﬂ uence-rate at the surface Φ0, and the 
wavelength dependent constants factor k (back-scatter) and exponent µeﬀ  (scattering 
and absorption):
Φ (z) = Φ0 k e
-µ
e 
 z
At 630 nm and in non-pigmented skin values for k (2.63) and µeﬀ  (0.359 mm
-1) have 
been calculated.104 What also can be derived from this formula is that the ﬂ uence-rate 
exponentially decreases with the distance into the skin. Using this formula, an estimation 
of the maximum penetration depth of 2.8 mm of red light (630 nm) can be calculated. 
The main chromophores (light absorbing substrates) in the skin are: proteins, melanin 
and hemoglobin. Considering the absorption spectra of these chromophores one can 
see that at higher wavelengths less light is absorbed and more light is admitted. For that 
reason, the wavelength range from 600-1300 nm is also called the ‘optical window’ of the 
skin (ﬁ gure 10). However, Planck’s equation shows these wavelengths to be less energetic 
compared with short wavelengths. Thus, regarding its optical characteristics, the skin has 
a natural protection against the toxic eﬀ ects of UVR compared with visible light, which is 
advantageous from an evolutionary point of view. However, from a therapeutical point 
of view, this limits the use of short wavelengths in the treatment of deeper skin lesions. 
This is why for the photodynamic treatment of NMSC, red light (630 nm) is commonly 
used. Red light can penetrate the skin up to 2.8 mm, so transepidermal and lesions in 
the upper dermis can also be irradiated. However, red light is less eﬃ  cient in activation 
of PpIX compared with blue light but by increasing the total light dose this can be 
compensated for. 
Figure 10: The main chromophores in 
the skin.
The main chromophores in the skin are: water, 
proteins, melanin and hemoglobin. Less light is 
absorbed from 600-1300 nm which is therefore 
also called the ‘optical window’ of the skin.
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For FDAP, red light is not preferred for reasons previously described. In addition, with 
FDAP induction of ﬂ uorescence is pursued without causing any unwanted photodynamic 
eﬀ ects, which may damage the tissues of interest. Since blue light is highly eﬃ  cient in 
activation of PpIX, irradiation with blue light for longer periods results in photobleaching 
with loss of ﬂ uorescence. The limited penetration depth of blue light (<1 mm) must also 
be considered when performing FDAP. Fluorescence detected with FDAP thus yields 
hardly any information from deeper structures inside the diseased tissue.  
In conclusion, for an optimal activation of PpIX, not only the absorption spectrum of PpIX 
but also the absorption characteristics of the skin have to be considered. Practically, this 
means that for the photodynamic treatment of deep skin lesions red light is preferred 
over blue light. Consequently, a higher total light dose is required to activate an 
equivalent amount of PpIX. For FDAP, blue light is preferred but the limited penetration 
depth and its photobleaching eﬀ ects have to be taken into account.
1.5.5 Detection systems and light sources
For excitation of PpIX a simple Wood’s light, named after the American physicist Robert 
Wood (1868-1955), can be used. Wood’s light systems consist of a UV lamp (370-
405 nm) and are used in dermatology for the detection of certain skin infections and 
hypopigmented skin lesions. These light sources are highly eﬃ  cient in the induction 
of ﬂ uorescence with FDAP, because of their spectral overlap with the Soret band in 
the absorption spectrum of PpIX, and that is exactly what is their main disadvantage. 
Photobleaching occurs very rapidly, resulting in loss of PpIX ﬂ uorescence within a few 
seconds. As the intensity of the ﬂ uorescence is very weak compared with the surrounding 
light, it takes a trained photographer to photograph these lesions accurately. Moreover, 
quantitative data cannot be derived from these pictures since the illumination of the 
lesion and the photographic procedure are not standardized.105 
Fortunately, special digital detection systems have been developed to record ﬂ uorescence 
images more accurately with the ability to perform measurements afterwards. The 
Dyaderm® (Biocam GmbH, Regensburg, Germany) is one of these digital detection 
systems and is used for the FDAP procedures described in this thesis (ﬁ gure 11). The 
system consists of a ﬂ ash light (Xenon light source with a custom band-pass ﬁ lter (370-
440 nm)) and a 12-bit Sony CCD camera combined in one adjustable arm coupled to a 
Pentium IV computer equipped with custom made image capturing. The ﬂ ashlight emits 
7 light pulses per second to the skin, which are recorded by the CCD camera equipped 
with a special Schott GG 455 long-pass ﬁ lter to ﬁ lter out the excitation light. As PpIX 
ﬂ uorescence emission consists of light in the red spectrum, the red pixels of the CCD 
camera are used to generate a ﬂ uorescence image. In this way a normal coloured image 
and a ﬂ uorescence image can be processed in real-time, which can also be laid on to 
each other. Because of the short exposition time to the excitation light, photobleaching 
of PpIX is minimized in this way. The ﬁ xed distance between the skin, light source and 
camera and the ﬁ xed exposure time of the camera permit standardized images to be 
recorded, which can be used for quantitative analysis afterwards.106 This device was used 
in the experiments described in chapters 2-4.
In literature, several mostly custom-built detection systems have been reported to 
measure PpIX ﬂ uorescence in vivo in various skin conditions.20;96;107-109 107;110-112  In the next 
paragraph these studies are brieﬂ y reviewed. 
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1.5.6 Clinical studies on FDAP in the skin and oral mucosa
The clinical application and beneﬁ t of ALA-induced ﬂ uorescence was ﬁ rst demonstrated 
in bladder tumors.113 In the meantime several other medical specialties have evaluated 
the use of FDAP in their speciﬁ c ﬁ eld. For example, it has been shown that a higher 
sensitivity can be achieved with the addition of FDAP to conventional endoscopy in the 
diagnosis of dysplasia in patients with Barrett’s oesophagus.114 Promising results using 
FDAP have also been reported in the detection of cervical cancer.115 In the skin, most 
clinical studies on FDAP have been conducted in BCC. Demarcation of these lesions 
can be quite problematic and since these are often located in the head and neck area 
where there is not much space for extensive surgery, preservation of healthy skin during 
surgical excision of the tumor is preferred. FDAP may aid in delineating these tumors, 
thus reducing the amount of healthy tissue being unnecessarily excised. 
Martin et al. reported lack of selectivity of PpIX ﬂ uorescence for BCC after topical 
application of ALA, using a custom-built ﬂ uorescence imaging system.96 The macroscopic 
images were compared with histological localization of PpIX but a weak correlation was 
found. In nBCCs microscopic ﬂ uorescence was found to be more superﬁ cial compared 
with sBCCs. In general macroscopic ﬂ uorescence correlated well with the clinical tumor 
margins. The authors concluded macroscopic ﬂ uorescence to be a poor predictor for 
histological localization PpIX, especially in nBCCs. They hypothesized this to be related to 
decreased penetration of ALA in nodular lesions. 
In contrast, Peng et al. reported a selective distribution of porphyrins in histologically thick 
(>0.5 mm) BCCs after topical application of MAL.95 Application times of 3 and 18 hours 
were studied and PpIX ﬂ uorescence was recorded at various depths, using microscopic 
ﬂ uorescence photometry. Highest ﬂ uorescence was seen at 18 hours incubation with 
MAL compared with 3 hours, but due to the higher ﬂ uorescence induced in normal 
surrounding skin, the selectivity ratio was higher at 3 hours. The authors concluded 
porphyrin ﬂ uorescence by MAL to be homogeneously and selectively distributed in 
thick BCCs, probably due to an increased penetration of the more lipophilic methylester 
compared with ALA. 
Wennberg et al. compared macroscopic ﬂ uorescence, histological and clinical size in 
various types of BCCs after 4 hours application of ALA.112 All BCCs were excised using 
Figure 11: The Dyaderm®  uorescence imaging system (A) and its emission spectrum in 
relation to Wood’s light and PpIX absorption and emission spectra (B).
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Mohs micrographic surgery. A digital ﬂ uorescence imaging system was used to record 
macroscopic ﬂ uorescence. A ﬂ uorescence intensity of 1.4 times normal surrounding 
ﬂ uorescence was chosen as a threshold to discriminate between normal ﬂ uorescence 
and tumor ﬂ uorescence. Correlation between ﬂ uorescence and histology was judged to 
be in one of the categories good, partial or no correlation. From the 30 BCCs that were 
examined 50% showed good and 23% showed partial correlation. In the remaining 
lesions no correlation at all was found. The authors concluded further optimization of 
this technique to be necessary. A follow-up study from the same group conﬁ rmed the 
ﬂ uorescence threshold limit of 1.4 to be valid for FDAP in facial BCCs.108 By studying ALA 
application times of 1-4 hours the authors concluded 3 hours incubation to yield the 
optimum ﬂ uorescence contrast. In addition, normal skin ﬂ uorescence was found to be 
maximal at 2 hours incubation. 
Table 1: Fluorescencecharacteristics of some skin diseases.*
Skin disease Intensity Homogeneity Demarcationyes no sharp vague
BCC: super cial 1 2 3 4 x x
BCC: morpheaform 1 2 3 4 x x
BCC: nodular 1 2 3 4 x x
SCC: super cial 1 2 3 4 x x
SCC: nodular 1 2 3 4 x x
SCC: ulcerating 1 2 3 4 x x
Keratoacanthoma 1 2 3 4 x x
Paget’s disease 1 2 3 4 x x
Bowen’s disease 1 2 3 4 x x
Actinic Keratosis A 1 2 3 4 x x
Actinic Keratosis B 1 2 3 4 x x
Mycosis fungoides 1 2 3 4 x x
Kaposi-sarcoma 1 2 3 4 x x
Malignant melanoma – metastasis 1 2 3 4 x
Lupus erythematodes 1 2 3 4 x x
Psoriasis: guttate 1 2 3 4 x x
Psorasis: plaque type A 1 2 3 4 x x
Psoriasis: plaque type B 1 2 3 4 x x
Atopic dermatitis 1 2 3 4 x x
Acne vulgaris 1 2 3 4 x x
Darier’s disease 1 2 3 4 x x
Normal skin: Face 1 2 3 4 x
Normal skin: Trunk 1 2 3 4 x
Normal skin: Intertriginous 1 2 3 4 x
Fluorescence intensity is semi-quantitative in relation to ﬂ uorescence reference. 
A = without hyperkeratosis, B = with hyperkeratosis.
* Fritsch C, Neumann NJ, Ruzicka T et al. Photodiagnostic test procedures. Part 3: Fluorescence diagnosis with delta-aminolaevulinic-acid induced 
porphyrins (FDAP) in dermatology. Hautarzt 2000; 51: 528-43.
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Andersson-Engels et al. used a four-dimensional ﬂ uorescence imaging system to study 
ALA-induced ﬂ uorescence in BCCs, BD and cutaneous T cell lymphoma before and 
after PDT.111 In this study not only PpIX ﬂ uorescence, but also background ﬂ uorescence 
(autoﬂ uorescence) in tumor and normal tissue was recorded, in order to enhance 
ﬂ uorescence contrast. By measuring the photodegradation products of PpIX - which 
have a ﬂ uorescence maximum at 670 nm - during and after PDT, the system was able to 
monitor the treatment dose delivered during PDT.
Stenquist et al. also combined PpIX ﬂ uorescence with background ﬂ uorescence to obtain 
a better ﬂ uorescence contrast in facial BCCs following ALA application.107 When irradiated 
with blue light, green ﬂ uorescence is emitted from the skin (470 nm), which is regarded 
to be tissue autoﬂ uorescence. Since autoﬂ uorescence has been reported to be lower in 
tumor tissue compared with normal skin, probably due to an increased metabolism in the 
tumor, by taking the ratio between PpIX ﬂ uorescence and autoﬂ uorescence, increased 
ﬂ uorescence contrast between tumor and normal skin can be achieved. By comparing 
speciﬁ c tumor ﬂ uorescence with histopathology, a good correlation was found in 5 out 
of the 12 patients. In the remaining 7 patients a partial correlation was found. Compared 
with a previous study from the same group112, using this technique the authors were able 
to improve the correlation between ﬂ uorescence and histopathology furthermore. 
Fritsch et al. extensively studied FDAP in various skin diseases.18;19 A short summary 
of the ﬂ uorescence characteristics of a number of skin diseases is depicted in table 1. 
Skin diseases such as lentigo maligna (melanoma), melanocytic nevi, seborrhoic warts, 
common warts and (amelanotic) malignant melanoma did not show any ﬂ uorescence 
following application of ALA. This may be related to their hyperkeratotic nature or 
presence of melanin, which may hamper the penetration of the photosensitizer and/or 
light. 
FDAP has also proven to be beneﬁ cial in the diagnosis of oral (pre)malignancies. Zheng 
et al. examined 118 oral lesions with FDAP using a digitized ﬂ uorescence endoscopic 
imaging system.116 A 0.4 % ALA solution, with which patients were asked to rinse for 15 
minutes, followed by a 2 hours incubation period was used to induce PpIX ﬂ uorescence. 
After the ﬂ uorescence was recorded, biopsies were taken. Lesions were histologically 
classiﬁ ed as normal, hyperplastic, dysplastic, carcinoma in situ and SCC. A sensitivity 
of 92% and speciﬁ city of 96% were achieved to discriminate benign from dysplastic 
lesions. Furthermore, to discriminate benign lesions from carcinoma in situ and SCC a 
sensitivity and speciﬁ city of 98% and 96% were achieved respectively. A similar study was 
performed by Sharwani and colleagues but a lower sensitivity (83-90%) and speciﬁ city 
(79-89%) were found to discriminate benign from dysplastic lesions.117 Thus, FDAP seems 
a useful non-invasive diagnostic tool to discriminate between benign and (pre)malignant 
oral lesions. Facilitated penetration of ALA in mucosal lesions compared with skin lesions 
most probably explains the high reliability of FDAP in mucosa compared with the skin. 
In conclusion, although the results of FDAP on the skin are hopeful, it is still not able to 
replace histology. The diﬀ erent methodologies used in the diﬀ erent studies make results 
diﬃ  cult to compare. Therefore, optimization and standardization of the FDAP procedure 
furthermore is needed to make FDAP a more reliable tool in dermatology. 
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 1.6 Photodynamic therapy in dermatology
 
1.6.1  Introduction
Photodynamic therapy (PDT) is a non-invasive procedure in which a photoactive 
substance (photosensitizer) is activated upon irradiation with light. When the activated 
photosensitizer reacts with molecular oxygen, reactive oxygen species are formed 
which are cytotoxic (ﬁ gure 9). Since the aﬃ  nity of diﬀ erent tissues to accumulate the 
photosensitizer varies, only those that highly accumulate the photosensitizer are 
(selectively) destroyed. In dermatology the topical ‘photosensitizer’ ALA or esteriﬁ ed 
derivatives are used which are precursors of PpIX, an endogenous photosensitizer. 
Various skin diseases have been reported to preferentially accumulate PpIX and thus 
are theoretically suitable for photodynamic treatment. These include various forms of 
NMSC such as, AK, BD and BCC, in which PDT has been studied extensively. Several non-
oncological indications have also been studied, such as psoriasis, common warts and 
acne but the role of PDT in treatment of these lesions is limited compared with NMSC. 
A short summary of the clinical eﬃ  cacy of PDT in these skin diseases is presented in 
paragraph 1.6.4. Because of its high eﬃ  cacy, selectivity and superior cosmetic outcome, 
PDT has been increasingly gaining interest in dermatology over the last few years and is 
now a standard treatment modality in most dermatological clinics. 
1.6.2 Photodynamic damage
1.6.2.1 Introduction
Responses to photodynamic treatment are dependent on the photosensitizer used, 
the illumination conditions, the oxygenation status of the tissue and the type of cells 
involved. The subcellular localization of the photosensitizer is of special importance, since 
it determines the localization of the primary damage. The physicochemical properties 
of the photosensitizer play an important role herein. Close proximity of the sensitizer 
and the target tissue is essential because 1O2 (the principle reactive oxygen species) can 
diﬀ use only 20 nm during its lifetime. Thus, photodynamic damage will preferentially 
occur in those tissues where both high concentrations of the sensitizer and oxygen can be 
found. Once the photodynamic reaction has taken place, a cascade of cellular reactions 
and signaling pathways is initiated, causing histological changes. The light dose and the 
availability of the substrates eventually determine the ﬁ nal histological outcome. In this 
context, the term ‘photodynamic dose’ is commonly used, which is the product between 
the concentration of the photosensitizer in the tissue and the light dose. In the following 
paragraphs more on this can be found. 
1.6.2.2 Subcellular localization of the photosensitizer
As already mentioned above, not only the localization in the tissue but also the 
subcellular localization of the photosensitizer plays an important role in photodynamic 
damage. Intracellular distributions in cultured cells have been determined for a range of 
photosensitizers with widely diﬀ ering structures. The important structural features are (1) 
the net ionic charge, (2) the degree of hydrophobicity and (3) the degree of asymmetry 
present in the molecule.118
Lysosomes have been proposed to be critical intracellular targets for localization of 
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photosensitizers. Several photosensitizers localize in lysosomes and upon illumination 
they can cause cell death via two diﬀ erent routes: via the release of lysosomal enzymes 
in the cytosol, or via relocalization of the photosensitizer after illumination to other, non-
lysosomal targets.119 However, mitochondria have been thought to be the key targets 
for ALA-PDT, since porphyrins (being lipophilic and cationic charged) have shown to be 
eﬀ ective inducers of apoptosis via mitochondrial damage. The mitochondrial localization 
of many lipophilic photosensitizers seems an important factor for the induction of 
rapid apoptosis that does not occur with photosensitizers that localize preferentially in 
lysosomes or the plasma membrane.120
1.6.2.3 Direct cellular toxicity: cell death pathways and genotoxic potential
It has been known for years that cells can respond to photodynamic damage by initiating 
a rescue response and/or by undergoing cell death either in an apoptotic or in a necrotic 
fashion. Some of the eﬀ ector-mechanisms of cell death are activated in both routes. 
The main diﬀ erence is that apoptosis requires several active processes within the cell, 
including signaling, protein modiﬁ cation and cleavage of DNA; in other words: it is an 
ordered process by which a cell that is damaged beyond repair disposes of itself. Necrosis 
is a less controlled way of cell death resulting in cell debris instead of apoptotic cells 
(bodies).3 A third mechanism called ‘the bystander-eﬀ ect’ is also observed after PDT.121 
In this mechanism, cells adjacent to cells that are directly killed by phototoxic eﬀ ects, 
are indirectly killed by intercellular communications or diﬀ usible ROS in the extracellular 
space. To what extent this pathway eventually contributes to the overall PDT eﬀ ects is 
still unclear. 
Photodynamic treatment with photosensitizers that localize in the mitochondria, 
induces cytochrome c release from the mitochondria into the cytosol.122 The release of 
cytochrome c from the mitochondria is an early event in the execution of photosensitized 
apoptosis.122-124 Via activation of caspase 3, by formation of a complex of cytochrome c 
with apoptosis activating factor-1 (APAF-1), dATP and procaspase 9, apoptotic pathways 
are initiated. An alternative apoptotic pathway after PDT has been demonstrated via 
activation of caspase 8. In this pathway, activation of a membrane bound photosensitizer 
leads to activation of CD95/FAS receptor, its ligand and cytochrome c subsequently.125 
Important modulators of apoptosis are members of the bcl-2 family, which consists 
of proteins with anti- and proapoptotic activity. However, the precise roles of these 
proteins in the modulation of PDT-induced apoptosis remain unclear. In addition, PDT 
may also activate cellular signaling pathways that may support or counteract apoptosis, 
cellular proliferation and diﬀ erentiation. These pathways involve the epidermal growth 
factor receptor (EGFR), transcription factor NF-κB and MAPK-pathways. The net eﬀ ects 
on apoptosis by activation of these pathways are highly dependent upon cell-type and 
illumination parameters. For a extensive review on these pathways, the reader is referred 
to an excellent review of Castano et al.126 
Mitochondria are not the only subcellular sites where PDT induced apoptosis may be 
induced. Plasma membrane events and lysosomal processes might be involved as well, 
although their relative contribution remains to be fully elucidated. Lysosomally localized 
photosensitizers are thought to be responsible for cytotoxicity by means of necrosis, 
probably via the direct release of lysosomal contents into the cytosol.119 However, 
it is unclear to what extent this pathway contributes to the net photodynamic eﬀ ect. 
Moreover, necrosis may also be secondarily induced by hypoxia resulting from PDT-
induced vascular damage. Also when apoptotic pathways are blocked by apoptosis-
inhibitors (BAPTA-AM, Forskolin, DSF and Z.VAD.fmk), cells are redirected to necrosis.127
When sublethal photodynamic doses are delivered, cells are not removed via apoptosis 
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but may be repaired. PDT has been shown to increase P21 protein, which is involved 
in regulation of the cell-cycle by preventing progression to the G1-phase resulting in 
growth arrest. Similar eﬀ ects are known to take place after UVR exposition. However, 
there is conﬂ icting evidence whether P53 protein, a major cell-cycle regulating protein, 
plays a role in PDT-induced apoptosis.128-130 In addition, it is unknown whether PDT-
mediated growth arrest is secondary to genotoxic damage, which has been considered 
a common mechanism after UVR exposure. PDT has shown to cause DNA base oxidative 
damage, strand breaks and cross-links in vitro.131 The physicochemical properties 
of the photosensitizer are very important herein, because for genotoxic eﬀ ects the 
photosensitizer must be able to enter the nucleus. Lipophilic photosensitizers, such 
as ALA-induced porphyrins, are not able to enter the nucleus but preferably bind 
the membranes, including the nuclear membrane. Since DNA damage, resulting in 
chromosomal aberrations and mutations has been reported with these photosensitizers, 
it is thought that DNA in proximity of the nuclear membrane would be susceptible to 
PDT-generated damage.132 Moreover, the mutagenic potential varies between cell-lines, 
possibly reﬂ ecting diﬀ erences in repair capacity or damage surveillance mechanisms. 
There was no diﬀ erence in the PDT-induced cytotoxicity levels between normal and DNA 
repair–deﬁ cient ﬁ broblasts, suggesting that nuclear damage is not an important factor of 
PDT-mediated cytotoxicity.133;134 ALA has been reported to have mutagenic eﬀ ects, even 
in the absence of light.135 However, in a photocarcinogenesis study in which nude mice 
were repeatedly treated with ALA-PDT (20% ALA, 70 J/cm2 once weekly for 30 weeks) 
no skin carcinomas were observed. Nude mice that were treated with UVR developed 
multiple skin tumors. When mice were treated with UVR in combination with ALA-PDT a 
delay in tumor development was observed compared with mice that were only treated 
with UVR.136 Thus, repeated ALA-PDT seems to protect against UVR-induced skin tumors 
in nude mice. In contrast, Finlan and colleagues reported oxidative stress-mediated 
8-oxo-7,8-dihydroguanine (8-oxoG) DNA damage in normal skin 24 hours after ALA-
PDT (125 J/cm2). However, contrary to treatment with psoralen UVA, no upregulation of 
the p53-pathway, which is involved in the elimination of genomic damage, was seen. 
Accordingly, the authors pointed at the potential hazard of accumulation of DNA damage 
after PDT.137
Although ALA and (ALA-)PDT seem able to induce DNA damage, the question remains to 
what extent these observations are relevant in vivo. The properties of the photosensitizer 
and photodynamic dose have in vitro been proven to be of great importance because 
they determine where the damage takes place and whether a cell can survive or dies. 
In humans, the host inﬂ ammatory and immune responses also provide an additional 
protection against genotoxic damage being transferred to the daughter cells. Although 
with the current evidence the risk for secondary skin carcinoma after ALA-PDT seems 
low, especially in patients with skin conditions predisposed to skin cancer, for example as 
a result of immunosuppressive medication, more studies must be carried out to evaluate 
the long term carcinogenic risk of ALA-PDT.
1.6.2.4 In ammation and immune responses
PDT may induce stress responses as described previously. Especially at low doses that 
do not induce direct cell death, cell physiology may be altered. Activation of various 
inﬂ ammation and immunologic pathways may enhance the direct phototoxic eﬀ ects 
during PDT, inducing immunogenic and non-immunogenic anti-tumor responses. The 
immunogenic eﬀ ects of PDT really became clear after a study of Korbelik et al. who 
showed that the recurrence rates after PDT in immunocompetent tumor-bearing mice 
were signiﬁ cantly lower compared with immunocompromised (SCID) mice.138 Initial 
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ablation of the tumors with PDT was achieved in both mice but long-term cures were 
only obtained in the immunocompetent mice. However, bone marrow transfer to the 
SCID mice restored the ability of PDT to produce long-term cures, which points at the 
necessity of a functioning immune system to obtain complete long-term anti-tumor 
response to PDT. There are now thought to be two aspects to the eﬀ ect of PDT on the 
immune response against cancer: (1) anti-tumor activity of PDT-induced inﬂ ammatory 
cells and (2) generation of a long-term anti-tumor immune response. For both eﬀ ects 
sublethal photodynamic doses are thought to be suﬃ  cient.
The inﬂ ammatory signaling after PDT initiates a massive regulated invasion of neutrophils, 
mast cells and monocytes/macrophages.139 Anti-cancer immunity elicited by PDT has the 
attributes of an inﬂ ammation primed immune development process and bears similarities 
to the immune reaction induced by tumor inﬂ ammation caused by bacterial vaccines 
or some cytokines. Macrophages phagocytize large numbers of cancer cells killed or 
damaged by the cytotoxic eﬀ ects of PDT. Directed by powerful inﬂ ammation-associated 
signaling, the antigen presenting cells will process tumor-speciﬁ c peptides and present 
them on their membranes in the context of major histocompatibility class II molecules. 
Presentation of tumor peptide antigens, accompanied by intense accessory signals, 
creates conditions for the recognition of tumor antigens by CD4 helper T lymphocytes. 
These lymphocytes become activated and in turn sensitize cytotoxic CD8 T cells to 
Figure 12: PDT mediated tissue responses. 
There are generally three main mechanisms that contribute to the anti-tumor eﬀ ects observed after PDT. Firstly, the ROS 
that are created can directly kill tumor cells by apoptosis and necrosis, but PDT can also damage the tumor-associated 
vasculature resulting in tissue deprivation of oxygen and nutrients and tissue infarction consequently. Finally, PDT is 
able to induce an immune response against the tumor cells. These mechanisms may also inﬂ uence each other and work 
together for an optimum anti-tumor response.140
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tumor-speciﬁ c epitopes. The activity of tumor-sensitized lymphocytes is not limited to 
the original PDT-treated site but can include disseminated and metastatic lesions of the 
same cancer. Thus, although the PDT treatment is localized to the tumor site, its eﬀ ect 
can have systemic attributes due to the induction of an immune reaction.140 
1.6.2.5 Vascular e ects
Microvascular collapse can be observed following PDT and can lead to severe and 
persistent post-PDT tumor hypoxia.141 Endothelial damage may lead to vessel leakage, 
leukocyte adhesion, platelet aggregation and thrombus formation subsequently. PDT 
may also lead to vessel constriction via inhibition of the release of nitric oxide by the 
endothelium.142 Prostaglandins are thought to play an important role herein since non-
steroid anti-inﬂ ammatory drugs (NSAIDs) have been shown to partially or completely 
inhibit these microvascular responses.143 Light dosimetry seems to play an important 
role in PDT-induced tissue damage via these vascular eﬀ ects, e.g. premature shutdown 
of the oxygen supplying vasculature will result in suboptimal PDT. More on this can be 
found in the next paragraph.
1.6.2.6 In uence of the photodynamic dose and irradiation parameters on the
 photodynamic e ects 
It is not exactly known to what extent the three mechanisms in ﬁ gure 12 contribute 
individually to the anti-tumor eﬀ ects of PDT. However, for optimal cytotoxic eﬀ ects 
suﬃ  cient amounts of photosensitizer and light are required at the target site. When 
cytotoxicity is not the primary goal but rather modulation of the immune system 
is preferred, massive necrosis and tumor destruction must be prevented. In the 
photodynamic treatment of inﬂ ammatory skin disorders, these immunomodulatory 
eﬀ ects in particular are thought to be responsible for the clinical eﬃ  cacy observed 
after PDT.144 This may be achieved by lowering of the photodynamic dose, but the cell 
type and state and local oxygen availability may also prompt cells to speciﬁ c response 
patterns. During PDT the photosensitizer and oxygen concentrations decline with 
increasing illumination time and due to vascular responses the oxygen concentration 
may decline furthermore. Therefore, light dosimetry may have critical eﬀ ects on the net 
photodynamic eﬀ ect. For instance, a total light dose of 37 J/cm2 delivered at diﬀ erent 
ﬂ uence-rates may result in diﬀ erent photodynamic eﬀ ects. At low ﬂ uence-rates less 
ROS are formed per unit time (in abundance of oxygen), which lowers the risk of the 
tumor supplying vasculature to be shut down prematurely, thus preventing premature 
hypoxia of the target tissue that will impede the photodynamic reaction. Consecutively, 
a suﬃ  cient amount of oxygen will be available at the target site for photodynamic killing. 
Analogously, high ﬂ uence-rates may lead to premature depletion of oxygen resulting in 
suboptimal PDT. Also at high ﬂ uence-rates skin temperature may rise, increasing the risk 
of non-speciﬁ c thermal eﬀ ects on the skin and necrosis accordingly.145 Several studies 
have compared the photodynamic eﬀ ects using various ﬂ uence-rates. 
Robinson et al. were the ﬁ rst to demonstrate an increase in the PDT-induced damage 
with decreasing ﬂ uence-rate. They reported that reducing the ﬂ uence rate from 150 to 
50 mW/cm2 resulted in a signiﬁ cant increase in the visual skin damage score following 
PDT of normal and ultraviolet-B-induced tumors in hairless mouse skin.146 Similar ﬁ ndings 
were reported by Bissonnette et al. who studied the inﬂ uence of ﬂ uence and ﬂ uence-
rate on murine skin with respect to the histopathological changes.147 They reported 
epidermal photodamage to be more pronounced and deeper in the skin at low ﬂ uence-
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rates and high ﬂ uences. In a study of Ericson et al. photobleaching of PpIX was measured 
during the photodynamic treatment of AKs in humans, using various ﬂ uence-rates (30-
75 mW/cm2).148 At low ﬂ uence-rates, a lower ﬂ uence was required to bleach the same 
amount of PpIX compared with higher ﬂ uence-rates, indicative for increased oxygen 
depletion at high ﬂ uence-rates, since photobleaching is an oxygen dependent process. 
This was conﬁ rmed by Busch et al. who performed actual measurements of the intra-
lesional partial oxygen pressure (pO2) and reported signiﬁ cantly higher pO2 values at 30 
mW/cm2 compared with 75 and 150 mW/cm2 after a standardized ﬂ uence.149 Compared 
to oxygen-favoring low ﬂ uence-rate treatment regimens, the induction of hypoxia 
during high ﬂ uence rate PDT is associated with poorer tumor response, characterized by 
fewer tumor cures and a shorter time to tumor regrowth.150-152 Both decreases in direct 
tumor cytotoxicity and a failure to sustain reductions in the perfusion of tumor-adjacent 
vasculature have been identiﬁ ed as causes of poor treatment eﬃ  cacy at high ﬂ uence 
rate; however, the vascular component of this response overwhelmingly dominated 
long-term outcome. This was demonstrated through administration of a nitric oxide 
inhibitor immediately after PDT, which led to inhibition of post-illumination reperfusion 
in the treatment ﬁ eld and corresponding improvements in response.153 
Another interesting way to enhance the PDT-induced damage has been reported by 
subdivision of the total ﬂ uence into two illuminations (fractionated illumination) separated 
by a period in which no light is delivered (dark-interval).154 Since the photobleaching rate 
decays during the illumination, the majority of the available photosensitizer in the tissue 
will be consumed at the beginning of the illumination. For example when 100 J/cm2 is 
delivered, the photodynamic dose will be higher in the ﬁ rst 50 J/cm2 compared with 
the second half of the illumination. By inserting a dark-interval, of 2 hours for example, 
between the two illuminations, resynthesis of porphyrins will occur in this period 
resulting in a higher porphyrin concentration at the beginning of the second illumination 
and a higher photodynamic dose accordingly. Shorter dark-intervals (multiple intervals 
of minutes to seconds) have been reported to allow reoxygenation to take place, also 
resulting in increased PDT-induced damage.155 Moroever, light fractionation has not only 
been reported to induce more but also deeper phototoxic damage. Several fractionation 
schemes have been studied by Robinson and colleagues.102;156 A two-fold illumination 
scheme of 5 + 95 J/cm2 (2h dark-interval) at 50 mW/cm2 proved to be signiﬁ cantly more 
eﬀ ective in the induction of visual skin damage compared with 50 + 50 J/cm2. Reducing 
the ﬂ uence in the second fraction to 45 J/cm2 and the ﬂ uence-rate of the ﬁ rst fraction 
to 5 mW/cm2, resulted in less PDT-induced damage. These pre-clinical data were later 
conﬁ rmed in the treatment of BCC with ALA-PDT (4h ALA) comparing a single illumination 
of 75 J/cm2 with a two-fold illumination scheme consisting of 20 + 80 J/cm2 (2h dark-
interval).157 In this study, a signiﬁ cantly higher complete response rate immediately after 
treatment and at 1 year was found in favor of the fractionated illumination. Thus, at the 
cost of a longer total treatment time, fractionated illumination is able to improve the 
clinical outcome of ALA-PDT in BCC and possibly other indications as well. Interestingly, 
the same group performed a similar pre-clinical study in mice using MAL-PDT in 
which they found no signiﬁ cant diﬀ erences in visual skin damage between a two-fold 
illumination scheme of 5 + 95 J/cm2 (50 mW/cm2) compared with a single illumination 
of 100 J/cm2 (50 mW/cm2).158 However, the photobleaching rates between ALA and MAL 
did not signiﬁ cantly diﬀ er, indicative for comparable amounts of singlet oxygen that 
have been produced. The authors hypothesized this to be related to diﬀ erences in the 
biodistribution within the epidermis of MAL compared with ALA. 
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1.6.2.7 Clinical aspects of ALA-PDT 
Already a few seconds after the illumination has started, patients may notice a prickling 
sensation at the treatment site which may become more intense during the treatment, 
sometimes becoming so severe that the treatment needs to be discontinued. When the 
illumination is stopped the pain rapidly subsides from a sharp, burning pain to a more 
dull pain of an inﬂ ammatory process. The sharp pain during illumination is thought to be 
of neurogenic origin as a result of intense nerve stimulation by ROS and hyperthermia 
or uptake of ALA by the peripheral nerve endings.98;159 The dull pain after PDT is thought 
to be caused by the release of inﬂ ammatory mediators.160 Pain during the treatment is 
the predominant and sometimes limiting side eﬀ ect but varies largely between patients. 
Lesion characteristics such as size and localization, irradiation parameters and the 
choice of the photosensitizer have been reported to inﬂ uence pain perception during 
PDT. Increased pain perception was reported in larger lesions and lesions located on the 
head.161 Green light was found to be less painful but equally eﬀ ective in the treatment 
of AKs, but not BD, compared with red light.162;163 In an increasing number of clinical 
reports, MAL-PDT is found to be less painful compared with ALA-PDT, probably due to 
its increased selectivity.92;164 Pain during and after PDT can be treated by local anesthesia 
(ﬁ eld-block, nerve block), oral or topical analgesics and cooling. However, despite these 
measures, pain can be so severe that the treatment must be discontinued.157;165 
Apart from pain, erythema, edema and crusting are commonly seen after and 
during PDT, which mostly resolve after a couple of weeks.166 Sometimes, temporary 
hyperpigmentation occurs in the treatment area.167 Scarring and ulceration are very rare 
at therapeutical doses. However, hyperthermic injury as a result from high ﬂ uence-rates 
has been thought to increase the risk of scarring. Long-lasting photosensitivity doesn’t 
seem to be a great problem with topical ALA because within 48 hours all porphyrins are 
cleared from the body and systemic eﬀ ects are not regarded relevant.94;166   
 
1.6.2.8 Histological changes after ALA-PDT
Microscopically and biochemically detectable changes of cellular and organelle 
membranes can be observed as early events occurring after PDT.168 The formation 
of blebs, multiple balloon-like structures protruding from the plasmatic membrane, 
followed by the cessation of cell division and cell lysis, occurs within hours after PDT.8 
However, the ﬁ nal histological features observed after PDT are dependent on localization 
of the photosensitizer and the photodynamic dose. As already mentioned, apoptosis 
and necrosis are frequently seen after PDT. Apoptosis after PDT can histologically be 
detected by the formation of ‘apoptotic cell bodies’, which have a typical condensed 
nucleus and an enlarged eosinophilic cytoplasm, sometimes with vacuolization.137;169 This 
has been conﬁ rmed by the TUNEL -staining, which is a more speciﬁ c method to detect 
apoptosis.169 Necrosis results in cell debris and the immune and inﬂ ammatory responses 
are histologically characterized by inﬁ ltration of the skin by inﬂ ammatory cells, generally 
neutrophils in the acute phase and lymphocytes after a couple of days.169 Vascular injury 
manifests histologically as thrombosis or/and vasculitis.25 Although scarring is not a 
common feature of PDT, dermal ﬁ brosis after PDT of sBCC and SCC has been reported 
by Fink-Puches and colleagues, but this could probably be related to their unusual 
treatment protocol.29 Inﬂ ux of melanocytes one week after PDT has been reported by 
Monfrecola et al., explaining the hyperpigmentation often seen after PDT.167    
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1.6.3 Light sources, which one to use?
In the literature numerous light sources for PDT have been described by diﬀ erent authors. 
In the early days of PDT, custom-built light sources were used because simply no speciﬁ c 
light sources were available at that time. In the key study ﬁ rstly describing the use of 
topical ALA by Kennedy et al., a slide-projector equipped with special ﬁ lters was used to 
treat BCC.7 As the use of PDT became more widespread, specialized light sources became 
available. An adequate light source for PDT should meet to the following criteria: 
The light must be able to penetrate the skin deep enough and1. 
must be able to activate the photosensitizer. In other words the emission spectrum 2. 
of the light source should match the absorption spectrum of the photosensitizer.
Preferably, the light source must also have a large irradiation ﬁ eld, with a constant 
ﬂ uence-rate over the illumination area, which is high enough, so that multiple lesions 
can be treated at once in a limited amount of time.
Coherent (Light Ampliﬁ cation by Stimulated Emission of Radiation) as well as incoherent 
light sources (such as metal halide, Intense Pulsed Light and Light Emitting Diodes light 
sources) can be used for PDT, just as long as the above criteria are fulﬁ lled. However, 
light dosimetry must be adjusted according to the individual spectral properties when 
switching between the diﬀ erent light sources. A broadband metal halide light source, 
such as the PDT 1200 L (Waldmann Medische Techniek B.V., Tiel, The Netherlands) emits 
wavelengths ranging from 600-750 nm. A narrowband light source, such as the Omnilux® 
Red (Waldmann), has a much smaller range (633+/-3 nm). When a ﬂ uence of 100 J/cm2 
is delivered at a given ﬂ uence-rate, more energy is delivered to PpIX by the narrowband 
light source. For that reason, the concept of ‘total eﬀ ective ﬂ uence’ was introduced, as 
proposed by H. Moseley, which enables physicians to calculate equivalent light doses 
between diﬀ erent light sources, based on the spectral properties.170 Consequently, 
diﬀ erent light sources can be compared. However, for an optimal comparison of the 
clinical studies on PDT, in which a variety of diﬀ erent light sources is used, standardization 
of the illumination parameters is preferred. 
Nowadays, narrowband LED devices are increasingly used because of their large and 
homogenous illumination ﬁ eld, constant irradiance over time and ﬂ exibility compared 
with metal halide light sources. In addition, because of the narrow emission spectra only 
the relevant wavelengths are delivered into the skin activating only the photosensitizer, 
without potential side eﬀ ects as a result from non-speciﬁ c activation of other 
chromophores in the skin. These light sources are believed to dominate all other light 
sources on the market, shortly.  
1.6.4 Clinical evidence for the use of topical PDT
Before Metvix® became widely available in Europe, most clinical studies were 
performed using a non-standardized treatment protocol. Because of the variations in 
the pre-treatment procedure, incubation time and formulation of the photosensitizer, 
illumination parameters and follow-up period, comparisons between the studies are 
somewhat hindered. In the following two paragraphs a concise overview of the current 
clinical recommendations on the use of topical PDT in dermatology is given, based on 
the available literature.
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1.6.4.1 PDT in the treatment of non-melanoma skin cancers
Recently, an extensive review including clinical guidelines based on an international 
consensus on the use of PDT for NMSC was published by the International society for 
PDT in dermatology (I-PDT).171 Their recommendations are brieﬂ y summarized in table 2.
Table 2: Recommendations for the treatment of NMSC with PDT: An international consensus.*
Indication Score Summary of recommendations
Actinic keratosis A, I PDT is a highly eff ective treatment for AK, off ering the advantage of 
excellent cosmetic outcome, and should therefore be considered as a 
fi rst-line therapy. 
A, I MAL-PDT has a superior cosmetic outcome compared with 
cryotherapy.
Bowen’s disease A, I Topical PDT is eff ective in BD, achieving good cosmesis, and is at least 
as eff ective as cryotherapy or 5-FU, but with fewer adverse events. 
Topical PDT should be considered as a fi rst-line therapy for BD.
Basal cell carcinoma A, I PDT is an eff ective and reliable treatment option for sBCC that off ers 
excellent cosmetic outcomes.
A, I PDT off ers an advantage in the treatment of large, extensive and 
multiple lesions.
A, I MAL-PDT has demonstrated long-term eﬃ  cacy in nBCC as well as 
sBCC, with 5-year follow-up data.
A, I MAL-PDT is an eff ective and reliable treatment option for nBCC less 
than 2 mm depth with the advantage of good cosmetic outcome.
Squamous cell carcinoma C, II-iii There is insuﬃ  cient evidence to support the routine use of topical 
PDT for SCC.
Cancer prevention B, I PDT may be considered as a means of preventing AK in 
immunosuppressed transplant patients.
C, III PDT may be considered as a means of preventing SCC in 
immunosuppressed patients.
C, II-iii PDT may be considered as a means of preventing BCC in 
immunosuppressed patients.
Scoring system for strength of recommendations and quality of evidence:
A-E: There is A:good / B:fair / C:poor evidence to support the use of the procedure.There is D:fair / E:good evidence to support the rejection of the procedure.
I Evidence obtained from at least one properly designed, randomized controlled trial.
II-i Evidence obtained from well-designed controlled trials without randomization.
II-ii Evidence obtained from well-designed cohort or case-control analytical studies, preferably from more than one center or research group.
II-iii Evidence obtained from multiple time series with or without the intervention. Dramatic results in uncontrolled experiments could also be regarded as this type of evidence.
III Opinions of respected authorities based on clinical experience, descriptive studies or reports of expert committees.
IV Evidence inadequate due to problems of methodology.
* Braathen LR, Szeimies RM, Basset-Seguin N et al. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international 
consensus. International Society for Photodynamic Therapy in Dermatology, 2005. J.Am.Acad.Dermatol. 2007; 56: 125-43.
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1.6.4.2 PDT for other indications
Although PDT is currently not approved for the treatment of other indications than 
AK, BD and BCC, several clinical studies have been performed in various other skin 
diseases. Theoretically, PDT may be clinically eﬀ ective in every skin disease in which 
PpIX ﬂ uorescence can be observed. The pathogenesis of the skin disease in combination 
with the site where the photodynamic reaction takes place, will eventually determine 
the clinical response. Generally spoken, in inﬂ ammatory skin diseases, modulation of the 
immune system, but not cytotoxicity, is thought to be the primary goal. Massive necrosis 
must therefore be prevented. These immunomodulatory eﬀ ects in particular are thought 
to be responsible for the clinical eﬃ  cacy observed after PDT.144 This can be achieved by 
delivering a relatively low photodynamic dose over a longer period of time. In table 3 a 
summary of the available clinical experience on PDT for non-oncological skin diseases 
together with clinical recommendations, is presented. A more extensive overview on the 
treatment of psoriasis with PDT can be found further on.      
Table 3: Other indications for PDT.
Indication Studies Clinical experience and recommendations
Acne inversa 172;173
Although clinical improvement has been reported in some 
patients, due to the limited penetration into the skin, the role of 
PDT in treatment of inverse acne seems limited.  
Acne vulgaris 172;174-185
Promising clinical results have been achieved in infl ammatory 
acne in particular. Multiple treatments are needed for optimal 
results. Side eff ects can be severe.   
Alopecia areata 186;187 Due to disappointing clinical eﬃ  cacy, PDT for the treatment of alopecia areata is not recommended.  
Condylomata acuminata 188-193 Although genital warts may respond well to PDT, adequate delivery of light seems problematic. 
Cutaneous leishmaniasis 194-198 PDT may be a good alternative when conventional treatments have failed. 
Cutaneous T cell 
lymphomas
199-206
Various small studies have reported clinical as well as histological 
improvement. However, the optimal regimen needs to be 
established.
Darier’s disease 207 Clinical improvement observed in a study of 6 patients. Based on the limited data no general recommendations can be given.  
Epidermodysplasia 
verruciformis
208
Clinical improvement was observed in a case-study. However, 
based on the limited data no general recommendations can be 
given.  
Granulomatous skin 
diseases
209;210
Case-studies in necrobiosis lipoidica and cutaneous sarcoidosis 
have reported clinical improvement after multiple PDT sessions. 
Based on the limited data no general recommendations can be 
given.  
Hypertrichosis 211 Due to disappointing clinical eﬃ  cacy, PDT for the treatment of hypertrichosis is not recommended.  
Keloids 144;212 Due to disappointing clinical eﬃ  cacy, monotherapy with PDT for the treatment of keloids is not recommended.
Lichen ruber planus 213;214 PDT may be benefi cial in oral lichen planus in particular. Based on the limited data no general recommendations can be given. 
Lichen sclerosis 215 Clinical improvement has been observed. However, based on the limited data no general recommendations can be given.
Malignant melanoma 26
Although in vitro and in mice melanoma cells have been proven 
sensitive to photodynamic treatment, PDT in humans is not 
recommended due to the disappointing clinical eﬃ  cacy of this 
highly malignant tumor. 
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Morphea 216-218
Promising clinical results have been achieved. When PUVA 
therapy is contraindicated or has failed, PDT may be an 
alternative. However, based on the limited data no general 
recommendations can be given.   
Mycobacterial infections 219
Clinical improvement has been observed in a case-study. 
However, based on the limited data no general recommendations 
can be given.  
Neavus sebaceous 220 Due to disappointing clinical eﬃ  cacy, PDT for the treatment of n. sebaceous is not recommended.  
Photoageing 221-225
Although clinical improvement has been reported in various 
studies, no long-term (safety) data are present which need to be 
considered when treating cosmetic indications. 
Pseudo-lymphomas 226;227 Clinical improvement has been observed in 3 patients. Based on the limited data no general recommendations can be given.  
Psoriasis 44;93;228-236
Although clinical improvement has been reported by various 
authors, based on the variable clinical eﬃ  cacy together with the 
relatively severe side-eff ects, PDT using the studied treatment 
protocols, is not recommended as a fi rst-line treatment for 
psoriasis. 
Rosacea 237
Clinical improvement has been observed in 3 out of 4 patients. 
However, based on these data no general recommendations can 
be given.  
Sebaceous gland 
hyperplasia
238;239 Promising clinical results have been achieved. However, based on the limited data no general recommendations can be given.  
Verrucae planae 240
Clinical improvement was observed in a case-study. However, 
based on the limited data no general recommendations can be 
given.  
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 1.7 Actinic Keratoses
1.7.1 Introduction and epidemiology
The words actinic keratosis (keratosis actinica) literally mean: lesions with increased 
keratinization caused by light. In 1869 Isidor Neumann ﬁ rst described changes in 
the ageing skin, which were later referred to as ‘keratoma senile’ or ‘keratosis senilis’ 
by Dubreuilh and Freudenthal. It was Dubreuilh who integrated these lesions into his 
concept of precancerous lesions.244 Because they are caused by sunlight, Pinkus renamed 
these lesions to solar or actinic keratosis. 
AKs are especially seen in elderly, fair-skinned Caucasians with a typical history of 
signiﬁ cant sun exposure.245 It is recognized by some as being the most common in situ 
cancerous lesion. The global prevalence of these lesions varies strongly. In Western-
Europe, Wales, a prevalence of 23% has been reported but in Queensland, Australia, AK 
is very common with a prevalence of 60% in individuals over age 40.246;247 In contrast, in 
black individuals AKs are seldom seen. In speciﬁ c populations, such as patients taking 
immunosuppressive drugs, AKs are more prevalent compared with immunocompetent 
individuals.         
1.7.2 Clinical aspects and risk of malignant transformation
Clinically, AKs appear in a variety of forms depending on the histological subtype or stage 
they are in. In general they are hyperkeratotic lesions arising on the sun-exposed areas. 
They often start as erythematous macules, which become rough with minimal scaling 
(keratosis). As they progress, they can become hyperkeratotic and indurated, sometimes 
on an erythematous base. AKs, if left untreated, may evolve to SCC. Several risk factors 
have been identiﬁ ed for this, which are discussed further on. The likelihood of a fully 
developed SCC evolving from a given AK varies depending on the number of risk factors 
present and has been estimated to occur at a rate of 0.075-0.096% per lesion per year, 
up to values of even 20% per lesion per year.248;249 Generally this means that 1-10% of AK 
will develop into SCC over a 10-year period.250;251 From these data it was also estimated 
that as many as 26.9% of AKs may undergo spontaneous regression. In another study, a 
spontaneous regression rate of 21% over a 12-month period was reported.247    
So far there are no parameters available that predict which speciﬁ c actinic keratosis 
will progress to SCC and which AK will regress spontaneously, but lesions clinically 
characterized by induration, pain and ulceration are at particular risk, especially in 
immunocompromised patients. Over the last years, the relationship between AK and 
SCC has been a topic for much debate in literature, as AK is believed not to be separate 
entity but a SCC in situ.252;253   
1.7.3 Histopathology
Histologically, AK is characterized by the presence of atypical keratinocytes at the 
basal cell layer of the epidermis, which in advanced lesions may extend into the entire 
epidermis. The epidermal keratinocytes of the acrosyringia and acrotrichia are spared 
and show a normal appearance and keratinization, reﬂ ecting a normal orthokeratotic 
corniﬁ ed layer. There are often small round buds at the basal layer which protrude into 
the papillary dermis. The maturation of the keratinocytes in the epidermis is defective 
resulting in parakeratosis alternating with hyperkeratosis. Acantholysis with subrabasal 
clefts may be seen. AK can be divided into the following histological types: hypertrophic, 
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atrophic, Bowenoid, acantholytic, lichenoid and proliferative. AK almost always has solar 
elastosis in the dermis and often shows an inﬁ ltrate of lymphocytes and plasma cells.254
A SCC of the skin is a malignant neoplasm of epidermal keratinocytes. The thickened 
surface of the epidermis shows conﬂ uent parakeratosis and compact orthokeratosis. 
There is a loss of orderly maturation with atypical keratinocytes throughout the full 
thickness of the epidermis. The atypical keratinocytes have eosinophilic and sometimes 
pale or vacuolated, cytoplasm (a sign of faulty corniﬁ cation) as well as whorls of 
parakeratosis within aggregations of neoplastic cells (horn pearls). There is an increased 
number of atypical mitotic and dyskeratotic, or necrotic keratinocytes throughout the 
epidermis. The nuclei of the atypical keratinocytes are crowded, pleomorphic and often 
large and hyperchromatic.
The histological and cytopathological changes seen in the individual cells of AK and 
invasive SCC are identical and not indistinguishable from one another. Both show atypical 
keratinocytes with loss of polarity, nuclear pleomorphism, disordered maturation and 
increased numbers of mitotic ﬁ gures; many of them atypical and pleomorphic.255 It is not 
possible to tell where AK ends and SCC begins; for these reasons AK is viewed as an early 
in situ SCC.
 Figure 13: Clinical appearance (A) and histopathology (B) of AK and SCC.
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1.7.4  Pathogenesis
1.7.4.1 General aspects of carcinogenesis
In general oncology, three steps have been identiﬁ ed in the progression from a normal 
cell to a malignant cell, these include: (1) initiation, (2) promotion and (3) conversion. In 
the progression from AK to SCC, these steps are also applicable.249
Initiation is the process of the induction of DNA damage by a carcinogen, eventually 
leading to genomic mutations. These mutations may aﬀ ect the tumor suppressor genes, 
which code for transcription factors. Transcription factors are proteins involved in the 
regulation of the cell-cycle, which are activated upon stress or DNA damage. Often DNA 
damage will cause the presence of free-ﬂ oating genetic material as well as other signs, 
and will trigger enzymes and pathways, which lead to the activation of tumor suppressor 
genes. The functions of such genes are to arrest the progression of cell-cycle (G1-arrest) 
in order to carry out DNA repair, preventing mutations from passing on to daughter 
cells. However, a mutation can damage the tumor suppressor gene itself, or the signal 
pathway which activates it, “switching it oﬀ ”. The invariable consequence of this is that 
DNA repair is hindered or inhibited, allowing DNA damage to accumulate, increasing the 
risk of cancer consequently. Genomic mutations may also aﬀ ect proto-oncogenes, which 
are genes involved in the proliferation of cells. These genes code for proteins involved 
in the signal-transduction pathways of cell growth. When these genes are damaged, 
uncontrollable cell growth may occur, stimulating carcinogenesis. These mutated proto-
oncogenes are called oncogenes. Well-known proto-oncogenes are the: ras, fos and myc 
families. Although mutations in these proto-oncogenes have been increasingly found in 
NMSC, their exact roles in cutaneous carcinogenesis remain to be elucidated. However, 
initiated cells do not necessarily have to continue in the carcinogenic process and may 
live on without becoming malignant. With respect to the skin, at this stage no clinical 
signs can be seen.  
Since initiation per se does not automatically lead to cancer, a promotor must be applied 
after an initiator to fulﬁ ll its carcinogenic eﬀ ect. Promotion is the process of creating an 
environment that facilitates the initiated cells to progress in carcinogenesis by enabling 
them to expand clonally. For example, DNA damage in one allele of the p53 tumor 
suppressor gene does not lead to cancer, but when the second allele is also damaged 
cellular p53 function is impaired, increasing the risk of cancer. This is also known as the 
‘multi-hit model’ in carcinogenesis.256 Clinically, a premalignant tumor can be seen at this 
stage.
After continuous promotion of the initiated cells, the premalignant lesion may be 
converted to a malignancy with metastatic potential by a process called conversion. 
Some carcinogens, such as UVR, are involved in the process of promotion and initiation 
as well and are therefore called ‘complete carcinogens’. 
1.7.4.2 UVR induced carcinogenesis and P53, the guardian of the genome
Although proto-oncogenes are also believed to be involved in cutaneous carcinogenesis, 
their precise role remains to be elucidated.257 The activation of oncogenes is not 
supposed to be an early event in cutaneous carcinogenesis but that they rather may play 
a role in the conversion of a premalignant lesion to a rapidly growing malignant tumor. 
However, the tumor suppressor gene p53 is generally believed to play a prominent role 
in the pathogenesis of AK and SCC.   
The p53 gene is located on the short arm of chromosome 17 (17p13). Its gene product, 
P53 protein, is involved in regulation of the cell-cycle by interference with cell-cycle 
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regulating proteins (cyclin-dependent kinases, CdK) and the induction of apoptosis. 
When DNA damage is induced, P53 is able to shut down the cell-cycle (G0/G1-arrest) 
so that the damage can be repaired by the induction of DNA repair enzymes. When 
cells are heavily damaged and are beyond repair, P53 is able to eliminate these cells by 
means of apoptosis. In this way P53 acts as a guardian of the genome. When the p53 
gene is damaged by itself, it may not be able to fulﬁ ll its protective role, resulting in the 
accumulation of genomic damage, stimulating carcinogenesis.245 As p53 is a recessive 
gene, both alleles need to be aﬀ ected to cause malfunction of the p53-pathway. 
This process is also called ‘loss of heterozygosity’ (LOH), which is common event in 
carcinogenesis. 
UVR is regarded to be the most important carcinogen in NMSC. UVR is a complete 
carcinogen and may cause direct and indirect genomic damage. UVB (290-320 nm) can 
cause C⇒T and CC⇒TT transitions at dipyrimidine sites. These characteristic mutations 
are also called ‘UV signature mutations’. Indirect genomic damage is mainly caused by UVA 
(320-400 nm) by the formation of ROS.258 In addition, UVR also has immunosuppressive 
eﬀ ects by reducing the number and function of epidermal Langerhans cells. It 
is also capable of stimulating leucocytes to release immunosuppressive soluble 
mediators that aﬀ ect antigen presentation, including interleukin-10, which enter the 
circulation and thereby also induce systemic immunosuppression. Another important 
immunomodulatory eﬀ ect of UVR is the induction of regulatory T cells that appear to 
play a role in UV-induced tolerance.259 Increased numbers of UV signature mutations in 
both p53 alleles have been found in SCC as well as AK, indicating a prominent role of UVR 
in the (early) induction of these forms of skin cancer.260 
Taken together, UVR plays an important role in the formation of squamous skin cancers by 
direct mutagenic eﬀ ects p53 (initiation), which are promoted by its immunosuppressive 
eﬀ ects (promotion). 
1.7.4.3 Other carcinogens
Apart from UVR, various other carcinogens have been identiﬁ ed which are known to play 
a role in the development of skin cancer.
1.7.4.3.1 Chemicals
Several chemicals have been identiﬁ ed as promotors, initiators or complete carcinogens. 
Generally, cancer induction by chemicals is dose dependent. 
A well-known chemical carcinogen is arsenic. In the past, arsenic has been used in 
medicine for the treatment of numerous diseases, including psoriasis, but has also 
been reported as a contaminant in drinking water. Chronic exposure to arsenic has 
been associated with an increased risk of numerous forms of cancer including BD, BCC 
and SCC. Arsenic is thought to be a cocarcinogen or promotor, which enhances the 
carcinogenic eﬀ ects of UVR. Increased amounts of p53 mutations, not bearing the UV-
signature, have been found in arsenic induced skin cancers, but the precise linkage 
between p53 mutations and arsenic exposure is not clear. Both in vitro and in vivo studies 
in which induction of BD by arsenic was studied, indicated that arsenic exposure was 
associated with G2/M cell-cycle arrest and DNA aneuploidy. These cellular abnormalities 
may associate with p53 dysfunction induced by arsenic. Non-toxic doses of arsenic have 
also been reported to increase UVB-induced apoptosis. Finally, chronic arsenic exposure 
has been associated with dysfunction of the immune system.261
Other well-known skin carcinogens are: nitrosamines (tobacco), alkylating agents 
(chemotherapeutic drugs) and polycyclic aromatic hydrocarbons (tar).
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1.7.4.3.2 Viruses
The carcinogenic potential of viruses has been discovered over the last few years, 
Generally, two groups of viruses have been associated with cutaneous carcinogenesis: (1) 
the human papillomaviruses (HPV), which are associated with viral warts and cutaneous 
squamous cancers, and (2) retroviruses, such as the human T cell lymphotropic virus 
group, which are associated with cutaneous lymphomas.262 The cutaneous HPVs are 
subdivided into the classical types associated with warts and the epidermodyplasia 
verruciformis types, which have been renamed as β-papillomaviruses. HPVs have been 
thought to be cocarcinogenic.263 The early viral protein E6 of some β-papillomaviruses 
may impair the process of DNA repair or prevent apoptosis after exposure to UVR.264 In 
this way, DNA damage may accumulate in the skin increasing the risk of skin cancer.
1.7.4.3.3 Immunosuppressive drugs
The increased prevalence of skin cancer in immunosuppressive patients has been thought 
to be mainly caused by a decreased ability of the immune system to eliminate genomically 
damaged cells, given the fact that skin cancers stimulate the immune system. However, 
over last few years it has become clear that certain immunosuppressive drugs, such as 
azathioprine, can also cause direct genomic damage by photosensitization of DNA to 
UVA radiation or by interfering with DNA repair.265;266 In addition, immunosuppressive 
drugs may also impair the host resistance to HPV, promoting its carcinogenic eﬀ ects 
consequently.  
Figure 14: Events involved in cutaneous carcinogenesis.
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1.7.4.4 Progression from AK to invasive SCC: a matter of semantics…
Historically, many dermatologists agreed that AK should be considered a precancerous 
lesion. Over the years, increasing evidence has become available to support the view 
that AK and SCC are one and the same entity and that AK should be considered SCC 
in situ.267 To emphasize this, other authors have used terms as ‘superﬁ cial’ or ‘incipient’ 
SCC, when referring to AK.253;268 Many studies are suggestive of the close relationship 
of AK to invasive SCC. Speciﬁ cally, an overwhelming majority of invasive SCCs appear 
to be associated with contiguous AKs (about 90%).269 Hurwitz and Monger found that 
97% of the 459 cutaneous SCCs that they studied occurred next to an AK.270 Among the 
165 cutaneous SCC cases studied by Mittelbronn et al., 136 (82.4%) had concomitant 
AKs (deﬁ ned as AKs within an 8-mm radius of the SCC), and 13 SCC lesions (7.9%) had 
concomitant SCC in situ.271 Takemiya et al. reported that 31 (58.5%) of 53 SCC patients 
had an AK in the same histological section.272 Günthner et al. reviewed 1101 SCCs to ﬁ nd 
that 983 (97.2%) had changes consistent with “SCC in situ” at the periphery or within the 
conﬁ nes of the SCC.273 They proposed that this was an underestimate due to inadequate 
margins of removal and proposed that with suﬃ  cient margins, all SCC would be found to 
have SCC in situ at their margins or within them. In literature, confusion exists regarding 
the terminology and deﬁ nitions used for AK and SCC. These semantic diﬀ erences 
complicate the analysis of the progression of AK to invasive SCC. 
The fact that increased numbers of UV signature mutations in both p53 alleles have been 
demonstrated in SCC (over 90%) as well as AK, does not only indicate a prominent role 
of UVR in the (early) induction of these forms of skin cancer, but that these lesions share 
common pathogenetic pathways.260 The relatively high percentage of LOH observed in 
AKs compared with SCC could also be interpreted to emphasize the malignant potential 
of AKs.274 
1.7.4.5 Aneuploidy
1.7.4.5.1 Introduction
Aneuploidy can be seen as the result of genetic deletions and ampliﬁ cations leading to 
chromosomal aberrations and thus an abnormal DNA-content. It has been suggested 
that aneuploidy represents the most common malignancy-speciﬁ c cell marker with 
several aspects correlating with malignancy-grade, tumor stage and prognosis.275 In 
NMSC the presence of aneuploidy has been described by various authors, with reported 
aneuploidy frequencies varying from 40-69% for AK, 94-100% for BD, 58% for SCC and 
48% for keratoacanthoma.275-278 However, its precise role in skin cancer remains obscure. 
In chapter 4, the role of aneuploidy as a potential progression marker in various stages of 
AK is investigated. 
1.7.4.5.2 Types of aneuploidy
Cells with less than a diploid chromosome content are referred to as having hypodiploid 
aneuploidy. Cells with more than a diploid but less than a tetraploid complement of 
chromosomes are referred to as having hyperdiploid aneuploidy. When DNA content is 
measured with DNA cytometry, the degree of aneuploidy can be expressed by means of 
the DNA index (DI), which is deﬁ ned as the ratio between the DNA content in the G1-phase 
of the aneuploid and the diploid cells. Consequently, a diploid tumor has a DI of 1 and a 
tetraploid tumor, having twice as much chromosomes, a DI of 2. To describe DI’s outside 
these values, terms like near-diploidy (0.90<DI<1.10), hyperdiploidy (1.11<DI1.40), 
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hypotetraploidy (1.41<DI<1.80), near-tetraploidy (1.81<DI<2.20) and hypertetraploidy 
(DI>2.21) are used.279 The concept of DI is further clariﬁ ed in paragraph 4.1.   
1.7.4.5.3 Aneuploidy in cancer: a driving force or a remnant?
About one hundred years ago, it was Theodor Boveri who reported the events occurring 
after unequal segregation of chromosomes during the ﬁ rst mitotic divisions of fertilized 
sea urchin eggs. Furthermore, he postulated that misdistribution of chromosomes 
might be a cause of tumor development and birth defects. Later it appeared that 
most solid tumor cells are aneuploid and various cancer cell lines show ‘chromosomal 
instability’ (CIN), meaning that they frequently lose and gain whole chromosomes during 
divisions.280 Besides this, these tumors also appeared to have acquired a number of 
mutations in oncogenes and tumor suppressor genes. This has fuelled the debate over 
whether aneuploidy is an essential contributor to, or merely a remnant of, oncogenic 
transformation The products of most mutated oncogenes or tumor suppressor alleles 
have eﬀ ects on cellular proliferation and survival. However, what is the reason, if any, that 
aneuploidy is the most commonly observed genetic alteration in many types of tumors? 
One possibility is that the ability of a population of cells to redistribute whole 
chromosomes facilitates tumorigenesis by increasing the chance of LOH of a tumor 
suppressor gene (i.e. p53 or cell-cycle proteins). Or this ability might, in eﬀ ect, amplify 
an oncogene by duplicating the chromosome that harbors the mutated allele. 
From an evolutionary point of view, this ability enables cells to adapt to diﬀ erent, 
potentially harmful, environments. It is now thought that the cellular resistance to some 
chemotherapeutic drugs is based on this mechanism.281 In this way, aneuploidy can be 
seen as a driving force for cancer. Furthermore, when the p53 gene is aﬀ ected, more DNA 
damage may accumulate. Additionally, when a gene coding for a cell-cycle protein is 
aﬀ ected, this may lead to aberrant cell divisions (mitosis). Both these events will in the 
end result in even more aneuploidy, and so on. Here, aneuploidy can be seen as an eﬀ ect 
of tumorigenesis.280;282 
Recently, tetraploidy has been reported to be an ominous state in mammalian tissues. 
In many human tumors, cells with tetraploid DNA arise as an early step in tumorigenesis 
and precede the formation of aneuploid cells.283 P53-null cells appeared to be particularly 
prone to this, emphasizing the important role of p53 as a guardian of the genome.284
In conclusion, the rearrangement of chromosomes (CIN), resulting in aneuploidy, is 
frequently observed phenomenon in cancer. Whether this has to be regarded a driving 
force for or just a remnant of tumorigenesis, still remains unclear.
1.7.5 Classifi cation of actinic keratoses
Over the years, various diﬀ erent classiﬁ cation schemes have been proposed for AK by 
various authors, reﬂ ecting the controversy in literature about their nature. However, up 
till today there is no general consensus which classiﬁ cation scheme best reﬂ ects the 
biological behavior of these lesions enabling the physician to separate the ‘benign’ AKs 
from the potentially dangerous AKs.
1.7.5.1 Keratinocytic Intraepidermal Neoplasia  
To emphasize the progressive nature of AKs, Cockerell and colleagues have proposed 
the keratinocytic intraepidermal neoplasia (KIN) classiﬁ cation system, analogous to the 
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Figure 15: The role of aneuploidy in cutaneous carcinogenesis.
CIN and VIN grading system for cervical and vulval cancers.268 In this system, a clinical 
combined with a histological assessment is graded into three categories (KIN I-III). KIN I 
lesions are ﬂ at, pink macules on solar damaged skin, without roughness or hyperkeratosis. 
Histologically, focal atypia of the keratinocytes is seen, but is not exceeding the lower 
third of the epidermis. KIN II lesions are pink to red with a hyperkeratotic surface and 
variable induration. Histologically, focal atypia of the keratinocytes remains limited to the 
lower two thirds of the epidermis. The acrosyringia and acrotrichia are typically spared. 
The most advanced form are KIN III lesions, which are red, scaly and indurated plaques 
with histologically transepidermal atypia, including the adnexal structures. Striking 
acanthosis and expansion of epidermal retia is usually present. The acanthosis is most 
often irregular and papillomatosis, hyperkeratosis, parakeratosis and loss of the granular 
layer are characteristic. Bowenoid AK, some lesions currently identiﬁ ed as hyperplastic 
AKs and SCC in situ are all forms of KIN III. After KIN III, when invasion into the dermis 
occurs, lesions are referred to as SCC.
Although this classiﬁ cation is an enormous improvement over the conventional 
histological assessment as it underlines the progressive nature of AKs, many authors have 
criticized it for various reasons. Firstly, it depends on both a clinical and a histological 
evaluation which is not always feasible in daily practice. Secondly, the term KIN not only 
describes AK and BD, but also many other lesions such as seborrheic keratosis. Thirdly, it 
implies an obligatory serial progression through all three KIN stages before microinvasion 
occurs, which is not always correct since low-grade KIN lesions (KIN I or II) may directly 
be converted to SCC.285 In addition, physicians may wrongfully consider low-grade KIN 
lesions to be more benign compared with KIN III lesions, underestimating their malignant 
potential consequently. 
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1.7.5.2 Proliferative Actinic Keratosis
In 1994, Goldberg proposed a classiﬁ cation scheme by subdividing AKs into two 
categories: proliferative (PAKs) and non-proliferative AKs.286 He stated this to be a clinically 
useful classiﬁ cation since according to him, PAKs are associated with increased resistance 
to standard treatments, having an increased tendency towards progression into SCC.287 
Clinically, PAKs look very similar to regular AKs but are relatively rapid growing lesions of 
more than 1 cm in diameter. Micro ulcerations are frequently observed on the surface. 
Contrary to conventional histological assessment of AKs, the acrosyringia and acrotrichia 
are not spared. 
Goldberg recommended these lesions to be treated more aggressively compared with 
non-PAKs. However, limited clinical evidence has supported the more aggressive nature 
of PAKs.      
1.7.5.3 In amed Actinic Keratosis
Berhane and colleagues proposed a classiﬁ cation system based on the assumption that 
clinical inﬂ ammation of AKs is associated with malignant transformation into SCC. These 
AKs have a erythematous border and are tender upon palpation. They therefore deﬁ ned 
three categories of AKs, being: asymptomatic AKs (AAKs), inﬂ amed AKs (IAKs) and SCC.288 
However, no consensus exists on the meaning of the inﬂ ammatory inﬁ ltrate. Some 
authors, postulated this to be a defense mechanism, which, if successful, would lead to 
regression of the AKs and, if unsuccessful, to the progression to invasive SCC. Although 
this classiﬁ cation could theoretically be useful for physicians and patients to separate 
the ‘good’ AKs from the ‘bad’, there is relatively limited clinical evidence supporting the 
inﬂ ammation hypothesis in AK as a obligatory route towards invasive SCC.   
1.7.5.4 In situ SCC types of AK 
Stockﬂ eth and colleagues, recently proposed a classiﬁ cation system which is a modiﬁ ed 
version of the KIN classiﬁ cation system by Cockerell.254 According to them, the KIN system 
does not call AKs what they really are, namely SCCs in situ. They therefore proposed the 
term ‘in situ SCC type AK’ to be used in stead of AK. The in situ SCCs are subdivided into 
three categories (grade I-III) analogous to the KIN classiﬁ cation. Consequently, AKs can 
be categorized as: ‘early in situ SCC Type AK I, ‘early in situ SCC Type AK II’ and ‘in situ SCC 
Type AK III’.
 
1.7.6 Treatments
Based on the controversy on the nature of AKs, there is much debate between 
dermatologists over whether an AK should be treated or not, and if, with what kind of 
treatment. In the Netherlands, for example, no general guidelines are available. Recently, 
the British Association of Dermatologists published their guidelines based on literature 
from 1966 until 2004. Their recommendations are brieﬂ y summarized in table 4.
AKs are a heterogeneous group of lesions, which may occur on diﬀ erent sites of the body. 
The diﬀ erent treatments for AK have diﬀ erent modes of action, clinical eﬃ  cacy and side 
eﬀ ect proﬁ les consequently. Based on the clinical appearance, localization and biological 
behavior of the lesions in combination with patient characteristics and preferences, a 
customized treatment regime must be chosen for the individual patient, which accounts 
for these factors.   
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Table 4: Treatments for AK.*
Treatment Score Summary of recommendations
No therapy A, IIii
Based on clinical studies in which spontaneous regression was 
reported, refrainment from treatment can be justifi ed, especially 
for mild AKs.
Emollients A, I
Emollients have been used in the placebo arm of many studies. 
They do not likely reverse the biological process but rather 
improve the clinical manifestations. They can be useful in mild 
AKs.
Sun block A, I Sunblocks have combined emollient and photoprotective eff ects. They have been proven eff ective in the prevention of SCC.
Salicylic acid 
ointment A-III
It does not likely reverse the biological process but rather 
improves the clinical manifestations by its keratolytic eff ect. It 
can be useful in mild AKs, alone, or as a pre-treatment for other 
therapies.
5- uorouracil cream 
(Efudix®) A, I
Very eff ective. Particularly useful when treating fi eld-
cancerization.
Imiquimod 
(Aldara®) B, I
Very eff ective. Particularly useful when treating fi eld-
cancerization. More expensive than 5-FU with more potential 
side-eff ects, including systemic symptoms.
Diclofenac gel (3%) B, I Eff ective in the treatment of mild AKs, with few side-eff ects.
Tretinoin cream B, I Eff ective when treating photodamage. Less eff ective for AKs. Not signifi cantly more eff ective than emollients and sun block. 
Surgery - There are no trials of surgical therapy of AKs. Surgery is only useful when SCC is suspected. 
Cryosurgery and 
cryotherapy A, I
These destructive therapies have been reported very eff ective but 
are highly dependent on the treatment parameters (e.g. number 
of freeze-thaw cycles) and the person by whom the treatment is 
performed.
PDT A, I Very eff ective, with very good cosmetic results.See the relevant paragraphs earlier in this thesis.
Laser, chemical 
peels, 
electrodesiccation 
and dermabrasion
C, III
These destructive therapies have been reported eff ective but are 
highly dependent on the treatment parameters and the person 
by whom the treatment is performed. 
Systemic retinoids B, I
May be eff ective when treating patients with lots of 
hyperkeratotic lesions. Relatively many side-eff ects compared 
with topical treatments. It is unknown whether retinoids protect 
against malignant transformation into SCC.
Scoring system for strength of recommendations and quality of evidence:
A-E: There is A:good / B:fair / C:poor evidence to support the use of the procedure.There is D:fair / E:good evidence to support the rejection of the procedure.
I Evidence obtained from at least one properly designed, randomized controlled trial.
II-i Evidence obtained from well-designed controlled trials without randomization.
II-ii Evidence obtained from well-designed cohort or case-control analytical studies, preferably from more than one center or research group.
II-iii
Evidence obtained from multiple time series with or without the intervention. 
Dramatic results in uncontrolled experiments could also be regarded as this type of 
evidence.
III Opinions of respected authorities based on clinical experience, descriptive studies or reports of expert committees.
IV Evidence inadequate due to problems of methodology.
* de Berker D, McGregor JM, Hughes BR; British Association of Dermatologists Therapy Guidelines and Audit Subcommittee. Guidelines for 
the management of actinic keratoses. Br J Dermatol. 2007 Feb;156(2):222-30. 
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 1.8 Psoriasis
1.8.1 Introduction and epidemiology
Although psoriasis has been recognized at least since Biblical times, Robert Willan (1808) 
is credited for his ﬁ rst accurate description of psoriasis, as we know it today. He was the 
ﬁ rst to recognize psoriasis as an independent disease, which he referred to as “Willan’s 
leprosy.” However, it was the Viennese dermatologist Ferdinand von Hebra who ﬁ rst 
ascribed the name “psoriasis” from the Greek word meaning ‘to itch.’289  
Psoriasis is a chronic disease with a variable prevalence of 1-4% world wide, in which 
ethnic factors are thought to play a role. It is polygenetic disease and its course, 
which is characterized by remissions and exacerbations, may be inﬂ uenced by various 
exacerbating factors.290 Some putative loci for genetic susceptibility, in which PSORS1 
is considered most important, have been reported, but there has not been widespread 
replication of the results.291
Although psoriasis is primarily a skin disease, due to its chronic character, it may cause 
substantial psychological distress and impairment of the quality of life comparable to 
cancer, arthritis, hypertension, heart disease, diabetes, and depression.292
1.8.2 Clinical aspects
The typical psoriatic lesion is a sharply demarcated erythematous plaque covered 
by silvery white scales, which most commonly appear on the elbows, knees, scalp, 
umbilicus and lumbar area. This characteristic pattern is seen in the most common form 
of psoriasis, chronic plaque psoriasis (psoriasis vulgaris), which is seen in approximately 
90% of all psoriatic patients. Sometimes a blanching ring can be observed around the 
plaque, which is referred to as the ‘Woronoﬀ  ring’. The scaling in psoriasis has a typical 
appearance. If scales are scratched oﬀ  from a lesion, the scales cohere similar as the 
wax ﬂ akes scraped from a candle. The is called the ‘candle wax sign’. When all scales are 
scraped oﬀ , characteristic pinpoint bleedings may occur, which is called the ‘Auspitz 
sign’.293 Psoriatic lesions sometimes give rise to itch and pain, but generally the cosmetic 
aspects of the disease are responsible for most of the disease burden. 
Another form of psoriasis appears mainly in the intertriginous areas and is called ‘inverse’ 
or ‘intertriginous psoriasis’ (psoriasis inversa). It is also called ‘ﬂ exural psoriasis’ as the 
lesions are also located on the ﬂ exor sites of the body. In about 30% of patients with 
chronic plaque psoriasis, inverse psoriasis can also be observed. Eruptive guttate psoriasis 
(psoriasis guttata) is an acute form of psoriasis, which is characterized by small droplet-
like lesions and is often the initial manifestation of the disease. This form may typically 
be triggered by streptococcal infection, preceding the skin eruption by 2-3 weeks.294 
Palmoplantar pustulosis (psoriasis pustulosis palmoplantaris, M. Andrews-Barber) in a 
special form characterized by erythematous plaques with yellow-brown sterile pustules 
on the palms and the soles. However, genetic analysis has shown this form to have 
diﬀ erent causes compared with psoriasis vulgaris, therefore it is now thought to be a 
comorbidity rather than a form of psoriasis.295 ‘Acrodermatitis continua suppurativa 
Hallopeau’ is also a localized pustular form, aﬀ ecting the distal ends of the ﬁ ngers and 
toes with involvement of the nails. Some less frequently occurring but severe forms of 
psoriasis are ‘erythrodermic psoriasis’ and ‘general pustular psoriasis (von Zumbusch)’, 
which is an acute form in which small, monomorphic sterile pustules develop in painful 
inﬂ amed skin. The patient has a fever and is systemically unwell. Erythrodermic psoriasis 
may be the end stage of initially localized forms of psoriasis and may be life-threatening. 
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Although psoriasis is mainly conﬁ ned to the skin, extracutaneous manifestations may 
also occur at the nails (psoriasis unguium) and joints (psoriasis arthropathica, psoriatic 
arthritis). Psoriatic arthritis has been underestimated over the years and its prevalence 
is now thought to be as high as 25% in psoriatic patients.296 In addition, in about 10% of 
the patients with psoriatic arthritis, the arthritis appears prior to the skin manifestations 
of psoriasis.289
Although psoriasis is a chronic disease of an unknown primary origin, in which genetic 
predisposition is thought to play an important role, several triggering factors are known. 
Trauma to the skin may elicit a lesion in previously uninvolved skin, which is known as 
the ‘Koebner phenomenon’. It can predominantly be observed in active inﬂ ammatory 
psoriasis. Any physical injury of the skin may induce a Koebner reaction, such as shaving, 
rubbing, scratching, burning etcetera. Some psoriatic treatments with proinﬂ ammatory 
potential, such as phototherapy and anthralin, may also induce the Koebner response in 
unstable psoriasis. Usually the Koebner reaction appears 7-14 days after injury.297 
Guttate psoriasis is a typical form of psoriasis which is triggered by infection. Tonsillitis 
or pharyngitis, especially caused by streptococcal infections are well-known triggering 
factors. Throat infections may also provoke (recalcitrant) plaque-type psoriasis.298 
Furthermore, deterioration of psoriasis has also been associated with HIV-infection.299 
Typical drugs known to evoke psoriasis include lithium, beta-adrenergic blocking 
agents, anti-malarials and NSAIDs.300 However, any drug which may potentially cause a 
drug eruption, may exacerbate psoriasis by Koebnerization. Psychological stress is also 
known to worsen psoriasis, but the mechanisms behind this remain obscure.301 One 
might hypothesize that neuro-immunological processes may modulate disease activity. 
However, as the disease itself may cause psychological distress, caution should be taken 
when interpreting the role of stress in psoriasis as stress could also be a confounder 
rather than a causative factor. The same can be said on alcohol, smoking and obesity, 
which have also been known to have a higher prevalence in psoriatic patients. Finally, the 
facts that the incidence of psoriasis shows a peak at puberty and menopause and that 
an increased disease activity reported during pregnancy, indicate that endocrinologic 
changes may play a role in psoriasis. 
Awareness is increasing that psoriasis as a disease is more than skin deep and that it 
is associated with systemic disorders, including Crohn’s disease, diabetes mellitus (type 
II), metabolic syndrome, depression and cancer.289 It is unclear whether cancers are 
related to the disease or to its treatment, in particular immunosuppressive drugs and 
photo(chemo)therapy.
1.8.3 Histopathological and functional aspects of psoriatic skin
1.8.3.1 General histology
Lesional psoriatic skin is characterized by (1) increased proliferation, (2) disturbed 
diﬀ erentiation (keratinization) and (3) inﬂ ammation. Histologically, this is reﬂ ected by 
hyper- and parakeratosis, acanthosis, regular elongation of the rete-ridges, thinning of 
the suprapapillary plate and focal absence of the granular layer. Characteristic are the 
epidermal formation of spongiotic micropustules of Kogoj and microabcesses of Munro, 
containing neutrophils. 
In the dermis elongation and turtuosity of blood vessels is observed and also long 
edematous papillae. The increased vascularity in the dermis is thought to be the result 
from angiogenic factors, such as vascular endothelial growth factor (VEGF), produced 
by epidermal keratinocytes. This is accompanied by the presence of a mononuclear 
perivascular inﬁ ltrate, which is principally composed of T cells mainly localized in the 
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papillary dermis. Sometimes exocytosis can be observed.1 In non-lesional psoriatic skin 
these features are absent. 
1.8.3.2 Typical immunohistological features 
Apart from the general histological features described above, typical immuno-
histochemical features can be seen in psoriatic skin.  
1.8.3.2.1 Proliferation and diff erentiation
In psoriasis, mitotic activity of the basal keratinocytes is increased by as much as a factor 
of 50, so keratinocytes need only 3-5 days in order to move from the basal layer to the 
corniﬁ ed layer (instead of 28-30 days normally). The increased proliferative activity can 
be demonstrated increased positivity for MIB-1 (Immunotech, Marseilles, France) in the 
epidermis. MIB-1 is an antibody directed against the cell-cycle associated Ki67-antigen, 
which is expressed throughout the whole cell-cycle except in G0 and early G1, thus 
representing the epidermal proliferative compartment. 
As a result from hyperproliferation, immature keratinocytes appear throughout the 
epidermis. Keratin 10 (K10) is expressed in mature keratinocytes and can therefore be 
seen in the suprabasal layers of normal skin. However, in psoriasis K10 is absent just above 
the basal layer but is seen, if present at all, much higher in the epidermis just below the 
stratum corneum, indicative for disturbed keratinization. Another way to demonstrate 
this, is by looking at ﬁ laggrin expression. Filaggrin is involved in the formation of 
keratohyalin granules. In normal skin ﬁ laggrin is present in the stratum corneum and the 
stratum granulosum and supports cutaneous hydration. In general, active psoriasis is 
known for its absent or discontinuous ﬁ laggrin expression.302 
1.8.3.2.2 Infl ammation
Inﬁ ltrate analysis in psoriasis shows an abundance of T cells, which can be demonstrated 
by immunohistochemical staining of ‘cluster of diﬀ erentiation’ antigens (CD-markers), 
which are speciﬁ c cell-surface proteins which can be found on the cell membranes 
Figure 16: Clinical appearance (A) and histopathology (B) of psoriasis.
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of immunocytes. All T cells bear the T cell-receptor complex, which includes the CD3-
antigen. Almost all T cells have either the CD4 (T-helper) or the CD8 (cytotoxic T cells) 
marker on their surface. They are both predominantly found in the dermis, where CD4+ 
T cells dominate, while in the epidermis CD8+ T cells are the dominant population. By far 
the largest part of all inﬁ ltrating T cells in the psoriatic plaque is of the CD45RO+ (memory 
eﬀ ector) subtype rather than the CD45RA+ (naive) subtype. The memory eﬀ ector T cells 
are cells which have been activated in the lymph nodes to perform speciﬁ c immunologic 
tasks (adaptive immunity), in contrast to the naïve T cells, which have not been activated 
yet.303;304 The pathogenic T cells are thought to interact with keratinocytes eliciting a 
T-helper 1 (TH1) response, characterized by the production of type I cytokines, such as 
interleukin-2 (IL-2), tumor necrosis factor-α (TNF-α) and interferon-γ (IFN-γ), which results 
in keratinocyte activation and the psoriasis phenotype. 
These processes are discussed in detail in the next paragraphs. For the 
immunohistochemical pictures of CD3, CD4, CD8 and CD40RO staining in psoriatic skin, 
the reader is referred to chapter 3. 
1.8.3.3 Stratum corneum integrity
The abnormal structure of the psoriatic epidermis, the granular and corniﬁ ed layer in 
particular, could be the explanation for the impaired epidermal barrier function found in 
psoriasis compared with normal skin. Several studies reporting increased transepidermal 
water loss (TEWL) levels up to 20 times normal support this.43;305;306 As a result from 
abnormal barrier function, epidermal keratinocytes may become activated producing 
various inﬂ ammatory cytokines, including TNF-α and IFN-γ.307 This could also be a 
plausible explanation for the mechanism behind the Koebner phenomenon, explaining 
why minor damage to psoriatic skin may trigger psoriatic activity. It would also explain 
why occlusion of a psoriatic lesion alone clears many psoriatic lesions.308 
In a report from Ghadially et al., TEWL and stratum corneum structure were studied in 
normal skin, active and chronic plaque psoriasis and erythrodermic psoriasis. A correlation 
between psoriatic phenotype and stratum corneum structure and function was found, 
showing increased TEWL and structural abnormalities in active and erythrodermic 
psoriasis compared with chronic psoriasis and normal skin. However, no diﬀ erences 
were found in TEWL and stratum corneum structure between uninvolved psoriatic skin 
and normal skin, which does not explain why uninvolved psoriatic skin is sensitive to 
Koebnerization.
Interestingly, despite these abnormalities in barrier function, psoriatic skin appears to 
be more resistant to invasion by microorganisms compared with normal skin, possibly 
by compensatory activation of members of the cellular immune system, particularly T 
cells expressing natural killer (NK)-receptors, and increased expression of anti-microbial 
proteins.307;309
1.8.4 Pathogenesis
For many years, psoriasis was thought to be a primary keratinization disorder of 
the skin. This is not surprising as histological ﬁ ndings indeed show prominent 
epidermal abnormalities as described previously. In the early eighties, these epidermal 
abnormalities were suggested to be T cell driven. Some years later as the type I/type II T 
cell paradigm emerged, the T cell hypothesis was reﬁ ned and psoriasis was regarded as 
a type I T cell-associated disease with a prominent role for IFN-γ. The success of TNF-α-
blocking agents (biologicals) in the treatment of psoriasis points towards involvement of 
the innate immune system in its pathogenesis. In the next paragraph, a concise overview 
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is given on these recent insights based on the current knowledge. As these models are 
continuously subjected to modiﬁ cations according to new insights, for an up-to-date 
overview the reader is referred to current literature. 
1.8.4.1 A model for the immunopathogenesis of psoriasis
1.8.4.1.1 Dysregulation of innate and adaptive immunity
Psoriasis in now considered to be an immune-mediated, organ-speciﬁ c inﬂ ammatory 
disease, in which intralesional T cells trigger primed basal keratinocytes to proliferate and 
perpetuate the disease process. A clue to the involvement of T cells in the pathogenesis 
of psoriasis was given after observation of the successful treatment results by T cell-
blocking agents, such as cyclosporin, in the late seventies.310 Because the trigger for the 
inﬂ ammation remains unknown, it can be debated whether psoriasis can be regarded 
an auto-immune disease.  Therefore, with the current knowledge it is best to consider 
psoriasis a genetically programmed disease of dysregulated inﬂ ammation, which is 
triggered by environmental stimuli (infections, medications, antigenic stimuli, physical 
and/or emotional stimuli).311
Both adaptive and innate immune responses contribute to the pathophysiology of 
psoriasis. The innate immune system is designed as a ﬁ rst barrier against pathogens and 
acts rapidly, without developing long-lasting immunity. It is more primitive compared 
with the adaptive immune system, which acts slower but has more advanced features. 
Upon primary exposure to an antigen, it is able to develop long-lasting immunity, which 
will protect the host in the future. Examples of this are vaccination or immunization. 
Innate and adapted immune system are highly interactive and play critical role in initiating 
inﬂ ammation and modifying immune responses.  Both innate and adaptive immune 
systems share common eﬀ ector molecules (cytokines and chemokines). In normal skin 
from healthy individuals, these two systems work together to protect the host against 
external pathogens without causing skin disease. In psoriasis, a dysregulation in the 
innate immune system has been proposed as an initiator of the psoriatic inﬂ ammatory 
response.312 Several ﬁ ndings support this.
In psoriatic inﬁ ltrates certain subsets of T cells, expressing NK-receptors, can be 
demonstrated, which are able to produce high amounts of IFN-γ in the presence of CD1d 
(which is highly expressed in psoriatic keratinocytes) positive keratinocytes.313 These NK-T 
cells are members of the innate immune system and may play a role in the increased 
resistance against microorganisms observed in psoriasis. Typical NK-T cells are CD4-/CD8- 
or CD4+.311 In the pathogenesis of other TH1-mediated diseases, such as diabetes mellitus 
type II, these cells have also been implicated.314 In addition, impaired barrier function 
in psoriatic skin may enhance the CD1d-related NK-T cell production of IFN-γ thereby 
initiating an immune response where bacterial superantigens (SAgs) may act as triggers. 
The appearance of skin lesions following bacterial pharyngitis, may also be explained by 
this phenomenon. NK-T cells are thought to be the initiators which represent a bridge 
between innate and adaptive immunity. They are ably to secrete polarizing cytokines 
such as IFN-γ, favoring TH1 cell diﬀ erentiation. Their close proximity near keratinocytes 
suggests that keratinocytes may acts as antigen-presenting cells (APCs) to NK-T cells. 
However, the exact role of NK-T cells in psoriasis still remains obscure.312
Normally, antigens are continuously presented by APCs, via their major histocompatibility 
complexes (MHC) molecules class I (CD8+) and II (CD4+), to the T cell receptor complex 
(TCR) of naïve T cells (CD45RA+) in the local lymph nodes. When a pathogen is presented 
to these cells an immune response is initiated to clear the body from the pathogen. 
In psoriasis, these naïve T cells are believed to be activated by an unknown antigen 
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into memory eﬀ ector (CD45RO+) T cells, which are able to interact with keratinocytes 
and APCs, initiating an early psoriatic lesion. Thus, the major populations of T cells are 
mature, skin-homing (skin-homing receptor cutaneous lymphocyte-associated antigen, 
CLA+), activated memory cells. Both CD4+ and CD8+ T cells are present, with the CD4+ T 
cells being present mostly in the dermis and CD8+ cells in the epidermis. There are two 
subsets of CD8+ T cells: an epidermal homing subset expressing CD103, which enables 
them to interact with keratinocytes, and a subset that remains in the dermis, which may 
be in transit to or from the epidermis.311 These activated T cells may locally respond to 
antigens presented by APCs, producing TH1 cytokines, which may trigger keratinocyte 
hyperplasia. In general, the CD4+ cells are thought to be mainly involved in sustaining 
inﬂ ammation, whereas the CD8+ cells because of their migrating capacities are thought 
to be involved in driving keratinocyte hyperplasia in the early psoriatic lesion. However, 
as previously mentioned, keratinocytes in turn may also produce cytokines, which may 
contribute to maintenance of an inﬂ ammatory response by their strong chemotactic 
eﬀ ects on neutrophils and other T cells.
Several subsets of T cells are able to modulate immune responses rather than acting as 
eﬀ ectors of inﬂ ammation. The importance of these cells was already described in the 
early 1970s.315 At that time they were referred to as ‘suppressor T cells’. Depletion of these 
cells has been associated with auto-immune disease. Because these cells can regulate 
the eﬀ ects of CD4+ and CD8+ cells, they are called: ‘regulatory T cells’ (Treg). They are 
thought to be activated by immature dendritic cells (DCs) in the peripheral lymph nodes, 
in contrast to mature DCs, which are thought to be involved in the initiation of psoriasis. 
Dysfunction or absence of Tregs has been postulated as an explanation for the sustained 
T cell responses in psoriatic lesions.316 In the table below, the relevant T cells in psoriasis 
are summarized.311
Table 5: Types of T cells that play a role in psoriasis.*
T cell subset Restriction 
element
Antigens 
recognized
Role in psoriasis
CD4+ T cell, TCR α/β 
(conventional T-helper cells)
Class II MHC Processed 
polypepetides
Produce TH1 cytokines (IL-2, IFN-γ, TNF-α) and 
sustain inﬂ ammation.
CD8+ T cell, TCR α/β 
(conventional T-cytotoxic cells)
Class I MHC Processed 
polypepetides
Migrate in epidermis, produce TH1 cytokines, may 
drive KC hyperplasia.
NKT cells, TCR α/β (NK 
T lymphocytes) (double 
negative or CD4+ NKT cells)
CD1d, class I 
MHC
Glycolipids, both 
endogenous 
and microbial 
derived.
May recognize KC glycolipids, produce IFN-γ, drive 
TH1 inﬂ ammation.
CD25+ CD4+, TCR α/β 
(T-regulatory cells)
Class II MHC Processed 
polypepetides
Deﬁ cient functional suppressor activity in skin and 
blood of patients with psoriasis.
* Gaspari AA. Innate and adaptive immunity and the pathophysiology of psoriasis. J.Am.Acad.Dermatol. 2006; 54: S67-S80.
1.8.4.1.2 The role of the keratinocytes: passive or active?
Are the epidermal keratinocytes only suﬀ erers from the dictatorial regime of the 
immune system, or do they have active roles in the immunopathogenesis of psoriasis? 
As already mentioned, keratinocytes may act as pro-inﬂ ammatory cells by producing 
(TH1) cytokines for example upon disruption of the skin barrier by tape-stripping.
307 In 
psoriasis, supernatants of psoriatic lesional keratinocytes, but not normal keratinocytes 
were able to activate puriﬁ ed CD4+ cells, emphasizing their potential role in initiation of 
an inﬂ ammatory response.317 
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Additional data indicating that intrinsic alterations of keratinocytes are necessary to induce 
psoriasis could be erroneously obtained from a study by Wrone-Smith et al. using severe 
combined immunodeﬁ ciency (SCID) mouse xenograft models, in which the injection of 
autologous immunocytes into the dermis of transplanted mice induced psoriasis only in 
prelesional symptomless skin of psoriatic patients but not in skin from normal controls.318 
However, in this study normal skin was injected with activated autologous immunocytes 
(from non-psoriatic patients). Some years later, the same authors reported that they 
were able to induce psoriatic lesions even in normal skin from healthy volunteers after 
dermal injection with allogenic immunocytes from psoriatic patients. From these studies 
it can be derived that the blood-derived immunocytes in psoriatic patients cannot 
be compared with activated immunocytes from healthy volunteers, which points at a 
primary role of an aberrant immune system in the pathogenesis of psoriasis.313 
But endogenous defects in keratinocytes, i.e. overexpression of the transcription factor 
STAT3 or lack of the inhibitor of nuclear factor (NF)-κB kinase 2 (IKK2), have been reported 
to induce psoriatic phenotypes in mice.319;320 However, the development of psoriatic 
lesions in mice overexpressing STAT3 depended on the presence of activated T cells, 
whereas the inﬂ ammatory responses occurring in the skin of IKK2 deﬁ cient mice were 
mediated by TNF-α.   
In addition, supernatants from psoriatic lesional skin-derived CD4+ T cells have been 
reported to transform β-integrin K1/K10- proliferating cell nuclear antigen (PCNA)- stem 
cells of psoriatic patients, but not normal healthy skin, into PCNA+ active cycling cells. 
Supernatants were found to contain high amounts of IFN-γ. However, IFN-γ has also been 
known for its anti-proliferative properties on normal keratinocytes, indicating a defective 
response of psoriatic keratinocytes to IFN-γ.321 
In conclusion, from these studies can be concluded that an intrinsically dysregulated 
Figure 17: Proposed model for the immunopathogenesis of psoriasis.
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interrelation between keratinocytes and cells of both innate and adaptive immunity is a 
key step in the pathogenesis of psoriasis. 
1.8.4.2 In conclusion
Although in the pathogenesis of psoriasis current knowledge remains fragmentary, the 
following working model may be proposed (ﬁ gure 17).
Psoriasis is a genetically determined skin disease characterized by a hyperresponsive 
innate immune system, which is triggered by a yet unknown stimulus. These exaggerated 
innate immune responses, performed by NK-T cells, DCs, neutrophils and keratinocytes, 
subsequently lead to recruitment and activation of preferentially TH1 cells and subsequent 
secretion of TH1 cytokines. Keratinocytes, which are responsive to these cytokines 
(especially IFN-γ), start to proliferate to form lesions with psoriasiform hyperplasia. The 
chronic nature of the psoriasis lesions indicates a deﬁ ciency in the  downregulation 
mechanisms and/or alternatively the persistence of an (yet) unknown trigger.322
1.8.5  Established treatments for psoriasis 
As the primary cause of psoriasis is still not known, there is no single treatment available 
which will cure the disease. Over the years many eﬀ ective treatments have become 
available. However, as psoriasis is a heterogeneous disease, in general there is no way to 
predict whether a certain treatment modality will be eﬀ ective in an individual patient. 
In addition, most treatments have temporary eﬀ ects, and cessation of the treatment 
will frequently result in relapses of the disease. Furthermore, especially in the systemic 
treatments cumulative toxicity and adverse treatment eﬀ ects may be a problem, which 
sometimes requires switching to alternative treatment modalities. Dependent on the 
psoriatic phenotype and therapy, adequate therapeutic maintenance of the psoriatic 
skin generally insists on enormous eﬀ orts which have to be made by the patient, such 
as frequent evaluation visits to the hospital and daily application of topical therapies. 
Hopefully, increasing knowledge on the pathogenic processes in psoriasis may 
eventually result in more eﬀ ective and maybe curable treatments. In the next paragraphs 
established treatments for psoriasis will be brieﬂ y discussed. Relevant for this thesis is 
the photodynamic treatment of psoriasis. This will be discussed in more detail.
1.8.5.1 Topical treatments
Topical therapy remains the mainstay of treatment for most patients, especially those 
with limited disease. Although eﬀ ective for individual plaques, it is time consuming, and 
compliance is a substantial issue.
1.8.5.1.1 Emollients and keratolytics
Although emollients, such as vaselin (petrolatum), lanette or paraﬃ  n, do not contain 
pharmacologically active metabolites, they may have therapeutic eﬀ ects by hydrating the 
skin and improving the roughness and scaling observed in psoriatic plaques.323 Because 
of this and their safety, patients commonly use emollients to maintain their skin. 
Keratolytics, such as urea and salicylic acid, are mostly used to remove scales and 
hyperkeratosis. They are also used as penetration enhancers for other topical treatments 
and for the light during photo(chemo)therapy.323 In some experiments described in this 
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thesis, salicylic acid in petrolatum was used as a pre-treatment, to enhance penetration 
of ALA and PpIX ﬂ uorescence consequently. 
1.8.5.1.2 Coal tar
Coal tar is a mixture of thousands of compounds, which has been used for the treatment 
of psoriasis for more than a century. Its highly eﬀ ective in the treatment of itch, and 
therefore it is mostly used in the treatment of atopic dermatitis. Its precise mechanism 
of action is unknown, but it is believed to have anti-inﬂ ammatory, anti-bacterial, anti-
pruritic and anti-mitotic eﬀ ects. Because of its typical smell and its supposed carcinogenic 
and teratogenic eﬀ ects, which have only been demonstrated in animal studies and 
occupational settings, its use is limited.324 However, tar shampoos are universally used for 
the treatment of psoriasis on the scalp.
 
1.8.5.1.3 Vitamin D3-derivatives
Vitamin D3-derivatives have become ﬁ st-line therapy for plaque psoriasis either as 
monotherapy or in combination. They inhibit epidermal proliferation and modulate 
diﬀ erentiation and inﬂ ammation.325 Although initial clinical responses with these 
preparations are inevitably slower than with higher potency corticosteroid agents, 
their longer-term safety proﬁ le makes them valuable for maintenance therapy. They 
are very useful in combination with other therapies such as corticosteroids (Dovobet®) 
or phototherapy, improving their risk-beneﬁ t ratio. In the Netherlands, calcipotriol and 
calcitriol are the two registered topical vitamin D3 analogues, with the former being 
slightly more eﬀ ective.326 Lesional or perilesional skin irritation manifesting as pruritus, 
dryness and erythema is seen in up to 35% of patients and seems to be reduced with 
ongoing treatment. Clinically relevant hypercalcaemia is rarely seen, but may theoretically 
occur. 
1.8.5.1.4 Corticosteroids
Topical corticosteroids remain the most widely prescribed treatment for psoriasis 
worldwide. They possess anti-proliferative, anti-inﬂ ammatory and immunosuppressive 
properties.293 Important targets are the T cells. According to their strength topical 
corticosteroids can be divided into four potency groups (class I-IV). A systemic review has 
shown that class III-IV steroids are more eﬃ  cacious for psoriasis than class I-II steroids.327 
Additionally, penetration can be augmented by occlusion or subtle changes in the vehicle. 
However, dosage-dependent side eﬀ ects may limit the use of these highly eﬃ  cacious 
agents, such as skin atrophy, teleangiectasia, striae distensae, purpura, tachyphylaxis and 
systemic eﬀ ects such as adrenal insuﬃ  ciency.328 Combination with other therapies, such 
as vitamin D3-derivatives, may ultimately reduce their cumulative dose.   
1.8.5.1.5 Dithranol
Dithranol, also known as cignolin or anthralin, is a chemically synthesized analogue 
of chrysarobin. Although its exact mode of action is still unknown, dithranol has been 
reported to exert its anti-psoriatic eﬀ ects by interference with epidermal growth, 
keratinization and inﬂ ammation.293 Recent investigative work has revealed that dithranol 
directly aﬀ ects mitochondria to induce apoptosis.329 Because of its obligatory irritative 
eﬀ ects on the skin, dithranol is preferably used in a day-care setting. Dithranol is regarded 
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an eﬀ ective anti-psoriatic therapy with a good long-term safety proﬁ le.
1.8.5.1.6 Calcineurin inhibitors
Calcineurin inhibitors, such as tacrolimus and pimecrolimus, are mainly used for the 
treatment of atopic dermatitis. Like cyclosporin, they inhibit T cell activation by binding 
to the calcineurin-calmodulin complex and thus prevent the transcription of pro-
inﬂ ammatory cytokines, such as IL-2. Their eﬃ  cacy in psoriasis is limited unless they are 
used under occlusion or on thinner areas of the skin, such as the face or skin folds.326 
1.8.5.2 Photo(chemo)therapy
When topical treatments fail and/or when large body surface areas are involved, 
phototherapy can be a eﬀ ective alternative. Psoriasis can be eﬀ ectively treated with 
psoralen-UVA (PUVA) photochemotherapy and broadband UVB phototherapy, however, 
because of a better beneﬁ t-risk ratio, narrowband UVB is nowadays the treatment of 
choice.330
The anti-psoriatic eﬀ ects of UVR are thought to be mediated by reduction of the 
number of epidermal Langerhans cells, lesional T cells and induction of apoptosis in 
keratinocytes as well as inﬂ ammatory cells. Therefore, UVR has anti-inﬂ ammatory and 
immunosuppressive eﬀ ects. Since UVA is able to penetrate deeper into the skin, its eﬀ ects 
can also be found in the dermis in contrast to UVB, which primary eﬀ ects are found in the 
epidermis.101 
The use of broadband UVB (290-320 nm) for the treatment of psoriasis was ﬁ rst thoroughly 
documented by Goeckerman, who used UVB in combination with coal tar.331 Some years 
later, UVB alone was proven to be eﬀ ective in the treatment of psoriasis.332 The duration 
and remission after UVB therapy is relatively long compared with corticosteroids, but its 
use is limited because of its probably dose-dependent carcinogenic eﬀ ects. However, to 
date no evident increases in NMSC have been reported in psoriatics which have been 
chronically treated with UVB therapy.333 PUVA therapy is highly eﬀ ective in psoriasis, but 
in contrast to UVB, cumulative toxicity has been clearly demonstrated.334 
1.8.5.3 Systemic treatments
When topical therapy and/or phototherapy are not eﬀ ective, fail to induce long-term 
remissions or are not preferred otherwise, systemic therapy may be indicated. Moreover, 
systemic therapy is the ﬁ rst-line treatment of extracutaneous manifestations of psoriasis 
such as nail psoriasis and psoriatic arthritis. 
1.8.5.3.1 Retinoids
Oral retinoids, also known as vitamin A-derivatives, are synthetic hormones that bind to 
nuclear retinoid receptors, thereby altering gene transcription and returning keratinocyte 
proliferation and diﬀ erentiation to normal. Mostly used in psoriasis is the third generation 
retinoid acitretin (Neotigason®) which at a dose of 0.5 mg/kg is eﬀ ective to treat psoriasis 
vulgaris but pustular and erythrodermic forms in particular.326 Retinoids may be easily 
combined with other therapies such as phototherapy, increasing clinical eﬃ  cacy and 
reducing their cumulative dose.335 However, retinoids are highly teratogenic so the use in 
females with child-bearing potential is limited and side-eﬀ ects, such as mucocutaneous 
dryness, can be awkward but these are dose related. Retinoids are relatively safe when 
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used for longer periods, since they have no immunosuppressive eﬀ ects. 
1.8.5.3.2 Methotrexate
Methotrexate (MTX) is a folic acid antagonist which interferes with purine synthesis and 
thus inhibits DNA synthesis and cell replication; it also has speciﬁ c T cell suppressive 
eﬀ ects. Therefore, MTX has anti-mitotic and anti-inﬂ ammatory eﬀ ects.326 MTX is highly 
eﬀ ective in the treatment of moderate-to-severe psoriasis as well as psoriatic arthritis. 
Doses from 7.5-22.5 mg/week are clinically eﬀ ective. Oral folic acid may be added to 
reduce its side-eﬀ ects (and probably its eﬃ  cacy), such as gastrointestinal symptoms, 
macrocytic anemia and stomatitis.336;337 Long-term use of MTX is associated with liver 
ﬁ brosis and cirrhosis, which requires periodical evaluation by means of a liver biopsy but 
this is a controversial subject, since new non-invasive diagnostic test are emerging.
1.8.5.3.3 Fumarates
Oral fumaric-esters have been proven eﬀ ective in psoriasis, with psoriasis area and 
severity indices (PASI) approaching MTX and cyclosporin. Fumarates are naturally 
occurring molecules that link the urea and citric acid cycles, with their beneﬁ t in psoriasis 
now considered to be consequent mainly due to NFκB inhibition and T cell apoptosis.338 
The most frequently observed side-eﬀ ects, such as ﬂ ushing and gastrointestinal 
discomfort, are generally well tolerated and the long-term beneﬁ t-risk ratio permits 
eﬀ ective and safe management of psoriasis.
1.8.5.3.4 Cyclosporin
Cyclosporin is a useful and eﬀ ective short-term treatment for moderate-to-severe 
psoriasis but is less eﬀ ective for active psoriatic arthritis.326;339 Cyclosporin inhibits the 
calcineurin phosphatase-initiated activation of T cells but may also exert direct eﬀ ects on 
keratinocytes.340 It is highly eﬀ ective in inducing a rapid remission of psoriasis, but requires 
careful monitoring for nephrotoxicity and hypertension.341 Additionally, an increased risk 
of NMSC exists, especially in patients previously treated with PUVA.342 Considering the 
cumulative toxicity, cyclosporin has no role in the long-term management of psoriasis.
 
1.8.5.3.5 Biological agents
An appreciation of the immune pathways critical to the pathogenesis of psoriasis has led 
to the development of new agents that target these speciﬁ c steps. Biological agents, also 
known as biologicals or biologics, are recombinant molecules that are designed on the 
basis of genetic sequences from various organisms and that are often similar or identical 
to proteins produced by human beings. They include fusion proteins, recombinant 
proteins and monoclonal antibodies.326 Biologicals interfere with the interaction between 
T cells and APCs (ﬁ gure 20). 
The speciﬁ c T cell agents alefacept and efalizumab bind to CD2 and leucocyte function 
associated antigen-1 (LFA-1) on memory eﬀ ector T cells respectively, thereby inhibiting 
T cell activation. Additionally, efalizumab also inhibits adhesion of T cells and endothelial 
cells thus preventing circulating T cells from entering the skin. Alefacept also has apoptotic 
eﬀ ects on T cells.343  The TNF-α-inhibitors (etanercept, inﬂ iximab and adalimumab) bind 
to TNF-α and/or its receptor, thereby antagonizing its eﬀ ects.344     
Biologicals have been proven highly eﬀ ective in psoriasis with impressive numbers of 
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patients achieving 75% reduction of their PASI (PASI 75) within 3 months. Over the last 10 
years, extensive clinical experience has been gathered with their use in Crohn’s disease 
and rheumatoid arthritis, but to a lesser extent in psoriatic patients. Theoretically, they 
may increase the risk of cancer and infections, but long-term studies must be carried out 
to determine whether these agents are safe when used over longer periods of time.326;344 
1.8.6 PDT in psoriasis
Topical application of ALA on psoriatic plaques induces preferential accumulation of 
PpIX, which makes psoriasis a potential indication for treatment with PDT.44 However, the 
photodynamic treatment of psoriasis appears to be less straightforward compared with 
NMSC.
In 1911, Henry Silver, a dermatologist from Chicago, ﬁ rst described the successful 
treatment of plaque type psoriasis with Hp following irradiation with UV light.3 Many 
decades later in 1994, Boehncke and colleagues reported a possible explanation for this 
by showing that PDT using Photosan-3, which is mixture of three diﬀ erent porphyrins, 
was able to suppress secretion of TH1 cytokines IL-1β, TNF-α and IL-6 in freshly isolated 
peripheral mononuclear cells from psoriatic patients in a dose dependent manner, 
which has also been reported after PUVA therapy.229 Shortly hereafter, a small clinical 
study by the same authors in three psoriatic patients showed PDT (10% ALA, 27 J/cm2 of 
red light) to be equally eﬀ ective as dithranol.228 Subsequently, Stringer and colleagues 
conducted a larger study on PDT in psoriasis, after they had observed lesional speciﬁ c 
PpIX ﬂ uorescence after application of ALA.44 In this study, a variable clinical response 
was observed after a single treatment of 2-16 J/cm2 visible light after application with 
20% ALA.233 Clinical eﬃ  cacy was improved furthermore when multiple treatments 
were performed but the unpredictable clinical response and patient discomfort was 
still a great problem.93 Bissonnette studied autoﬂ uorescence in psoriatic plaques and 
noted red ﬂ uorescence after irradiation with blue light, which after spectroﬂ uormetrical 
analysis turned out to be caused by PpIX.345 However, repeated exposures with blue light 
were not eﬀ ective to induce clinical improvement.346 Finally, after administration of oral 
Figure 18: Target sites for 
biological agents.344
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ALA following a single exposure with blue light, clinical improvement was observed.347 
Immunohistochemical assessment revealed induction of apoptotic T cells (TUNEL+/
CD3+), which could be a possible explanation for the clinical improvement observed 
after PDT. However, the prolonged generalized photosensitivity and the toxic eﬀ ects of 
systemically administered ALA, make this therapy less suitable for daily practice.
Further attempts to improve the clinical eﬃ  cacy of topical PDT in psoriasis were 
performed by Radakovic-Fijan and colleagues in two clinical trials, studying diﬀ erent ALA 
formulations (0.1, 1 and 5%; 20 J/cm2, 60 mW/cm2, Waldmann PDT 1200L) and light doses 
(5, 10 and 15 J/cm2, 60 mW/cm2, Waldmann PDT 1200L; 1% ALA).235;236 Irradiations were 
performed on three plaques, twice weekly for a maximum of 12 weeks. In addition to 
severe pain, which sometimes required cessation of the treatment, clinical results were 
disappointing, showing a signiﬁ cantly higher reduction in the psoriasis severity index 
(PSI) after 20 J/cm2 (59%) compared with 5 and 10 J/cm2. The diﬀ erent ALA formulations 
showed 37.5, 45.6 and 51.2% reductions in baseline PSI with no signiﬁ cant diﬀ erences 
between the diﬀ erent ALA formulations. The authors concluded PDT using these 
protocols not to be suitable for the treatment of psoriasis.
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 1.9 Outline of the thesis
1.9.1 Introduction and clinical relevance
Skin cancer is the most common form of cancer. Its incidence is dramatically rising with 
an increase of 80% in the total number of skin cancer patients to be expected in the 
Netherlands from 2000 to 2015.348 Moreover, also multiple skin cancers are seen per 
patient clinically as as well subclinically (ﬁ eld-cancerization). Consequently, this puts a 
heavy burden on general practitioners and dermatologists, requiring adequate diagnostic 
tools and therapeutic modalities. Psoriasis is a chronic skin disease, with major impact on 
the quality-of-life.292 Since no curable treatments are available yet, patients must rely on 
maintenance treatments, some of which having cumulative toxic eﬀ ects.    
Photodynamic therapy in dermatology is a relatively new non-invasive treatment 
modality, in which lesional tissue is sensitized with a topical photosensitizer-precursor 
(ALA) and destroyed upon irradiation with visible light subsequently. Since in most skin 
diseases a preferential accumulation in lesional skin is observed, only lesional tissue is 
aﬀ ected by this treatment. With ﬂ uorescence diagnosis with ALA-induced porphyrins, 
accumulation of the photosensitizer (PpIX) can be studied by illumination of the lesion 
to induce speciﬁ c ﬂ uorescence. Since the intensity of the ﬂ uorescence diﬀ ers between 
skin diseases, ﬂ uorescence data might well be of value for diagnostic purposes.  
Considering the expected increases in skin cancer, PDT and FDAP could be useful in 
the diagnosis and treatment of these cancers and its precursor lesions (AK). PDT is 
considered a selective therapy, which is particularly useful to treat sun-damaged skin 
(ﬁ eld-cancerization), thereby possibly reducing the incidence of invasive skin cancers. 
FDAP could be a useful tool in the early detection of these lesions, as well as DNA 
aneuploidy which is regarded the most common malignancy-speciﬁ c cell marker with 
several aspects correlating with malignancy-grade. Besides, FDAP as well as PDT share the 
beneﬁ t of being non-invasive procedures. Since PDT is considered a safe therapy without 
cumulative toxic eﬀ ects, it could be an alternative treatment option for conventional 
phototherapy currently used in the treatment of psoriasis.
1.9.2 Current problems
The precise mechanisms on the preferential accumulation of PpIX in diﬀ erent tissues 
as well as within the epidermis, have not yet been fully elucidated. Moreover, several 
internal factors are known to inﬂ uence the processes of ALA-uptake (penetration through 
the stratum corneum and diﬀ usion into the skin) and PpIX formation (synthetic capacity 
of the heme-cycle). But several external factors regarding the FDAP procedure are also 
known to inﬂ uence the ﬂ uorescence acquired with FDAP. Knowledge on these factors 
and mechanisms is crucial to be able to better interpret ﬂ uorescence data acquired 
with FDAP and to optimize PDT furthermore. Veriﬁ cation of these ﬂ uorescence data and 
standardization of the procedure would make FDAP a more reliable tool.
Although PDT has been reported to clinically improve psoriasis, its histological eﬀ ects 
are not known. Neither has an explanation been found for the variable treatment results 
reported in literature. Assessment of the PpIX ﬂ uorescence characteristics in psoriatic 
plaques might provide a clue.
Also few data are available on the cellular processes involving the progression of an early 
AK to invasive disease. A progression marker to discriminate the ‘good’ from the ‘bad’ 
AKs would be of great clinical use. Aneuploidy might be a possible candidate, but a non-
invasive procedure such as FDAP would be particularly useful. 
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1.9.3 Aims and research design
In this thesis, PpIX accumulation is studied in normal skin and the hyperproliferative skin 
diseases: psoriasis and AK, with special focus on the putative mechanisms explaining 
the mutual diﬀ erences observed herein. Furthermore, the value of FDAP as a diagnostic 
tool and DNA aneuploidy as a progression marker in various stages of AK is evaluated, in 
order to detect early invasive disease. Additionally, the clinical and immunohistochemical 
eﬀ ects of PDT and FDAP in the treatment of psoriasis are investigated, as these could 
give a potential clue to optimize this therapy.
In the context of these questions, the following aims were formulated:
Ia To investigate PpIX content in lesional and non-lesional skin in AK and psoriasis in vivo following application 
of ALA and to correlate this with PpIX ﬂ uorescence acquired with FDAP.
Ib To investigate PpIX accumulation without interference of the stratum corneum, in lesional and non-lesional 
skin in AK, psoriasis and normal skin following application of ALA.
Ic To investigate preferential accumulation of PpIX within the epidermis, in order to characterize the target 
cells for PDT and FDAP.
These studies will be described and discussed in chapter 2.
IIa To evaluate the clinical and histological eﬀ ects of PDT in psoriasis and to assess PpIX ﬂ uorescence during 
PDT.
IIb To study preferential accumulation of PpIX within psoriatic plaques by means of FDAP and to correlate this 
to histologic morphology and immunohistochemical psoriatic activity markers. 
These studies will be described and discussed in chapter 3.
IIIa To study DNA aneuploidy and proliferation in diﬀ erent stages of KIN and to assess their roles as potential 
progression markers.   
IIIb To evaluate the value of FDAP as a diagnostic tool to discriminate between diﬀ erent stages of keratinocytic 
intraepidermal neoplasias (KIN, conventionally classiﬁ ed as AK or Bowen’s disease) or proliferative status.
These studies will be described and discussed in chapter 4.
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The following research designs were developed to reach these aims:
Ia After incubation with ALA, lesional and non-lesional skin from patients with psoriasis and AK, PpIX 
ﬂ uorescence at the skin (macroscopic ﬂ uorescence) was recorded with FDAP. Afterwards, biopsies were 
taken from lesional and non-lesional skin and PpIX, as well as dsDNA as an epidermal reference, was 
extracted for spectroﬂ uorometrical analysis. PpIX ﬂ uorescence at the skin (FDAP) was correlated to PpIX 
content in the skin. 
Ib Biopsies from lesional and non-lesional skin from patients with psoriasis and AK were ex vivo incubated 
with ALA. Afterwards, PpIX and dsDNA were extracted for spectroﬂ uorometrical analysis.
Ic Biopsies from normal skin were ex vivo incubated with ALA and frozen sections were studied with 
ﬂ uorescence microscopy to evaluate the distribution of PpIX throughout the epidermis. According to these 
results, PpIX was measured with ﬂ ow cytometry in the basal and suprabasal epidermal compartment. 
Additional in vitro studies were performed on PpIX accumulation in cell cultures during diﬀ erent growth 
phases and after induction of terminal diﬀ erentiation.
IIa After keratolytic pre-treatment, psoriatic plaques were treated with fractionated ALA-PDT and contralateral 
plaques were treated with placebo PDT. During PDT, PpIX ﬂ uorescence was recorded using FDAP. Psoriatic 
severity was assessed using the SUM-score and biopsies were taken before and after PDT from the ALA and 
placebo-treated sites. Immunohistochemistry was performed to assess psoriatic activity using markers for 
proliferation, keratinization and inﬂ ammation. 
IIb After keratolytic pre-treatment and incubation with ALA, FDAP was performed on psoriatic plaques. 
Biopsies were taken from high- and low ﬂ uorescing sites within the plaques and were analyzed by 
(immuno)histochemistry to assess histological morphology (stratum corneum thickness) and psoriatic 
activity using markers for proliferation, keratinization and inﬂ ammation. Afterwards, stratum corneum 
thickness was correlated to macroscopic ﬂ uorescence acquired with FDAP.
IIIa Biopsy specimens from patients with NMSC were analyzed with quantitative DNA ﬂ ow cytometry to 
assess ploidy status. Furthermore, (immuno)histochemistry was performed to assess KIN-grade and Ki67 
expression. Afterwards, correlations between these parameters were studied. 
IIIb FDAP was performed on patients with ﬁ eld-cancerization and biopsies were taken from diﬀ erent lesions. 
(Immuno)histochemistry was performed on these biopsies for histopathological classiﬁ cation, using the 
KIN- as well as conventional histopathological classiﬁ cation, assessment of Ki67-antigen expression, 
a marker for proliferation, and stratum corneum thickness. Afterwards, correlations between these 
parameters were studied. 
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      Chapter2
Accumulation of protoporphyrin-IX 
in actinic keratoses, psoriasis and
normal skin following application of 
aminolevulinic acid and its correlation 
with fluorescence diagnosis 
This chapter was based on the following publications:
Smits T, Robles CA, van Erp PE, van de Kerkhof PC, Gerritsen MJ. Correlation between macroscopic 
fluorescence and protoporphyrin IX content in psoriasis and actinic keratosis following application of 
aminolevulinic acid. J Invest Dermatol 2005; 125(4):833-839.
Smits T, Laarhoven AIM, Staassen A, van Erp PE, van de Kerkhof PC, Gerritsen MJ. Induction of 
protoporphyrin-IX by aminolaevulinic acid in actinic keratosis, psoriasis and normal skin: preferential 
porphyrin enrichment in differentiated cells. Br J Dermatol 2009, in press. 
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Correlation Between Macroscopic Fluorescence and
Protoporphyrin IX Content in Psoriasis and Actinic Keratosis
Following Application of Aminolevulinic Acid
Tim Smits, Cesar A. Robles, Piet E. J. van Erp, Peter C. M. van de Kerkhof, and Marie-Jeanne P. Gerritsen
Department of Dermatology, Radboud University Nijmegen Medical Centre, GL Nijmegen, The Netherlands
In fluorescence diagnosis with 5-aminolevulinic acid (ALA)-induced porphyrins (FDAP), protoporphyrin IX (PpIX)
accumulation can be macroscopically visualized. Interpretation of these data is still problematic because of the low
reproducibility of the procedure and poor understanding of the mechanisms involved in PpIX tumor selectivity. In
this study, PpIX accumulation is investigated in patients with psoriasis and actinic keratosis (AK) following FDAP.
For this purpose, desquamated lesional and non-lesional skin were incubated with 20% ALA ointment for 3 h, FDAP
was performed, and highly fluorescing lesional skin and non-lesional skin were biopsied. In extracts from these
biopsies, PpIX, protein, and dsDNA were quantified by spectrofluorometry. Digital images acquired with FDAP were
analyzed using image analysis software. PpIX per biopsy in lesional skin in both psoriasis and AK was significantly
higher than in non-lesional skin (po0.05). When corrected for epidermal involvement, only lesional psoriatic
skin showed significantly higher PpIX levels than non-lesional skin. The PpIX-ratio lesional:non-lesional skin
(mean(pmol per mL) � SEM) was 4.12 � 0.91 in psoriasis and 1.96 � 0.24 in AK. In FDAP, the ratio of lesional:
non-lesional skin was 1.77 � 0.06 in psoriasis and 1.37 � 0.07 in AK. Macroscopic fluorescence and PpIX content
appeared to be well correlated (r¼ 0.73), thus making FDAP a good predictor of PpIX content.
Key words: actinic keratosis/5-ALA/fluorescence diagnosis/protoporphyrin IX/psoriasis
J Invest Dermatol 125:833 –839, 2005
Photodynamic therapy with 5-aminolevulinic acid (ALA) or
its methylester (MAL) as a topical photosensitizer is gaining
interest in an increasing number of dermatological centers.
In this treatment the preferential accumulation of endog-
enous porphyrines, in particular protoporphyrin IX (PpIX), in
lesional skin after incubation with ALA/MAL is used to treat
various skin diseases (Kennedy et al, 1990; Foley, 2003). As
PpIX has characteristic fluorescence properties, its prefer-
ential accumulation in certain cell types can also be used as
a cellular marker. In fluorescence diagnosis with ALA-in-
duced porphyrins (FDAP), lesional and non-lesional skin is
irradiated with blue (Wood’s) light after incubation of the skin
with ALA. As PpIX shows red fluorescence when excited by
blue light, PpIX accumulating cells can be visualized after
irradiation with Wood’s light (Fritsch et al, 2000). In cases
where demarcation of lesional skin is clinically problematic
or in dermatological screening of field cancerized skin,
FDAP may provide additional information. Interpretation of
these data is still problematic because of the low repro-
ducibility of the procedure due to the numerous factors in-
fluencing fluorescence detection and poor understanding of
the mechanisms involved in PpIX tumor selectivity.
Several different fluorescence detection techniques have
been described by other authors studying PpIX fluores-
cence in human skin and mucosa (Andersson-Engels et al,
1995; Inaguma and Hashimoto, 1999; Wennberg et al, 1999;
Leunig et al, 2001; Ericson et al, 2003b). Because of the
different procedures that have been used, the results are
difficult to compare. Wennberg et al reported a 50% cor-
relation between macroscopic fluorescence imaging and
histological mapping in 22 basal cell carcinoma (BCC)
(Andersson-Engels et al, 1995; Wennberg et al, 1999). Lack
of selectivity and great variation in microscopic intra- and
inter-tumor fluorescence in BCC have been described by
Martin et al (1995), whereas Peng et al (2001) found a highly
selective and homogenous PpIX fluorescence in nodular
BCC after 3 h incubation with MAL. Ericson et al (2003b)
reported that macroscopic fluorescence levels 1.4 times
above the mean normal skin fluorescence were associated
with an abnormal condition in patients with facial BCC after
3–4 h incubation with ALA. The question remains, however,
whether these high fluorescence values are generally as-
sociated with pathologic skin conditions. Macroscopic flu-
orescence intensity after incubation with ALA has been
shown to differ in various skin diseases. Psoriasis has been
reported to have the highest macroscopic fluorescence
values but homogenicity appears to be a problem when
lesions are not pretreated with a keratolytic agent (Fritsch
et al, 2000). Macroscopic fluorescence intensity and intr-
alesional PpIX content after ALA incubation have been
Abbreviations: AK, actinic keratosis; ALA, 5-aminolevulinic acid;
BCC, basal cell carcinoma; FDAP, fluorescence diagnosis with 5-
aminolevulinic acid-induced porphyrins; NS, normal skin; PpIX,
protoporphyrin-IX
Copyright r 2005 by The Society for Investigative Dermatology, Inc.
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studied by Fritsch et al (1999). In this study, macroscopic
fluorescence intensity was assessed by the human eye
and given a value from 0 till 4 according to a fluorescence
standard. With new digital imaging techniques, however,
macroscopic fluorescence can be measured in vivo
more accurately (Ackermann et al, 2000). In the same
study, porphyrins were extracted, assessed by spectro-
fluorometry, and expressed per gram total protein. As PpIX
is thought to be mainly formed in the epidermis, a more
specific epidermal reference to relate PpIX content to would
be more appropriate. As most PpIX is formed in the ep-
idermis and most cellular nuclei are located intraepiderm-
ally, DNA content would be a suitable epidermal marker, The
use of DNA as an epidermal reference has already been
proven useful in several studies (van de Kerkhof et al,
1983a, b).
The aim of this study was to investigate PpIX accumu-
lation in psoriasis and actinic keratosis (AK) and their sur-
rounding clinically normal skin incubated with 20% ALA
ointment for 3 h and to correlate these data to macroscopic
fluorescence using a digital fluorescence imaging system.
When this correlation is known, macroscopic fluorescence
measured on the skin could be used as an estimate for
actual PpIX content in the skin.
Results
Fluorescence spectrometry Fluorescence emission spec-
tra (lexcitation¼408 nm, slit¼ 10 nm) from ALA-treated skin
samples showed maxima at around 630 nm with a smaller
peak at around 700 nm. As PpIX is the predominant ALA-
induced porphyrin metabolite (83.8%–92.6%) (Fritsch et al,
1999) and considering the emission maxima obtained from
the ALA-treated samples to resemble the PpIX reference
standard emission peak, one can assume these emission
maxima at 630 nm to be predominantly caused by PpIX
(Fritsch et al, 1999) (Fig 1). These maxima were most pro-
nounced in ALA-treated skin samples from psoriasis, actinic
keratoses, and their non-lesional skin, respectively. Basal
levels of PpIX were below background fluorescence and
therefore not accurately measurable.
Tissue PpIX content after ALA Lesional skin incubated
with 20% ALA for 3 h showed higher total PpIX content than
non-lesional skin in both psoriasis and AK. Lesional psoria-
tic skin showed higher PpIX levels compared with lesional
skin in AK and non-lesional skin from psoriasis and AK,
respectively (Fig 2, Table I).
Tissue dsDNA content In psoriasis and AK, lesional
dsDNA content was higher compared with non-lesional
skin in both diseases. Lesional psoriatic dsDNA content,
however, was not statistically different from dsDNA content
in lesional AK. When normal surrounding skin in AK and
psoriasis was compared, normal surrounding skin in pso-
riasis appeared to contain more dsDNA than normal sur-
rounding skin in AK (Fig 3, Table I).
Tissue PpIX content after ALA corrected for dsDNA -
When correcting PpIX content for dsDNA content, psoriasis
again showed statistically significantly higher levels of PpIX
compared with normal psoriatic skin. In AK, however, PpIX
levels in lesional skin did not differ from PpIX levels in non-
lesional skin. PpIX content in lesional psoriatic skin was also
higher than in lesional skin in AK (Fig 4, Table I).
Photobleaching studies The PpIX emission peak (630 nm)
declined following irradiation with 415 � 5 nm at 40 mW per
cm2 (po0.001) (Fig 5). With increasing fluence, a second
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Figure1
Emission spectrum of extracts from 20% 5-aminolevulinic acid
(ALA) (3 h)-incubated psoriatic skin samples and protoporphyrin-IX
(PpIX) reference standard. PS-ALA: psoriatic lesion after 20% ALA (3
h), NS-ALA: normal skin in psoriasis after 20% ALA (3 h). The emission
spectra (lexcitation¼408 nm) of 20% ALA (3 h) incubated psoriatic skin
samples and PpIX reference standard are very similar.
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Figure 2
Tissue protoporphyrin-IX (PpIX) content after 20% 5-amino-
levulinic acid (3 h). From 4 mm punch biopsies, PpIX was extracted
and quantified by spectrofluorometry. �po0.05, ���po0.001. Error
bars denote standard errors of the mean.
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peak arose at 670 nm, which is thought to be the photo-
product of PpIX (Ppp) (Ericson et al, 2003a). The decline in
the PpIX emission peak was most pronounced in pure PpIX
solutions obtained from the PpIX reference standard kit
compared with PpIX-enriched normal skin extracts (Fig 6).
Two-way ANOVA also revealed a significant difference be-
tween the PpIX-enriched and the pure PpIX solutions
(po0.01). This indicates a slower photobleaching of PpIX-
enriched normal skin extracts and is also demonstrated by
a greater fluence required to halve the initial PpIX content
(Fig 6). Considering these half-lives to be relatively high,
possible photobleaching effects due to ambient light expo-
sure during the extraction procedure can therefore be
neglected.
Image analysis In both psoriasis and actinic keratoses,
incubation with 20% ALA for 3 h induced a statistically sig-
nificant increase in lesional skin: normal skin fluorescence
ratio. In psoriasis, this increase was more pronounced than
in AK (Table I, Figs 7 and 8).
Correlation between PpIX content and macroscopic flu-
orescence When all corrected fluorescence data from the
Dyaderm system were compared with their accompanying
PpIX values, a positive correlation was found as seen in
Fig 9. Correlation analysis revealed a correlation coefficient
of r¼ 0.73. When correlation curves for AK and psoriasis
were analyzed separately, the correlation coefficient for AK
appeared to be somewhat higher compared with psoriasis
(r¼0.79 vs 0.69, respectively).
Discussion and Conclusions
Treatment with ALA ointment under an occlusive dressing
for 3 h of lesional and non-lesional skin in AK and psoriasis
induces an increase in biochemical tissue porphyrin con-
tent. This increase was significantly higher in lesional skin
compared with non-lesional skin and was most pronounced
in psoriasis when compared with AK, which is in accord-
ance with other studies (Fritsch et al, 1999). In our study,
porphyrin content was quantified using a PpIX reference
standard. This can be justified as PpIX is the predominant
porphyrin comprising about 75% (Fritsch et al, 1999) of total
ALA-induced porphyrins after 3 h incubation. This also be-
comes clear when the emission spectra obtained from ALA-
treated skin and the PpIX reference standard are compared
(Fig 1). Although the composition of porphyrin metabolites
is known to change in time following ALA application, po-
rphyrin patterns, however, do not significantly differ be-
tween various skin diseases, including normal skin, BCC,
squamous cell carcinoma (SCC), and psoriasis (Fritsch et al,
1999). Furthermore, one can discuss whether these exact
porphyrin compositions are clinically relevant when
Table I. Summary of results
Skin type
PpIX
(pmol per mL)
dsDNA
(lg per mL)
PpIX/dsDNA (pmol
PpIX per lg dsDNA)
PpIX ratio
after ALA
Macroscopic fluorescence ratio
Before ALA After ALA
Psoriasis 27.4 � 3.1 1.7 � 0.2 16.3 � 2.4 4.1 � 0.9 0.90 � 0.03 1.77 � 0.06
Normal skin (psoriasis) 7.80 � 0.81 1.1 � 0.2 7.5 � 1.5
Actinic keratosis 11.8 � 2.6 1.5 � 0.3 7.7 � 1.4 2.0 � 0.2 0.98 � 0.03 1.37 � 0.07
Normal skin (actinic keratosis) 6.2 � 1.9 0.58 � 0.09 7.6 � 1.9
Values are denoted � standard error of the mean.
PpIX, protoporphyrin IX; ALA, 5-aminolevulinic acid.
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Figure 3
Tissue dsDNA content. From 4 mm punch biopsies, dsDNA was
extracted and quantified by spectrofluorometry. �po0.05. Error bars
denote standard errors of the mean.
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Tissue protoporphyrin-IX (PpIX) content after 20% 5-amino-
levulinic acid (3 h) corrected for dsDNA. PpIX values were divided
by their accompanying dsDNA values. �po0.05. Error bars denote
standard errors of the mean.
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performing FDAP as changes in ‘‘porphyrin-like fluores-
cence’’ (630 nm) are measured.
In our study, porphyrins were measured after 3 h ALA
application. This timepoint was found to have optimal
tumor: normal skin contrast ratio when performing FDAP
according to Ericson et al (2003b). For higher lesional flu-
orescence values, a longer incubation period up to 6 h is
needed, but surrounding (normal) skin fluorescence also
increases, thus reducing fluorescence contrast ratio. Tumor:
normal skin ratios of total biochemical tissue porphyrin
content peak between 1 and 4 h of ALA incubation in BCC
and SCC; in psoriasis, however, this ratio is optimal after
6 h ALA incubation (Fritsch et al, 1999).
As PpIX is formed and accumulated mainly in the epi-
dermis, PpIX data were also corrected for epidermal in-
volvement using dsDNA as an epidermal reference. After
this correction, in AK, no statistically significant increase in
PpIX per mg dsDNA was seen any longer after ALA treat-
ment. But, PpIX per mg dsDNA in psoriasis was still signif-
icantly higher after ALA treatment. These findings suggest
different mechanisms being mainly responsible for in-
creased PpIX formation in psoriasis and AK. In psoriasis,
increased PpIX formation per cell may play a more impor-
tant role than in AK. Various mechanisms have been pro-
posed for this by other investigators. Alterations in the
heme-biosynthethic pathway in hyperproliferative tissue are
thought to play an important role in preferential PpIX accu-
mulation including increased porphobilinogen deaminase
(PBGD) and/or decreased ferrochelatase activity (Hinnen
et al, 1998; Krieg et al, 2002). An increased uptake of ALA
by pathologic tissue may also be responsible for increased
PpIX formation, for example due to a defective skin barrier
function, which has been suggested by Martin et al (1995) in
BCC. In psoriasis this may also be the case as defects in
stratum corneum structure have been described (Ghadially
et al, 1996).
Our data show no statistically significant differences in
PpIX content per cell in lesional AK compared with sur-
rounding non-lesional AK. This suggests the number of cells
producing PpIX to be the most important factor for mac-
roscopic skin fluorescence in vivo as seen with FDAP. This is
in parallel with our findings that dsDNA content is signifi-
cantly increased in lesional AK compared with non-lesional
surrounding skin. Although it can not be excluded that in AK
alterations in the heme-biosynthetic pathway or increased
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Figure 5
Emission spectra of irradiated protoporphyrin-IX-enriched normal
skin sample solutions. Excitation wavelength was set to 408 nm.
Samples were exposed to 0, 2.4, 36, 144, and 288 J per cm2 using the
Waldmann Omnilux Blue (415 � 5 nm, 40 mW per cm2). Note that the
630 nm emission maximum declines and a new maximum arises at 670
nm following higher fluences. Fluorescence intensity was measured in
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Photobleaching of protoporphyrin-IX (PpIX)-enriched normal skin
extracts and PpIX solutions. PpIX-enriched normal skin extracts ap-
peared to be less susceptible to photobleaching compared with pure
PpIX solutions (po0.01). Fluorescence intensity was measured in rel-
ative units. NS, normal skin. Error bars denote standard errors of the
mean.
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Macroscopic fluorescence in vivo (FDAP) ratio lesional skin: non-
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incubation with 20% 5-aminolevulinic acid ointment for 3 h.
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uptake of ALA may also play a role, this could not be dem-
onstrated in our study. Additional studies analyzing PpIX
accumulation in cell cultured systems of AK and psoriasis
could provide further information concerning this issue.
Initially, total protein was measured as an epidermal ref-
erence value but this did not appear to be an appropriate
reference eventually: protein levels in the biopsies between
lesional and non-lesional skin in psoriasis did not differ
much from each other with a large standard deviation,
which could be explained by the fact that the amount of
dermis in the biopsies was not standardized. As lesional
skin in psoriasis is known to have higher epidermal protein
levels because of the higher proliferation rate, this suggests
the dermis to have a substantial contribution to total protein
content, thus overshadowing differences in epidermal pro-
tein content (van Erp and van de Kerkhof, 1988). DsDNA
quantification revealed evident differences in the four skin
types and appeared to be a good marker for the amount of
epidermal keratinocytes. In hyperproliferative skin condi-
tions, total DNA content is commonly increased due to in-
creased DNA synthesis, which can be a disturbing factor
when a comparison is made with normoproliferative skin. In
a study of Bauer et al (1981), the percentage of cells in the
S-phase in psoriasis appeared to be increased compared
with normal skin (9.7% vs 2.7%). In non-involved psoriatic
skin, this percentage of cells in S-phase was 3.8%. To the
best of our knowledge, in AK, these exact percentages are
not known but when proliferation indices (PI) of psoriasis
and AK were compared (using Ki-67 expression) in a study
of Caldwell et al (1997) AK appeared to have a PI that is 1.26
times the PI in psoriasis. This means that in our samples,
dsDNA values as a marker of the total number of epidermal
keratinocytes could be overestimated. When correcting our
dsDNA data accordingly, lesional psoriatic skin and AK data
had to be decreased by 7.25% and 9.14%, respectively,
and their non-lesional skin to a lesser extent. These cor-
rections, however, did not have a significant effect on our
overall data.
Our results show a positive relation between macro-
scopic fluorescence as measured with our digital imaging
system and biochemical tissue PpIX content. Although
other authors have described in vivo measuring of PpIX,
macro-, and microscopic fluorescence imaging after ALA
treatment or combinations, to the best of knowledge, no
one has linked digital macroscopic imaging directly to bi-
ochemical tissue porphyrin content (Martin et al, 1995;
Figure 8
Normal, fluorescence, and pseudo-color images from psoriatic skin in vivo. Before (A–C) and after incubation with 20% 5-aminolevulinic acid
(ALA) ointment for 3 h (D–F). Incubation with 20% ALA (3 h) ointment induced a remarkable increase in red fluorescence, which was more
pronounced in lesional skin.
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Figure 9
Correlation between protoporphyrin-IX content in the skin and
macroscopic fluorescence at the skin. r¼0.73, po0.001. Dotted
lines indicate 95% confidence intervals.
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Wennberg et al, 1999; Ericson et al, 2003b). Especially in the
lower fluorescence range up to 1.0 fluorescence intensity, in
which most actinic keratotic lesions lie, this correlation was
particularly strong (Fig 9). When psoriatic and AK values
were analyzed separately, the slope of the correlation curve
in psoriasis showed a more vertical course (not shown). This
might be explained by the limited penetration into the
deeper skin layers of the blue excitation light in our imaging
system. PpIX deep in the epidermis, which is still detectable
by spectrofluorometric analysis might not be fully excited
and detected by FDAP. This is one of the main limitations of
FDAP and emphasizes the need for adequate desquamat-
ion before performing FDAP. The question remains to what
extent PpIX fluorescence is influenced by a non-standard-
ized desquamation procedure, e.g., curretage, as external
injury to the skin may induce false-positive fluorescence by
a disrupted stratum corneum and/or increased wound re-
pair theoretically. As basal PpIX levels in psoriatic stratum
corneum are increased compared with other skin diseases
(Bissonnette et al, 1998) inadequate desquamation can also
lead to false-positive fluorescence values when performing
FDAP. In our study protocol, desquamation was achieved
by the use of 10% salicylic acid in vaseline twice daily 1 wk
prior to the day of investigation, thus preventing any inter-
ference of scales.
When properly standardized as performed with our dig-
ital imaging system, FDAP appeared to be a good measure
for PpIX content in the skin. This can be helpful in the clin-
ical setting when PpIX accumulation is used for example as
a guiding tool in taking biopsies in field cancerized skin, in
demarcation of (non-melanoma) skin tumors or to evaluate
the treatment efficacy in non-melanoma skin cancer. Fur-
ther studies are, however, needed to scrutinize the mech-
anisms involved in preferential PpIX accumulation and the
factors influencing FDAP, so that fluorescence values can
be adequately interpreted. These data and a standardized
treatment protocol are needed to assess the sensitivity and
specificity of the procedure so that FDAP can become a
more reliable diagnostic tool.
Material and Methods
Study population This study was approved by the local ethics
committee and was conducted according to the Declaration of
Helsinki Principles. After given their written informed consent, 11
patients with plaque-type psoriasis and 11 patients with AK were
included in this study. All patients had a long history of psoriasis or
AK that was histologically confirmed. The studied lesions were all
located on the extremities. Lesional skin was pretreated with 10%
salicylic acid in vaseline for 1 wk prior to the day of ALA application
to remove any scales that could interfere with ALA uptake and/or
light penetration. Prior to ALA application, lesions were photo-
graphed with the DyaDerm digital imaging system (Biocam GmbH,
Regensburg, Germany) after desinfection with 80% denaturated
alcohol vol/vol. Afterward, 20% 5-ALA ointment (Medac Gmbh,
Wedel, Germany) was applied to an area of 5 � 8 cm including
lesional and non-lesional skin. Over this area, Tegaderm (3 M
Pharmaceuticals, Zoeterwoude, the Netherlands) and aluminum
foil were applied as an occlusive dressing and to protect against
unwanted light effects. Three hours later, the ALA ointment was
removed, again photographs were taken with the digital imaging
system, and 4 mm punch biopsies were taken from non-lesional
skin and fluorescing lesional skin.
Image-capturing procedure The DyaDerm digital imaging system
consists of a flash light (Xenon light source with a custom band-
pass filter (370–440 nm)) and a 12-bit Sony CCD camera combined
in one adjustable arm coupled to a Pentium IV computer equipped
with custom-made image capturing software (Dyaderm Pro v1.4,
Biocam GmbH). The flash light emits 7 light pulses per second to
the skin, which are recorded by the CCD camera (exposure time
100 ms) equipped with a special Schott GG 455 longpass filter to
filter out the excitation light. As PpIX fluorescence emission con-
sists of light in the red spectrum, the red pixels of the CCD camera
(spectral sensitivity at 630 nm between 85% and 90%) were used
to generate a fluorescence image. In this way, a normal colored
image and a fluorescence image were processed in real time. Be-
cause of the short exposition time to the excitation light, photo-
bleaching of PpIX was minimalized in this way. To correct for
different lighting environments between pictures, a fluorescence
reference standard (Maccal 8044, 738-00, Multifoil, Utrecht, the
Netherlands) was included on every image. Images were recorded
in 16-bit grayscale TIFF format.
Skin biopsy procedure The 4 mm punch biopsies were taken in a
darkened room under local anesthesia with 1% xylocain–adrenalin
from highly fluorescing lesional and non-lesional skin after 3 h in-
cubation with 20% ALA ointment. Highly fluorescing areas from
lesional skin were located with the digital imaging system and
marked to identify the site of biopsy. Biopsies from non-lesional
(surrounding) skin were taken out of an area representing mean
non-lesional skin fluorescence. Here again, the site of the biopsy
was carefully selected and marked with the digital imaging system
so that macroscopic fluorescence at the site of biopsy and PpIX
per biopsy matched. Samples were directly frozen into liquid ni-
trogen afterward. To minimize possible PpIX stability problems,
tissue extraction and spectrofluorometrical analysis of PpIX was
performed on the same day.
Tissue extraction procedure The 4 mm punch biopsies were
trimmed to remove a large part of the dermis, frozen in liquid ni-
trogen, and homogenized at 2,000 r.p.m. with the Microdismem-
brator U (B. Braun Biotech International, Melsungen, Germany) for
2 min. Chloroform:methanol (2:1 vol/vol, Merck KgaA, Darmstadt,
Germany) mixture was used as an extraction medium. Mixtures
were centrifuged for 15 min at 15,000 r.p.m. (23,140 � g), and the
supernatant was collected for further analysis. A second extraction
cycle was performed by adding the same amount of chloro-
form:methanol (2:1 vol/vol) mixture to the pellet. This mixture was
vortexed for at least 5 min until a new suspension was formed and
centrifuged for 15 min at 15,000 r.p.m. (23,140 � g). Subsequently,
the supernantant was collected and added to the supernatant from
the first extraction cycle. The PpIX extraction procedure was iden-
tical to the procedure used by Inaguma and Hashimoto (1999)
apart from our homogenization technique. For dsDNA and protein
extraction out of the remaining pellet, phosphate-buffered saline
(B. Braun, Melsungen, Germany) was used as an extraction me-
dium with a similar extraction protocol as decribed above. All these
steps were performed in a dark laboratory environment taking ul-
timate care to prevent exposure of the specimens to light.
Spectrofluorometric analysis In the supernatant, the PpIX con-
tent was assessed by fluorescence spectrophotometry (Shimadzu
RF-5001 PC, Den Bosch, the Netherlands); excitation was set to
408 nm (slit 10 nm) and emission was recorded at 630 nm (slit 10
nm). An emission spectrum (excitation wavelength set at 408 nm)
was also recorded in the range from 450 to 800 nm. For quanti-
fication, a PpIX reference standard was used (Porphyrin Products
Inc., Logan, Utah). Chloroform:methanol (2:1 vol/vol) mixture was
used as a diluent. For protein quantification and dsDNA quantifi-
cation, the Nano Orange protein quantitation kit (Molecular Probes,
Eugene, Oregon) and Picogreen dsDNA quantitation kit (Molecular
Probes) were used, respectively.
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Photobleaching studies and recovery To evaluate possible PpIX
loss due to photobleaching during the extraction protocol and to
assess the internal validity, several photobleaching studies were
performed. In these studies, four different PpIX solutions from the
PpIX calibration curve (84, 33, 12 and 5 pmol per mL PpIX) and four
normal skin extracts with addition of four different PpIX solutions
(104, 54, 26, 13 and 3 pmol per mL PpIX) were exposed to various
fluences (0, 2.4, 36, 144 and 288 J per cm2) using the Waldmann
Omnilux Blue (415 � 5 nm, 40 mW per cm2, Waldmann Medische
Techniek B.V., Tiel, the Netherlands). These PpIX-enriched normal
skin extracts were produced by mixing 100 mL of PpIX solution with
900 mL of the normal skin extract, resulting in comparable PpIX
concentrations as the four pure PpIX solutions. At each fluence, an
emission spectrum (lexcitation¼ 408 nm, slit¼ 10 nm) was recorded.
The PpIX-enriched concentrations were chosen in the same range
as our measurements of PpIX in ALA-treated skin and were in the
reliable range of our calibration curve. Normal skin was obtained
from excess skin from patients undergoing abdominal plastic
surgery.
Image analysis The 16-bit grayscale TIFF fluorescence images
were imported in NIH ImageJ software (http://rsb.info.nih.gov/ij/).
Because the Xenon light source used for excitation has the highest
intensity in the center of the illuminated area, shading correction
was performed by means of the following algorithm:
S ¼ I=C with C ¼ B=BImax
where B is the blank image (image from a white homogenous
background recorded with the Dyaderm system), BImax the highest
intensity of blank image, I the (uncorrected) image, C the normal-
ized shading image, and S the shading corrected image.
Subsequently, the mean pixel value of the biopsy sites and flu-
orescence standard were measured and recorded. To correct for
different lighting conditions between the pictures, all measured
values were divided by the value of the accompanying fluores-
cence reference standard.
Statistical analysis For analysis of PpIX content, dsDNA values,
and macroscopic fluorescence in vivo a paired two-tailed Stu-
dent’s t-test was used. A p-valueo0.05 was regarded as statis-
tically significant. Correlation analysis of PpIX content and
macroscopic fluorescence in vivo was performed using Pearson’s
correlation analysis. All statistical calculations were performed us-
ing Statistica 6.0 software (Statsoft Inc., http://www.statsoft.com).
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Summary
Background In photodynamic therapy the endogenous photosensitizer protoporphy-
rin IX (PpIX) is synthesized following topical application of aminolaevulinic acid
(ALA). However, different tissues have distinct PpIX-accumulating properties,
due to differences in penetration of ALA through the stratum corneum and ⁄or
alterations in the haem cycle. Preferential PpIX accumulation has been reported
in terminally differentiated cell cultures but ex vivo data are lacking.
Objectives To study the intrinsic PpIX-accumulating capabilities of skin explants
from lesional and nonlesional skin in psoriasis and actinic keratosis, with normal
skin serving as a control, and to study PpIX accumulation in relation to differen-
tiation status in normal skin.
Methods Skin explants from patients with psoriasis, actinic keratosis and normal
skin were incubated with ALA and PpIX was measured spectrofluorometrically.
PpIX was measured in basal (b1-integrin-positive) and suprabasal (b1-integrin-
negative) keratinocytes in normal skin. In addition, PpIX accumulation was
studied in cell cultures at different levels of confluence and after induction of
terminal differentiation.
Results No significant differences in PpIX content were found between the differ-
ent tissues. However, increased PpIX was found in b1-integrin-negative compared
with b1-integrin-positive cells. In addition, in subconfluent cell cultures less PpIX
was found compared with confluent cell cultures. Induction of terminal differen-
tiation in vitro, however, resulted in less PpIX, which was likely to be related to
cell volume.
Conclusions As no significant differences in PpIX synthesis could be found between
the different tissue types, these data emphasize the importance of the penetration
route of ALA through the stratum corneum. Preferential PpIX accumulation
observed in suprabasal epidermal keratinocytes and confluent cell cultures points
towards a terminal differentiation-specific effect.
Photodynamic therapy (PDT) is a noninvasive two-stage pro-
cedure that requires administration of a photosensitizing
agent followed by illumination of the tumour with visible
light. The preferential accumulation of endogenous porphy-
rins into the skin after incubation with aminolaevulinic acid
(ALA) or its methyl ester is used to treat various skin dis-
eases.1,2 As ALA is an intermediate in the haem biosynthetic
pathway, exogenous application of ALA results in increased
protoporphyrin IX (PpIX) synthesis by bypassing ALA syn-
thase, a rate-limiting enzyme which is negatively controlled
by haem.3 Once activated by light of the appropriate wave-
length, together with oxygen, porphyrins can form reactive
oxygen species that can cause tissue damage. As PpIX also
has characteristic fluorescence properties, its preferential
accumulation in certain tissue types can be used as a
diagnostic tool. In fluorescence diagnosis with ALA-
induced porphyrins (FDAP), the skin is irradiated with blue
(408 nm) light following application of ALA. As PpIX shows
red fluorescence when excited by blue light, PpIX-accumulat-
ing cells can be visualized accordingly. Macroscopic fluores-
cence intensity after incubation with ALA has been shown to
differ in various skin diseases. In a previous study we have
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shown PpIX accumulation to be higher in psoriasis compared
with actinic keratosis (AK) and macroscopic fluorescence on
the skin to be a good predictor of PpIX content in the skin.4
However, it is not known exactly what causes these different
affinities for PpIX accumulation in different tissue types.
Alterations in permeability properties of the stratum corneum
and ⁄or differences in the haem biosynthetic pathway are
believed to play a role, although systematic in vivo studies are
lacking.
Several reports have shown the stratum corneum to be an
important factor in inter- and intralesional differences in
macroscopic fluorescence. In some of these reports PpIX flu-
orescence was shown to be negatively correlated with the
thickness of the stratum corneum.5,6 In other reports disrup-
tion of the stratum corneum integrity or removal of the
stratum corneum by tape stripping was associated with
increased PpIX fluorescence.7,8 These data point towards
penetration of the hydrophilic photosensitizer through the
lipophilic stratum corneum being an important determinant
for ALA-induced PpIX fluorescence. In this context, it would
be interesting to know the intrinsic capability of different
tissues to accumulate PpIX without interference of the stra-
tum corneum. Also, the affinity of PpIX to accumulate in
different epidermal cell types throughout the epidermis
would be of particular interest, as earlier reports have
shown increased PpIX accumulation after induction of termi-
nal differentiation in vitro.9,10 Knowledge on this may help
to explain the different susceptibility of various skin diseases
to PDT.
Therefore, in the present study, to assess PpIX accumulation
without interference of the stratum corneum, PpIX content
was measured ex vivo in human skin explants from different
skin conditions after incubation with ALA. To study preferen-
tial accumulation of PpIX in differentiated and nondifferenti-
ated cells, PpIX fluorescence was measured in basal and
suprabasal epidermal keratinocytes after incubation with ALA.
Additional experiments were performed by comparing PpIX
accumulation in epidermal cell cultured systems during differ-
ent growth phases, using a model that has been proven useful
to induce terminal differentiation in vitro.11
Materials and methods
Patients and biopsy procedure
This study was approved by the local medical ethics commit-
tee and was conducted according to the Declaration of Hel-
sinki principles. Ten patients with AK and 13 patients with
plaque-type psoriasis were included in this study after giving
their written informed consent. Four-millimetre punch biop-
sies were taken from lesional and surrounding nonlesional
skin located on the extremities after performing local anaes-
thesia with 1% lidocaine–adrenaline. Whenever possible, two
biopsies were taken from the same target to be able to com-
pare the effects with and without ALA within the same target
later on. Biopsies from normal skin for in vitro and ex vivo
experiments were taken from excess skin from patients who
had undergone abdominal plastic surgery. The samples were
collected on the same day surgery took place and were stored
in a special storage medium (SM) at 37 �C which consisted of
RPMI (Gibco, Breda, the Netherlands) supplemented with
10% fetal calf serum, 1% penicillin-streptomycin, 1% L-gluta-
mine and 20 mmol L)1 HEPES (Gibco).
Incubation time and aminolaevulinic acid concentration
In order to assess the optimal incubation conditions for PpIX
accumulation in vitro, human keratinocytes were incubated
with different ALA concentrations (0, 0Æ1, 1Æ0 and
10 mmol L)1) for different incubation times (1, 4, 16 and
24 h) and different incubation media [phosphate-buffered sal-
ine (PBS), RPMI, keratinocyte growth medium (KGM) with
and without growth factors (GF), and SM]. The results from
these pilot experiments are depicted in Figure 1.
(a)
(b)
Fig 1. Incubation experiments. (a) Aminolaevulinic acid (ALA)
concentrations up to 1 mmol L)1 showed higher protoporphyrin IX
(PpIX) accumulation. However, incubation with 10 mmol L)1 ALA
resulted in decreased PpIX fluorescence. Increasing the incubation
time also resulted in higher PpIX accumulation. Although incubation
for 16 and 24 h showed highest PpIX fluorescence, 4 h proved to be
efficient for reliable flow cytometric measurements. (b) From the
different growth media only phosphate-buffered saline (PBS) was
shown to be unsuitable for incubation with ALA. Therefore, also
due to practical reasons, 4 h incubation with 1 mmol L)1 ALA in
keratinocyte growth medium (KGM) without serum, with and
without growth factors (GF), was chosen for the in vitro experiments.
SM, storage medium; a.u., arbitrary units.
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Skin explant cultures
An explant culture system, adopted from Fritsch et al.,12 was
used which proved to be effective to study PpIX accumulation.
The biopsies were immediately stored in SM at 37 �C until
final incubation with ALA. To make sure that PpIX fluores-
cence from our samples was induced by ALA, several control
incubations were performed without ALA.
Before incubation with ALA the biopsies were washed in
PBS and excess dermis was removed for an optimal penetra-
tion of nutrients and ALA into the epidermis during incuba-
tion. Then, the biopsies were immersed in serum-free
medium containing 1 mmol L)1 ALA (Medac GmbH, Wedel,
Germany) in RPMI with 20 mmol L)1 HEPES for 16 h (over-
night) at 37 �C. During incubation the vials were protected
from light and were gently shaken. All biopsies were pro-
cessed on the same day as they were taken.
Flow cytometry
Skin biopsies
Biopsies from excess abdominal normal skin were incubated
for 4 h at 37 �C in a 1 mmol L)1 ALA ⁄PBS mixture. Controls
were incubated in PBS without ALA. Afterwards, a cell suspen-
sion was made by incubation with a 0Æ05% trypsin–ethylene-
diamine tetraacetic acid (EDTA) mixture (Gibco). Then, cells
were incubated with anti-b1-integrin (CD29, clone K20; Dako
BV, Heverlee, Belgium) for 10 min and suspended in PBS for
flow cytometry (Epics Elite; Coulter Corporation, Hialeah, FL,
U.S.A.). An air-cooled argon laser (20 mW, 488 nm) was
used for excitation. For detection a BP 625–635 nm filter (red
signal) and a photomultiplier were used. The amount of PpIX
per cell was determined. Between these steps cells were
washed in PBS. Experiments were performed three times and
mean values were calculated.
Cultured keratinocytes
Human primary keratinocytes, which also originated from the
patients who underwent abdominal plastic surgery, were
suspended in KGM + GF and seeded in culture plates at a
concentration of 5000 cells cm)2. The cells were grown at
37 �C in 95% humidified air with 5% CO2. KGM + GF con-
sists of keratinocyte basal medium (Cambrex, East Rutherford,
NJ, U.S.A.) supplemented with penicillin-streptomycin
(100 U mL)1; Gibco), bovine pituitary extract (Cambrex),
ethanolamine (0Æ1 mmol L)1; Sigma Aldrich, St Louis, MO,
U.S.A.), phosphoethanolamine (0Æ1 mmol L)1; Sigma
Aldrich), hydrocortisone (0Æ5 lg mL)1; BD Biosciences, Bed-
ford, MA, U.S.A.), insulin (5 lg mL)1; Sigma Aldrich) and
epidermal growth factor (10 ng mL)1; Sigma Aldrich). After
5 days the medium was refreshed and then, dependent on the
cell density, every 2 days. To study PpIX accumulation during
different phases of growth, cultured keratinocytes were incu-
bated with 1 mmol L)1 ALA in KGM + GF for 4 h at different
levels of confluence (10, 30, 50, 70, 90 and 100%), which
was determined by microscopy. To study PpIX accumulation
after induction of terminal differentiation, cells were grown
until 100% confluence was reached. Thereafter, some cultures
were further incubated for 48 h using KGM + GF and others
using only KGM without GF, which proved to be a suitable
model to induce terminal differentiation in vitro.11 After
incubation with 1 mmol L)1 ALA in KGM for 4 h, cells were
harvested with 0Æ05% trypsin–EDTA and washed in PBS. The
harvested cells were suspended in PBS and measured flow
cytometrically. The amount of PpIX per cell was determined.
Experiments were performed three times and mean values
were calculated.
Biochemical extraction of protoporphyrin IX,
double-stranded DNA and spectrofluorometry
Tissues and media
The protocol was adopted from Inaguma and Hashimoto13
and was similar to that used in an earlier report of our group.4
After 16 h the biopsies were taken out of the vials and washed
in PBS. These were then put in Teflon shaking flasks which
were frozen into liquid nitrogen and homogenized at
2000 r.p.m. in the Mikro-Dismembrator U (B. Braun
Biotech International, Melsungen, Germany). A chloroform ⁄
methanol (CM) (2 : 1; Merck, Darmstadt, Germany) mixture
was used as extraction medium, which was added to the
flasks. The suspensions were vortexed and centrifuged
(23 140 g for 15 min) and the supernatants were collected for
further analysis. Afterwards a second extraction cycle was per-
formed by again adding extraction medium to the remaining
pellet. This mixture was resuspended, centrifuged again and
the new supernatant was added to the supernatant from the
first extraction cycle. All these steps were performed in a dark
environment to minimize photodegradation of PpIX. For
extraction of double-stranded DNA (dsDNA) out of the
remaining pellet an extraction protocol identical to that used
for PpIX4 was used, with PBS instead of CM as the extraction
medium.
Although it is known that PpIX leaking into the medium
during incubation with serum-free incubation is minimal,14
PpIX was also assessed in the incubation media. When the
biopsies were removed, the media were vacuum dried in a
speed vacuum concentrator system (Speed Vac SPD111V;
Savant Instruments Inc., Holbrook, NY, U.S.A.) with a pump
system (Gel Pump GP110; Savant Instruments). When the
media were fully dried, 1700 lL CM and 300 lL PBS was
added. After these were properly mixed, the mixture was cen-
trifuged (926 g for 5 min) and the CM fraction (containing
PpIX) was collected for spectrofluorometric analysis.
PpIX in the extracts was measured using a Shimadzu
RF-5001 PC (Shimadzu, Den Bosch, the Netherlands) spectro-
fluorometer with the excitation wavelength set to 408 nm
(slit 10 nm) and the emission wavelength set to 630 nm
(slit 10 nm). Emission spectra were also recorded in the
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range of 500–800 nm to verify that the measurements were
porphyrin (PpIX) specific. A PpIX reference standard was used
for quantification of the fluorescence (Porphyrin Products Inc.;
Logan, UT, U.S.A.). For quantification of dsDNA, Picogreen
dsDNA quantitation kit (Molecular Probes, Invitrogen, Breda,
the Netherlands) was used.4
Cultured keratinocytes
After incubation with ALA, cells were harvested with 0Æ05%
trypsin–EDTA and washed in PBS. The cells were suspended
in 1 mL PBS and centrifuged (1646 g, 15 min). The superna-
tant was removed and the pellet was dissolved in 1000 lL
CM (2 : 1) mixture and vortexed. The solution was centri-
fuged (1646 g, 15 min) and the supernatant was put in a
sterile test tube. The pellet was suspended in 500 lL CM and
centrifuged again. The new supernatant was added to super-
natant of the first extraction and measured with a Perkin
Elmer LS-55 spectrofluorometer (Perkin Elmer, Groningen,
the Netherlands), using an excitation wavelength of 410 nm
(slit 2Æ5 nm) and an emission wavelength of 635 nm (slit
2Æ5 nm). The pellet was stored at )80 �C for DNA extraction
subsequently.
Fluorescence microscopy
To study PpIX formation within the biopsies and to check
whether ALA penetration throughout the skin explants was
optimal, fluorescence microscopy was performed on frozen
sections from the skin explants after incubation with ALA.
Biopsies were washed in PBS, embedded in Tissue-Tek OCT
compound (Miles Scientific, Napierville, IL, U.S.A.) and
directly frozen into liquid nitrogen. Afterwards 14-lm sec-
tions were cut which were mounted on a glass slide. Fluores-
cence microscopy was performed using a Zeiss Axioskop 2
microscope (Zeiss, Sliedrecht, the Netherlands) with a CCD
(charge coupled device) camera (Zeiss Axiocam MRc5). For
excitation of PpIX a custom filter was used (Exc 460, BP
630 ⁄15; Zeiss). For the background image a standard 4¢,6-di-
amidino-2-phenylindole (DAPI) filter (Exc 365 ⁄12, LP 397;
Zeiss) was used. At 10 · and 20 · magnification exposure
times of 2 and 1Æ5 s were used, respectively, for PpIX. For the
DAPI filter an exposure time of 400 ms was chosen at all
magnifications.
Statistics
To compare PpIX and dsDNA levels between the skin explants
and PpIX fluorescence between the different cell cultures one-
way analysis of variance was used when multiple variables
were compared. An unpaired two-tailed Student’s t-test was
used when only two variables were compared. Biopsies within
the same patient were analysed using a paired two-tailed
Student’s t-test.
All statistical calculations were performed using Statistica
6.0 (Statsoft Benelux BV, Groningen, the Netherlands) and
Microsoft Excel 2000 (Microsoft, Schiphol, the Netherlands).
P < 0Æ05 was considered statistically significant.
Results
No significant differences in PpIX content were found in
explant cultures of psoriasis, AK and normal skin after incuba-
tion with ALA.
Tissue protoporphyrin IX content in normal skin and
lesional/nonlesional skin in psoriasis and actinic
keratosis
No differences were found in PpIX content when comparing
lesional and nonlesional skin in psoriasis and AK. However, in
lesional skin as well as nonlesional psoriatic skin significantly
more PpIX was found compared with lesional and nonlesional
skin in AK. PpIX content in normal (control) skin was compa-
rable with that in psoriatic skin. However, normal (control)
skin contained significantly more PpIX compared with lesional
and nonlesional skin in AK (Fig. 2a).
Tissue DNA content in normal skin and lesional/
nonlesional skin in psoriasis and actinic keratosis
In lesional psoriatic skin as well as in AK significantly higher
DNA content was found compared with nonlesional skin.
Lesional as well as nonlesional psoriatic skin also contained
significantly more DNA than nonlesional AK. Moreover,
significantly more DNA was found in lesional psoriatic skin
compared with normal (control) skin (Fig. 2b). These data
are in accordance with a previous study from our group.4
Tissue protoporphyrin IX content in normal skin and
lesional/nonlesional skin in psoriasis and actinic
keratosis corrected for DNA content
When PpIX content was corrected for the number of PpIX-
producing cells, using dsDNA as an epidermal marker, no sig-
nificant differences were found between any of the lesion
types although nonlesional skin in psoriasis and AK tended to
have higher PpIX content, in the same range as that of normal
skin, compared with lesional skin in both psoriasis and AK
(Fig. 2c).
Basal protoporphyrin IX (PpIX) levels and induction
of PpIX by aminolaevulinic acid
Several biopsies from psoriasis, AK and normal skin were
incubated without ALA to make sure that PpIX from the
samples that were incubated with ALA (Fig. 2d) was
induced by ALA (and not a basal value). With our current
protocol, PpIX content in these samples proved to be below
the detection limit, resulting in the absence of a specific PpIX
peak at 630 nm in the emission spectra. Hence, PpIX
measured in our samples can be regarded to be induced by
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ALA. An estimation for the basal PpIX levels would be
somewhere below 5 pg PpIX ng)1 DNA with a tendency
of nonlesional skin towards higher PpIX levels. When
PpIX values of all the ALA-incubated biopsies were compared
with their nonincubated equivalents significantly higher
PpIX content was found in the ALA-incubated biopsies
(P < 0Æ001).
Protoporphyrin IX fluorescence is predominantly found
in the suprabasal layers of the epidermis
Biopsies incubated without ALA showed no specific (red) por-
phyrin-like fluorescence (Fig. 3a). In contrast, in the biopsies
that were incubated with ALA a strong red fluorescence
was seen indicating induction of porphyrins (Fig. 3b–d).
This fluorescence was principally confined to the epidermis
and showed a homogeneous distribution throughout the
entire length of the epidermis (Fig. 3b). Interestingly, the
fluorescence pattern showed a preferential distribution towards
higher fluorescence in the upper layers of the epidermis com-
pared with the basal keratinocytes (Fig. 3d), which was also
seen at the border of the biopsies (Fig. 3c).
Protoporphyrin IX leakage into the incubation media
is negligible
PpIX levels in the media proved relatively low compared with
the tissues. From the 28 biopsies from psoriatic lesional and
nonlesional skin that were incubated with ALA, in only 11
biopsies were PpIX levels above the detection limit. In the
other 17 biopsies PpIX was below the detection limit. In AK
only five of the 20 biopsies that were incubated with ALA
showed detectable PpIX values. All PpIX values detectable in
the media were always lower than the tissue values. Thus,
PpIX leakage into the media during incubation does not seem
to be a significant factor.
(a) (b) 
(d) (c) 
Fig 2. Protoporphyrin IX (PpIX) and DNA content in psoriasis, actinic keratosis and normal skin. PpIX and double-stranded DNA content in skin
explants from psoriasis, actinic keratosis and normal skin were measured with spectrofluorometry following incubation with aminolaevulinic acid
(ALA) (a–c). The emission spectra from the ALA-incubated skin samples showed a characteristic peak at 630 nm that coalesced with the PpIX
reference standard (d). PSO, lesional psoriatic skin; PSO NS, nonlesional psoriatic skin; AK, lesional skin in actinic keratosis; AK NS, nonlesional
skin in actinic keratosis; NS, normal skin from healthy controls. *P < 0Æ05, **P < 0Æ01, ***P < 0Æ001. Error bars indicate SEM.
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Significantly more protoporphyrin IX fluorescence
is detected in confluent compared with subconfluent
cell cultures
When PpIX accumulation in cell cultures at different levels of
confluence was compared, increased PpIX fluorescence was
found in cell cultures with higher levels of confluence. Espe-
cially between near-confluent (90%) and confluent (100%)
cell cultures there appeared to be a great difference in PpIX
fluorescence. When the subconfluent cell cultures were mutu-
ally compared, there still was a tendency towards higher PpIX
fluorescence in higher levels of confluence, although this was
less obvious (Fig. 4a).
Induction of terminal differentiation by omission
of growth factors from the culture medium results
in decreased protoporphyrin IX (PpIX) fluorescence
per cell while the total amount of PpIX does not change
Interestingly, when terminal differentiation was induced by
omission of GF from the culture medium, PpIX fluorescence
per cell appeared to be lower compared with the cells that
were incubated with the addition of GF (Fig. 4b). However,
when the total amount of PpIX per cell culture corrected for
the number of cells using dsDNA was measured spectrofluoro-
metrically, PpIX fluorescence did not significantly differ
between the cells that were incubated with or without GF
(not shown).
Increased protoporphyrin IX fluorescence is detected
in suprabasal epidermal cells compared with basal
epidermal cells
When biopsies from normal skin were incubated with ALA
and cell suspensions were labelled with antibody to CD29,
the negative population showed significantly higher PpIX
content compared with the positive population (Fig. 5). As
(a) (b) (c) (d)
Fig 3. Fluorescence microscopy of skin explant cultures. No porphyrin-like fluorescence is seen in normal skin incubated without aminolaevulinic
acid (ALA) (a). However, incubation with 1 mmol L)1 ALA (16 h) induced red fluorescence confined to the epidermis (b–d), typically sparing
the basal keratinocytes (d). The dotted line indicates the dermoepidermal junction.
(a)
(b)
Fig 4. Protoporphyrin IX (PpIX) accumulation in cell cultures of
different levels of confluence and after induction of terminal
differentiation by omission of growth factors. (a) Human
keratinocytes from normal skin were incubated with 1 mmol L)1
aminolaevulinic acid (ALA) for 4 h and PpIX fluorescence was
measured flow cytometrically. Mean ± SD PpIX fluorescence taken
from three separate experiments at each level of confluence was
plotted. *P < 0Æ001, difference from 100% confluence. (b) Cell
cultures were grown until 100% confluence was reached (n = 6).
Thereafter, terminal differentiation was induced in half of the cell
cultures by omission of growth factors from the medium. After
incubation with 1 mmol L)1 ALA for 4 h, PpIX fluorescence was
measured flow cytometrically. Mean ± SD PpIX fluorescence was
plotted (n = 3). *P < 0Æ001. a.u., arbitrary units.
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CD29-positive cells are found mainly in the basal layer of
the epidermis and CD29-negative cells are located in the
suprabasal layers (Fig. 6), CD29 can, conversely, be used as
a marker for terminal differentiation. Hence, increased accu-
mulation of PpIX in the CD29-negative population thus
points at a preferential accumulation of PpIX in differenti-
ated cells.
Discussion
In a previous study from our group it was shown that with
FDAP in psoriasis and AK significantly more PpIX fluorescence
was detected in lesional skin compared with nonlesional skin
and that generally PpIX fluorescence in psoriasis was increased
compared with AK.4 When these PpIX fluorescence values
were compared with the actual PpIX content in the skin sam-
ples, only in lesional psoriatic skin was more PpIX found
compared with nonlesional psoriatic skin and lesional and
nonlesional skin in AK. Basically, this could be explained by
an increased penetration of ALA through the stratum corneum
and ⁄or increased PpIX synthesis. In the present study, incuba-
tion with ALA of skin explant cultures from normal skin,
lesional and nonlesional skin of patients with psoriasis and AK
(a)
(b)
Fig 5. Protoporphyrin IX (PpIX) accumulation in normal skin in
CD29-negative and CD29-positive populations. Skin biopsies from
normal skin were incubated with 1 mmol L)1 aminolaevulinic acid
(ALA) for 4 h, except for the negative controls. After trypsinization,
cells were labelled with antibody to CD29. Subsequently, in the
CD29-positive and CD29-negative populations, PpIX fluorescence was
measured with flow cytometry. (a) Flow cytometric two-parameter
histogram showing the CD29-positive (green) and CD29-negative
(blue) populations and their PpIX fluorescence. (b) Mean ± SD PpIX
fluorescence in the CD29-positive and CD29-negative populations
taken from three separate experiments is plotted. The white bars
indicate the control CD29-positive and CD29-negative populations
which were not incubated with ALA. *P < 0Æ05, **P < 0Æ01. a.u.,
arbitrary units.
(a)
(b)
Fig 6. CD29-positive and K10-positive cells in normal skin are
complementary. Immunohistochemical staining for CD29 shows
immunoreactivity in the basal layers of the epidermis (a, green
staining), in contrast to K10 (a well-known marker for terminal
differentiation), which shows immunoreactivity in the suprabasal
layers (b, red staining). Therefore, negativity for CD29 can be used
as a marker for terminal differentiation. Immunohistochemistry was
performed on frozen sections (7 lm) from normal skin using
antibodies to CD29 (anti-b1-integrin, clone K20; Dako BV, Heverlee,
Belgium) and K10 (anti-K10, clone RKSE60; Monosan, Uden, the
Netherlands). Protocols were similar to those of Korver et al.18 and
Kleinpenning et al.5
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induced significant amounts of PpIX. However, we did not
find significant differences between the different tissues. As
the penetration route through the stratum corneum by ALA is
bypassed in the skin explant model, this could point to a
prominent role for the stratum corneum in psoriasis with
respect to preferential accumulation of PpIX. This is in accor-
dance with a study of Ghadially and colleagues who reported
the stratum corneum integrity in psoriasis to be impaired.15
Moreover, with respect to PpIX fluorescence, the stratum cor-
neum thickness has also been reported to play an important
role in various skin diseases.5,6,8 Our data show that the dif-
ferences in fluorescence observed with FDAP cannot be
explained by differences in the intrinsic capability of the dif-
ferent tissues to accumulate PpIX.
A serum-free medium was chosen to minimize leakage of
PpIX to the extracellular space (medium) during incubation as
reported by other authors.12,14 To verify this, PpIX was also
measured in the media and proved to be very low (often
below the detection limit). Thus, tissue PpIX content appears
to be a good representation of total PpIX produced by the skin
explants.
Fluorescence microscopy of normal skin explants incubated
with ALA showed homogeneous red fluorescence throughout
the entire epidermis. Interestingly, lower fluorescence or no
fluorescence was found in the basal layers of the epidermis,
which could not be explained by impaired penetration of ALA
as this was also seen at the border of the biopsies. As previous
studies have shown increased PpIX accumulation in terminally
differentiated cells, we conducted further experiments to
investigate whether this preferential distribution of PpIX
throughout the epidermis could be related to differentiation
status.9,10 We therefore studied PpIX accumulation in basal
and suprabasal cells using b1-integrin to discriminate between
these cells. Significantly more PpIX was detected in suprabasal
cells (which show a higher grade of differentiation compared
with basal cells).
In addition, we conducted in vitro experiments in which
PpIX accumulation was compared between subconfluent and
confluent cell cultures. Higher PpIX content was found in the
latter, which is in accordance with earlier findings by Moan
and colleagues who reported PpIX accumulation to increase
with increasing cell density.16 They speculated that when cells
approach confluence, as a result of contact inhibition, more
energy is available for porphyrin synthesis, but supporting evi-
dence is lacking. From their data no cell-cycle dependence was
found except for simple volume dependence. When confluent
cell cultures in our study were further incubated without GF
for 48 h (which induces terminal differentiation) PpIX fluores-
cence per cell decreased, while comparable amounts of PpIX
per cell culture in the differentiated and confluent cell cultures
were found spectrofluorometrically. This might be explained
by the larger cell volume found in fully differentiated cells. To
explain the decrease in PpIX amount per cell in fully differen-
tiated cells, one might hypothesize that the increase in volume
during differentiation might be higher compared with the
relative increase in PpIX synthesis. Moreover, the decreased
sensitivity of the spectrofluorometric compared with the flow
cytometric analytical method might also play a role. An impor-
tant question remains as to what extent our monolayer cul-
tures can be compared with human skin in vivo or ex vivo, as
Sato and colleagues were able to increase PpIX accumulation
only after induction of differentiation by vitamin D in 3D
organotypic, but not monolayered, cultures of keratinocytes.10
The present study shows that the differences in PpIX accu-
mulation between different tissues from various skin diseases
as observed with FDAP cannot be explained by their intrinsic
capability to accumulate PpIX. Therefore, the penetration of
ALA in these tissues seems to play an important role therein.
However, not only the total amount of PpIX per tumour but
also the distribution throughout the tissue (PpIX per cell)
determines the photodynamic effects observed after PDT. Our
data show a preferential accumulation of PpIX in terminally
differentiated human keratinocytes ex vivo. Similar findings have
been reported by other authors, who showed a differentia-
tion-specific increase in PpIX accumulation and PDT-induced
cytotoxicity in vitro.9,10,17 Similar to these studies, the correl-
ation between differentiation status and PpIX accumulation in
the present study was studied only in normal skin and data in
AK, Bowen’s disease and basal cell carcinoma are unknown.
However, the findings in this study are clinically relevant as
they may help in understanding the specific photodynamic
effects in different skin lesions, which may explain the differ-
ent susceptibilities of different skin conditions to PDT and
their behaviour during FDAP.
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Summary
Background Topical 5-aminolaevulinic acid (ALA)-photodynamic therapy (PDT) for
the treatment of psoriasis has been evaluated in a few studies. In these studies
different treatment parameters were used, there was a variable clinical response,
and a nonhomogeneous fluorescence was seen after irradiation with Wood’s
light.
Objectives To study the clinical effectiveness, immunohistochemical changes and
protoporphyrin IX accumulation in ALA-PDT in patients with psoriasis.
Methods Eight patients with stable plaque psoriasis with symmetrical involvement
were included in the study. Two symmetrical plaques were randomly allocated
to PDT either with 10% ALA or with placebo. Irradiation consisted of 2 and
8 J cm)2 with a dark interval of 2 h (Waldmann PDT 1200 L, 600–750 nm,
40 mW cm)2) once weekly for 4 weeks. Before, during and after irradiation,
fluorescence diagnosis was performed. Biopsies were taken at baseline, week 1
and week 6 for immunohistochemical assessment. Psoriatic plaques were clinic-
ally assessed using the plaque severity (sum) score. Fluorescence diagnosis was
performed and expression of immunohistochemical markers for proliferation,
differentiation and T-cell infiltration [Ki67, keratin 10 (K10), CD4, CD8 and
CD45RO] was assessed.
Results From week 1 up to week 6, ALA-PDT gave a significant reduction in the
number of Ki67+ nuclei, while the K10 expression increased. After 6 weeks sig-
nificant improvement was observed for CD8 and CD45RO. These changes were
absent in the placebo-treated lesions. The sum scores were also significantly
lower in the ALA-treated plaques. Heterogeneity of macroscopic fluorescence was
observed during treatment despite keratolytic treatment.
Conclusions The present study shows that clinical improvement during fractionated
ALA-PDT in psoriasis parallels histological improvement as seen in normalization
of epidermal proliferation, differentiation and infiltration of relevant T-cell sub-
sets. Optimizing the current treatment protocol may increase clinical efficacy fur-
ther.
Over the last few years photodynamic therapy (PDT) with
topical 5-aminolaevulinic acid (ALA) has been gaining interest
in more and more dermatological centres and its clinical effic-
acy has convinced many dermatologists to implement this
therapy in their daily practice. Although more randomized
controlled studies are still needed and 5-year follow-up data
are mostly lacking, PDT has been proven to be clinically
effective in nonmelanoma skin cancer including actinic kerato-
sis, Bowen’s disease and (superficial) basal cell carcinoma. As
protoporphyrin IX (PpIX)-accumulating skin disorders in gen-
eral may be a potential target for PDT, other (nononcological)
indications have also been studied or are currently under eval-
uation. Psoriasis has been shown to accumulate PpIX selec-
tively and its susceptibility to PDT has been previously studied
by various authors.1–5 In these studies clinical efficacy varied
largely but results are difficult to compare because of the
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the treatment of psoriasis has been evaluated in a few studies. In these studies
different treatment parameters were used, there was a variable clinical response,
and a nonhomogeneous fluorescence was seen after irradiation with Wood’s
light.
Objectives To study the clinical effectiveness, immunohistochemical changes and
protoporphyrin IX accumulation in ALA-PDT in patients with psoriasis.
Methods Eight patients with stable plaque psoriasis with symmetrical involvement
were included in the study. Two symmetrical plaques were randomly allocated
to PDT either with 10% ALA or with placebo. Irradiation consisted of 2 and
8 J cm)2 with a dark interval of 2 h (Waldmann PDT 1200 L, 600–750 nm,
40 mW cm)2) once weekly for 4 weeks. Before, during and after irradiation,
fluorescence diagnosis was performed. Biopsies were taken at baseline, week 1
and week 6 for immunohistochemical assessment. Psoriatic plaques were clinic-
ally assessed using the plaque severity (sum) score. Fluorescence diagnosis was
performed and expression of immunohistochemical markers for proliferation,
differentiation and T-cell infiltration [Ki67, keratin 10 (K10), CD4, CD8 and
CD45RO] was assessed.
Results From week 1 up to week 6, ALA-PDT gave a significant reduction in the
number of Ki67+ nuclei, while the K10 expression increased. After 6 weeks sig-
nificant improvement was observed for CD8 and CD45RO. These changes were
absent in the placebo-treated lesions. The sum scores were also significantly
lower in the ALA-treated plaques. Heterogeneity of macroscopic fluorescence was
observed during treatment despite keratolytic treatment.
Conclusions The present study shows that clinical improvement during fractionated
ALA-PDT in psoriasis parallels histological improvement as seen in normalization
of epidermal proliferation, differentiation and infiltration of relevant T-cell sub-
sets. Optimizing the current treatment protocol may increase clinical efficacy fur-
ther.
Over the last few years photodynamic therapy (PDT) with
topical 5-aminolaevulinic acid (ALA) has been gaining interest
in more and more dermatological centres and its clinical effic-
acy has convinced many dermatologists to implement this
therapy in their daily practice. Although more randomized
controlled studies are still needed and 5-year follow-up data
are mostly lacking, PDT has been proven to be clinically
effective in nonmelanoma skin cancer including actinic kerato-
sis, Bowen’s disease and (superficial) basal cell carcinoma. As
protoporphyrin IX (PpIX)-accumulating skin disorders in gen-
eral may be a potential target for PDT, other (nononcological)
indications have also been studied or are currently under eval-
uation. Psoriasis has been shown to accumulate PpIX selec-
tively and its susceptibility to PDT has been previously studied
by various authors.1–5 In these studies clinical efficacy varied
largely but results are difficult to compare because of the
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different treatment parameters that were used. Various mecha-
nisms have been proposed for the clinical effect of ALA-PDT
in psoriasis. Boehncke et al.5 reported topical ALA-PDT to have
inhibitory effects on tumour necrosis factor-a, interleukin
(IL)-1 and IL-6 secretion in a dose-dependent manner, which
has also been reported in psoralen + ultraviolet A therapy,
whereas Bissonette et al.6 found PDT with systemic ALA to
induce apoptosis in CD3+ cells. Pain during irradiation is one
of the main drawbacks in PDT, and this was the case in sev-
eral reports on PDT of psoriasis. Considering the discomfort
of this treatment and the variable clinical efficacy, several
authors therefore concluded PDT to be unsuitable for the
treatment of psoriasis.7,8 On the other hand, there is a perma-
nent need for new treatment modalities in the treatment of
psoriasis as topical therapies are not always successful and
demand the patient’s utmost compliance; moreover, cumula-
tive toxicity and carcinogenicity of many systemic and
photo(chemo)therapies are limitations in the long run.
Although the long-term safety of PDT remains to be estab-
lished, current data do not point in the direction of PDT hav-
ing carcinogenic potential. Taking these factors into account,
if efficacy could be increased by optimizing the treatment pro-
tocol, PDT of psoriasis would be of additional value in the
current treatment arsenal.
While previous studies on PDT in psoriasis have focused
mainly on the clinical efficacy, knowledge on the histological
effects of PDT in psoriasis is crucial, better to understand the
mechanism responsible for the clinical improvement in PDT
of psoriasis. These data may also be used to optimize the
treatment protocol further. Therefore, the aim of the present
study was to evaluate the clinical and histological effects of
PDT in psoriasis with respect to the histological hallmarks of
psoriatic plaques, these being epidermal hyperproliferation,
abnormal keratinization and T-cell infiltration. For this pur-
pose, several immunohistochemical markers were chosen
including Ki67 (epidermal proliferation), keratin 10 (K10;
epidermal keratinization), CD4 (helper T cells), CD8 (cyto-
toxic T-cells) and CD45RO (memory T-cells). As light frac-
tionation has been proposed as a possible way to improve
clinical efficacy,9 a twofold fractionated protocol with a dark
interval of 2 h was used. As lowering of the fluence rate has
also been reported to enhance the clinical response,10,11
40 mW cm)2 was chosen as a standard fluence rate during
the irradiation process. To study PpIX formation and photo-
bleaching in the treated areas, which can also be informative
in understanding the photodynamic effects in psoriasis, fluor-
escence intensity on the skin was assessed using a digital
fluorescence imaging system.
Patients and methods
Patients
This study was approved by the local medical ethics commit-
tee. The recruitment period lasted from August until Septem-
ber 2004 and the treatment period from September until
December 2004. Eight patients selected out of our research
database (age range 39–64 years; five men and three women)
with stable plaque psoriasis with symmetrical involvement
were included in this study after giving their written informed
consent. All the lesions were located on the legs. Lesions were
treated with 10% salicylic acid in petrolatum for 1 week prior
to the baseline visit to remove excess scales that could poten-
tially interfere with ALA and light penetration. Patients were
not allowed to use any systemic psoriatic treatments or topical
medication on these lesions for at least 4 weeks. Medication
known potentially to aggravate psoriatic lesions, such as
b-blockers, was also not allowed. Patients were requested to
refrain from sun exposure during the treatment period.
Photodynamic therapy
At the baseline visit two contralateral psoriatic lesions were
randomized by means of a special computer algorithm to
either PDT with 10% ALA ointment (Medac GmbH, Wedel,
Germany) or the vehicle (Medac GmbH). Before the ALA oint-
ment or vehicle was applied lesions were photographed. Sub-
sequently, according to the randomization outcome, ALA
ointment and vehicle were applied under an occlusive dressing
(Tegaderm; 3M Pharmaceuticals, Zoeterwoude, the Nether-
lands) to enhance ALA penetration. The occlusive dressing was
covered by aluminium foil to avoid premature photobleaching
effects. After 4 h the ointments and foils were removed and
the skin surface was cleaned using 80% denaturated alcohol
v/v. Thereafter the first light fraction of 2 J cm)2 was deliv-
ered [Waldmann PDT 1200 L (Waldmann Medische Techniek
BV, Tiel, the Netherlands), 600–750 nm, 40 mW cm)2].
Lesions were covered again with the occlusive dressing and
aluminium foil for 2 h, after which a second light fraction of
8 J cm)2 was delivered using the same irradiation parameters.
The same irradiation protocol was applied once every week
for 4 weeks.
To evaluate the clinical response, the sum score, a widely
used method to measure the plaque severity, was assessed for
both lesions at each visit. In this score erythema, induration
and desquamation are each scored on a five-point scale as: 0,
absent; 1, minimal (very light pink, hardly any elevation, rare
scale); 2, mild (light red/pink, slight elevation, poorly defined
scale); 3, moderate (red, moderate elevation, defined scales);
or 4, severe (very red, marked ridge, heavy scaling). Finally, a
global sum score (range 0–12) was defined as the sum of all
three scores together, reflecting plaque severity.
Biopsy procedure
At the baseline visit, week 1 and 2 weeks after the last treat-
ment (week 6), 4-mm punch biopsies from the treated psori-
atic lesions were taken under local anaesthesia with 1%
xylocaine-adrenaline. Biopsies were embedded in Tissue-Tek
OCT compound (Miles Scientific, Napierville, IL, U.S.A.) and
directly frozen into liquid nitrogen. Biopsies were stored at
) 80 �C until further processing.
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Fluorescence diagnosis
Fluorescence intensity on the skin was recorded at every visit
before and directly after each irradiation using a digital fluor-
escence imaging system (DyaDerm; Biocam GmbH, Regens-
burg, Germany). The DyaDerm digital imaging system consists
of a flash light [xenon light source with a custom bandpass
filter (370–440 nm)] and a 12-bit Sony CCD camera com-
bined in one adjustable arm coupled to a Pentium IV compu-
ter equipped with custom-made image capturing software
(Dyaderm Pro v. 1.4; Biocam GmbH). The flash light emits
seven light pulses per second to the skin which are recorded
by the CCD camera (exposure time 100 ls) equipped with a
special Schott GG 455 longpass filter to filter out the excitation
light. As PpIX fluorescence emission consists of light in the
red spectrum, the red pixels of the CCD camera were used to
generate a fluorescence image. In this way a normal-coloured
image and a fluorescence image were processed in real time.
Because of the short exposure time to the excitation light,
photobleaching of PpIX was minimized. To correct for differ-
ent lighting environments between pictures, a fluorescence
reference standard (Maccal 8044, 738-00; Multifoil, Utrecht,
the Netherlands) was included on every image. Images were
recorded in 16-bit grey-scale TIFF format.
Analysis of fluorescence images
Sixteen-bit grey-scale TIFF fluorescence images were imported
in NIH ImageJ software (http://rsb.info.nih.gov/ij/). Because
the xenon light source used for excitation has the highest
intensity in the centre of the illuminated area, shading correc-
tion was performed by means of the following algorithm:
S ¼ I/C, where C ¼ B/BImax; B ¼ blank image (image from a
white homogeneous background recorded with the Dyaderm
system), BImax ¼ highest intensity of B, I ¼ (uncorrected)
image, C ¼ normalized shading image and S ¼ shading cor-
rected image. Photobleaching in psoriatic lesions was assessed
by measuring the mean pixel intensity of highly fluorescing
regions within a psoriatic plaque. Measurements were always
performed in the same area within a plaque.
Immunohistochemistry
Frozen sections (7 lm) were cut from the skin samples for
immunohistochemical assessment. These were air-dried for
30 min and fixed in cold acetone for 10 min. After blocking
for 5 min for endogenous peroxidase, using 0Æ2% sodium
azide (Dako, Copenhagen, Denmark), sections were washed in
phosphate-buffered saline (PBS; B. Braun, Melsungen, Ger-
many) for 10 min before incubation with primary antibodies.
The following primary antibodies (mouse antihuman) were
used, diluted in 1% bovine serum albumin (Sigma, St Louis,
MO, U.S.A.)/PBS: anti-CD4 (clone MT310; 1 : 200), anti-CD8
(clone DK25; 1 : 200), anti-CD45RO (clone UCHL1;
1 : 100), Ki67 (clone MIB-1; 1 : 200) (all from Dako) and
K10 (clone RKSE60; 1 : 100) (Monosan Laboratories, Uden,
the Netherlands). Sections were washed in PBS for 15 min.
Secondary IgG-labelled polymer, horseradish peroxidase anti-
mouse EnVision+ (Dako) was added for 30 min. The sections
were washed again for 15 min in PBS. To visualize the stain-
ing we used AEC+ High Sensitivity Substrate Chromogen for
10 min (Dako). Counterstaining was performed with Mayer’s
haematoxylin (Sigma). The sections were washed in tap water,
dried, and mounted in glycerol gelatine (Sigma).
Furthermore, haematoxylin and eosin (H&E) staining was
performed on every biopsy specimen. After dehydration in
alcohol and Histosafe, the sections were mounted in Per-
mount. With these H&E sections we verified that the biopsies
under study fulfilled the psoriasis-specific histological criteria.
Immunohistochemical analysis
Analysis of digital microscopic images was done using IP-lab
software (Scanalytics Inc., Fairfax, VA, U.S.A.). In order to ana-
lyse Ki67+ cells, digital photographs were made at · 100 mag-
nification covering the entire epidermis. A line following the
basement membrane was drawn and its length was measured.
All positive cells above this line were counted and divided by
the length of the basement membrane so the number of positive
cells per millimetre length of basement membrane could be
calculated.
For quantification of K10+ cells, digital photographs were
made at · 50 magnification. The surface K10+ (epidermal)
cells were measured and divided by the total epidermal sur-
face. Thus epidermal differentiation was defined as percentage
K10+ epidermal surface.
T-cell subsets (CD4, CD8 and CD45RO) were analysed by
counting all positive cells in the epidermis and dermis sepa-
rately. These numbers were divided by the length of the stratum
corneum. In this way T-cell subsets were expressed as the num-
ber of positive cells per millimetre (epi)dermis. All slides were
encoded to assure that the analysis was performed blindly.
Statistics
To compare mean sum scores, mean fluorescence intensity
and expression of Ki67, K10, CD4, CD8 and CD45RO
between the two treatment regimens a two-tailed Student’s
t-test was used. One-way analysis of variance was used to ana-
lyse differences between time points within each marker.
When significant changes were found, Duncan’s post hoc test
was performed for analysis between time points. P < 0Æ05 was
regarded as statistically significant. Microsoft Excel 2000 and
Statistica 6.0 software (Statsoft Inc., http://www.statsoft.com)
were used for statistical calculations.
Results
Clinical efficacy
Although some patients experienced some burning and sting-
ing during the irradiation, generally the treatment was well
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different treatment parameters that were used. Various mecha-
nisms have been proposed for the clinical effect of ALA-PDT
in psoriasis. Boehncke et al.5 reported topical ALA-PDT to have
inhibitory effects on tumour necrosis factor-a, interleukin
(IL)-1 and IL-6 secretion in a dose-dependent manner, which
has also been reported in psoralen + ultraviolet A therapy,
whereas Bissonette et al.6 found PDT with systemic ALA to
induce apoptosis in CD3+ cells. Pain during irradiation is one
of the main drawbacks in PDT, and this was the case in sev-
eral reports on PDT of psoriasis. Considering the discomfort
of this treatment and the variable clinical efficacy, several
authors therefore concluded PDT to be unsuitable for the
treatment of psoriasis.7,8 On the other hand, there is a perma-
nent need for new treatment modalities in the treatment of
psoriasis as topical therapies are not always successful and
demand the patient’s utmost compliance; moreover, cumula-
tive toxicity and carcinogenicity of many systemic and
photo(chemo)therapies are limitations in the long run.
Although the long-term safety of PDT remains to be estab-
lished, current data do not point in the direction of PDT hav-
ing carcinogenic potential. Taking these factors into account,
if efficacy could be increased by optimizing the treatment pro-
tocol, PDT of psoriasis would be of additional value in the
current treatment arsenal.
While previous studies on PDT in psoriasis have focused
mainly on the clinical efficacy, knowledge on the histological
effects of PDT in psoriasis is crucial, better to understand the
mechanism responsible for the clinical improvement in PDT
of psoriasis. These data may also be used to optimize the
treatment protocol further. Therefore, the aim of the present
study was to evaluate the clinical and histological effects of
PDT in psoriasis with respect to the histological hallmarks of
psoriatic plaques, these being epidermal hyperproliferation,
abnormal keratinization and T-cell infiltration. For this pur-
pose, several immunohistochemical markers were chosen
including Ki67 (epidermal proliferation), keratin 10 (K10;
epidermal keratinization), CD4 (helper T cells), CD8 (cyto-
toxic T-cells) and CD45RO (memory T-cells). As light frac-
tionation has been proposed as a possible way to improve
clinical efficacy,9 a twofold fractionated protocol with a dark
interval of 2 h was used. As lowering of the fluence rate has
also been reported to enhance the clinical response,10,11
40 mW cm)2 was chosen as a standard fluence rate during
the irradiation process. To study PpIX formation and photo-
bleaching in the treated areas, which can also be informative
in understanding the photodynamic effects in psoriasis, fluor-
escence intensity on the skin was assessed using a digital
fluorescence imaging system.
Patients and methods
Patients
This study was approved by the local medical ethics commit-
tee. The recruitment period lasted from August until Septem-
ber 2004 and the treatment period from September until
December 2004. Eight patients selected out of our research
database (age range 39–64 years; five men and three women)
with stable plaque psoriasis with symmetrical involvement
were included in this study after giving their written informed
consent. All the lesions were located on the legs. Lesions were
treated with 10% salicylic acid in petrolatum for 1 week prior
to the baseline visit to remove excess scales that could poten-
tially interfere with ALA and light penetration. Patients were
not allowed to use any systemic psoriatic treatments or topical
medication on these lesions for at least 4 weeks. Medication
known potentially to aggravate psoriatic lesions, such as
b-blockers, was also not allowed. Patients were requested to
refrain from sun exposure during the treatment period.
Photodynamic therapy
At the baseline visit two contralateral psoriatic lesions were
randomized by means of a special computer algorithm to
either PDT with 10% ALA ointment (Medac GmbH, Wedel,
Germany) or the vehicle (Medac GmbH). Before the ALA oint-
ment or vehicle was applied lesions were photographed. Sub-
sequently, according to the randomization outcome, ALA
ointment and vehicle were applied under an occlusive dressing
(Tegaderm; 3M Pharmaceuticals, Zoeterwoude, the Nether-
lands) to enhance ALA penetration. The occlusive dressing was
covered by aluminium foil to avoid premature photobleaching
effects. After 4 h the ointments and foils were removed and
the skin surface was cleaned using 80% denaturated alcohol
v/v. Thereafter the first light fraction of 2 J cm)2 was deliv-
ered [Waldmann PDT 1200 L (Waldmann Medische Techniek
BV, Tiel, the Netherlands), 600–750 nm, 40 mW cm)2].
Lesions were covered again with the occlusive dressing and
aluminium foil for 2 h, after which a second light fraction of
8 J cm)2 was delivered using the same irradiation parameters.
The same irradiation protocol was applied once every week
for 4 weeks.
To evaluate the clinical response, the sum score, a widely
used method to measure the plaque severity, was assessed for
both lesions at each visit. In this score erythema, induration
and desquamation are each scored on a five-point scale as: 0,
absent; 1, minimal (very light pink, hardly any elevation, rare
scale); 2, mild (light red/pink, slight elevation, poorly defined
scale); 3, moderate (red, moderate elevation, defined scales);
or 4, severe (very red, marked ridge, heavy scaling). Finally, a
global sum score (range 0–12) was defined as the sum of all
three scores together, reflecting plaque severity.
Biopsy procedure
At the baseline visit, week 1 and 2 weeks after the last treat-
ment (week 6), 4-mm punch biopsies from the treated psori-
atic lesions were taken under local anaesthesia with 1%
xylocaine-adrenaline. Biopsies were embedded in Tissue-Tek
OCT compound (Miles Scientific, Napierville, IL, U.S.A.) and
directly frozen into liquid nitrogen. Biopsies were stored at
) 80 �C until further processing.
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Fluorescence diagnosis
Fluorescence intensity on the skin was recorded at every visit
before and directly after each irradiation using a digital fluor-
escence imaging system (DyaDerm; Biocam GmbH, Regens-
burg, Germany). The DyaDerm digital imaging system consists
of a flash light [xenon light source with a custom bandpass
filter (370–440 nm)] and a 12-bit Sony CCD camera com-
bined in one adjustable arm coupled to a Pentium IV compu-
ter equipped with custom-made image capturing software
(Dyaderm Pro v. 1.4; Biocam GmbH). The flash light emits
seven light pulses per second to the skin which are recorded
by the CCD camera (exposure time 100 ls) equipped with a
special Schott GG 455 longpass filter to filter out the excitation
light. As PpIX fluorescence emission consists of light in the
red spectrum, the red pixels of the CCD camera were used to
generate a fluorescence image. In this way a normal-coloured
image and a fluorescence image were processed in real time.
Because of the short exposure time to the excitation light,
photobleaching of PpIX was minimized. To correct for differ-
ent lighting environments between pictures, a fluorescence
reference standard (Maccal 8044, 738-00; Multifoil, Utrecht,
the Netherlands) was included on every image. Images were
recorded in 16-bit grey-scale TIFF format.
Analysis of fluorescence images
Sixteen-bit grey-scale TIFF fluorescence images were imported
in NIH ImageJ software (http://rsb.info.nih.gov/ij/). Because
the xenon light source used for excitation has the highest
intensity in the centre of the illuminated area, shading correc-
tion was performed by means of the following algorithm:
S ¼ I/C, where C ¼ B/BImax; B ¼ blank image (image from a
white homogeneous background recorded with the Dyaderm
system), BImax ¼ highest intensity of B, I ¼ (uncorrected)
image, C ¼ normalized shading image and S ¼ shading cor-
rected image. Photobleaching in psoriatic lesions was assessed
by measuring the mean pixel intensity of highly fluorescing
regions within a psoriatic plaque. Measurements were always
performed in the same area within a plaque.
Immunohistochemistry
Frozen sections (7 lm) were cut from the skin samples for
immunohistochemical assessment. These were air-dried for
30 min and fixed in cold acetone for 10 min. After blocking
for 5 min for endogenous peroxidase, using 0Æ2% sodium
azide (Dako, Copenhagen, Denmark), sections were washed in
phosphate-buffered saline (PBS; B. Braun, Melsungen, Ger-
many) for 10 min before incubation with primary antibodies.
The following primary antibodies (mouse antihuman) were
used, diluted in 1% bovine serum albumin (Sigma, St Louis,
MO, U.S.A.)/PBS: anti-CD4 (clone MT310; 1 : 200), anti-CD8
(clone DK25; 1 : 200), anti-CD45RO (clone UCHL1;
1 : 100), Ki67 (clone MIB-1; 1 : 200) (all from Dako) and
K10 (clone RKSE60; 1 : 100) (Monosan Laboratories, Uden,
the Netherlands). Sections were washed in PBS for 15 min.
Secondary IgG-labelled polymer, horseradish peroxidase anti-
mouse EnVision+ (Dako) was added for 30 min. The sections
were washed again for 15 min in PBS. To visualize the stain-
ing we used AEC+ High Sensitivity Substrate Chromogen for
10 min (Dako). Counterstaining was performed with Mayer’s
haematoxylin (Sigma). The sections were washed in tap water,
dried, and mounted in glycerol gelatine (Sigma).
Furthermore, haematoxylin and eosin (H&E) staining was
performed on every biopsy specimen. After dehydration in
alcohol and Histosafe, the sections were mounted in Per-
mount. With these H&E sections we verified that the biopsies
under study fulfilled the psoriasis-specific histological criteria.
Immunohistochemical analysis
Analysis of digital microscopic images was done using IP-lab
software (Scanalytics Inc., Fairfax, VA, U.S.A.). In order to ana-
lyse Ki67+ cells, digital photographs were made at · 100 mag-
nification covering the entire epidermis. A line following the
basement membrane was drawn and its length was measured.
All positive cells above this line were counted and divided by
the length of the basement membrane so the number of positive
cells per millimetre length of basement membrane could be
calculated.
For quantification of K10+ cells, digital photographs were
made at · 50 magnification. The surface K10+ (epidermal)
cells were measured and divided by the total epidermal sur-
face. Thus epidermal differentiation was defined as percentage
K10+ epidermal surface.
T-cell subsets (CD4, CD8 and CD45RO) were analysed by
counting all positive cells in the epidermis and dermis sepa-
rately. These numbers were divided by the length of the stratum
corneum. In this way T-cell subsets were expressed as the num-
ber of positive cells per millimetre (epi)dermis. All slides were
encoded to assure that the analysis was performed blindly.
Statistics
To compare mean sum scores, mean fluorescence intensity
and expression of Ki67, K10, CD4, CD8 and CD45RO
between the two treatment regimens a two-tailed Student’s
t-test was used. One-way analysis of variance was used to ana-
lyse differences between time points within each marker.
When significant changes were found, Duncan’s post hoc test
was performed for analysis between time points. P < 0Æ05 was
regarded as statistically significant. Microsoft Excel 2000 and
Statistica 6.0 software (Statsoft Inc., http://www.statsoft.com)
were used for statistical calculations.
Results
Clinical efficacy
Although some patients experienced some burning and sting-
ing during the irradiation, generally the treatment was well
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tolerated by all patients and no additional analgesics were nee-
ded. These sensations were more intense during the second
light fraction of 8 J cm)2.
Psoriatic lesions showed some evident clinical improvement
during the treatment period which was reflected in a statisti-
cally significant decrease in the clinical plaque severity (sum)
score (P ¼ 0.009) (Figs 1a and 2). Moreover, starting at
week 1, the mean sum score of the ALA-treated lesions was
significantly lower as compared with the placebo-treated
lesions. Classical psoriatic plaques of a few centimetres in size
with clinically normal surrounding skin showed the best clin-
ical improvement. This started most frequently in the periphery
of the plaque. Areas within a plaque that clinically improved
were usually followed by hyperpigmentation. In two patients
an increase in the total psoriatic surface area was observed in
the ALA-treated sites, highly suggestive for Koebnerization.
Fluorescence intensity on the skin
After a 4-h incubation with ALA, psoriatic plaques showed
selectively higher fluorescence compared with the surround-
ing (nonlesional) skin (Figs 3 and 4). However, fluores-
cence within most plaques was not homogeneous, despite
clinically adequate keratolytic treatment 1 week prior to the
baseline visit. Lesional fluorescence intensity after a 4-h
incubation with ALA was 2Æ57 times higher compared with
baseline fluorescence (before ALA application). The first
light fraction of 2 J cm)2 caused no statistically significant
photobleaching (2Æ4%). During the 2-h dark interval there-
after, fluorescence intensity again increased up to 2Æ99 times
baseline fluorescence, indicating new PpIX formation. After
the second fraction of 8 J cm)2, a statistically significant
decrease in fluorescence intensity (26Æ69%) was observed.
Fig 1. Clinical sum scores and immunohistochemical changes during fractionated 5-aminolaevulinic acid (ALA)- or vehicle-photodynamic therapy.
(a) Clinical sum scores at baseline and weeks 1, 2, 3 and 6. The sum scores of the ALA-treated sites significantly decreased (P ¼ 0Æ009), whereas
the vehicle-treated sites did not show any significant changes during treatment (P ¼ 0Æ239). (b) Ki67 expression significantly declined in the
ALA-treated sites during treatment (P < 0Æ001), but not in the placebo-treated sites (P ¼ 0Æ275). (C) K10 expression significantly increased in the
ALA-treated sites during treatment (P ¼ 0Æ007), but not in the placebo-treated sites (P ¼ 0Æ651). (d–f) Epidermal and dermal expression of
CD4+, CD8+ and CD45RO+ cells, respectively. Epidermal CD4+ cells in the vehicle-treated sites showed statistically significant increases, whereas
CD4+ cells in the ALA-treated sites did not show any statistically significant changes. Dermal CD45RO+ cells showed a statistically significant
decrease during ALA treatment. Although the number of epidermal CD45RO+ cells also showed a marked decrease, this was not statistically
significant. The opposite was observed with respect to the number of CD8+ cells, where a significant epidermal decrease in the ALA-treated site
was seen, vs. a nonsignificant dermal decrease. Results are shown as mean ± SEM.
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However, fluorescence was still 2Æ13 times baseline fluores-
cence.
Immunohistochemistry
Epidermal proliferation and differentiation
Epidermal proliferation decreased during PDT as shown by a
significant reduction in the number of epidermal Ki67+ cells
()60%; P ¼ 0Æ001) (Figs 1b and 5). Epidermal K10 expression,
however, increased significantly, indicating normalization of
differentiation (+16%; P ¼ 0Æ007) (Figs 1c and 5). These chan-
ges were in parallel with the clinical improvement of the psori-
atic lesions and were absent in the placebo-treated lesions.
T-cell infiltration
CD8+ cells were mainly seen in the papillary dermis and to a
lesser extent in the epidermis (Figs 1e and 5). From baseline
to week 6 the number of epidermal CD8+ cells showed a
marked decrease ()36%; P ¼ 0Æ036) in the ALA-treated
lesions. In the dermis a decrease was also noted, but this was
not statistically significant ()31%; P ¼ 0Æ232). The number of
CD45RO+ cells, however, decreased in both epidermis
()48%; P ¼ 0Æ034) and dermis ()43%; P ¼0Æ013) (Figs 1f
and 5). CD4+ cells in the ALA-treated lesions did not show
any significant changes in either dermis ()21%; P ¼0Æ429) or
epidermis ()13%; P ¼ 0Æ112) (Fig. 1d). The placebo-treated
lesions did not show any significant changes in the studied
T-cell subsets except for a significant increase in the number
of epidermal CD4+ cells (+34%; P ¼ 0Æ029).
Fluorescence patterns
Although the studied psoriatic lesions were pretreated with a
keratolytic agent, most lesions showed inhomogenous fluores-
cence, mostly in a follicular pattern and different at the differ-
ent days the treatment took place (Fig. 4). From the clinical
appearance of the lesions the distribution of fluorescence
within the plaque was not always predictable. Fluorescence
values at some sites within the plaques were lower than nor-
mal surrounding skin fluorescence. Epidermal skin barrier also
appeared to influence PpIX formation and distribution within
the plaques as high fluorescence values were always seen
around the sites of biopsy.
Fig 2. Clinical improvement in 5-aminolaevulinic acid-photodynamic
therapy-treated psoriatic plaques. After four treatments most psoriatic
plaques clinically improved as reflected by a reduction in the plaque
severity (sum) score. This was not seen in the placebo and untreated
lesions. Note the partial response and the postinflammatory
hyperpigmentation.
4
3.5
* **
3
2.5
2
1.5
N
or
m
al
iz
ed
 fl
uo
re
sc
en
ce
 (r.
u
.)
1
0.5
0
Before ALA After ALA (4 h) After ALA (6 h)After ALA (4 h)
+2 J cm–2
After ALA (6 h)
+8 J cm–2
Fig 3. Photobleaching of protoporphyrin IX
during fractionated 5-aminolaevulinic acid
(ALA)-photodynamic therapy (PDT).
Macroscopic fluorescence was measured
during fractionated ALA-PDT at several time
points using the DyaDerm imaging system.
Statistically significant changes in fluorescence
were seen at 4 h incubation and after
illumination with the second light dose of
8 J cm)2, while the first light dose did not
induce statistically significant photobleaching.
Fluorescence values are depicted in relative
units (r.u.) mean +/) SEM with baseline
fluorescence set to 1Æ0. *P < 0Æ001,
**P < 0Æ01.
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tolerated by all patients and no additional analgesics were nee-
ded. These sensations were more intense during the second
light fraction of 8 J cm)2.
Psoriatic lesions showed some evident clinical improvement
during the treatment period which was reflected in a statisti-
cally significant decrease in the clinical plaque severity (sum)
score (P ¼ 0.009) (Figs 1a and 2). Moreover, starting at
week 1, the mean sum score of the ALA-treated lesions was
significantly lower as compared with the placebo-treated
lesions. Classical psoriatic plaques of a few centimetres in size
with clinically normal surrounding skin showed the best clin-
ical improvement. This started most frequently in the periphery
of the plaque. Areas within a plaque that clinically improved
were usually followed by hyperpigmentation. In two patients
an increase in the total psoriatic surface area was observed in
the ALA-treated sites, highly suggestive for Koebnerization.
Fluorescence intensity on the skin
After a 4-h incubation with ALA, psoriatic plaques showed
selectively higher fluorescence compared with the surround-
ing (nonlesional) skin (Figs 3 and 4). However, fluores-
cence within most plaques was not homogeneous, despite
clinically adequate keratolytic treatment 1 week prior to the
baseline visit. Lesional fluorescence intensity after a 4-h
incubation with ALA was 2Æ57 times higher compared with
baseline fluorescence (before ALA application). The first
light fraction of 2 J cm)2 caused no statistically significant
photobleaching (2Æ4%). During the 2-h dark interval there-
after, fluorescence intensity again increased up to 2Æ99 times
baseline fluorescence, indicating new PpIX formation. After
the second fraction of 8 J cm)2, a statistically significant
decrease in fluorescence intensity (26Æ69%) was observed.
Fig 1. Clinical sum scores and immunohistochemical changes during fractionated 5-aminolaevulinic acid (ALA)- or vehicle-photodynamic therapy.
(a) Clinical sum scores at baseline and weeks 1, 2, 3 and 6. The sum scores of the ALA-treated sites significantly decreased (P ¼ 0Æ009), whereas
the vehicle-treated sites did not show any significant changes during treatment (P ¼ 0Æ239). (b) Ki67 expression significantly declined in the
ALA-treated sites during treatment (P < 0Æ001), but not in the placebo-treated sites (P ¼ 0Æ275). (C) K10 expression significantly increased in the
ALA-treated sites during treatment (P ¼ 0Æ007), but not in the placebo-treated sites (P ¼ 0Æ651). (d–f) Epidermal and dermal expression of
CD4+, CD8+ and CD45RO+ cells, respectively. Epidermal CD4+ cells in the vehicle-treated sites showed statistically significant increases, whereas
CD4+ cells in the ALA-treated sites did not show any statistically significant changes. Dermal CD45RO+ cells showed a statistically significant
decrease during ALA treatment. Although the number of epidermal CD45RO+ cells also showed a marked decrease, this was not statistically
significant. The opposite was observed with respect to the number of CD8+ cells, where a significant epidermal decrease in the ALA-treated site
was seen, vs. a nonsignificant dermal decrease. Results are shown as mean ± SEM.
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However, fluorescence was still 2Æ13 times baseline fluores-
cence.
Immunohistochemistry
Epidermal proliferation and differentiation
Epidermal proliferation decreased during PDT as shown by a
significant reduction in the number of epidermal Ki67+ cells
()60%; P ¼ 0Æ001) (Figs 1b and 5). Epidermal K10 expression,
however, increased significantly, indicating normalization of
differentiation (+16%; P ¼ 0Æ007) (Figs 1c and 5). These chan-
ges were in parallel with the clinical improvement of the psori-
atic lesions and were absent in the placebo-treated lesions.
T-cell infiltration
CD8+ cells were mainly seen in the papillary dermis and to a
lesser extent in the epidermis (Figs 1e and 5). From baseline
to week 6 the number of epidermal CD8+ cells showed a
marked decrease ()36%; P ¼ 0Æ036) in the ALA-treated
lesions. In the dermis a decrease was also noted, but this was
not statistically significant ()31%; P ¼ 0Æ232). The number of
CD45RO+ cells, however, decreased in both epidermis
()48%; P ¼ 0Æ034) and dermis ()43%; P ¼0Æ013) (Figs 1f
and 5). CD4+ cells in the ALA-treated lesions did not show
any significant changes in either dermis ()21%; P ¼0Æ429) or
epidermis ()13%; P ¼ 0Æ112) (Fig. 1d). The placebo-treated
lesions did not show any significant changes in the studied
T-cell subsets except for a significant increase in the number
of epidermal CD4+ cells (+34%; P ¼ 0Æ029).
Fluorescence patterns
Although the studied psoriatic lesions were pretreated with a
keratolytic agent, most lesions showed inhomogenous fluores-
cence, mostly in a follicular pattern and different at the differ-
ent days the treatment took place (Fig. 4). From the clinical
appearance of the lesions the distribution of fluorescence
within the plaque was not always predictable. Fluorescence
values at some sites within the plaques were lower than nor-
mal surrounding skin fluorescence. Epidermal skin barrier also
appeared to influence PpIX formation and distribution within
the plaques as high fluorescence values were always seen
around the sites of biopsy.
Fig 2. Clinical improvement in 5-aminolaevulinic acid-photodynamic
therapy-treated psoriatic plaques. After four treatments most psoriatic
plaques clinically improved as reflected by a reduction in the plaque
severity (sum) score. This was not seen in the placebo and untreated
lesions. Note the partial response and the postinflammatory
hyperpigmentation.
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Fig 3. Photobleaching of protoporphyrin IX
during fractionated 5-aminolaevulinic acid
(ALA)-photodynamic therapy (PDT).
Macroscopic fluorescence was measured
during fractionated ALA-PDT at several time
points using the DyaDerm imaging system.
Statistically significant changes in fluorescence
were seen at 4 h incubation and after
illumination with the second light dose of
8 J cm)2, while the first light dose did not
induce statistically significant photobleaching.
Fluorescence values are depicted in relative
units (r.u.) mean +/) SEM with baseline
fluorescence set to 1Æ0. *P < 0Æ001,
**P < 0Æ01.
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However, fluorescence was still 2Æ13 times baseline fluores-
cence.
Immunohistochemistry
Epidermal proliferation and differentiation
Epidermal proliferation decreased during PDT as shown by a
significant reduction in the number of epidermal Ki67+ cells
()60%; P ¼ 0Æ001) (Figs 1b and 5). Epidermal K10 expression,
however, increased significantly, indicating normalization of
differentiation (+16%; P ¼ 0Æ007) (Figs 1c and 5). These chan-
ges were in parallel with the clinical improvement of the psori-
atic lesions and were absent in the placebo-treated lesions.
T-cell infiltration
CD8+ cells were mainly seen in the papillary dermis and to a
lesser extent in the epidermis (Figs 1e and 5). From baseline
to week 6 the number of epidermal CD8+ cells showed a
marked decrease ()36%; P ¼ 0Æ036) in the ALA-treated
lesions. In the dermis a decrease was also noted, but this was
not statistically significant ()31%; P ¼ 0Æ232). The number of
CD45RO+ cells, however, decreased in both epidermis
()48%; P ¼ 0Æ034) and dermis ()43%; P ¼0Æ013) (Figs 1f
and 5). CD4+ cells in the ALA-treated lesions did not show
any significant changes in either dermis ()21%; P ¼0Æ429) or
epidermis ()13%; P ¼ 0Æ112) (Fig. 1d). The placebo-treated
lesions did not show any significant changes in the studied
T-cell subs ts except for a g ificant increase in the number
of epidermal CD4+ ce ls (+34%; P ¼ 0Æ029).
Fluorescence patterns
Although the studied psoriatic lesions were pretreated with a
keratolytic agent, most lesions showed inhomogenous fluores-
cence, mostly in a follicular pattern and different at the differ-
e t days the treatment took place (Fig. 4). From the clinical
appearance of the lesions the distribution of fluorescence
within the plaque wa not always predictable. Fluorescence
values at some sit s within th plaques were lower than nor-
mal surrounding skin fluorescence. Epidermal skin barrier also
appeared to influence PpIX formation and distribution within
th plaques as hig fluor scence values were always seen
around the sites of biopsy.
Fig 2. Clinical improvement in 5-aminolaevulinic acid-photodynamic
therapy-treated psoriatic plaques. After four treatments most psoriatic
plaques clinically improved as reflected by a reduction in the plaque
severity (sum) score. This was not seen in the placebo and untreated
lesions. Note the partial response and the postinflammatory
hyperpigmentation.
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were seen at 4 h incubation and after
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8 J cm)2, while the first light dose did not
induce statistically significant photobleaching.
Fluorescence values are depicted in relative
units (r.u.) mean +/) SEM with baseline
fluorescence set to 1Æ0. *P < 0Æ001,
**P < 0Æ01.
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Discussion
Four fractionated PDT sessions of 2 + 8 J cm)2 (2-h dark inter-
val) with 10% ALA ointment induced clinical improvement in
psoriatic plaque severity as measured by a statistically significant
lower sum score compared with the sites that were treated with
vehicle-PDT. Several authors have described clinical improve-
ment of psoriasis after multiple PDT sessions but an optimal
treatment protocol has not yet been established.1–4,7,12 Most
authors agree that the dose per treatment session required for a
clinical improvement must not be too high, as Koebnerization
and severe pain during irradiation have been reported.8 In our
study in two patients an increase in psoriatic activity was
observed in the ALA-treated sites, but not in the placebo-treated
sites. In these sites new psoriatic lesions arose, which is highly
suggestive for the Koebner phenomenon as nonlesional psoriatic
Fig 4. Clinical (a–c), fluorescence (d–f) and
pseudocolour images (g–i) from the same
patient after 5-aminolaevulinic acid
application (4 h) at baseline (a, d, g), week 1
(b, e, h) and week 2 (c, f, i). The
distribution of fluorescence varied largely at
the different time points and was generally in
a follicular pattern. Note that at the sites of
biopsy fluorescence was always present.
Fig 5. Immunohistochemistry. Ki67, keratin
10 (K10), CD8 and CD45RO stainings at
baseline, week 1 and week 6. Ki67 and K10
are displayed at · 100 magnification; T-cell
subsets are displayed at · 50 magnification.
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skin is also affected by photodynamic effects. Although various
factors have been reported to modulate the Koebner response,13
in our patients this was unpredictable. In this light, it would be
interesting to study the photodynamic effects of methyl-
aminolaevulinate (MAL)-PDT which is now licensed in almost
every European country. As MAL has been reported to accumu-
late more selectively than ALA,14 the risk of Koebnerization
could theoretically be reduced. To the best of our knowledge,
the exact differences in PpIX formation in psoriasis between
MAL and ALA have not been studied yet. However, when PpIX
is regarded to accumulate in psoriasis and nonmelanoma skin
cancer by similar mechanisms, with MAL (as Metvix�; Galderma,
Fort Worth, TX, U.S.A.) one might expect less pronounced
photodynamic effects in nonlesional skin (e.g. Koebnerization)
compared with lesional skin. It is unknown, however, how PpIX
levels between 10% ALA cream and Metvix relate, as Metvix
contains a relatively high concentration (160 mg g)1) of MAL
compared with the 100 mg g)1 ALA that was used in our study,
although in a study of Fritsch et al.14 MAL appeared to be less
potent than ALA with respect to PpIX formation in actinic kera-
tosis. Considering the fact that 1% ALA cream in a study of
Radakovic-Fijan et al.7 was able to exert pronounced photo-
dynamic effects in the treatment of psoriasis, the concentration
of MAL in Metvix cream might be too high for this indication.
Koebnerization thus appears to be a significant adverse
event that is most likely to be dependent on the photo-
dynamic dose, although an exact dose–effect relationship has
not yet been established. On the other hand, photodynamic
doses that are too low do not appear to be therapeutically
effective.1–3,8 In a recent study Radakovic-Fijan et al.7 reported
no significant differences in the clinical response between 5
and 10 J cm)2, whereas 20 J cm)2 appeared to be more
effective. In this study 1% ALA ointment was used. As psori-
asis has been reported to accumulate PpIX strongly, lower
concentrations of ALA than used for dermato-oncological indi-
cations may be sufficient to exert a beneficial clinical effect. In
addition, the primary goal of PDT in psoriasis is not likely to
be the cytotoxic effect, for which a few higher photodynamic
doses are required, but rather the immunomodulatory effect
in which exposure to multiple lower photodynamic doses
over a longer period of time is thought to be required. Con-
sidering the fact that at the end of the second illumination
macroscopic fluorescence was still 2Æ13 times above baseline
fluorescence, in our study depletion of PpIX cannot be held
responsible for the mediocre clinical efficacy.
Fractionation of the light dose in two fractions with a
dark interval in between has been reported as a way to
enhance PpIX formation as resynthesis of PpIX is thought to
take place in the dark period. Moreover, during the dark
period reoxygenation of the tissue may lead to additional
singlet oxygen and reactive oxygen species formation.15
These events may account for the increased PDT-induced
photodamage. Lowering of the fluence rate has also been
reported to result in more and deeper PDT-induced photo-
damage by a similar mechanism.10 As mean fluorescence
directly after the first illumination did not show a statisti-
cally significant decrease, it is likely that if the amount of
photobleaching is regarded to be related to photodynamic
effect, then the first dose of 2 J cm)2 was too low to exert
a significant clinical effect. The second illumination, how-
ever, did induce statistically significant photobleaching. In
this light, a twofold illumination scheme of 5 + 5 J cm)2
might be more effective, but the risk of Koebnerization may
theoretically be increased. As penetration of ALA cream is
one of the main problems in the treatment of dermal pro-
cesses, lowering of the fluence rate may be more useful
than light fractionation.
Increased epidermal proliferation, abnormal keratinization
and dermal infiltration of T-cells and neutrophils are the histo-
logical hallmarks of plaque psoriasis, whereas normalization of
these parameters is associated with clinical improvement. In
our biopsies normalization of epidermal proliferation was
seen, as reflected by a significant decrease in Ki67 expression,
which is a cell cycle-associated antigen expressed in all parts
of the cell cycle except G0 and early G1, thus representing the
epidermal proliferative compartment.16 Normalization of
keratinization was also observed, as seen in an increase in
expression of epidermal K10, a marker for terminal differenti-
ation which is generally decreased in psoriasis.17
Analysis of T-cell infiltration also showed statistically signifi-
cant increases in epidermal CD4+ cells in the vehicle-treated
sites, whereas CD4+ cells in the ALA-treated sites did not
show any statistically significant changes. The photodynamic
effect might be responsible for the stabilization of the CD4
influx into the skin. Dermal and epidermal CD45RO+ cells
showed a statistically significant decrease during ALA treat-
ment. With respect to the number of CD8+ cells, a significant
epidermal decrease in the ALA-treated site was seen, as
opposed to a nonsignificant dermal decrease.
Thus, the current treatment protocol as described in our
study demonstrated pronounced antipsoriatic effects on epi-
dermal keratinocytes with respect to proliferation and differen-
tiation. A decrease in the number of CD45RO+ cells was the
only statistically significant dermal effect that was observed.
This is not surprising when the penetration depth of the light
source and ALA cream used are considered. PDT with topical
ALA exerts its main effects on the surface of the skin where
the amount of light energy and photosensitizer concentration
are the highest. Hence its effects are expected to be found
mainly in the epidermis.
Heterogeneity of fluorescence on the skin as well as histo-
logically within psoriatic plaques has been described by var-
ious authors.2,7,18 A part of this seems to be related to the
amount of hyperkeratosis within a psoriatic plaque, as pre-
treatment with a keratolytic agent improves fluorescence
homogeneity.18 It is not known what causes the remaining
heterogeneity of fluorescence after clinically efficient desqua-
mation, as observed in our patients. These variations in fluor-
escence might explain the variable and mostly partial clinical
response seen after PDT.
The present study reconfirms that PDT has an antipsoriatic
efficacy and is well tolerated. Because of the variable clinical
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Discussion
Four fractionated PDT sessions of 2 + 8 J cm)2 (2-h dark inter-
val) with 10% ALA ointment induced clinical improvement in
psoriatic plaque severity as measured by a statistically significant
lower sum score compared with the sites that were treated with
vehicle-PDT. Several authors have described clinical improve-
ment of psoriasis after multiple PDT sessions but an optimal
treatment protocol has not yet been established.1–4,7,12 Most
authors agree that the dose per treatment session required for a
clinical improvement must not be too high, as Koebnerization
and severe pain during irradiation have been reported.8 In our
study in two patients an increase in psoriatic activity was
observed in the ALA-treated sites, but not in the placebo-treated
sites. In these sites new psoriatic lesions arose, which is highly
suggestive for the Koebner phenomenon as nonlesional psoriatic
Fig 4. Clinical (a–c), fluorescence (d–f) and
pseudocolour images (g–i) from the same
patient after 5-aminolaevulinic acid
application (4 h) at baseline (a, d, g), week 1
(b, e, h) and week 2 (c, f, i). The
distribution of fluorescence varied largely at
the different time points and was generally in
a follicular pattern. Note that at the sites of
biopsy fluorescence was always present.
Fig 5. Immunohistochemistry. Ki67, keratin
10 (K10), CD8 and CD45RO stainings at
baseline, week 1 and week 6. Ki67 and K10
are displayed at · 100 magnification; T-cell
subsets are displayed at · 50 magnification.
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skin is also affected by photodynamic effects. Although various
factors have been reported to modulate the Koebner response,13
in our patients this was unpredictable. In this light, it would be
interesting to study the photodynamic effects of methyl-
aminolaevulinate (MAL)-PDT which is now licensed in almost
every European country. As MAL has been reported to accumu-
late more selectively than ALA,14 the risk of Koebnerization
could theoretically be reduced. To the best of our knowledge,
the exact differences in PpIX formation in psoriasis between
MAL and ALA have not been studied yet. However, when PpIX
is regarded to accumulate in psoriasis and nonmelanoma skin
cancer by similar mechanisms, with MAL (as Metvix�; Galderma,
Fort Worth, TX, U.S.A.) one might expect less pronounced
photodynamic effects in nonlesional skin (e.g. Koebnerization)
compared with lesional skin. It is unknown, however, how PpIX
levels between 10% ALA cream and Metvix relate, as Metvix
contains a relatively high concentration (160 mg g)1) of MAL
compared with the 100 mg g)1 ALA that was used in our study,
although in a study of Fritsch et al.14 MAL appeared to be less
potent than ALA with respect to PpIX formation in actinic kera-
tosis. Considering the fact that 1% ALA cream in a study of
Radakovic-Fijan et al.7 was able to exert pronounced photo-
dynamic effects in the treatment of psoriasis, the concentration
of MAL in Metvix cream might be too high for this indication.
Koebnerization thus appears to be a significant adverse
event that is most likely to be dependent on the photo-
dynamic dose, although an exact dose–effect relationship has
not yet been established. On the other hand, photodynamic
doses that are too low do not appear to be therapeutically
effective.1–3,8 In a recent study Radakovic-Fijan et al.7 reported
no significant differences in the clinical response between 5
and 10 J cm)2, whereas 20 J cm)2 appeared to be more
effective. In this study 1% ALA ointment was used. As psori-
asis has been reported to accumulate PpIX strongly, lower
concentrations of ALA than used for dermato-oncological indi-
cations may be sufficient to exert a beneficial clinical effect. In
addition, the primary goal of PDT in psoriasis is not likely to
be the cytotoxic effect, for which a few higher photodynamic
doses are required, but rather the immunomodulatory effect
in which exposure to multiple lower photodynamic doses
over a longer period of time is thought to be required. Con-
sidering the fact that at the end of the second illumination
macroscopic fluorescence was still 2Æ13 times above baseline
fluorescence, in our study depletion of PpIX cannot be held
responsible for the mediocre clinical efficacy.
Fractionation of the light dose in two fractions with a
dark interval in between has been reported as a way to
enhance PpIX formation as resynthesis of PpIX is thought to
take place in the dark period. Moreover, during the dark
period reoxygenation of the tissue may lead to additional
singlet oxygen and reactive oxygen species formation.15
These events may account for the increased PDT-induced
photodamage. Lowering of the fluence rate has also been
reported to result in more and deeper PDT-induced photo-
damage by a similar mechanism.10 As mean fluorescence
directly after the first illumination did not show a statisti-
cally significant decrease, it is likely that if the amount of
photobleaching is regarded to be related to photodynamic
effect, then the first dose of 2 J cm)2 was too low to exert
a significant clinical effect. The second illumination, how-
ever, did induce statistically significant photobleaching. In
this light, a twofold illumination scheme of 5 + 5 J cm)2
might be more effective, but the risk of Koebnerization may
theoretically be increased. As penetration of ALA cream is
one of the main problems in the treatment of dermal pro-
cesses, lowering of the fluence rate may be more useful
than light fractionation.
Increased epidermal proliferation, abnormal keratinization
and dermal infiltration of T-cells and neutrophils are the histo-
logical hallmarks of plaque psoriasis, whereas normalization of
these parameters is associated with clinical improvement. In
our biopsies normalization of epidermal proliferation was
seen, as reflected by a significant decrease in Ki67 expression,
which is a cell cycle-associated antigen expressed in all parts
of the cell cycle except G0 and early G1, thus representing the
epidermal proliferative compartment.16 Normalization of
keratinization was also observed, as seen in an increase in
expression of epidermal K10, a marker for terminal differenti-
ation which is generally decreased in psoriasis.17
Analysis of T-cell infiltration also showed statistically signifi-
cant increases in epidermal CD4+ cells in the vehicle-treated
sites, whereas CD4+ cells in the ALA-treated sites did not
show any statistically significant changes. The photodynamic
effect might be responsible for the stabilization of the CD4
influx into the skin. Dermal and epidermal CD45RO+ cells
showed a statistically significant decrease during ALA treat-
ment. With respect to the number of CD8+ cells, a significant
epidermal decrease in the ALA-treated site was seen, as
opposed to a nonsignificant dermal decrease.
Thus, the current treatment protocol as described in our
study demonstrated pronounced antipsoriatic effects on epi-
dermal keratinocytes with respect to proliferation and differen-
tiation. A decrease in the number of CD45RO+ cells was the
only statistically significant dermal effect that was observed.
This is not surprising when the penetration depth of the light
source and ALA cream used are considered. PDT with topical
ALA exerts its main effects on the surface of the skin where
the amount of light energy and photosensitizer concentration
are the highest. Hence its effects are expected to be found
mainly in the epidermis.
Heterogeneity of fluorescence on the skin as well as histo-
logically within psoriatic plaques has been described by var-
ious authors.2,7,18 A part of this seems to be related to the
amount of hyperkeratosis within a psoriatic plaque, as pre-
treatment with a keratolytic agent improves fluorescence
homogeneity.18 It is not known what causes the remaining
heterogeneity of fluorescence after clinically efficient desqua-
mation, as observed in our patients. These variations in fluor-
escence might explain the variable and mostly partial clinical
response seen after PDT.
The present study reconfirms that PDT has an antipsoriatic
efficacy and is well tolerated. Because of the variable clinical
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effect and mediocre clinical efficacy compared with other
established topical treatments, PDT of psoriasis using the cur-
rent protocols would not be recommended as a first-line treat-
ment option. However, in certain patients with limited
chronic plaque psoriasis where conventional treatments have
failed, PDT can be an alternative. Perhaps the addition of top-
ical corticosteroids to PDT might enhance clinical efficacy fur-
ther and reduce the risk of Koebnerization. More studies are
needed, better to understand PpIX formation and its photo-
dynamic effects in psoriasis so that an optimized treatment
protocol can be developed.
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Summary
Background Psoriasis has been shown to highly accumulate protoporphyrin IX
(PpIX), but a variable distribution within plaques after fluorescence diagnosis is
seen. It is unknown what causes this heterogeneity of fluorescence in psoriatic
skin, despite adequate keratolytic treatment. Variations in fluorescence might
explain the variable and the mostly partial clinical response of psoriasis seen after
photodynamic therapy (PDT).
Objectives This study examines morphological and immunohistochemical differ-
ences in inhomogeneous PpIX-induced fluorescence in stable plaque psoriasis.
Materials and methods Fourteen patients with stable plaque psoriasis were included in
this study. In each patient one psoriatic plaque was incubated with 20% 5-ami-
nolaevulinic acid (ALA) ointment for 3 h after keratolytic treatment. Fluorescence
diagnosis with ALA-induced porphyrins (FDAP) was performed and subsequently
high- and low-fluorescent psoriatic skin samples were biopsied. Biopsies were
investigated with respect to histological hyperkeratosis (thickness of stratum cor-
neum), proliferation (Ki-67 antigen), keratinization (K10, filaggrin) and inflam-
mation (CD3). Digital images acquired with FDAP were analysed using image
analysis software.
Results Inhomogeneous fluorescence was seen in 12 of the 14 plaques. A signifi-
cantly thicker stratum corneum was found in low-fluorescent psoriatic skin
compared with highly fluorescent skin. Fluorescence intensity and thickness of
the stratum corneum proved to be negatively correlated. The variable-fluorescent
parts of the lesional psoriatic skin showed no differences in epidermal prolifer-
ation, keratinization or inflammation.
Conclusions Heterogeneous ALA-induced fluorescence in psoriasis plaques related to
inhomogeneous distribution of PpIX in the epidermis may result from differences
in penetration of ALA and/or light within a plaque caused by differences in stra-
tum corneum thickness. The variable clinical response seen after PDT in psoriasis
could be explained by this. These findings are consistent with the general
assumption that optimal desquamation prior to FDAP or PDT is required for the
most favourable results.
Over recent years, there has been increasing interest in photo-
dynamic therapy (PDT) with topical 5-aminolaevulinic acid
(ALA) in dermatological practice. Although more randomized,
controlled studies are needed and long-term follow-up data
are lacking, PDT has proven to be clinically effective in super-
ficial skin (pre)malignancies including actinic keratosis, Bowen
disease and (superficial) basal cell carcinoma. In general, pro-
toporphyrin IX (PpIX)-accumulating skin disorders may be a
potential target for PDT. Besides the main oncological indica-
tions for PDT, other (nononcological) indications have also
been studied or are currently under evaluation. As PpIX has
characteristic fluorescence properties, its preferential accumula-
tion in certain cell types can also be used as a cellular marker.
In fluorescence diagnosis with ALA-induced porphyrins
(FDAP), lesional and nonlesional areas are irradiated with blue
light after incubation of the skin with ALA. As PpIX shows red
fluorescence when excited by blue light, PpIX accumulating
cells can be visualized.1 Psoriasis has been shown to accumu-
late PpIX selectively and its susceptibility to PDT has been pre-
viously studied by various authors.2–8 In these studies clinical
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effect and mediocre clinical efficacy compared with other
established topical treatments, PDT of psoriasis using the cur-
rent protocols would not be recommended as a first-line treat-
ment option. However, in certain patients with limited
chronic plaque psoriasis where conventional treatments have
failed, PDT can be an alternative. Perhaps the addition of top-
ical corticosteroids to PDT might enhance clinical efficacy fur-
ther and reduce the risk of Koebnerization. More studies are
needed, better to understand PpIX formation and its photo-
dynamic effects in psoriasis so that an optimized treatment
protocol can be developed.
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Summary
Background Psoriasis has been shown to highly accumulate protoporphyrin IX
(PpIX), but a variable distribution within plaques after fluorescence diagnosis is
seen. It is unknown what causes this heterogeneity of fluorescence in psoriatic
skin, despite adequate keratolytic treatment. Variations in fluorescence might
explain the variable and the mostly partial clinical response of psoriasis seen after
photodynamic therapy (PDT).
Objectives This study examines morphological and immunohistochemical differ-
ences in inhomogeneous PpIX-induced fluorescence in stable plaque psoriasis.
Materials and methods Fourteen patients with stable plaque psoriasis were included in
this study. In each patient one psoriatic plaque was incubated with 20% 5-ami-
nolaevulinic acid (ALA) ointment for 3 h after keratolytic treatment. Fluorescence
diagnosis with ALA-induced porphyrins (FDAP) was performed and subsequently
high- and low-fluorescent psoriatic skin samples were biopsied. Biopsies were
investigated with respect to histological hyperkeratosis (thickness of stratum cor-
neum), proliferation (Ki-67 antigen), keratinization (K10, filaggrin) and inflam-
mation (CD3). Digital images acquired with FDAP were analysed using image
analysis software.
Results Inhomogeneous fluorescence was seen in 12 of the 14 plaques. A signifi-
cantly thicker stratum corneum was found in low-fluorescent psoriatic skin
compared with highly fluorescent skin. Fluorescence intensity and thickness of
the stratum corneum proved to be negatively correlated. The variable-fluorescent
parts of the lesional psoriatic skin showed no differences in epidermal prolifer-
ation, keratinization or inflammation.
Conclusions Heterogeneous ALA-induced fluorescence in psoriasis plaques related to
inhomogeneous distribution of PpIX in the epidermis may result from differences
in penetration of ALA and/or light within a plaque caused by differences in stra-
tum corneum thickness. The variable clinical response seen after PDT in psoriasis
could be explained by this. These findings are consistent with the general
assumption that optimal desquamation prior to FDAP or PDT is required for the
most favourable results.
Over recent years, there has been increasing interest in photo-
dynamic therapy (PDT) with topical 5-aminolaevulinic acid
(ALA) in dermatological practice. Although more randomized,
controlled studies are needed and long-term follow-up data
are lacking, PDT has proven to be clinically effective in super-
ficial skin (pre)malignancies including actinic keratosis, Bowen
disease and (superficial) basal cell carcinoma. In general, pro-
toporphyrin IX (PpIX)-accumulating skin disorders may be a
potential target for PDT. Besides the main oncological indica-
tions for PDT, other (nononcological) indications have also
been studied or are currently under evaluation. As PpIX has
characteristic fluorescence properties, its preferential accumula-
tion in certain cell types can also be used as a cellular marker.
In fluorescence diagnosis with ALA-induced porphyrins
(FDAP), lesional and nonlesional areas are irradiated with blue
light after incubation of the skin with ALA. As PpIX shows red
fluorescence when excited by blue light, PpIX accumulating
cells can be visualized.1 Psoriasis has been shown to accumu-
late PpIX selectively and its susceptibility to PDT has been pre-
viously studied by various authors.2–8 In these studies clinical
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Sections were washed in PBS for 15 min. Secondary IgG-
labelled polymer, horseradish peroxidase antimouse EnVision+
(DAKO, Copenhagen, Denmark) was added for 30 min. The
sections were washed again for 15 min in PBS. To visualize
the staining, AEC (3-amino-9-ethylcarbazol) plus high-sensi-
tivity substrate chromogen for 10 min (DAKO) was used.
Counterstaining was performed with Mayer’s haematoxylin
(Sigma; St Louis, MO, U.S.A.). The sections were washed in
tap water, dried and mounted in glycerol gelatin (Sigma).
Furthermore, haematoxylin and eosin staining was per-
formed on every biopsy specimen. After dehydration in alco-
hol and Histosafe (Adamas Instruments bv; Leersum, the
Netherlands), these sections were mounted in Permount
(Fisher Scientific; Fair Lawn, NJ, U.S.A.). With these haema-
toxylin and eosin sections, we verified that the biopsies under
study fulfilled the psoriasis-specific histological criteria.
Morphological and immunohistochemical analysis
Analysis of digital microscopic images was done using Axio-
Vision Release 4Æ2 (Carl Zeiss GmbH, Go¨ttingen, Germany).
Digital photographs of the haematoxylin and eosin sections
were made at 50 · magnification to examine the morpholo-
gical characteristics, the thickness of the stratum corneum
and epidermis. To determine the thickness of the stratum
corneum the average thickness was calculated as total stra-
tum corneum surface including hyperkeratosis per milli-
meter length of stratum corneum in different biopsy
sections. The same procedure was used to assess the epider-
mal thickness.
In order to analyse Ki-67+ cells, digital photographs were
made at 100 · magnification covering the entire epidermis. A
line following the basement membrane was drawn and its
length was measured. All positive cells above this line were
counted and divided by the length of the basement membrane
so the number of positive cells per millimeter length of base-
ment membrane could be calculated. For quantification of
keratin 10 (K10)-positive cells digital photographs were made
at 50 · magnification. The surface of K10+ (epidermal) cells
was measured and divided by the total epidermal surface.
Thus epidermal differentiation was defined as percentage
K10+ epidermal surface. Filaggrin expression was assessed by
measuring the percentage of the length of the stratum cor-
neum and stratum granulosum that was stained.
CD3+ (T) cells were analysed by counting all positive cells
in the epidermis and dermis separately. These numbers were
divided by the length of the stratum corneum. In this way T
cells were expressed as the number of positive cells per milli-
meter (epi)dermis.
Statistics
To compare mean fluorescence intensity, stratum corneum
and epidermal thickness and expression of Ki-67, K10, filag-
grin and CD3 between the two regions of the lesions a two-
tailed Student’s t-test was used. P < 0Æ05 was regarded as
statistically significant. Microsoft Excel 2000 and Statistica 6Æ0
software [Statsoft Inc., http://www.statsoft.com (accessed 23
February 2006)] were used for statistical calculations.
Additionally, correlation analysis was performed to assess
the strength of the relationship between fluorescence intensity
and morphological or immunohistochemical characteristics.
The degree of association was measured by Pearson’s correla-
tion coefficient (r).
Results
Fluorescence intensity
In accordance with our previous results, psoriatic skin showed
selectively higher fluorescence compared with surrounding
nonlesional skin after 3-h incubation with ALA. Despite clinic-
ally adequate keratolytic treatment fluorescence was not
homogeneous within most plaques (12 of 14; 86%, Fig. 1).
The distribution of fluorescence within the plaque could not
be predicted by the clinical appearance of the lesions and was
seen predominantly in a follicular pattern. The intensity of
high-fluorescence lesional skin was 1Æ76 times higher than
low-fluorescence skin within plaques (Fig. 2a). Remarkably,
homogeneous fluorescence was seen in two patients (2 of 14;
14%).
Thickness of stratum corneum and epidermis
In both high- and low-fluorescent lesional skin hyperkerato-
sis and epidermal hyperplasia were seen histologically
(Fig. 3). The stratum corneum proved to be significantly
thicker in low-fluorescent psoriatic skin (1Æ64 times thicker,
Table 1 Primary antibodies (mouse antihuman) used for immunohistochemistry
Antibody Marker for Clone Dilution Supplier
Ki-67 Epidermal proliferation MIB-1 1 : 200 DAKOa
Keratin 10 Epidermal differentiation RKSE60 1 : 100 Monosanb
Filaggrin Epidermal differentiation BT576 1 : 6000 Biomedical Technologies Inc.c
CD3 T cells UCTH1 1 : 100 DAKO
aCopenhagen, Denmark; bUden, the Netherlands; cStoughton, MA, U.S.A.
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efficacy varied widely but results are difficult to compare
because of the different treatment parameters that have been
used.
Heterogeneity of fluorescence on the skin as well as histo-
logically within psoriatic plaques during FDAP have been des-
cribed before by various authors.3,7–10 In a previous study we
investigated the fluorescence in psoriatic lesions before and
after fractionated PDT.11 After a 4-h application of topical
10% ALA, psoriatic plaques showed selectively higher fluores-
cence compared with nonlesional skin. However, fluorescence
within most plaques was not homogeneous, despite clinically
adequate keratolytic treatment 1 week prior to the baseline
visit. The reason for the remaining heterogeneity of fluores-
cence after clinically efficient desquamation as observed in our
patients is unknown. Variable fluorescence seems to be related
in part to the amount of hyperkeratosis within a psoriatic
plaque, as pretreatment with a keratolytic agent improves fluor-
escence homogeneity.1,10 But an increased metabolic activity
of hyperproliferative parts within a psoriatic plaque and sub-
sequently an increased synthesis of PpIX may also influ-
ence fluorescence intensity.3,9 These variations in fluorescence,
indicating nonuniform sensitization with porphyrins, might
explain the variable and mostly partial clinical response seen
after PDT of psoriasis.
In the present study biopsies from high- and low-fluores-
cent parts within a psoriatic plaque were analysed by
(immuno-)histochemistry with respect to morphological
differences (stratum corneum and epidermal thickness) and
differences in psoriatic activity as reflected by epidermal
proliferation and differentiation and inflammation markers
between high- and low-fluorescent parts of the psoriatic
lesion.
Materials and methods
Patients
This study was approved by the local medical ethics commit-
tee. Fourteen patients (age range 45–70 years; 10 men, 4
women) with stable plaque psoriasis were included in this
study after giving their written informed consent. All the stud-
ied lesions were located on the lower extremities. Lesions
were treated with 10% salicylic acid in petrolatum for 1 week
prior to the baseline visit to remove excess scales that could
potentially interfere with ALA uptake and light penetration.
Patients were not allowed to use any systemic psoriatic treat-
ments or topical medication on these lesions for at least
4 weeks. Medication known to potentially aggravate psoriatic
lesions, such as b-blockers, was also not allowed.
Fluorescence diagnosis
After 3 h of incubation with 20% ALA ointment fluorescence
intensity on the skin was recorded using a digital fluorescence
imaging system (DyaDerm; Biocam GmbH, Regensburg, Ger-
many). The DyaDerm digital imaging system consists of a
flash light [Xenon light source with a custom band pass filter
(370–440 nm)] and a 12-bit Sony CCD camera combined in
one adjustable arm coupled to a Pentium IV computer
equipped with custom-made image-capturing software (Dya-
derm Pro v1Æ4, Biocam GmbH). The flash light emits light
pulses to the skin (rate 7 s)1), which are recorded by the
CCD camera (exposure time 100 ls) equipped with a special
Schott GG 455 long-pass filter to filter out the excitation light.
As PpIX fluorescence emission consists of light in the red
spectrum, the red pixels of the CCD camera were used to gen-
erate a fluorescence image. In this way a normal-coloured
image and a fluorescence image were processed in real time.
Because of the short exposure time to the excitation light,
photobleaching of PpIX was minimalized in this way. To cor-
rect for different lighting environments between pictures, a
fluorescence reference standard (Maccal 8044, 738-00, Multi-
foil; Utrecht, the Netherlands) was included on every image.
Images were recorded in 16-bit greyscale TIFF format.
Analysis of fluorescence images
TIFF fluorescence images (16-bit greyscale) were imported in
NIH ImageJ software [http://rsb.info.nih.gov/ij/ (accessed 23
February 2006)]. Because the Xenon light source used for
excitation has the highest intensity in the centre of the illu-
minated area, shading correction was performed by means of
the following algorithm:
S ¼ I
C
with C ¼ B
BImax
where B ¼ blank image (image from a white homogeneous
background recorded with the Dyaderm system), BImax ¼ high-
est intensity of blank image, I ¼ (uncorrected) image, C ¼ nor-
malized shading image and S ¼ shading corrected image.
Biopsy procedure
After FDAP, 4-mm punch biopsies from a high-fluorescent
part and from a low-fluorescent part of the psoriatic lesions
were taken under local anaesthesia with 1% xylocain–adren-
alin. In case of homogeneous fluorescence two 4-mm biopsies
of representative parts within the plaque were taken. Biopsies
were embedded in Tissue-Tek OCT compound (Miles Scienti-
fic; Naperville, IL, U.S.A.) and directly frozen in liquid nitro-
gen. Until further processing, biopsies were stored at )80 �C.
Immunohistochemistry
Frozen sections (7 lm) were cut from the skin samples for
immunohistochemical assessment. These were air-dried for
30 min and fixed in cold acetone for 10 min. Sections were
washed in phosphate buffered saline (PBS, B. Braun; Melsun-
gen, Germany) for 10 min before 1-h incubation with pri-
mary antibodies. The primary antibodies that were used,
diluted in 1% bovine serum albumin, are depicted in Table 1.
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Sections were washed in PBS for 15 min. Secondary IgG-
labelled polymer, horseradish peroxidase antimouse EnVision+
(DAKO, Copenhagen, Denmark) was added for 30 min. The
sections were washed again for 15 min in PBS. To visualize
the staining, AEC (3-amino-9-ethylcarbazol) plus high-sensi-
tivity substrate chromogen for 10 min (DAKO) was used.
Counterstaining was performed with Mayer’s haematoxylin
(Sigma; St Louis, MO, U.S.A.). The sections were washed in
tap water, dried and mounted in glycerol gelatin (Sigma).
Furthermore, haematoxylin and eosin staining was per-
formed on every biopsy specimen. After dehydration in alco-
hol and Histosafe (Adamas Instruments bv; Leersum, the
Netherlands), these sections were mounted in Permount
(Fisher Scientific; Fair Lawn, NJ, U.S.A.). With these haema-
toxylin and eosin sections, we verified that the biopsies under
study fulfilled the psoriasis-specific histological criteria.
Morphological and immunohistochemical analysis
Analysis of digital microscopic images was done using Axio-
Vision Release 4Æ2 (Carl Zeiss GmbH, Go¨ttingen, Germany).
Digital photographs of the haematoxylin and eosin sections
were made at 50 · magnification to examine the morpholo-
gical characteristics, the thickness of the stratum corneum
and epidermis. To determine the thickness of the stratum
corneum the average thickness was calculated as total stra-
tum corneum surface including hyperkeratosis per milli-
meter length of stratum corneum in different biopsy
sections. The same procedure was used to assess the epider-
mal thickness.
In order to analyse Ki-67+ cells, digital photographs were
made at 100 · magnification covering the entire epidermis. A
line following the basement membrane was drawn and its
length was measured. All positive cells above this line were
counted and divided by the length of the basement membrane
so the number of positive cells per millimeter length of base-
ment membrane could be calculated. For quantification of
keratin 10 (K10)-positive cells digital photographs were made
at 50 · magnification. The surface of K10+ (epidermal) cells
was measured and divided by the total epidermal surface.
Thus epidermal differentiation was defined as percentage
K10+ epidermal surface. Filaggrin expression was assessed by
measuring the percentage of the length of the stratum cor-
neum and stratum granulosum that was stained.
CD3+ (T) cells were analysed by counting all positive cells
in the epidermis and dermis separately. These numbers were
divided by the length of the stratum corneum. In this way T
cells were expressed as the number of positive cells per milli-
meter (epi)dermis.
Statistics
To compare mean fluorescence intensity, stratum corneum
and epidermal thickness and expression of Ki-67, K10, filag-
grin and CD3 between the two regions of the lesions a two-
tailed Student’s t-test was used. P < 0Æ05 was regarded as
statistically significant. Microsoft Excel 2000 and Statistica 6Æ0
software [Statsoft Inc., http://www.statsoft.com (accessed 23
February 2006)] were used for statistical calculations.
Additionally, correlation analysis was performed to assess
the strength of the relationship between fluorescence intensity
and morphological or immunohistochemical characteristics.
The degree of association was measured by Pearson’s correla-
tion coefficient (r).
Results
Fluorescence intensity
In accordance with our previous results, psoriatic skin showed
selectively higher fluorescence compared with surrounding
nonlesional skin after 3-h incubation with ALA. Despite clinic-
ally adequate keratolytic treatment fluorescence was not
homogeneous within most plaques (12 of 14; 86%, Fig. 1).
The distribution of fluorescence within the plaque could not
be predicted by the clinical appearance of the lesions and was
seen predominantly in a follicular pattern. The intensity of
high-fluorescence lesional skin was 1Æ76 times higher than
low-fluorescence skin within plaques (Fig. 2a). Remarkably,
homogeneous fluorescence was seen in two patients (2 of 14;
14%).
Thickness of stratum corneum and epidermis
In both high- and low-fluorescent lesional skin hyperkerato-
sis and epidermal hyperplasia were seen histologically
(Fig. 3). The stratum corneum proved to be significantly
thicker in low-fluorescent psoriatic skin (1Æ64 times thicker,
Table 1 Primary antibodies (mouse antihuman) used for immunohistochemistry
Antibody Marker for Clone Dilution Supplier
Ki-67 Epidermal proliferation MIB-1 1 : 200 DAKOa
Keratin 10 Epidermal differentiation RKSE60 1 : 100 Monosanb
Filaggrin Epidermal differentiation BT576 1 : 6000 Biomedical Technologies Inc.c
CD3 T cells UCTH1 1 : 100 DAKO
aCopenhagen, Denmark; bUden, the Netherlands; cStoughton, MA, U.S.A.
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efficacy varied widely but results are difficult to compare
because of the different treatment parameters that have been
used.
Heterogeneity of fluorescence on the skin as well as histo-
logically within psoriatic plaques during FDAP have been des-
cribed before by various authors.3,7–10 In a previous study we
investigated the fluorescence in psoriatic lesions before and
after fractionated PDT.11 After a 4-h application of topical
10% ALA, psoriatic plaques showed selectively higher fluores-
cence compared with nonlesional skin. However, fluorescence
within most plaques was not homogeneous, despite clinically
adequate keratolytic treatment 1 week prior to the baseline
visit. The reason for the remaining heterogeneity of fluores-
cence after clinically efficient desquamation as observed in our
patients is unknown. Variable fluorescence seems to be related
in part to the amount of hyperkeratosis within a psoriatic
plaque, as pretreatment with a keratolytic agent improves fluor-
escence homogeneity.1,10 But an increased metabolic activity
of hyperproliferative parts within a psoriatic plaque and sub-
sequently an increased synthesis of PpIX may also influ-
ence fluorescence intensity.3,9 These variations in fluorescence,
indicating nonuniform sensitization with porphyrins, might
explain the variable and mostly partial clinical response seen
after PDT of psoriasis.
In the present study biopsies from high- and low-fluores-
cent parts within a psoriatic plaque were analysed by
(immuno-)histochemistry with respect to morphological
differences (stratum corneum and epidermal thickness) and
differences in psoriatic activity as reflected by epidermal
proliferation and differentiation and inflammation markers
between high- and low-fluorescent parts of the psoriatic
lesion.
Materials and methods
Patients
This study was approved by the local medical ethics commit-
tee. Fourteen patients (age range 45–70 years; 10 men, 4
women) with stable plaque psoriasis were included in this
study after giving their written informed consent. All the stud-
ied lesions were located on the lower extremities. Lesions
were treated with 10% salicylic acid in petrolatum for 1 week
prior to the baseline visit to remove excess scales that could
potentially interfere with ALA uptake and light penetration.
Patients were not allowed to use any systemic psoriatic treat-
ments or topical medication on these lesions for at least
4 weeks. Medication known to potentially aggravate psoriatic
lesions, such as b-blockers, was also not allowed.
Fluorescence diagnosis
After 3 h of incubation with 20% ALA ointment fluorescence
intensity on the skin was recorded using a digital fluorescence
imaging system (DyaDerm; Biocam GmbH, Regensburg, Ger-
many). The DyaDerm digital imaging system consists of a
flash light [Xenon light source with a custom band pass filter
(370–440 nm)] and a 12-bit Sony CCD camera combined in
one adjustable arm coupled to a Pentium IV computer
equipped with custom-made image-capturing software (Dya-
derm Pro v1Æ4, Biocam GmbH). The flash light emits light
pulses to the skin (rate 7 s)1), which are recorded by the
CCD camera (exposure time 100 ls) equipped with a special
Schott GG 455 long-pass filter to filter out the excitation light.
As PpIX fluorescence emission consists of light in the red
spectrum, the red pixels of the CCD camera were used to gen-
erate a fluorescence image. In this way a normal-coloured
image and a fluorescence image were processed in real time.
Because of the short exposure time to the excitation light,
photobleaching of PpIX was minimalized in this way. To cor-
rect for different lighting environments between pictures, a
fluorescence reference standard (Maccal 8044, 738-00, Multi-
foil; Utrecht, the Netherlands) was included on every image.
Images were recorded in 16-bit greyscale TIFF format.
Analysis of fluorescence images
TIFF fluorescence images (16-bit greyscale) were imported in
NIH ImageJ software [http://rsb.info.nih.gov/ij/ (accessed 23
February 2006)]. Because the Xenon light source used for
excitation has the highest intensity in the centre of the illu-
minated area, shading correction was performed by means of
the following algorithm:
S ¼ I
C
with C ¼ B
BImax
where B ¼ blank image (image from a white homogeneous
background recorded with the Dyaderm system), BImax ¼ high-
est intensity of blank image, I ¼ (uncorrected) image, C ¼ nor-
malized shading image and S ¼ shading corrected image.
Biopsy procedure
After FDAP, 4-mm punch biopsies from a high-fluorescent
part and from a low-fluorescent part of the psoriatic lesions
were taken under local anaesthesia with 1% xylocain–adren-
alin. In case of homogeneous fluorescence two 4-mm biopsies
of representative parts within the plaque were taken. Biopsies
were embedded in Tissue-Tek OCT compound (Miles Scienti-
fic; Naperville, IL, U.S.A.) and directly frozen in liquid nitro-
gen. Until further processing, biopsies were stored at )80 �C.
Immunohistochemistry
Frozen sections (7 lm) were cut from the skin samples for
immunohistochemical assessment. These were air-dried for
30 min and fixed in cold acetone for 10 min. Sections were
washed in phosphate buffered saline (PBS, B. Braun; Melsun-
gen, Germany) for 10 min before 1-h incubation with pri-
mary antibodies. The primary antibodies that were used,
diluted in 1% bovine serum albumin, are depicted in Table 1.
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(HF ¼ 40Æ2 positive cells per mm, LF ¼ 42Æ4 positive cells
per mm, P ¼ 0Æ82). The number of dermal CD3+ cells also
showed no significant changes between both fluorescent
groups (HF ¼ 296Æ7 positive cells per mm, LF ¼ 273Æ4 posi-
tive cells per mm, P ¼ 0Æ69) (Table 2, Fig. 3).
Correlation between fluorescence intensity and stratum
corneum thickness
All corrected fluorescence data (including homogeneous-fluor-
escent lesional skin) from the Dyaderm system were com-
pared with their accompanying stratum corneum thickness
values. Correlation analysis revealed a negative correlation
coefficient of r ¼ )0Æ41 (Fig. 4). Thus the relation between
fluorescence intensity and thickness of the stratum corneum
appeared to be weakly correlated.
Discussion
In the present study application of 20% ALA ointment for 3 h
under an occlusive dressing induced heterogeneous fluores-
cence within most psoriatic plaques. Fluorescence was meas-
ured after 3 h of ALA application. This time point has an
optimal ratio between lesional and normal skin. For higher
fluorescence values a longer incubation period of 6 h in psori-
asis is needed, but contrast is reduced as surrounding non-
lesional skin fluorescence is also increasing.9 Each plaque had
an equal clinical appearance after efficient desquamation and
fluorescence distribution was not predictable. Smits et al.11
demonstrated macroscopic fluorescence and PpIX content to
be well correlated. Hence differences in fluorescence intensity
may therefore be comparable to variations in PpIX accumula-
tion.
This inhomogeneous fluorescence in FDAP on psoriatic skin
has been described by several authors, but a reason for the
variable fluorescence has thus far not been established.3,4,7,8,10
Differences in the presence of hyperkeratosis in lesional skin
acting as a mechanical barrier against penetration of ALA and/
or light may be one explanation, but variations in metabolic
activity within psoriatic cells inducing variable synthesis of
ALA-induced porphyrins could be another.3,7,9
Psoriasis is histologically characterized by epidermal hyper-
proliferation, abnormal keratinization and dermal infiltration
of mainly T cells. Keratinocytes proliferate and mature rapidly
so that terminal differentiation, normally occurring in granular
keratinocytes and then squamous corneocytes, is abnormal. In
both high- and low-fluorescent lesional skin an equal
amount of epidermal hyperproliferation was seen as reflected
by an increase in Ki-67 expression. No statistically significant
differences were found between both groups. Ki-67 is a cell-
cycle-associated antigen expressed in all parts of the cell cycle
except G0 and G1, representing the epidermal proliferative
compartment.12 Despite fluorescence intensity, an equal dis-
turbance of keratinization was also observed as a decrease in
K10 expression, which is a marker for terminal differentiation
and is generally decreased in psoriasis.13 Another structural
marker for differentiation is filaggrin. Filaggrin is involved in
the formation of keratohyalin granules. In normal skin filag-
grin is present in the stratum corneum and the stratum gra-
nulosum and supports cutaneous hydration. In general, active
psoriasis is known for its absent or discontinuous filaggrin
expression.14,15 In the studied biopsies aggregation of
Table 2 Histological results from high- and
low-fluorescent psoriatic skin (HF and LF) HF lesional
skin ± SEM
LF lesional
skin ± SEM P-value
Fluorescence intensity (a.u.) 1Æ00 ± 0Æ06 0Æ57 ± 0Æ06 < 0Æ001
Stratum corneum thickness (mm) 0Æ054 ± 0Æ009 0Æ084 ± 0Æ017 0Æ036
Epidermal thickness (mm) 0Æ262 ± 0Æ090 0Æ275 ± 0Æ036 0Æ688
Ki-67+ nuclei 85Æ7 ± 18Æ6 68Æ9 ± 10Æ2 0Æ382
K10 expression (%) 58Æ2 ± 2Æ99 55Æ4 ± 5Æ15 0Æ628
Filaggrin (%) 82Æ6 ± 4Æ57 78Æ7 ± 6Æ41 0Æ475
Epidermal CD3+ cells 40Æ2 ± 5Æ54 42Æ4 ± 8Æ94 0Æ819
Dermal CD3+ cells 296Æ7 ± 64Æ8 273Æ4 ± 44Æ4 0Æ686
Values are denoted ± SEM. a.u., arbitrary units
Fig 4. Correlation between fluorescence intensity and stratum
corneum thickness, r ¼ )0Æ41. Dotted lines indicate 95% confidence
intervals.
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P < 0Æ05) compared with high-fluorescent skin (Fig. 2b). The
epidermis was equally broadened throughout the heterogene-
ic-fluorescent plaque (Table 2).
Immunohistochemistry
Epidermal proliferation Epidermal proliferation was increased in
both high- and low-fluorescent parts of psoriatic skin as
shown by an increased number of epidermal Ki-67+ cells.
The number of Ki-67+ cells was not significantly different in
high- or low-fluorescent lesional skin (HF ¼ 86 positive cells
per mm basement membrane, LF ¼ 69 positive cells per mm
basement membrane, P ¼ 0Æ38) (Table 2, Fig. 3).
Epidermal differentiation The epidermal K10 expression was used
to assess the extent of keratinization and appeared to be
equally decreased throughout the plaque (HF ¼ 58%, LF ¼
55%, P ¼ 0Æ51) (Table 2, Fig. 3). The aggregation of kera-
tinocytes in the psoriatic plaque was reduced as shown by the
decreased expression of filaggrin. In high- and low-fluorescent
lesional skin no statistically significant differences were
observed (HF ¼ 83%, LF ¼ 79%, P ¼ 0Æ48) (Table 2, Fig. 3).
T-cell infiltration CD3+ cells were seen mainly in the papillary
dermis and to a lesser extent in the epidermis. In the high-
fluorescent affected skin epidermal CD3+ cells were not signi-
ficantly different compared with low-fluorescent lesional skin
(a) (b) (c) 
Fig 1. Clinical and fluorescence images from one patient after 5-aminolaevulinic acid application. (a) Clinical image with marked low-fluorescent
lesional skin (1) and high-fluorescent lesional skin (2). (b) Fluorescence image of the same plaque in which heterogeneous fluorescence is seen.
(c) Pseudo-colour image of (b).
(a)
(b)
Fig 2. Morphological and immunohistochemical differences in
psoriatic plaques with heterogeneous fluorescence after 5-
aminolaevulinic acid application. (a) Normalised fluorescence. The
intensity of high-fluorescent (HF) skin was significantly higher than in
low-fluorescent (LF) skin; *P < 0Æ001. (b) The stratum corneum was
statistically significantly thicker in low-fluorescent skin compared with
high-fluorescent skin; *P < 0Æ05. Error bars denote SEM.
Fig 3. Morphological and immunohistochemical images of both low- and high-fluorescent psoriatic skin. Haematoxylin and eosin, Ki-67, keratin
10 (K10) and filaggrin stainings of heterogeneous fluorescent lesional skin are displayed at 100 · magnification. CD3 is displayed at 50 ·
magnification. Haematoxylin and eosin sections showed a significantly thicker stratum corneum in low-fluorescent psoriatic skin.
Immunohistochemically no differences in epidermal proliferation, differentiation and inflammation were found between high- and low-fluorescent
skin.
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(HF ¼ 40Æ2 positive cells per mm, LF ¼ 42Æ4 positive cells
per mm, P ¼ 0Æ82). The number of dermal CD3+ cells also
showed no significant changes between both fluorescent
groups (HF ¼ 296Æ7 positive cells per mm, LF ¼ 273Æ4 posi-
tive cells per mm, P ¼ 0Æ69) (Table 2, Fig. 3).
Correlation between fluorescence intensity and stratum
corneum thickness
All corrected fluorescence data (including homogeneous-fluor-
escent lesional skin) from the Dyaderm system were com-
pared with their accompanying stratum corneum thickness
values. Correlation analysis revealed a negative correlation
coefficient of r ¼ )0Æ41 (Fig. 4). Thus the relation between
fluorescence intensity and thickness of the stratum corneum
appeared to be weakly correlated.
Discussion
In the present study application of 20% ALA ointment for 3 h
under an occlusive dressing induced heterogeneous fluores-
cence within most psoriatic plaques. Fluorescence was meas-
ured after 3 h of ALA application. This time point has an
optimal ratio between lesional and normal skin. For higher
fluorescence values a longer incubation period of 6 h in psori-
asis is needed, but contrast is reduced as surrounding non-
lesional skin fluorescence is also increasing.9 Each plaque had
an equal clinical appearance after efficient desquamation and
fluorescence distribution was not predictable. Smits et al.11
demonstrated macroscopic fluorescence and PpIX content to
be well correlated. Hence differences in fluorescence intensity
may therefore be comparable to variations in PpIX accumula-
tion.
This inhomogeneous fluorescence in FDAP on psoriatic skin
has been described by several authors, but a reason for the
variable fluorescence has thus far not been established.3,4,7,8,10
Differences in the presence of hyperkeratosis in lesional skin
acting as a mechanical barrier against penetration of ALA and/
or light may be one explanation, but variations in metabolic
activity within psoriatic cells inducing variable synthesis of
ALA-induced porphyrins could be another.3,7,9
Psoriasis is histologically characterized by epidermal hyper-
proliferation, abnormal keratinization and dermal infiltration
of mainly T cells. Keratinocytes proliferate and mature rapidly
so that terminal differentiation, normally occurring in granular
keratinocytes and then squamous corneocytes, is abnormal. In
both high- and low-fluorescent lesional skin an equal
amount of epidermal hyperproliferation was seen as reflected
by an increase in Ki-67 expression. No statistically significant
differences were found between both groups. Ki-67 is a cell-
cycle-associated antigen expressed in all parts of the cell cycle
except G0 and G1, representing the epidermal proliferative
compartment.12 Despite fluorescence intensity, an equal dis-
turbance of keratinization was also observed as a decrease in
K10 expression, which is a marker for terminal differentiation
and is generally decreased in psoriasis.13 Another structural
marker for differentiation is filaggrin. Filaggrin is involved in
the formation of keratohyalin granules. In normal skin filag-
grin is present in the stratum corneum and the stratum gra-
nulosum and supports cutaneous hydration. In general, active
psoriasis is known for its absent or discontinuous filaggrin
expression.14,15 In the studied biopsies aggregation of
Table 2 Histological results from high- and
low-fluorescent psoriatic skin (HF and LF) HF lesional
skin ± SEM
LF lesional
skin ± SEM P-value
Fluorescence intensity (a.u.) 1Æ00 ± 0Æ06 0Æ57 ± 0Æ06 < 0Æ001
Stratum corneum thickness (mm) 0Æ054 ± 0Æ009 0Æ084 ± 0Æ017 0Æ036
Epidermal thickness (mm) 0Æ262 ± 0Æ090 0Æ275 ± 0Æ036 0Æ688
Ki-67+ nuclei 85Æ7 ± 18Æ6 68Æ9 ± 10Æ2 0Æ382
K10 expression (%) 58Æ2 ± 2Æ99 55Æ4 ± 5Æ15 0Æ628
Filaggrin (%) 82Æ6 ± 4Æ57 78Æ7 ± 6Æ41 0Æ475
Epidermal CD3+ cells 40Æ2 ± 5Æ54 42Æ4 ± 8Æ94 0Æ819
Dermal CD3+ cells 296Æ7 ± 64Æ8 273Æ4 ± 44Æ4 0Æ686
Values are denoted ± SEM. a.u., arbitrary units
Fig 4. Correlation between fluorescence intensity and stratum
corneum thickness, r ¼ )0Æ41. Dotted lines indicate 95% confidence
intervals.
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P < 0Æ05) compared with high-fluorescent skin (Fig. 2b). The
epidermis was equally broadened throughout the heterogene-
ic-fluorescent plaque (Table 2).
Immunohistochemistry
Epidermal proliferation Epidermal proliferation was increased in
both high- and low-fluorescent parts of psoriatic skin as
shown by an increased number of epidermal Ki-67+ cells.
The number of Ki-67+ cells was not significantly different in
high- or low-fluorescent lesional skin (HF ¼ 86 positive cells
per mm basement membrane, LF ¼ 69 positive cells per mm
basement membrane, P ¼ 0Æ38) (Table 2, Fig. 3).
Epidermal differentiation The epidermal K10 expression was used
to assess the extent of keratinization and appeared to be
equally decreased throughout the plaque (HF ¼ 58%, LF ¼
55%, P ¼ 0Æ51) (Table 2, Fig. 3). The aggregation of kera-
tinocytes in the psoriatic plaque was reduced as shown by the
decreased expression of filaggrin. In high- and low-fluorescent
lesional skin no statistically significant differences were
observed (HF ¼ 83%, LF ¼ 79%, P ¼ 0Æ48) (Table 2, Fig. 3).
T-cell infiltration CD3+ cells were seen mainly in the papillary
dermis and to a lesser extent in the epidermis. In the high-
fluorescent affected skin epidermal CD3+ cells were not signi-
ficantly different compared with low-fluorescent lesional skin
(a) (b) (c) 
Fig 1. Clinical and fluorescence images from one patient after 5-aminolaevulinic acid application. (a) Clinical image with marked low-fluorescent
lesional skin (1) and high-fluorescent lesional skin (2). (b) Fluorescence image of the same plaque in which heterogeneous fluorescence is seen.
(c) Pseudo-colour image of (b).
(a)
(b)
Fig 2. Morphological and immunohistochemical differences in
psoriatic plaques with heterogeneous fluorescence after 5-
aminolaevulinic acid application. (a) Normalised fluorescence. The
intensity of high-fluorescent (HF) skin was significantly higher than in
low-fluorescent (LF) skin; *P < 0Æ001. (b) The stratum corneum was
statistically significantly thicker in low-fluorescent skin compared with
high-fluorescent skin; *P < 0Æ05. Error bars denote SEM.
Fig 3. Morphological and immunohistochemical images of both low- and high-fluorescent psoriatic skin. Haematoxylin and eosin, Ki-67, keratin
10 (K10) and filaggrin stainings of heterogeneous fluorescent lesional skin are displayed at 100 · magnification. CD3 is displayed at 50 ·
magnification. Haematoxylin and eosin sections showed a significantly thicker stratum corneum in low-fluorescent psoriatic skin.
Immunohistochemically no differences in epidermal proliferation, differentiation and inflammation were found between high- and low-fluorescent
skin.
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keratinocytes was decreased as reflected by a reduced filaggrin
expression throughout the plaque. The observed reduction in
filaggrin expression was less decreased than expected in active
psoriasis.16 Chronic stable plaque psoriasis as selected for this
study is a probable explanation for this minimal reduction in
filaggrin expression. Analysis of CD3+ cells showed an
increase of T cells in both epidermis and dermis. Comparing
high- and low-fluorescent lesional skin significant dissimilari-
ties in T cell counts could not be demonstrated. The CD3 anti-
gen is normally expressed on the cell surface of the mature
thymocytes and resting or activated peripheral blood lympho-
cytes.17 Therefore, according to these study results, differences
in psoriatic activity—as a possible explanation for the variable
metabolic conversion of ALA to PpIX reflected by heterogene-
ous fluorescence as seen in fluorescence diagnosis—could not
be demonstrated, assuming penetration of ALA and/or light to
be a constant factor. To ascertain this conclusion, more studies
are needed to examine the exact PpIX metabolism by measur-
ing the effects of enzyme activity involved in the haem syn-
thesis in relation to unpredictable fluorescence intensity in
FDAP.
Thickness of the stratum corneum and epidermis were
investigated to examine to what extent the mechanical barrier
function of the stratum corneum and the number of metaboli-
cally active cells could be responsible for differences in fluor-
escence intensity within psoriatic plaques. Epidermal thickness
is a parameter for clinical induration and the number of meta-
bolically active cells.11 No significant differences in epidermal
thickness were found between high- and low-fluorescent
lesional skin. The stratum corneum proved to be significantly
thicker in low-fluorescent lesional skin suggesting a
decreased penetration of ALA and/or light compared with
high-fluorescent lesions, which were found to have a signifi-
cantly thinner stratum corneum. No differences were seen in
the presence of parakeratosis. Parakeratosis is also a histologi-
cal characteristic of psoriasis and results from incomplete
keratinization resulting in the retention of nuclei in the stra-
tum corneum.18 Homogeneous fluorescence with a high
intensity was observed in two plaques. Biopsies obtained from
these homogeneous high-fluorescent lesions verified an
equally thickened stratum corneum comparable to the high-
fluorescent samples from heterogeneously fluorescent lesional
skin samples. Also, correlation analysis showed a weak negat-
ive correlation between the fluorescence intensity of the psori-
atic skin and thickness of the stratum corneum.
The stratum corneum is the principle barrier to percutane-
ous penetration of exogenous substances. Psoriasis is known
for its functional and structural defects of the stratum corneum
resulting in an abnormal permeability barrier. Transepidermal
water loss levels are increased in desquamating dermatoses
such as psoriasis as aggregation between keratinocytes is
decreased.19,20 These study results suggest that not only a
decreased aggregation of keratinocytes in stable plaque psori-
asis, established by a reduction of filaggrin expression in the
samples of both low- and high-fluorescence lesional skin, but
in particular the mechanical barrier formed by the stratum
corneum is responsible for diffusion rate of ALA and/or pen-
etration of light.
In an earlier study by our group heterogeneous fluorescence
intensity in the psoriatic skin with a variable clinical response on
PDT was demonstrated.8 More studies are needed to investigate
whether heterogeneous fluorescence in FDAP is related to inho-
mogeneous clinical improvement of plaque psoriasis after PDT.
In conclusion, the psoriatic activity within one plaque was
homogeneous, not explaining the heterogeneity of fluores-
cence intensity seen within plaque psoriasis. Thus, it appears
plausible that it is not the metabolic activity of psoriasis but
mainly the mechanical barrier formed by the stratum corneum
that is responsible for differences in fluorescence intensity
because of variable penetration of ALA and/or light. Pretreat-
ment aimed at the removal of hyperkeratosis seems to be of
the utmost importance and is therefore strongly recommended
for the most favourable results in FDAP and PDT.
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keratinocytes was decreased as reflected by a reduced filaggrin
expression throughout the plaque. The observed reduction in
filaggrin expression was less decreased than expected in active
psoriasis.16 Chronic stable plaque psoriasis as selected for this
study is a probable explanation for this minimal reduction in
filaggrin expression. Analysis of CD3+ cells showed an
increase of T cells in both epidermis and dermis. Comparing
high- and low-fluorescent lesional skin significant dissimilari-
ties in T cell counts could not be demonstrated. The CD3 anti-
gen is normally expressed on the cell surface of the mature
thymocytes and resting or activated peripheral blood lympho-
cytes.17 Therefore, according to these study results, differences
in psoriatic activity—as a possible explanation for the variable
metabolic conversion of ALA to PpIX reflected by heterogene-
ous fluorescence as seen in fluorescence diagnosis—could not
be demonstrated, assuming penetration of ALA and/or light to
be a constant factor. To ascertain this conclusion, more studies
are needed to examine the exact PpIX metabolism by measur-
ing the effects of enzyme activity involved in the haem syn-
thesis in relation to unpredictable fluorescence intensity in
FDAP.
Thickness of the stratum corneum and epidermis were
investigated to examine to what extent the mechanical barrier
function of the stratum corneum and the number of metaboli-
cally active cells could be responsible for differences in fluor-
escence intensity within psoriatic plaques. Epidermal thickness
is a parameter for clinical induration and the number of meta-
bolically active cells.11 No significant differences in epidermal
thickness were found between high- and low-fluorescent
lesional skin. The stratum corneum proved to be significantly
thicker in low-fluorescent lesional skin suggesting a
decreased penetration of ALA and/or light compared with
high-fluorescent lesions, which were found to have a signifi-
cantly thinner stratum corneum. No differences were seen in
the presence of parakeratosis. Parakeratosis is also a histologi-
cal characteristic of psoriasis and results from incomplete
keratinization resulting in the retention of nuclei in the stra-
tum corneum.18 Homogeneous fluorescence with a high
intensity was observed in two plaques. Biopsies obtained from
these homogeneous high-fluorescent lesions verified an
equally thickened stratum corneum comparable to the high-
fluorescent samples from heterogeneously fluorescent lesional
skin samples. Also, correlation analysis showed a weak negat-
ive correlation between the fluorescence intensity of the psori-
atic skin and thickness of the stratum corneum.
The stratum corneum is the principle barrier to percutane-
ous penetration of exogenous substances. Psoriasis is known
for its functional and structural defects of the stratum corneum
resulting in an abnormal permeability barrier. Transepidermal
water loss levels are increased in desquamating dermatoses
such as psoriasis as aggregation between keratinocytes is
decreased.19,20 These study results suggest that not only a
decreased aggregation of keratinocytes in stable plaque psori-
asis, established by a reduction of filaggrin expression in the
samples of both low- and high-fluorescence lesional skin, but
in particular the mechanical barrier formed by the stratum
corneum is responsible for diffusion rate of ALA and/or pen-
etration of light.
In an earlier study by our group heterogeneous fluorescence
intensity in the psoriatic skin with a variable clinical response on
PDT was demonstrated.8 More studies are needed to investigate
whether heterogeneous fluorescence in FDAP is related to inho-
mogeneous clinical improvement of plaque psoriasis after PDT.
In conclusion, the psoriatic activity within one plaque was
homogeneous, not explaining the heterogeneity of fluores-
cence intensity seen within plaque psoriasis. Thus, it appears
plausible that it is not the metabolic activity of psoriasis but
mainly the mechanical barrier formed by the stratum corneum
that is responsible for differences in fluorescence intensity
because of variable penetration of ALA and/or light. Pretreat-
ment aimed at the removal of hyperkeratosis seems to be of
the utmost importance and is therefore strongly recommended
for the most favourable results in FDAP and PDT.
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Abstract: Cutaneous squamous (pre)malignancies can be
classified according to the keratinocytic intraepidermal neoplasia
(KIN) classification. Aneuploidy can be seen as the result of
chromosomal aberrations leading to altered DNA content and has
been strongly associated with malignancy. Hyperproliferation is
also strongly associated with tumorigenesis. The aim of the study
was to analyse the presence and the amount of aneuploidy and
proliferation in the progression from intraepithelial neoplasm to
microinvasive carcinoma (miSCC). For this purpose, nuclei were
isolated from 116 formalin-fixed KIN lesions from 68 patients in
which DNA content was measured by flow cytometry.
Proliferation was assessed by immunohistochemical staining for
Ki67 as well as by flow cytometry. Aneuploidy was increasingly
found in higher KIN lesions, but not in normal skin. However, in
miSCC aneuploidy was relatively less frequently found. DNA
indices (mean ± SE) of KIN III-lesions (1.57 ± 0.05) were
significantly lower compared with KIN I/II lesions (1.71 ± 0.05).
Ki67 expression was strongly positively correlated with KIN grade,
and proved to be a good adjunct in the classification of KINs.
Thus, aneuploidy occurred more frequently in higher KIN lesions,
indicating cumulative damage during KIN progression. The lower
frequency of aneuploidy in miSCC compared with KIN III may
point at alternative routes towards invasive carcinoma besides
serial progression through all three KIN stages. Ki67 expression
appears a valuable marker in the classification of KINs.
Key words: actinic keratosis – aneuploidy – Bowen’s disease –
KIN – proliferation
Please cite this paper as: Aneuploidy and proliferation in keratinocytic intraepidermal neoplasias. Experimental Dermatology 2007; 16: 81–86.
Introduction
Skin cancer is the most common cancer in the Western
world, from which the majority is accounted for by non-
melanoma skin cancer (NMSC). The two most common
forms of NMSC include basal cell carcinoma and squamous
cell carcinoma (SCC). Actinic keratosis (AK) and Bowen’s
disease (BD) are generally regarded as cutaneous epithelial
premalignancies that are able to progress to invasive SCC.
However, over the last years increasing evidence has arisen
to support the hypothesis that AK and BD are in fact not
just precursors of SCC but that they are SCC in situ (1).
To emphasize this progressive nature Yantsos et al. (2) sug-
gested a classification system in which the amount of epi-
dermal atypical keratinocytes, combined with a clinical
evaluation is graded into three categories of keratinocytic
intraepidermal neoplasias (KIN). According to them a typ-
ical KIN I lesion comprises a clinical flat lesion with focal
atypia of the lower third of keratinocytes in the epidermis,
whereas a typical KIN II lesion appears clinically as a
(hyperkeratotic) papule with focal atypia of the lower two-
thirds of the epidermis. Diffuse atypia involving the full
thickness of the epidermis in a clinically indurated plaque
is regarded a typical KIN III lesion, formerly classified as
Bowenoid AK, BD or SCC in situ. Similar grading systems
have been developed in other epithelial neoplasias such as
prostate, cervix and vulvar cancer (PIN, CIN and VIN
respectively). Although this seems a clinically useful classifi-
cation, some authors have criticized this classification
mainly because of the fact that certain KIN II (probably
KIN I) lesions can directly be converted to SCC without
passing the KIN III stage (3).
Aneuploidy can be seen as the result of genetic deletions
and amplifications leading to chromosomal aberrations and
thus an abnormal DNA content. It has been suggested that
DNA aneuploidy represents the most common malignancy-
specific cell marker with several aspects correlating with
malignancy grade, tumor stage and prognosis (4). In
NMSC the presence of aneuploidy has been described by
various authors (4–7), with reported aneuploidy frequen-
DOI:10.1111/j.1600-0625.2006.00518.x
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cies varying from 40% to 69% for AK, 94–100% for BD,
58% for SCC and 48% for keratoacanthoma.
Data on the presence of aneuploidy in the context of
KIN classification are currently lacking. These could pro-
vide information on the cytogenetic changes accompanying
KIN progression, ultimately leading to invasive carcinoma.
The most common hallmark of tumorigenesis is prolifer-
ation, which has been reported to be increased in cutane-
ous (pre)malignancies (8).
The aim of the present study was to evaluate ploidy sta-
tus and proliferation in the subsequent stages of AK (KIN
I-III) and microinvasive SCC (miSCC) and to correlate this
with KIN grade/histopathology. Consequently, the value of
aneuploidy and proliferation as progressions markers in
cutaneous (pre)malignancies can be evaluated.
Because in their clinical behaviour as well as treatment
KIN I and KIN II lesions differ from KIN III lesions, KIN I
and II lesions will be referred to as low-grade KIN lesions
(LKIN) and KIN III lesions as high-grade KIN lesions
(HKIN) as proposed by Blokx et al.(9)
Materials and methods
Patient characteristics and processing of paraffin-
embedded skin biopsies
A total of 116 blocks of formalin-fixed, paraffin-embedded
skin biopsies from KIN I, KIN II, KIN III lesions and
microinvasive SCC (miSCC) from 68 patients were selected
for this study. In addition, eight biopsies from normal skin
were included as controls. The specimens were collected
from our pathology archives by means of a computer data-
base (PALGA) at the Department of Pathology of our hos-
pital. From these 68 patients, 28 received
immunosuppressive therapy (Table 1).
From each block, ten 50 lm slices were cut for flow cy-
tometric analysis and 6 lm slices were cut for
(immuno)histochemistry. The flow cytometric procedure
was adapted from Hedley et al. (10) and Schutte et al.
(11). The slices for flow cytometric analysis were collected
in a Cellsafe biopsy capsule (CellPath, Newton Powys, UK),
which in turn was put into a biopsy cassette. Subsequently,
the samples were deparaffinized with Histosafe three times
for 20 min and hydrated two times with 100% ethanol
(10 min), 96%, 70%, 50% ethanol and distilled water
(5 min) respectively. The biopsy capsules were then incuba-
ted in a 15-ml tube with 15 ml sodium citrate (0.01 M, pH
6.0) for 30 min at 80�C, rinsed two times in distilled water
and incubated again in 15 ml pepsin (0.5%; Sigma-Aldrich,
Zwijndrecht, the Netherlands) in sodium chloride (0.9%,
pH 1.5) two times for 15 min at 37�C. Afterwards, 15 ml
cold distilled water was added and the tubes were put on
ice. The tubes were vortexed and centrifuged for 5 min at
500 g at 4�C. The pellets were then dried and resuspended
in 4 ml bovine serum albumin (BSA; 0.5%) in phosphate-
buffered saline (PBS) and transferred to a 15-ml tube. The
old tubes were washed with 3 ml BSA solution and centri-
fuged for 5 min at 500 g at 4�C. The pellets were fixed in
2 ml ethanol (70%, )20�C) and stored at )20�C until flow
cytometrical analysis. On the day of analysis the tubes were
centrifuged for 5 min at 500 g at 4�C and the supernatant
was removed. In the pellet, the cell nuclei were resuspended
in 400 ll propidium iodide (Calbiochem; Merck KGaA,
Darmstadt, Germany) solution (40 lg/ml) and 40 ll 1%
RNase (Sigma-Aldrich) solution was added.
Immunohistochemistry
Slices (6 lm) were fixed on a glass slide, deparaffinized,
hydrated and washed in PBS subsequently. For Ki67-anti-
gen staining the sections were first pretreated in citrate buf-
fer (pH 6.0) using the microwave antigen-retrieval method.
Afterwards, immunohistochemical analysis was performed
after blocking for endogenous peroxidase using the Power-
Table 1 Patient, sample characteristics, ploidy and immune status. DNA indices are presented as mean ± standard error of the mean
Aneuploid
Diploid
Total number
Immune
suppression
No immune
suppression DNA index
Immune
suppression
No immune
suppression Total
Patients 28 40 68
Samples
Normal 0 0 – 8 1 7 8
KIN I 1 9 1.71 ± 0.05 68 27 21 48
KIN II 10 20 30
KIN III 5 9 1.57 ± 0.05 9 12 11 23
miSCC 1 1 1.62 ± 0.17 13 10 5 15
Total 7 19 – 98 60 64 124
KIN, keratinocytic intraepidermal neoplasia; miSCC, microinvasive carcinoma.
Smits et al.
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vision (Immunologic, Duiven, The Netherlands) staining
system with diaminobenzidine (DAB) as chromogen. The
sections were incubated for 1 h with the primary MIB-1
antibody (Dako, Heverlee, Belgium) directed against the
proliferation associated Ki67-antigen. For counterstaining
Mayer’s haematoxylin was used. Immunoreactivity was
scored semi-quantitatively in the following manner accord-
ing to Keating et al. (12): 0 ¼ only basal layer positivity,
1 ¼ positivity confined to basal one-third of the epidermis,
2 ¼ positivity confined to basal two-thirds of the epider-
mis, 3 ¼ transepidermal positive staining.
Haematoxylin–eosin staining was performed on every
slide for reassessment of the histopathological diagnosis
and KIN classification. All slides were assessed by one and
the same pathologist for uniformity.
Flow cytometrical data acquisition and analysis
All data were acquired on an EPICS Elite flow cytometer
(Coulter, Luton, UK). An air-cooled argon laser (20 mW,
488 nm) was used for propidium iodide excitation. For
detection, a 630-nm long-pass filter (red signal) and a pho-
tomultiplier were used. The area-to-peak ratio of the red
signal combined with scatter parameters was used to
exclude debris for further analysis and to discriminate
between doublets of diploid cells and tetraploid nuclei. As
a control lymphocytes were measured and the detection
was set at �100 cells/s. Usually 10 000 nuclei were meas-
ured. DNA histograms (Fig. 3) were constructed based on
DNA content measured in the nuclei. Modfit software
(Verity Software House, Topsham, ME, USA) was used to
analyse the DNA histograms. Criteria for flow cytometrical
analysis were adapted from the European Society for Ana-
lytic Cellular Pathology guidelines (13). Samples were clas-
sified as aneuploid when a DNA index of 1.2 or higher was
found.
Statistical analysis
Statistica 6.0 (Statsoft) and SPSS 10.0 for Windows soft-
ware were used for statistical calculations. Correlations
between histology, Ki67 antigen expression and SG2M sub-
sequently were analysed using one-way analysis of variance
(ANOVA) and Spearman’s rank order correlation analysis
(q).
Results
Aneuploidy frequency in squamous (pre)malignan-
cies
From the 124 biopsies that were analysed, in 26 (from 18
different patients) aneuploidy could be detected (21%).
Aneuploidy was only seen in the squamous (pre)malignan-
cies but not in normal skin (Fig. 1). The presence of
aneuploidy also appeared to be well correlated with
increasing KIN grade. Of the 48 KIN I lesions only three
(in two different patients) were found aneuploid (6%)
whereas in the 30 KIN II lesions and 23 KIN III lesions
that were studied, 7 (21%) and 14 (61%) were found
aneuploid (in 6 and 12 different patients respectively).
Interestingly, in only two samples (from two different
patients) out of the 15 microinvasive squamous cell carci-
noma (miSCC; 13%) aneuploidy was found.
DNA indices (mean ± SE), which are the ratios between
the mean channel number (DNA content) of the tumor
cells and the normal cells, were 1.71 ± 0.14 in KIN I,
1.71 ± 0.04 in KIN II, 1.57 ± 0.05 in KIN III and
1.62 ± 0.17 in SCC. These values point at chromosomal
gains/increased DNA content and could be classified as hy-
potetraploidy. Moreover, DNA indices in LKIN were also
statistically significantly higher than DNA indices from the
HKIN lesions: 1.71 vs. 1.57 (P < 0.05) (Table 1). Because
of the relatively low frequency of aneuploidy in SCC, statis-
tical power was too low for reliable comparisons.
Subanalysis of immune status on the occurrence of
aneuploidy revealed that aneuploidy was not more fre-
quently found in lesions from immunocompromised
patients (Table 1). In fact, in the biopsies from the patients
who received immunosuppressive drugs aneuploidy was
less frequently found. By calculating the odds ratio (0.436;
95% CI 0.167–1.136) immunosuppression appeared to have
a protective effect on the occurrence of aneuploidy,
although this was not statistically significant.
Proliferation in squamous (pre)malignancies
Significantly more Ki67-positive cells were seen in higher
KIN lesions (P < 0.000001) (Fig. 2). On and after KIN II,
proliferation was significantly increased compared with
normal skin (Fig. 4). Moreover, Ki67-antigen expression
appeared to be well correlated with KIN grade (q ¼ 0.756;
P < 0.01) (Fig. 4). This makes Ki67-antigen expression a
good marker for keratinocytic atypia. In miSCC however,
Figure 1. Frequency of aneuploidy in cutaneous squamous
(pre)malignancies and normal skin.
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Ki67-antigen expression was significantly increased com-
pared with normal skin but more heterogeneous compared
with the KIN lesions.
Significantly higher SG2M fractions were also found in
lesions with increasing KIN grade (P < 0.01). Assessment
of the SG2M fraction by flow cytometry also revealed a
positive correlation with KIN grade (q ¼ 0.258; P < 0.05),
although this was not as strong as for Ki67 (Fig. 5). KIN
III lesions had significantly higher SG2M fractions com-
pared with KIN I and KIN II lesions. SG2M fractions in
miSCC were significantly higher compared with KIN I
lesions but not compared with KIN II, III and normal skin.
Proliferation assessed by immunohistochemistry and flow
cytometry appeared to be weakly correlated (q ¼ 0.282;
P < 0.05)
Conclusion and discussion
In the present study aneuploidy was detected more fre-
quently in lesions with increasing KIN grade, whereas in
normal skin aneuploidy was not found, which emphasizes
the malignant potential these lesions have. Increasing
aneuploidy rates in actinic keratosis (AK) and Bowen’s dis-
ease (BD) have been reported in earlier studies (4–7) but
these studies are difficult to compare due to different tech-
niques, sample sizes and definitions of aneuploidy, that
were used. In the present study a large pool of skin biop-
sies was analysed with respect to proliferation and the pres-
ence of aneuploidy. Interestingly, aneuploidy was less
Figure 2. Immunohistochemical staining for
Ki67 antigen. In a KIN III lesion there is
transepidermal expression of the Ki67 antigen
(b) whereas in a KIN I lesion there is only Ki67
positivity of the basal one-third of the
epidermis(a).
(a) (b)
Figure 3. Flow cytometrical DNA histograms. (a) A normal DNA histogram from a diploid lesion (normal skin) shows a large peak at around 76
representing the cells in G1. At twice this distance at around 152 a small peak is seen representing the cells with a double DNA content that are in
G2. The plateau between G1 and G2 represents the cells that are in the S-phase. (b) In this lesion (KIN III) an extra peak between G1 and G2 is seen
at around 127 which represents the G1 peak from the aneuploid cells. The ratio between the G1 peak of the aneuploid and diploid cells represents
the DNA index, which is 127/76 ¼ 1.67, indicating an increased DNA content in the aneuploid cells compared with the diploid cells.
Figure 4. Ki67 antigen expression in cutaneous squamous
(pre)malignancies and normal skin. Ki67 expression is scored into four
categories (see text). *P < 0.05, ***P < 0.001, ****P < 0.0001. SE,
standard error.
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frequently found in microinvasive carcinoma (miSCC),
which seems peculiar when miSCC is regarded to be an
end stage in the progression of KIN lesions as proposed by
Cockerell (14) This is in accordance with Korabiowska
et al. who also found that with respect to ploidy parame-
ters AK are closer related to SCC than BD and therefore
have a higher risk of progression to SCC despite a generally
lower degree of atypia (15). There could be several explana-
tions for this. First, the development of miSCC apparently
does not always involve passage through all three KIN sta-
ges. This would suggest that somewhere in KIN stage I/II a
subclone or multiple subclones of atypical keratinocytes
break through the basement membrane into the papillary
dermis to become an invasive carcinoma, even before the
upper layers of the epidermis have become atypical. There-
fore, aneuploidy does not seem to be a good marker for
invasive disease. The assumption that serial passage
through all three KIN stages is obligatory for invasive dis-
ease is one of the main criticisms of the KIN classification
(3). This finding is in accordance with a study from Reh-
man et al. (16) who found an increased frequency of ‘loss
of heterozygosity’ in AK compared with SCC. They there-
fore concluded the relation between the accumulation of
genetic change and behaviour for non-melanoma skin can-
cer (NMSC) not to be straightforward. In addition, other
factors such as the immune system may also influence the
progressive course of a squamous (pre)malignancy. More-
over, aneuploidy as measured with the current flow cyto-
metrical technique only provides data on DNA quantity;
what this actually means in terms of dysfunction of tumor-
suppressor genes cannot be derived from these data.
Secondly, with the current flow cytometrical detection
technique of aneuploidy it is impossible to detect minute
clones and to distinguish between clones with slightly dif-
ferent DNA contents. Therefore, there has to be a certain
amount of abnormal cells with a substantial amount of
altered DNA content to be recognized by this technique.
Consequently, with the current technique aneuploidy in
near-diploid tumors might be underestimated.
Our data show that HKIN samples have decreased DNA
indices compared with LKIN samples (1.57 ± 0.05 vs.
1.71 ± 0.05). Assuming serial progression from LKIN to
HKIN lesions, this indicates decreases in DNA content
(chromosomal losses) during KIN progression and is in
parallel with the general hypothesis that polyploidy/tetrap-
loidy followed by aneuploidy is a frequent event in tumori-
genesis (17). In addition, in two recent articles it is
suggested that chromosomal nondisjunction results in tetra-
ploidization and that the tetraploid state is associated with a
predisposition to tumorigenesis in the absence of functional
p53 (18,19). As p53 is frequently mutated in cutaneous
(pre)malignancies, this fits well into the whole story (20).
Proliferation was found to increase with increasing KIN
grade. Because of the strong correlation, this indicates that
nuclear atypia parallels hyperproliferation in epidermal ker-
atinocytes and makes Ki67 a good marker for keratinocytic
nuclear atypia. In cervical intraepithelial neoplasias (CIN)
Ki67 expression has already proved to be a good adjunct in
the classification of CIN (21). In KIN, the same has also
been described by Blokx et al. (22) who found a strong
correlation in a series of nine renal transplant recipients.
However, in miSCC proliferation was heterogeneous with
Ki67 antigen expression somewhere between KIN I and II.
SG2M fraction also appeared to be positively correlated
with KIN grade, although this correlation was less strong.
It might be possible that because of the fact that more tis-
sue is needed with flow cytometry compared with immu-
nohistochemistry, surrounding tissue has also been
analysed causing more heterogeneous data. Moreover, skin
biopsies are relatively small and it is very difficult to isolate
only dysplastic tissue to achieve a better signal-to-noise
ratio. This problem could perhaps be solved by using the
microdissection technique to better isolate dysplastic cells
from heterogeneous lesions (23).
In conclusion, the current data show that aneuploidy
occurs increasingly in lesions with higher KIN grade, but in
miSCC less aneuploidy is seen compared with KIN III. This
might indicate that serial progression through all three KIN
stages ultimately leading to invasive carcinoma is not
straightforward. Proliferation measured by Ki67 expression
immunohistochemically appears to be a very good marker
for keratinocytic atypia and can be useful in the classifica-
tion of KINs. There is an urgent need for adequate pro-
gression markers in NMSC, not only to be able to predict
the clinical outcome but also to identify the pathogenetic
mechanisms involved in tumor progression. It would be
interesting to study what the presence of aneuploidy, as
measured in our skin samples, would mean in terms of
progression towards invasive carcinoma. Due to the small
Figure 5. SG2M fraction in cutaneous squamous (pre)malignancies and
normal skin. *P < 0.05, **P < 0.01. SE, standard error.
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size of skin (pre)malignancies, prospective studies on the
progression of skin tumors using the current analytical
techniques are extremely hard to perform facing numerous
technical and practical difficulties. Maybe with future tech-
niques requiring less sample material we will be able to
perform genetic analysis on these lesions without altering
their natural course. In the meantime we will have to rely
on retrospective data.
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Fluorescence diagnosis in keratinocytic
intraepidermal neoplasias
Tim Smits, MD,a Marloes M. Kleinpenning, MD,a Willeke A. M. Blokx, MD, PhD,b Peter C. M. van de
Kerkhof, MD, PhD,a Piet E. J. van Erp, PhD,a and Marie-Jeanne P. Gerritsen, MD, PhDa
Nijmegen, The Netherlands
Background: As different tissue types have distinct capabilities to accumulate protoporphyrin-IX,
fluorescence diagnosis with aminolevulinic acideinduced porphyrin (FDAP) could be used to discriminate
between different tissue types.
Objective: Protoporphyrin-IX accumulation and proliferation were studied in cutaneous squamous
(pre)malignancies to see whether FDAP could be used to discriminate between different stages of
keratinocytic intraepidermal neoplasia or proliferative status.
Methods: FDAP was performed in 14 patients (86 lesions) and biopsy specimens were taken, on which
(immuno)histochemistry was performed for histopathologic classification and assessment of Ki67-antigen
expression. Stratum corneum thickness was also measured.
Results: The fluorescence ratio (lesional:nonlesional skin) showed neither significant differences between
the different keratinocytic intraepidermal neoplasia stages, nor between different levels of Ki67-antigen
expression. Macroscopic fluorescence intensity and stratum corneum thickness were negatively correlated.
Limitations: Relatively few malignancies were biopsied.
Conclusions:With FDAP we were not able to discriminate between keratinocytic intraepidermal neoplasia
lesions or proliferative activity. However, hyperkeratosis appeared to be an important determinant in
variations in macroscopic fluorescence intensity. ( J Am Acad Dermatol 2007;57:824-31.)
P
hotodynamic therapy (PDT) with 5-amino-
levulinic acid (ALA) or its methylester as a
topical photosensitizer is now a widespread
treatmentmodality in actinic keratosis (AK), Bowen’s
disease (BD), and (superficial) basal cell carcinoma
in an increasing number of dermatologic centers. In
this treatment the preferential accumulation of en-
dogenous porphyrins, in particular protoporphyrin
IX (PpIX), in lesional skin after incubation with
ALA/methylester is used to treat various skin dis-
eases.1,2 As PpIX has characteristic fluorescence
properties, its preferential accumulation in certain
tissue types can also be used as a diagnostic tool. In
fluorescence diagnosis with ALA-induced porphyrin
(FDAP), lesional and nonlesional skin is irradiated
with blue (408 nm) light after incubation of the skin
with ALA. As PpIX shows red fluorescence when
excited by blue light, PpIX accumulating cells can be
visualized after irradiation with blue light. In cases
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AK: actinic keratosis
ALA: aminolevulinic acid
BD: Bowen’s disease
CCD: charged coupled device
FDAP: fluorescence diagnosis with
aminolevulinic acideinduced porphyrins
KIN: keratinocytic intraepidermal neoplasia
PDT: photodynamic therapy
PpIX: protoporphyrin-IX
SC: stratum corneum
SCC: squamous cell carcinoma
TIFF: tagged image file format
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where demarcation of lesional skin is clinically
problematic, in dermatologic screening of field-
cancerized skin, and to study PpIX accumulation
during PDT, FDAP may provide additional informa-
tion. Interpretation of these data is still problematic
because of the low reproducibility of the procedure
as a result of the numerous factors influencing
fluorescence detection and poor understanding of
the mechanisms involved in PpIX tumor selectivity.
Macroscopic fluorescence intensity after incubation
with ALA has been shown to differ in various skin
diseases. In a previous study we have shown PpIX
accumulation to be higher in psoriasis compared
with AK andmacroscopic fluorescence on the skin to
be a good predictor of PpIX content in the skin.3
However, the exact cause of these different affinities
for PpIX accumulation in different tissue types is
unknown. Alterations in permeability properties of
the stratum corneum (SC) and/or differences in the
heme biosynthetic pathway are believed to play a
role, although systematic in vivo studies are lacking.
For the application of FDAP in daily practice it
is of utmost importance to know the relationship
between the fluorescence data and histopathology
and to knowwhich factors can influence/disturb this
relationship. Because of the increasing incidence of
nonmelanoma skin cancer in the Western world field
cancerization is an increasing problem, in which
there are multiple (pre)malignant lesions diffusely
spread over ultraviolet-exposed skin in particular. To
treat these patients adequately, the physician often
needs to take multiple biopsy specimens of the
clinically highly suggestive lesions, which can be a
significant burden for the patient. A noninvasive
technique would, therefore, be of great value. Most
studies on FDAP have mainly focused on basal cell
carcinoma.4-8 Data on FDAP in squamous (pre)ma-
lignancies, however, are relatively scarce.9,10
Because epidermal squamous (pre)malignancies
comprise a spectrum from the premalignant AK and
BD to invasive carcinoma, Yantsos et al11 have
suggested a classification system, to emphasize this
progressive nature, in which the amount of epider-
mal atypical keratinocytes combined with a clinical
evaluation is graded into 3 categories of keratinocytic
intraepidermal neoplasia (KIN). According to them a
typical KIN-I lesion comprises a clinical flat lesion
with focal atypia of the lower third of keratinocytes
in the epidermis, whereas a typical KIN-II lesion
appears clinically as a (hyperkeratotic) papule with
focal atypia of the lower two thirds of the epidermis.
Diffuse atypia involving the full thickness of the
epidermis in a clinically indurated plaque is regarded
a typical KIN-III lesion, formerly classified as bowe-
noid AK, BD, or squamous cell carcinoma (SCC)
in situ. Similar grading systems have been developed
in other epithelial neoplasias such as prostate, cer-
vical, and vulvar cancer.
In this study macroscopic fluorescence intensity
is studied in cutaneous squamous (pre)malignancies
with respect to histopathologic KIN classification
and conventional histologic diagnosis. Other factors
influencing macroscopic fluorescence intensity are
also assessed including the thickness of SC, which
has been demonstrated to account for heteroge-
neous fluorescence within psoriatic plaques as
reported earlier by our group12 and proliferative
activity, which could theoretically be of influence on
PpIX accumulation.
METHODS
Patient characteristics
This study was approved by the local medical
ethics committee. Fourteen patients with a medical
history of nonmelanoma skin cancer and field
cancerization were included in this study after giving
written informed consent. Additional patient charac-
teristics are depicted in Table I.
Fluorescence diagnosis and biopsy procedure
Before the day FDAP took place, the skin areas
under study were pretreated with 5% or 10% salicylic
acid in petrolatum for 1 or 2weeks, depending on the
clinical picture, to get rid of excess scales and hyper-
keratosis until clinically satisfactory results were
achieved. On the day of the FDAP procedure, 20%
ALA cream (Medac GmbH, Wedel, Germany) was
applied under an occlusive dressing to these skin
areas. After 3 hours of incubation, fluorescence
intensity on the skin was recorded using a digital
fluorescence imaging system (DyaDerm, Biocam
GmbH, Regensburg, Germany). This system consists
of a flash light (xenon light sourcewith a customband
pass filter [370-440 nm]) and a 12-bit charged coupled
device (CCD) camera combined in one adjustable
arm coupled to a computer system equipped with
custom image capturing software (DyadermPro v1.4,
Biocam GmbH). The flash light emits 7 light pulses/s
to the skin, which are recorded by the CCD camera
(exposure time 100 microseconds) equipped with a
special long pass filter (Schott GG 455, Schott BV,
Tiel, TheNetherlands) to filter out the excitation light.
As PpIX fluorescence emission consists of light in the
red spectrum, the red pixels of the CCD camera were
used to generate a fluorescence image. In this way a
normal-colored image and a fluorescence image
were processed in real time. Because of the short
exposure time to the excitation light, photobleaching
of PpIX was minimized. To correct for different
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lighting environments between pictures, a fluores-
cence reference standard (Maccal 8044, 738-00,
Multifoil, Utrecht, The Netherlands) was included
on every image. Images were recorded in 16-bit gray-
scale tagged image file format (TIFF) format.
After FDAP, 4-mm punch biopsy specimens were
taken from selected lesions/skin areas of interest
under local anesthesia with 1% lidocaine-adrenalin.
Analysis of fluorescence images
The 16-bit gray-scale TIFF fluorescence images
were imported in software (ImageJ, National Insti-
tutes of Health, Bethesda, Maryland). Because the
xenon light source used for excitation had the
highest intensity in the center of the illuminated
area, shading correction was performed by means of
the following algorithm:
S ¼ I=C with C ¼ B=BImax
where B = blank image (image from a white homo-
geneous background recorded with the Dyaderm
system), BImax = highest intensity of blank image, I =
(uncorrected) image, C = normalized shading image,
and S = shading corrected image.
Histopathology and immunohistochemistry
The 6-�m slices were fixed on a glass slide,
deparaffinized, hydrated, and washed in phosphate-
buffered saline subsequently. For Ki67-antigen stain-
ing the sections were first pretreated in citrate buffer
(pH 6.0) using the microwave antigen-retrieval
method. Afterward, immunohistochemical analysis
was performed after blocking for endogenous
peroxidase using a staining system (Powervision,
Immunologic, Duiven, The Netherlands) with diami-
nobenzidine as chromogen. The sections were incu-
bated for 1 hour with the primary MIB-1 antibody
(Dako, Heverlee, Belgium) (1:100) directed against
the cell-cycle associated antigen Ki67. For counter-
staining, Mayer’s hematoxylin was used.
Hematoxylin-eosin staining was also performed
on every slide for assessment of the histopathologic
diagnosis and KIN classification. All slides were
assessed by one and the same pathologist (W. A.
M. B.) for uniformity.
Immunohistochemical and digital
image analysis
Immunoreactivity for the Ki67 antigen was scored
semiquantitatively in the following manner accord-
ing to Keating et al13: 0 = only basal layer positivity,
1 = positivity confined to basal third of the epidermis,
2 = positivity confined to basal two thirds of the
epidermis, 3 = transepidermal positive staining.
Analysis of digital microscopic images was done
using digital image analysis software (ImageJ,
National Institutes of Health). Digital photographs
of the hematoxylin and eosin sections were made at
350magnification. To determine the thickness of the
SC, the average thickness was calculated as total SC
surface including hyperkeratosis per millimeter
length of the SC in different biopsy sections.
Statistical analysis
To analyze Ki67 expression and KIN grade in
relation to fluorescence intensity, 1-way analysis of
Table I. Patient characteristics
No. Sex Age, y Immune suppressive drugs Lesions Body site R (P) Remarks
1 M 78 e 2 3 KIN II, 2 3 KIN III, 1 3 NS ue �0.30 (.70)
2 F 42 AZA 1 3 KIN II, 6 3 VH, 1 3 NS ue, le e
3 F 68 e 1 3 KIN I, 4 3 KIN II, 1 3 KIN III, 3 3 NS le �0.88 (.12)
4 F 52 e 6 3 KIN III, 2 3 NS ue, le �0.87 (.05)
5 F 80 e 4 3 KIN I, 3 3 KIN II, 6 3 KIN III le �0.14 (.67)
6 M 40 e 3 3 KIN II, 3 3 SCC ue �0.80 (.10) ACT
7 F 59 e 2 3 KIN II, 1 3 KIN III le �1.0 (\.01)
8 F 62 e 3 3 KIN I, 2 3 KIN II, 1 3 KIN III le �0.94 (.21) ACT
9 F 57 e 1 3 KIN I, 1 3 KIN II le �1.0 (0.10) ACT
10 F 84 e 2 3 KIN I, 4 3 KIN II c �0.87 (.03)
11 F 42 TA, PR, AZA 4 3 KIN I, 3 3 NS c �0.58 (.41) RTR
12 M 73 e 4 3 KIN II c �0.19 (0.80)
13 F 76 e 3 3 KIN I, 1 3 KIN II ue �1.0 (.10)
14 M 71 e 5 3 KIN II c �0.33 (.78)
ACT, Acitretin; AZA, azathioprine; c, chest; F, female; KIN, keratinocytic intraepidermal neoplasia; le, lower extremities; M, male; NS, normal-
appearing skin (no KIN); PR, prednisone; RTR, renal transplant recipient; SCC, squamous cell carcinoma; TA, tacrolimus; ue, upper extremities;
VH, verrucous hyperkeratosis.
R (P) denotes Pearson’s R and its P value from the correlation between fluorescence intensity and stratum corneum thickness in each patient.
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variance was used. For analysis between groups,
Duncan’s post hoc test was performed. Analysis of
fluorescence intensity in AK and BD, Ki67 expres-
sion, and SC thickness among the 4 diagnostic
categories was performed using an unpaired
Student t test. Correlation analysis of macroscopic
fluorescence and SC thickness was performed using
Pearson’s R. All statistical calculations were per-
formed using software (Statistica, Statsoft Inc, and
Excel 2000, Microsoft BV, Schiphol-Rijk, The
Netherlands). A P value less than .05 was considered
statistically significant.
RESULTS
Fluorescence diagnosis and histopathology
From the 86 lesions that were biopsied, 67
appeared to be KIN with the majority (32/67) being
KIN II and with comparable amounts of KIN-I
(18/67) and KIN-III (17/67) lesions. Three lesions
showed microinvasion and were classified as micro-
invasive SCC accordingly. Ten lesions did not show
nuclear atypia or other epidermal abnormalities and
were classified as normal-appearing skin. From these
10 lesions 5 showed dermal elastosis and were
subclassified as actinically damaged skin. In one
patient verrucous epidermal abnormalities (papillo-
matosis, acanthosis) were seen without evident
nuclear atypia; these lesions were classified as
verrucous hyperkeratosis consequently.
Nearly all lesions showedhigher fluorescence com-
pared with nonlesional skin except for some of the
verrucous hyperkeratoses and some hyperkeratotic
KIN lesions (Figs 1 to 3). Macroscopic fluorescence
between the different KIN lesions, however, did
not show statistically significant differences (P = .07)
(Fig 2,A).When the lesionswere classified according
to the conventional nomenclature, AKandBDdidnot
show significant differences (P = .16) (Fig 2, B). In
SCC the highest fluorescence ratios were found but
the low number and the fact that these came from a
single patient did not allow reliable statistical com-
parisons to be made.
Fig 1. Fluorescence ratio and histopathology. Fluores-
cence in lesional skin was higher than in normal-appear-
ing surrounding skin but between different keratinocytic
intraepidermal neoplasia (KIN ) stages no significant dif-
ferences were found. Values are depicted by standard box
plots in which horizontal line, gray box, and error bars
represent median value, first to third quartile, and highest
and lowest values, respectively. SCC, Squamous cell car-
cinoma. *P\ .05, **P\ .001.
Fig 2. A, Fluorescence ratio in keratinocytic intraepider-
mal neoplasia (KIN ). Mean fluorescence ratio (lesional
skin:nonlesional skin) was assessed in different KIN stages,
but no significant differences were found. B, Fluorescence
ratio in actinic keratoses and Bowen’s disease. Fluores-
cence ratio (lesional skin:nonlesional skin) was assessed
using conventional histologic classification, but no signif-
icant differences were found. Error bars, SEM.
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Fluorescence diagnosis and proliferation
Analysis of proliferative activity as assessed by
immunoreactivity for the Ki67 antigen did not reveal
any significant differences in fluorescence ratios
among the 3 levels of Ki67 expression (P = .46)
(Fig 4). Ki67 is a cell cycleeassociated antigen ex-
pressed in all parts of the cell cycle except G0, rep-
resenting the epidermal proliferative compartment.14
When the lesions were divided into 4 diagnostic
categories (true/false positives/negatives), with a
fluorescence ratio of 1.0 taken as a cut-off value
and KIN lesions/SCC and verrucous hyperkerato-
ses/normal-appearing skin classified as (pre)malig-
nant and benign lesions, respectively, lesions with a
fluorescence intensity lower than surrounding skin
(fluorescence ratio\ 1.0; true and false negatives)
had a significantly lower number of Ki671 cells than
lesions with a fluorescence ratio greater than 1.0
(true and false positives) (P \ .05) (Table II).
However, when Ki67 immunoreactivity from all 4
diagnostic categories was mutually compared only
a significant difference between the false-positive
and true-positive lesions (P\ .01) and true-positive
and true-negative lesions (P\ .01) was found.
Fluorescence and thickness of SC
Assessment of the thickness of the SC in relation to
the fluorescence intensity revealed a negative
correlation, which suggests SC to have a negative
effect on fluorescence intensity measured with FDAP
(Fig 5). This correlation was also assessed within
every patient if possible. Interestingly, in every
patient a negative correlation was seen, as reflected
by negative correlation coefficients (R) in Table I. In
addition, no association was found between the type
of keratin (orthokeratosis vs parakeratosis) and flu-
orescence intensity. However, the amount of
Fig 3. Images acquired with fluorescence diagnosis imaging system. Color (A), fluorescence
(B), and pseudocolor (C) images from two lesions classified as Bowen’s disease. Note that
fluorescence corresponds well with clinical picture. Color (D), fluorescence (E), and pseudo-
color (F) images from verrucous hyperkeratosis with no atypia. Lesional fluorescence is lower
than surrounding normal-appearing skin fluorescence.
Fig 4. Fluorescence ratio and Ki67 expression.
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samples with a solely orthokeratotic (nonparakera-
totic) SC was relatively small compared with the
samples with parakeratosis and, regarding the large
statistical variation of the fluorescence data, possible
differences in fluorescence intensity between the
parakeratotic and nonparakeratotic samples might
not be measurable at all.
When the lesions were divided into 4 diagnostic
categories, as described earlier, lesions with a fluo-
rescence intensity lower than surrounding skin (flu-
orescence ratio\1.0; true and false negatives) had a
significantly thicker SC than lesions with a fluores-
cence ratio greater than 1.0 (true and false positives)
(P = .01) (Table II). Moreover, in the true-positive
lesions the mean SC thickness was significantly
lower (P \ .05) compared with the false-negative
lesions. Also, in the false-positive lesions a signifi-
cantly lower SC thickness was found compared with
the false-negative lesions (P\.05). However, among
the other 4 diagnostic categories, no significant
differences in SC thickness were found.
DISCUSSION
In this study no differences were seen in the
different stages of KIN in their ability to accumulate
PpIX, although KIN-III lesions tended to have higher
fluorescence ratios than KIN- I/-II lesions. However,
fluorescence intensity in lesional skin was almost
always higher than nonlesional (surrounding) skin
but there were also a few skin lesions histologically
classified as normal-appearing skin that showed high
(false-positive) fluorescence (8 lesions) and lesions
with histologic atypia that showed low (false-nega-
tive) fluorescence (7 lesions) comparedwith normal-
appearing surrounding skin. Possible explanations
for this could be differences in SC thickness12 or
pigmentation in lesional skin compared with nonle-
sional skin but this could not be assessed because no
biopsy specimens were taken from nonlesional
(surrounding) skin. The lesions classified as verru-
cous hyperkeratosis, however, tended to have a
thicker SC than the other diagnoses, although this
was not statistically significant. In one patient with
numerous verrucous hyperkeratoses without atypia
lesional fluorescence was always lower than normal-
appearing surrounding skin fluorescence (Fig 3,D to
F ) but also compared with the KIN lesions (Fig 1).
Three samples were classified as SCC and showed
high macroscopic fluorescence. Unfortunately, be-
cause there were only 3 lesions that also came from a
single patient, reliable statistical comparisons were
not possible. However, it would be interesting in the
clinical setting to knowwhether FDAP can be used to
discriminate between intraepithelial squamous pre-
malignancies and invasive SCC. Further studies on
this are needed.
As penetration of the hydrophilic ALA through the
lipophilic SC is a prerequisite for PpIX formation,
which is predominantly synthesized by the epider-
mal keratinocytes, SC thickness and integrity can
influence macroscopic fluorescence in vivo.12 In our
samples a negative correlation was found between
Table II. Stratum corneum thickness, Ki67 immunoreactivity, and number of samples classified according to
fluorescence intensity and histopathology
KIN/SCC Normal-appearing skin/verrucous hyperkeratoses
No. SC thickness, mm Ki671 cells/mm BM No. SC thickness, mm Ki671 cells/mm BM
Fluorescence diagnosis
High fluorescence 64 0.089 (60.010) 32.59 (62.92) 11 0.069 (60.016) 18.76 (62.61)
Low fluorescence 7 0.281 (60.078) 20.75 (64.85) 4 0.336 (60.126) 19.13 (62.34)
SC thickness, Ki67 immunoreactivity, and number of lesions were classified into 4 diagnostic categories based on histopathology and
fluorescence intensity using a fluorescence ratio of 1.0 as a cut-off value with KIN lesions/SCC and normal-appearing skin/verrucous
hyperkeratoses classified as benign and (pre)malignant skin lesions, respectively. (Pre)-malignant lesions with high and low fluorescence
represent the true positives and false negatives, respectively. Benign lesions with high and low fluorescence represent the false positives and
true negatives, respectively. SC thickness and Ki67 positivity are expressed as mean values (6SEM).
BM, Basement membrane; KIN, keratinocytic intraepidermal neoplasia; SC, stratum corneum; SCC, squamous cell carcinoma.
Fig 5. Normalized fluorescence and thickness of stratum
corneum. R = �0.45. Dotted lines indicate 95% confidence
intervals.
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samples with a solely orthokeratotic (nonparakera-
totic) SC was relatively small compared with the
samples with parakeratosis and, regarding the large
statistical variation of the fluorescence data, possible
differences in fluorescence intensity between the
parakeratotic and nonparakeratotic samples might
not be measurable at all.
When the lesions were divided into 4 diagnostic
categories, as described earlier, lesions with a fluo-
rescence intensity lower than surrounding skin (flu-
orescence ratio\1.0; true and false negatives) had a
significantly thicker SC than lesions with a fluores-
cence ratio greater than 1.0 (true and false positives)
(P = .01) (Table II). Moreover, in the true-positive
lesions the mean SC thickness was significantly
lower (P \ .05) compared with the false-negative
lesions. Also, in the false-positive lesions a signifi-
cantly lower SC thickness was found compared with
the false-negative lesi ns (P\.05). However, among
the other 4 diagnostic categorie , no sig ifi ant
differences in SC thickness were found.
DISCUSSION
In this study no differences were seen in the
different stages of KIN in their ability to accumulate
PpIX, although KIN-III lesions tended to have higher
fluorescence ratios than KIN- I/-II lesions. However,
fluorescence intensity in lesional skin was almost
always higher than nonlesional (surrounding) skin
but there were also a few skin lesions histologically
classified as normal-appearing skin that showed high
(false-positive) fluorescence (8 lesions) and lesions
with histologic atypia that showed low (false-nega-
tive) fluorescence (7 lesions) comparedwith normal-
appearing surrounding skin. Possible explanations
for this could be differences in SC thickness12 or
pigmentation in le ional skin compar d with nonle-
sional skin but this could not b assessed because no
biopsy spec mens were taken from nonle ional
(surrounding) skin. Th lesions classified as ve ru-
cous hyperkerat sis, however, tended t have a
thicker SC than the other diagnoses, although this
was not statistically significant. In one patient with
numerous verrucous hyperkeratoses without atypia
lesional fluorescence was always lower than normal-
appearing surrounding skin fluorescence (Fig 3,D to
F ) but also compared with the KIN lesions (Fig 1).
Three samples were classified as SCC and showed
high macroscopic fluorescence. Unfortunately, be-
cause there were only 3 lesions that also came from a
single patient, reliable statistical comparisons were
not possible. However, it would be interesting in the
clinical setting to knowwhether FDAP can be used to
discriminate between intraepithelial squamous pre-
malignancies and invasive SCC. Further studies on
this are needed.
As penetration of the hydrophilic ALA through the
lipophilic SC is a prerequisite for PpIX formation,
which is predomina tly synthesized by the epider-
mal keratinocytes, SC thickness and integrity can
influence macroscopic fluorescence in vivo.12 In our
samples a negativ correlation was found between
Table II. Stratum corneum thickness, Ki67 immunoreactivity, and number of samples classified according to
fluorescence intensity and histopathology
KIN/SCC Normal-appearing skin/verrucous hyperkeratoses
No. SC thickness, mm Ki671 cells/mm BM No. SC thickness, mm Ki671 cells/mm BM
Fluorescence diagnosis
High fluorescence 64 0.089 (60.010) 32.59 (62.92) 11 0.069 (60.016) 18.76 (62.61)
Low fluorescence 7 0.281 (60.078) 20.75 (64.85) 4 0.336 (60.126) 19.13 (62.34)
SC thickness, Ki67 immunoreactivity, and number of lesions were classified into 4 diagnostic categories based on histopathology and
fluorescence int nsity us g a fluorescence ratio of 1.0 as a cut-off v lue with KIN lesions/SCC and n rmal-appearing skin/verrucous
hyperkeratoses classified as benign and (pre)malignant skin lesions, respectively. (Pr )-malignant lesions with high and low fluoresce ce
represent th t ue positives and false negatives, r sp ctively. B nign lesions with high and low fluorescence represent the fals ositives and
true negatives, respectiv ly. SC thickness and Ki67 positivity are expressed s mean values (6SEM).
BM, Basement membrane; KIN, keratinocytic intraepidermal neoplasia; SC, stratum corneum; SCC, squamous cell carcinoma.
Fig 5. Normalized fluorescence and thickness of stratum
corneum. R = �0.45. Dotted lines indi ate 95% confide ce
intervals.
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samples with a solely orthokeratotic (nonparakera-
t tic) SC was relatively sm ll compared with the
amples with paraker tosis and, regarding the large
statistical vari tion f the fluorescence data, possibl
differ ces in fluorescence intensity between the
parakeratotic and nonparakeratotic samples ight
not be measurable at all.
When the lesions were divided into 4 diagnostic
cat gories, as described earlier, lesions with a fluo-
rescence i te sity lower than surrounding skin (flu-
orescence ratio\1.0; true and false negatives) had a
significantly t icker SC than lesions with a fluores-
cence ratio greater than 1.0 (true and false positives)
(P = .01) (Table II). Moreover, in the true-positive
lesions the mean SC thickness was significantly
lo er (P \ .05) compared with the false-negative
lesions. Also, in the false-positive lesions a signifi-
cantly lower SC thickness was found compared with
the false-negative lesions (P\.05). However, among
the other 4 diagnostic categories, no significant
differe ces in SC thickness were found.
DISCUSSION
In this study no differences were seen in the
different stages of KIN in their ability to accumulate
PpIX, althoug KIN-III l sions tended to have higher
fluoresc nce ratios than KIN- I/-II lesions. However,
fluorescence intensity in lesional skin was almost
alw ys higher than nonlesional (surrounding) skin
but there were also a few skin lesions histologically
clas ified as normal-appearing skin that showed high
(false-positive) fluorescence (8 lesions) and lesions
with histologic atypia that showed low (false-nega-
tive) fluo scence (7 lesions) comparedwith normal-
appearing surrounding kin. Possible explanations
for this could be differences in SC thickness12 or
pigmentation in lesi al skin compared with nonle-
sional kin but this could not be assess d because no
biopsy specime s were taken from nonlesional
(surrounding) ski . The lesi s classified as verru-
cous hyp rkerato is, how ver, tended to have a
thicker SC than the ot er diagnoses, lthough this
was not statistically ignificant. In one patient with
numerou verrucous hyperkeratoses without atypia
lesional fluoresce ce w s always lower than normal-
appearing surrounding skin fluorescence (Fig 3,D to
F ) but also compared with the KIN lesions (Fig 1).
Three samples were classified as SCC and showed
high macr scopic fluorescence. Unfortunately, be-
cause there were only 3 lesions that also came from a
single patient, reliable statistical comparisons were
not possible. However, it would be interesting in the
clinical setting to knowwhether FDAP can be used to
discriminate between intraepithelial squamous pre-
malignancies and invasive SCC. Further studies on
this are needed.
As penetration of the hydrophilic ALA through the
lipophilic SC is a prerequisite for PpIX formation,
which is predominantly synthesized by the epider-
mal keratinocytes, SC thickness and integrity can
influence macroscopic fluorescence in vivo.12 In our
samples a negative correlation was found between
Table II. Stratum corneum th ckness, Ki67 immunoreactivity, and number of samples classified according to
fluorescence intensity and histopathology
KI /SCC Normal-appearing skin/verrucous hyperkeratoses
No. SC thickness, mm Ki671 cells/m BM No. SC thickness, mm Ki671 cells/mm BM
Fluorescence diagnosis
High fluorescence 64 0.089 (60.010) 32.59 (62.92) 1 0.069 (60.016) 18.76 (62.61)
Low fluorescence 7 0.2 1 (60.078) 20.75 (64.85) 4 0.336 (60.126) 19.13 (62.34)
SC thickness, Ki67 immunoreactivity, and number of lesi ns wer classified int 4 diagnostic categories based on histopathology and
fluorescence int nsity using a flu rescence rati of 1.0 as a cut-off value with KIN lesions SCC and normal-appearing skin/verrucous
hyperkeratoses classified as benig and (pre)malignant skin esion , respectively. (Pre)-malignant lesions with high and low fluorescence
repr en the true positives and fals negatives, respectively. Benign lesions with high and low fluor ce ce r pre ent the false positives and
true neg tives, res ec i el . SC thickness nd Ki67 positivity are expressed as mean values (6SEM).
BM, Baseme membrane; KIN, keratinocytic intraepid rmal neoplasi ; SC, stratum corneum; SCC, squamous cell carcinoma.
Fig 5. Normalized fluorescence and thickness of stratum
corneum. R = �0.45. Dotted lines indicate 95% confidence
intervals.
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amples with a s lely orth k rat tic (nonparakera-
totic) SC w s rela ively small compared with the
s mples with arakeratosis and, regarding the large
statistical variation of the fluorescence data, p ssible
differences in fluorescence i tensity be we n th
parakeratotic nd nonp rakeratotic samples might
not be measurable at all.
When the lesions were divided into 4 diag ostic
categories, s described earlier, lesions with a fluo-
rescence intensity low r than surrounding skin (flu-
orescence ratio\1.0; true and false negatives) had a
significantly thicker SC than lesions with a fluores-
cence ratio greater than 1.0 (true and false positives)
(P = .01) Table II). Mor over, in the true-positive
lesions the mean SC thickness was significantly
lower (P \ .05) compared with the false-negative
lesions. Also, i the false-positive lesions a signifi-
cantly lower SC thickness was found compared with
the false-negative lesions (P\.05). However, among
the other 4 diagnostic categories, no significant
diff rences n SC thick ess were found.
DISCUSSION
In this study no differe ces were s en in th
different stages of KIN in their ab lity to accumulate
PpIX, alth ugh KIN-III lesions tended to have higher
fluorescence ratios tha KIN- I/-II lesions. However,
fluorescence i ten ity in lesional skin w s almost
always higher than nonlesional (surr unding) ski
but th re were als a few skin lesions histologically
classified as normal- ppearing skin that showed hig
(fals -positive) fluore cence (8 lesions) and lesions
with histologic atypia that howed low (false-nega-
tive) flu resc nce (7 lesions) co paredwith normal-
appearing surr u ding skin. Possible explanations
for this could be differenc in SC thickness12 or
pig entation in lesional skin c mpared with nonle-
sional skin but thi could not be ass ssed becau no
biopsy specimens were taken from nonl sional
(surrounding) ki . Th lesions classified as verru-
cous yper ratosis, however, tended to have a
thicker SC than th other diagnos s, although this
was no stati tically sign ficant. In one patien with
umerous v rrucous hyperkerat s s without atypia
lesional fluorescence wa always lo er than normal-
appearing surr undi g skin fluorescence (Fig 3,D to
F ) but also comp red with th KIN lesions (Fig 1).
Thr e samples were cl ssified as SCC and showed
high macroscopic fluorescence. Unfortunately, be-
cause th re were only 3 lesi s that also came from
single patie t, reli ble statistical comparisons were
not possible. H wever, it would be interesting in the
clinical setting to knowwhether FDAP can be used to
discriminate between intraepithelial squamous pre-
malignancies and invasive SCC. Further studies on
this are needed.
As penetration of the hydrop ilic ALA t rough the
lipophilic SC is a prerequisite for PpIX f rmation,
hich is predom nantly synthesized by the epider-
mal keratinocyt s, SC thickness and integrity can
influence macros opic fluorescence in vivo.12 I our
samples a n gative correlation was fou d between
Table II. Stratum corneu thick ess, Ki67 immunoreactivity, nd number of sa ples classified according to
fluorescence intensity and hi topathology
KIN/SCC Normal-appearing s in/ver ucous hyperkeratoses
No. SC thickness, Ki671 cells/mm BM No. SC thickn ss, Ki671 cells/mm BM
Fluorescence diagnosis
High fluorescence 64 0.089 (60.01 ) 32.59 (62.92) 1 0.069 ( 0.016) 18.76 (62.6 )
Low fluorescence 0.281 (60.078) 20.75 (64.85) 4 0.336 (60.1 6) 9.13 (62.34)
SC thickness, Ki67 imm nor activity, and numb r lesions were clas ified into 4 diagnostic cate ories based n histopath logy and
fluoresc ce int n ity using a luor scence ratio of 1.0 as a cut-off value with KIN l sions/SCC and ormal- ppearing skin/v r ucous
hyperkeratoses cl ssifi d a be ign and (pre)malignant kin lesions, respect v ly. (Pre)-m lignant le ions with high and low fluor scence
represent the true positiv s and false neg tives, respectively. Benig lesions w t high and ow fluor scence represent the fals posi ives and
true negatives, r spectively. SC thickness and Ki67 positivity re expres ed as mean values (6SEM).
BM, Basement membrane; KIN, ker tinocytic intr epidermal neoplasia; SC, stratum c rneum; SCC, squ ous cell c rcinoma.
Fig 5. Normalize fluoresc nce and thickness of stratum
c rneum. R = �0.45. Dotted lines ndi ate 95% confidence
intervals.
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the thickness of the SC and fluorescence intensity,
indicating hyperkeratosis to be an important factor
in intrapatient and interpatient differences in fluo-
rescence intensity (Fig 5 and Table I). This is in
accordance with a significant thicker SC found in all
true and false negatives compared with the true and
false positives (P\ .01). The fact that a significantly
thinner SC was found in true-positive lesions com-
pared with the false-negative lesions also empha-
sizes the important role of the SC in fluorescence
intensity. In addition, a significant thicker SC was
found in the false-negative lesions compared with
false-positive lesions, but no significant differences
were found between the false-positive and true-
negative lesions. The latter can possibly be explained
by the relatively low number of true-negative lesions
and high variation (high SEM).
Differences in SC thickness are probably not an
explanation for the preferential accumulation of
PpIX in lesional skin compared with nonlesional
skin, because hyperkeratosis is very common in
hyperproliferative skin disorders that highly accu-
mulate PpIX. Disruptions in SC integrity overlying
a pathologic epidermis15 and/or alterations of the
heme biosynthetic pathway16,17 are thought to be
responsible for this. In a previous study of our group,
AK was found to accumulate significantly more PpIX
than surrounding nonlesional skin.3 However, when
correcting PpIX content for the number of epidermal
cells, differences in PpIX content between AK and
nonlesional surrounding skin disappeared, indicat-
ing the PpIX content per cell to be comparable in AK
versus nonlesional surrounding skin. Higher lesional
fluorescence in AK can, therefore, be explained by
an increased number of cells in lesional skin, leading
to a higher PpIX quantum yield. In conclusion, SC
thickness seems to play an important role in varia-
tions in fluorescence intensity. This should be con-
sidered when performing FDAP or PDT, for example
by curettage or adequate keratolytic treatments be-
fore the procedure. In our study 5% to 10% salicylic
acid in petrolatum was applied for 1 or 2 weeks
depending on the clinical picture, until clinically
adequate desquamation was achieved (as assessed
by the investigating physician). This would theoret-
ically increase fluorescence intensity by facilitating
penetration of ALA through the SC.18 As both lesional
and nonlesional (surrounding) skin were pretreated
with salicylic acid, the effects of different keratolytic
regimes on the fluorescence ratio (lesional:nonle-
sional skin) are assumed to be minimal.
Regulation of the enzymes in the heme synthesis
(metabolism) might be expected to be related to
proliferative activity as PpIX accumulation is in-
creased in many hyperproliferative (skin) disorders,
including psoriasis. Consequently, expression of the
cell cycleeassociated Ki67 antigen was assessed to
study its relation with respect to macroscopic fluo-
rescence intensity. However, no significant differ-
ences were found in the macroscopic fluorescence
ratios within various degrees of Ki67 expression,
although, in lesions with low fluorescence ratios
(\1.0, true and false negatives), significantly lower
Ki67 expression was seen compared with high fluo-
rescing lesions (fluorescence ratio [ 1.0, true and
false positives), most likely a result of the relatively
high number of true positives that are mostly hyper-
proliferative lesions. The significantly higher number
of Ki671 cells in the true positives compared with
the false positives and true negatives can also be
explained by this. However, no differences in Ki67
expression were found between the true negatives
compared with the false positives and true positives
compared with the false negatives. Therefore,
differences in Ki67 expression cannot explain vari-
ations in fluorescence intensity. FDAP, therefore,
cannot be used to discriminate between lesions
based on differences in proliferative activity. Moan
et al19 studied the relationship between PpIX accu-
mulation and cell-cycle phase and found cells in
G21M phase to have increased PpIX concentrations
compared with the G1 phase but this was only
related to the increased cell size during G21M.
Fukuda et al20 found no obvious cell-cycle depen-
dency after incubation of cultured mammalian epi-
thelial cells with ALA. They attributed the slight
differences in the PpIX concentrations, found in
different cell phases, to extracellular PpIX loss during
ALA incubation. Thus, proliferation does not seem
a determinant of PpIX accumulation but rather a
confounder.
In conclusion, in this study no significant differ-
ences were found in the macroscopic fluorescence
ratios between various stages of cutaneous squa-
mous (pre)malignancies, although a slight tendency
toward higher fluorescence ratios was seen in BD
compared with AK. Proliferative activity assessed by
expression of the Ki67 antigen also did not show
significant differences in the different KIN stages.
Thus, FDAP does not seem useful in the histopath-
ologic discrimination between these lesions nor can
it be used to assess proliferative activity, although it
might be interesting to further investigate the poten-
tial applicability of FDAP in the discrimination be-
tween premalignant squamous cutaneous lesions
and SCC based on the higher fluorescence intensity
observed in SCC compared with KIN lesions in this
study. However, SC thickness and macroscopic
fluorescence intensity appear negatively correlated
among patients but also within patients, indicating
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hyperkeratosis to be an important determinant in
variations in macroscopic fluorescence intensity.
More knowledge on the mechanisms of the prefer-
ential accumulation of PpIX in various tissue types
and the factors influencing this is needed to better
understand false-positive and false-negative out-
comes in FDAP,which alsomayhelpus tounderstand
the variable treatment efficacy observed in PDT.
The authors would like to thank Waldmann Medische
Techniek B.V., Tiel, The Netherlands, for providing the
DyaDerm Digital Imaging System and Josine Kanis for
additional help during the preparation of the manuscript.
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In this chapter the results of the experiments described in this thesis will be summarized 
and further discussed. The central theme of this thesis is to understand the differences 
observed in PpIX fluorescence between two different skin conditions, psoriasis and AK, 
in order to optimize PDT and FDAP in daily practice. Furthermore, the photodynamic 
treatment of psoriasis and aneuploidy as a potential progression marker in AK were 
investigated. Therefore, several aims (I-III) were defined in paragraph 1.9.3., which are 
extensively discussed in the chapters 2-4.
In chapter 2, PpIX accumulation is studied in the skin as well as at the skin by FDAP, in 
psoriasis, AK and normal skin according to aims Ia-c. The results are summarized and 
discussed in paragraph 5.1. 
In chapter 3, the clinical and histological effects of PDT and FDAP in psoriasis are studied 
according to aims IIa-b. The results are summarized and discussed in paragraph 5.2. 
In chapter 4, FDAP and aneuploidy are evaluated as diagnostic tools in field-cancerization 
according to aims IIIa-b. The results are summarized and discussed in paragraph 5.3. 
In paragraph 5.4 the main conclusions from chapters 2-4 are briefly summed up.
Finally, in paragraph 5.5 a general discussion is presented, including a model for the 
preferential accumulation of PpIX in psoriasis, AK and normal skin. 
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5.1 Accumulation of protoporphyrin-IX in actinic
 keratosis, psoriasis and normal skin following
 application of aminolaevulinic acid and its
 correlation with fl uorescence diagnosis  
AIM Ia To investigate PpIX content in lesional and non-lesional skin in AK and psoriasis in vivo following application of ALA 
and to correlate this with PpIX ﬂ uorescence acquired with FDAP.
In paragraph 2.1, PpIX accumulation was studied in patients with AK and psoriasis 
following application of 20% ALA cream for 3 hours. Afterwards, FDAP was performed 
and biopsies were taken from lesional and non-lesional skin. PpIX content was measured 
spectroﬂ uorometrically in these biopsies and this was compared with the ﬂ uorescence 
values acquired with FDAP, in order to see whether macroscopic ﬂ uorescence acquired 
with FDAP can be used as a measure for PpIX content in the skin. A summary of the results 
can be found in table 1 in paragraph 2.1. In lesional skin from both AK and psoriasis, 
increased PpIX ﬂ uorescence was observed compared with non-lesional (surrounding) 
skin. Moreover, a higher lesional : non-lesional ﬂ uorescence ratio in psoriasis was 
found compared with AK (1.77 vs. 1.37). PpIX content was also higher in lesional skin 
in both psoriasis and AK, with lesional : non-lesional PpIX content ratios of 4.1 and 2.0 
respectively. When PpIX content (per biopsy) between the four skin conditions was 
compared, this appeared to be higher in psoriatic lesional skin compared with the 
other skin conditions (ﬁ gure 2). Lesional skin in AK also contained more PpIX per biopsy 
compared with surrounding skin. However, when a correction was made for the number 
of cells, using dsDNA as an epidermal reference, only lesional skin in psoriasis still 
contained signiﬁ cantly more PpIX compared with surrounding skin. This indicates that 
the increased ﬂ uorescence observed with FDAP and PpIX content per biopsy in lesional 
skin in AK compared with surrounding skin cannot be explained by an increased PpIX 
content per cell, but solely by an increased number of cells, reﬂ ected by an increased 
amount of dsDNA, in lesional skin of AK (ﬁ gure 3). The increased amount of PpIX per cell in 
psoriatic lesional skin may well be the result of an increased penetration of ALA through a 
pathologic stratum corneum in lesional psoriatic skin and/or increased synthesis of PpIX 
by psoriatic keratinocytes. Furthermore, since in lesional psoriatic skin also a signiﬁ cantly 
higher amount of cells (DNA content) was found compared with non-lesional psoriatic 
skin, this may also contribute to the increased macroscopic ﬂ uorescence intensity in 
lesional psoriatic skin observed with FDAP, similar to AK. 
When ﬂ uorescence data acquired with FDAP were compared with PpIX content in the 
skin, a positive linear correlation was found (ﬁ gure 9). However, at higher PpIX content 
values the slope of the curve appeared to follow a more horizontal course, which can 
most probably be explained by the limited penetration depth of the blue excitation 
light from the digital imaging system. Consequently, PpIX located in the deeper layers 
of the skin may not be fully activated by the blue light. This appears to be an important 
limitation of FDAP, which should be considered when using this procedure. However, in 
AK, macroscopic ﬂ uorescence values and PpIX content were low enough to ﬁ t perfectly 
on the ﬁ rst part of the curve (r=0.79). The limited penetration depth of the blue light may 
therefore not be a problem when using FDAP for AK. The question remains whether this 
will be a signiﬁ cant problem when using FDAP for invasive carcinomas such as SCC and 
BCC. Thus, FDAP as performed in this study, appears to be a good method to estimate 
PpIX content in the skin, particularly in the low ﬂ uorescence range.   
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AIM Ib To investigate PpIX accumulation without interference of the stratum corneum, in lesional and non-lesional skin in AK, 
psoriasis and normal skin following application of ALA.
In paragraph 2.2 a study is described, in which some remaining issues from the previous 
study are addressed by studying PpIX accumulation without interference of the stratum 
corneum. In this study, PpIX accumulation was studied ex vivo in skin explants (biopsies) 
from lesional and non-lesional skin from patients with psoriasis and patients with AK. 
Also biopsies from normal skin were included as controls. The skin explants were 
incubated in a culture medium containing ALA and after 16 hours PpIX, as well as dsDNA, 
were extracted and measured spectroﬂ uorometrically. Since the penetration route of 
ALA through the stratum corneum is bypassed in this model, the intrinsic aﬃ  nities of 
the diﬀ erent skin conditions to accumulate PpIX (heme-biosynthetic pathway) can be 
studied. Increased amounts of PpIX per biopsy were found in (lesional and non-lesional 
skin) in patients with psoriasis as compared to patients with AK, but comparable amounts 
were found in normal skin from healthy controls (ﬁ gure 1). However, after correction using 
dsDNA, no signiﬁ cant diﬀ erences were found between the ﬁ ve skin conditions, although 
non-lesional skin in AK and psoriasis tended to have higher amounts of PpIX compared 
with lesional skin. This indicates that the increased PpIX content and macroscopic 
ﬂ uorescence acquired with FDAP observed in lesional skin in psoriasis and AK described 
in paragraph 2.1 cannot be explained by an increased PpIX metabolism. Thus, the ﬁ ve skin 
conditions appear to be equally capable of producing PpIX. The increased PpIX content 
per cell observed in lesional psoriatic skin, as described in paragraph 2.1, therefore must 
be the result of increased penetration of ALA through a pathologic stratum corneum.
 
AIM Ic To investigate preferential accumulation of PpIX within the epidermis, in order to characterize the target cells for PDT 
and FDAP.
Additionally, to verify whether ALA penetration and PpIX accumulation were 
homogeneous throughout the biopsies, ﬂ uorescence microscopy was performed on 
several skin explants. A homogeneous distribution of PpIX ﬂ uorescence was observed 
throughout the entire length of the epidermis, but interestingly less PpIX ﬂ uorescence 
was seen in the basal layers of the epidermis. Since preferential accumulation of PpIX has 
been reported in diﬀ erentiated cells, further studies were performed to quantify PpIX 
content in the basal and suprabasal layers of the epidermis. Therefore, skin explants from 
normal skin were incubated with ALA, whereafter PpIX was measured with ﬂ ow cytometry 
in the basal and suprabasal keratinocytes using β1-integrin as a marker to discriminate 
between these cells. In accordance with the ﬂ uorescence microscopic results, signiﬁ cantly 
increased amounts of PpIX were found in the suprabasal keratinocytes, which is indicative 
for a preferential accumulation in terminally diﬀ erentiated keratinocytes. 
Additional studies in cultured keratinocytes were performed to further investigate the 
relation between terminal diﬀ erentiation and PpIX accumulation. During diﬀ erent phases 
of growth, cells were incubated with ALA and PpIX was measured. Signiﬁ cantly more PpIX 
was induced by the conﬂ uent cultures, which show a higher degree of diﬀ erentiation, 
compared with the subconﬂ uent cultures, which are exponentially growing and 
are poorly diﬀ erentiated. So, these data support the earlier ﬁ ndings demonstrating 
preferential PpIX accumulation in terminally diﬀ erentiated cells. However, in another 
in vitro study, in which the same cultured keratinocytes were grown until complete 
conﬂ uence was reached, omission of growth factors out of the culture medium, which is a 
well-known method to induce terminal diﬀ erentiation, showed less PpIX production per 
cell after incubation with ALA compared with cells that continued to grow. Subsequent 
measurements of total PpIX content per cell culture revealed comparable amounts of 
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PpIX in the two diﬀ erent cell cultures. These ﬁ ndings may be explained by a larger cell 
volume of the diﬀ erentiated cells, resulting in a decreased PpIX concentration per cell. 
Potential increases in PpIX synthesis in the diﬀ erentiated cells may thus have well been 
overshadowed by an increased cell volume. 
Thus, explant cultures of biopsies from psoriasis, AK and normal skin are equally 
capable of accumulating PpIX. In lesional psoriatic skin, the disrupted integrity of 
the stratum corneum plays an important role, allowing more ALA to penetrate into 
the epidermis to be taken up by the epidermal keratinocytes to produce PpIX. In AK 
disruptions in stratum corneum integrity also play a role but this cannot fully account 
for the preferential accumulation in lesional skin observed with FDAP, which is caused 
by an increased number of PpIX-containing cells. Preferential accumulation of PpIX in 
suprabasal keratinocytes from normal skin, observed with ﬂ uorescence microscopy and 
ﬂ ow cytometry, may point at a terminal diﬀ erentiation speciﬁ c eﬀ ect.
5.2 PDT and FDAP in psoriasis
AIM IIa To evaluate the clinical and histological eﬀ ects of PDT in psoriasis and to assess PpIX ﬂ uorescence during PDT.
In paragraph 3.1 the clinical and immunohistochemical eﬀ ects of the photodynamic 
treatment of psoriasis were studied. After a keratolytic pre-treatment using 10% salicylic 
acid in petrolatum, unilateral plaques were treated with 10% ALA for 4 hours followed 
by two (fractionated) irradiations of 2 and 8 J/cm2 (Waldmann PDT 1200 L, 40 mW/cm2) 
separated by a dark-interval of 2 hours, once weekly for 4 weeks. Contralateral plaques 
were treated with placebo-PDT after the same pre-treatment with 10% salicylic acid in 
petrolatum. FDAP was performed before and after PDT to assess photobleaching of PpIX. 
Psoriatic severity was clinically assessed using the SUM-score. To study the histological 
eﬀ ects of ALA-PDT, biopsies were taken at baseline, after 1 week and at week 6 (2 weeks 
after the last treatment) on which immunohistochemistry was performed using markers 
for proliferation (Ki67), diﬀ erentiation (K10) and inﬂ ammation (CD4, CD8 and CD45RO).
Already one week after the ﬁ rst PDT session, immunohistochemical improvement in the 
ALA-treated sites was observed with respect to proliferation and keratinization, reﬂ ected 
by a decrease in Ki67 expression and increase in K10 expression. These oberservations 
were even more pronounced at week 6. These changes were absent in the placebo-
treated sites. Eﬀ ects on relevant T cell subsets were not noted until week 6, shown by 
decreases in the amounts of CD8+ and CD45RO+, but not CD4+ cells in the ALA-treated 
sites. Signiﬁ cant decreases were only observed in the amounts of epidermal CD8+ cells 
and dermal CD45RO+ cells. In the placebo-treated sites these changes were absent, but 
a signiﬁ cant increase in epidermal CD4+ cells was seen. Clinical improvement in the 
ALA-treated sites was already seen after one treatment, continuing until week 6. Mostly, 
partial clearance was seen but also worsening of the psoriatic plaques, indicative of 
Koebernization, was observed in 2 out of 8 patients. Some patients complained about 
pain during ALA-PDT, but this was no reason for discontinuation of the treatment. A 
signiﬁ cant increase of PpIX ﬂ uorescence (2.57x) in lesional psoriatic skin was seen after 
application of 10% ALA for 4 hours. After 2 J/cm2 no signiﬁ cant photobleaching was 
observed in contrast to the second illumination with 8 J/cm2. Directly after the second 
illumination PpIX ﬂ uorescence still remained 2.13 times baseline ﬂ uorescence, indicative 
of abundant PpIX intralesionally. Additionally, in most psoriatic plaques heterogeneous 
ﬂ uorescence was observed despite clinically adequate keratolytic pre-treatment.
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From the above it was concluded that PDT is able to clinically and histologically improve 
psoriasis. However, using the current treatment protocol, it is not recommended as 
a ﬁ rst-line treatment due to the partial response and the risk of Koebnerization. The 
heterogeneous ﬂ uorescence pattern observed with FDAP may be responsible for this. As 
a consequence, an inhomogeneous photodynamic dose is delivered over the epidermal 
surface resulting in areas with extensive and areas with minimal photodynamic damage. 
Fluorescence measurements indicate abundant amounts of intralesional PpIX in highly 
ﬂ uorescing areas, even after the second illumination pointing at 10% ALA for 4 hours 
to be suﬃ  cient to induce signiﬁ cant amounts of PpIX. The minimal photobleaching 
observed after the ﬁ rst illumination indicates the current fraction scheme to be 
suboptimal, requiring a higher ﬂ uence for the ﬁ rst illumination. Histologically, already 
after one treatment pronounced anti-psoriatic eﬀ ects were observed in the epidermis, 
reﬂ ected by a decrease in Ki67 expression and increase in K10 expression. Eﬀ ects on T 
cell subsets were not seen until week 6. It may well be imaginable that due to a reduced 
photodynamic dose at the deeper layers of the skin, as a result from impaired penetration 
of the light as well as the photosensitizer, multiple PDT treatments are required to exert 
signiﬁ cant dermal eﬀ ects. 
AIM IIb To study preferential accumulation of PpIX within psoriatic plaques by means of FDAP and to correlate this to histologic 
morphology and immunohistochemical psoriatic activity markers. 
In an additional study, described in paragraph 3.2, the heterogeneous ﬂ uorescence 
observed in the previous study was further studied. To address the question whether 
the heterogeneous ﬂ uorescence could be related to psoriatic activity or the limited 
penetration of the photosensitizer and/or light due to hyperkeratosis, FDAP was 
performed on psoriatic plaques following incubation with 20% ALA for 3 hours, after 
keratolytic pre-treatment. Biopsies, taken from high- and low ﬂ uorescing sites within the 
plaques, were analyzed by (immuno)histochemistry to assess histological morphology 
(stratum corneum thickness) and psoriatic activity using markers for proliferation (Ki67), 
keratinization (K10, ﬁ laggrin) and inﬂ ammation (CD3). 
No diﬀ erences were found in the activity markers between the high and low ﬂ uorescing 
sites. However, a signiﬁ cantly thinner stratum corneum was found in the biopsies taken 
from the high ﬂ uorescing lesions compared with the low ﬂ uorescing lesions. When the 
stratum corneum thickness was correlated to macroscopic ﬂ uorescence acquired with 
FDAP, a negative correlation was found, indicating hyperkeratosis to be a signiﬁ cant 
hindering factor with respect to ALA-induced accumulation of PpIX. Apparently, pre-
treatment of the lesions with 10% salicylic acid in petrolatum once daily for one week 
was not suﬃ  cient to remove all hyperkeratosis. 
Therefore, based on these data, removal of hyperkeratosis prior to the treatment seems 
an important way to optimize PDT in psoriasis, and probably in other skin conditions 
too. Consequently, a homogeneous photodynamic dose is delivered over the entire 
epidermal surface, minimizing the chance of Koebnerization and suboptimal PDT as a 
result of an insuﬃ  cient ﬂ uence. Considering the fact that psoriasis is a T cell mediated 
disease and PDT has its main eﬀ ects in the epidermis, targeting of dermal structures such 
as T cells without causing excessive photodynamic damage to the epidermis, probably 
requires multiple sessions of low dose PDT. Thus, the clinical eﬃ  cacy of PDT in psoriasis 
seems to be strongly dependent on the deliverance of an adequate photodynamic 
dose to the various targets in the skin, unlike PDT in NMSC, in which massive epidermal 
cytotoxicity is required. So, our data are consistent with the general assumption that 
modulation of the immune system by PDT, which is the main target in the treatment of 
inﬂ ammatory skin diseases, requires a treatment protocol consisting of multiple sessions 
with a low photodynamic dose.144
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5.3 Fluorescence diagnosis and DNA aneuploidy in
 keratinocytic intraepidermal neoplasias: in 
 search of a clinically useful progression-marker
AIM IIIa To study DNA aneuploidy and proliferation in diﬀ erent stages of KIN and to assess their roles as potential progression 
markers.   
In paragraph 4.1, DNA aneuploidy and proliferation were studied in diﬀ erent stages of 
KIN to assess their roles as potential progression markers. Therefore, biopsy specimens 
from patients with NMSC were analyzed with quantitative DNA ﬂ ow cytometry (FCM) to 
assess ploidy status and cell-cycle characteristics. Furthermore, (immuno)histochemistry 
was performed to assess KIN-grade and Ki67 expression. 
Aneuploidy was found more frequently in lesions with higher KIN-grade, but not 
in normal skin. In microinvasive SCC (miSCC) however, aneuploidy was found less 
frequently compared with KIN III lesions. The type of aneuploidy could be classiﬁ ed as 
hypotetraploidy with DNA indices from KIN I/II, KIN III lesions and miSCC of 1.71, 1.57 and 
1.62 respectively, indicating increased DNA content. Furthermore, aneuploidy appeared 
to be independent of immune status. Assessment of the proliferative compartment with 
FCM (% SG2M cells), revealed a positive correlation between the number of proliferative 
cells and increasing KIN-grade. Analogously, an even stronger correlation was found 
between KIN-grade and the immunohistochemical proliferation marker Ki67-antigen. 
Thus, aneuploidy is a frequently occurring event in (pre)malignancies and is associated 
with (cutaneous) carcinogenesis. Interestingly, aneuploidy was less frequently found 
in miSCC compared with KIN III lesions, which is in conﬂ ict with the assumption that 
progression from AK to miSCC is a serial process in which DNA damage increasingly 
accumulates with increasing KIN-grade ultimately leading to invasive carcinoma, as 
proposed by the KIN-classiﬁ cation. The lower DNA index found in miSCC compared 
with KIN III lesions is in accordance with this. Thus, from a cytogenetically point of view, 
miSCC lesions have more in common with KIN I/II lesions compared with KIN III lesions. 
This could mean that in KIN I/II lesions a subclone or multiple subclones of atypical 
keratinocytes are able to break through the basement membrane into the papillary 
dermis to become invasive SCC even before the upper layers of the epidermis have had a 
chance to show nuclear atypia. In addition, KIN III lesions were found to have decreased 
DNA indices compared with KIN I/II samples. Assuming serial progression from KIN 
I/II to KIN III lesions, this indicates decreases in DNA content (chromosomal losses) 
during KIN progression and is in parallel with the general hypothesis that polyploidy/
tetraploidy followed by aneuploidy is a frequent and early event in tumorigenesis. In 
addition, in two recent articles it is suggested that chromosomal non-disjunction results 
in tetraploidization and that the tetraploid state is associated with a predisposition to 
tumorigenesis in the absence of functional p53.284;349 As p53 is frequently mutated in 
cutaneous (pre)malignancies, this ﬁ ts well into the whole story.
In conclusion, the current data indicate malignant transformation from early KIN to 
invasive SCC not to be straightforward. However, aneuploidy as measured with our 
ﬂ ow cytometrical technique only provides quantitative data; what this actually means 
in terms of tumor suppressor gene (dys)function cannot be derived from these data. In 
addition, other factors such as the immune system may also inﬂ uence the progressive 
course of a squamous (pre)malignancy. Therefore, aneuploidy does not seem to be a 
good progression marker for invasive disease. Proliferation was found to be strongly 
correlated with KIN-grade, which indicates that nuclear atypia parallels hyperproliferation 
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in epidermal keratinocytes and makes Ki67 a good marker for keratinocytic nuclear 
atypia consequently.
AIM IIIb To evaluate the value of FDAP as a diagnostic tool to discriminate between diﬀ erent stages of keratinocytic 
intraepidermal neoplasias (KIN, conventionally classiﬁ ed as AK or Bowen’s disease) or proliferative status.
The potential value of FDAP as a non-invasive diagnostic procedure to discriminate 
between diﬀ erent stages of keratinocytic intraepidermal neoplasias is described in 
paragraph 4.2. In this study, FDAP was performed in patients with ﬁ eld-cancerization 
after keratolytic pre-treatment. Subsequently biopsies from diﬀ erent lesions were 
taken. (Immuno)histochemistry was performed on these biopsies for histopathological 
classiﬁ cation, using the KIN- as well as conventional classiﬁ cation, and assessment of 
Ki67-antigen expression and stratum corneum thickness. 
Although KIN III lesions tended to have increased lesional:non-lesional ﬂ uorescence ratios 
compared with KIN I and KIN II lesions, no statistically signiﬁ cant diﬀ erences between 
the diﬀ erent KIN lesions could be demonstrated. Six lesions classiﬁ ed as verrucous 
hyperkeratoses had signiﬁ cantly lower ﬂ uorescence ratios (mostly around 1) compared 
with normal skin, KIN I, KIN III and miSCC. The three SCCs that were biopsied had 
signiﬁ cantly higher ﬂ uorescence ratios compared with KIN II lesions and the verrucous 
hyperkeratoses. Analysis of proliferative activity as assessed by immunoreactivity for the 
Ki67 antigen also did not reveal any signiﬁ cant diﬀ erences in ﬂ uorescence ratios among 
the three levels of Ki67 expression, which is not surprising since Ki67 expression and KIN 
grade are highly correlated. However, when the lesions were divided into four diagnostic 
categories (true/false positives/negatives), with a ﬂ uorescence ratio of 1.0 taken as a cut-
oﬀ  value and KIN lesions/SCC and verrucous hyperkeratoses/normal skin classiﬁ ed as (pre)
malignant and benign lesions, respectively, lesions with a ﬂ uorescence intensity lower 
than surrounding skin (ﬂ uorescence ratio < 1.0; true and false negatives) were found to 
have a signiﬁ cantly lower number of Ki67+ cells than lesions with a ﬂ uorescence ratio 
greater than 1.0 (true and false positives). Additionally, when Ki67 immunoreactivity from 
all four diagnostic categories was mutually compared, a signiﬁ cant diﬀ erence between 
the false- and true-positive lesions and between the true-positive and -negative lesions 
was found. However, the reason for this would probably be the relative high number 
of true positive lesions which were mostly all hyperproliferative lesions. So, proliferative 
activity seems to be a confounder rather than the cause of high ﬂ uorescence.
When macroscopic ﬂ uorescence values were plotted against the stratum corneum 
thickness, a negative correlation was found indicating hyperkeratosis to be an 
important hindering factor with respect to PpIX accumulation. Analogously, lesions 
with a ﬂ uorescence intensity lower than surrounding skin (ﬂ uorescence ratio < 1.0; true 
and false negatives) had a signiﬁ cantly thicker stratum corneum than lesions with a 
ﬂ uorescence ratio greater than 1.0 (true and false positives). Moreover, in the true- and 
false-positive lesions the mean stratum corneum thickness was found to be signiﬁ cantly 
lower compared with the false-negative lesions. A summary of these data can be found 
in table II in paragraph 4.2. 
From the above it was concluded that FDAP cannot be used to discriminate between 
various KIN-stages. However a tendency towards higher macroscopic ﬂ uorescence 
was observed in KIN III lesions compared with KIN I/II lesions. This may be related to an 
increased number of epidermal cells in KIN III lesions (epidermal hyperplasia). Although 
there was a tendency towards an increased stratum corneum thickness in KIN III lesions 
compared with KIN I/II lesions, no statistically signiﬁ cant diﬀ erences were found. It may 
be imagineable that a slight thicker stratum corneum in KIN III lesions could decrease 
the ﬂ uorescence contrast between the KIN I/II and KIN III lesions. Considering the high 
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ﬂ uorescence observed in SCC, it might be interesting to perform further studies whether 
FDAP can be useful to discriminate between KIN and invasive carcinoma. Furthermore, 
macroscopic ﬂ uorescence seems independent of proliferative status but it is negatively 
correlated with stratum corneum thickness. Despite the fact that the patients in our 
study received a keratolytic pre-treatment with salicylic acid in petrolatum for 1-2 weeks 
prior to FDAP, hyperkeratosis still seemed to be responsible for variations in macroscopic 
ﬂ uorescence. As penetration of the hydrophilic ALA through the lipophilic stratum 
corneum is a prerequisite for PpIX formation, adequate keratolytic pre-treatment is 
essential for optimal results with PDT and FDAP.
5.4 General conclusions 
In this paragraph the general conclusions of this thesis are brieﬂ y summarized.
Psoriasis and AK preferentially accumulate PpIX compared with their non-lesional • 
skin following application of ALA.
Psoriasis shows a higher lesional : non-lesional PpIX ﬂ uorescence ratio as compared • 
to AK.
The higher macroscopic PpIX ﬂ uorescence observed with FDAP in AK is caused by • 
an increased number of PpIX-containing epidermal cells, while in psoriasis increased 
penetration through the stratum corneum also plays a role. 
The positive linear correlation found between macroscopic PpIX ﬂ uorescence and • 
PpIX content in the skin demonstrates that FDAP can be used to estimate PpIX 
content in the skin.
The fact that e• x vivo, no diﬀ erences in PpIX accumulation were found between 
diﬀ erent skin conditions, indicates a prominent role for the stratum corneum 
explaining the PpIX ﬂ uorescence diﬀ erences observed in vivo.
The suprabasal PpIX ﬂ uorescence pattern observed with ﬂ uorescence microscopy • 
within the epidermis which was conﬁ rmed by ﬂ ow cytometry, points at preferential 
accumulation of PpIX in diﬀ erentiated cells.
Fractionated ALA-PDT, but not placebo-PDT, was able to clinically improve psoriasis. • 
Fractionated ALA-PDT in psoriasis is able to reduce proliferation and relevant T cell • 
subsets and to normalize keratinization histologically, which were not seen after 
placebo-PDT. 
The heterogeneous ﬂ uorescence pattern observed with FDAP in psoriatic plaques, • 
cannot be explained by diﬀ erences in psoriasis activity markers but only by 
diﬀ erences in stratum corneum thickness, which was negatively correlated with 
ﬂ uorescence intensity.
Aneuploidy is more frequently found in lesions with higher KIN-grade. KIN III lesions • 
more frequently show aneuploidy compared with miSCC.
From a cytogenetically point of view, by comparing their DNA indices, KIN I/II lesions • 
have more in common with miSCC compared with KIN III lesions, indicating serial 
progression through all KIN-stages towards invasive SCC not to be straightforward.
FDAP is unsuitable to discriminate between lesions with diﬀ erent KIN-grade.• 
The negative correlation between macroscopic ﬂ uorescence and stratum corneum • 
thickness in AK, indicates hyperkeratosis to be a crucial factor in interlesional 
variations in PpIX ﬂ uorescence.
Macroscopic ﬂ uorescence intensity observed with FDAP is independent of • 
proliferative activity assessed with Ki67 expression.
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5.5 General discussion and recommendations for 
 the future
While reading paragraph 1.5.3 of this thesis, it becomes clear that still very limited data 
are available on the precise mechanisms involved in the preferential accumulation of 
PpIX in lesional tissue. Conﬂ icting data between the numerous studies can mostly be 
explained by the diﬀ erent models and conditions used in these studies. In addition, 
numerous factors, as described in paragraph 1.5.3.3, have been identiﬁ ed to inﬂ uence 
PpIX accumulation that may also hinder the coherence of these data.
Nonetheless, the excellent clinical results observed with PDT have made it to become 
a standard treatment modality for various forms of NMSC nowadays. However, there is 
still a signiﬁ cant number of lesions that show clinical recurrence within 3 years after PDT 
including some superﬁ cial and nodular BCCs in particular.171 A better understanding of 
the (preferential) accumulation of PpIX in these lesions may help to improve therapeutic 
eﬃ  cacy of PDT furthermore and the reliability of FDAP as a non-invasive diagnostic 
procedure possibly as well. 
From the studies described in chapters 2-4 in this thesis some general conclusions can be 
drawn which are presented and discussed below.
5.5.1 Proposed model for PpIX accumulation in psoriasis, actinic keratosis
 and normal skin
The process of PpIX accumulation is a complex and multistep process, which generally 
includes 3 phases the photosensitizer has to go through: (I) penetration through the 
stratum corneum, (II) cellular uptake and (III) metabolic conversion into porphyrins. 
Diﬀ erences in these phases between diﬀ erent tissue types account for the diﬀ erent 
pharmacokinetics and –dynamics of PpIX accumulation. These are intrinsic factors 
(properties of the tissue) but there are also extrinsic factors that inﬂ uence PpIX 
accumulation, such as the speciﬁ c properties of the drug used (e.g. vehicle, concentration, 
application time). 
In this thesis, studies on PpIX accumulation were performed in AK and psoriasis which 
both have in common to be hyperproliferative skin conditions. However, they signiﬁ cantly 
diﬀ er from each other by the fact that AK is a (pre)malignancy, while psoriasis is an 
benign inﬂ ammatory disease. Normal skin was included to serve as a control. From these 
studies, some general conclusions can be drawn with respect to PpIX accumulation in 
these skin conditions. These are discussed below and are summarized in ﬁ gure 19. The 
numbers between brackets in the text correspond to the numbers in this ﬁ gure. In (3) 
the situation of ALA penetration through a normal stratum corneum is displayed.
Proliferation does not appear a determinant of PpIX accumulation, since no correlation 
was found between Ki67 expression and macroscopic ﬂ uorescence intensity acquired 
with FDAP. This is in accordance with various in vitro studies, in which no obvious cell-
cycle dependency could be demonstrated but only a cell volume dependency with 
respect to PpIX accumulation.65;66 The preferential accumulation of PpIX in suprabasal 
cells, which are mostly non-proliferating cells, described in chapter 2 is also in parallel with 
this. Diﬀ erences in the PpIX synthetic capacity of biopsies from psoriasis, AK and normal 
skin could also not be demonstrated, which indicates that the variations in macroscopic 
ﬂ uorescence intensity observed with FDAP cannot be explained by diﬀ erences in the 
heme-biosynthetic pathway and/or uptake of ALA between these skin conditions. 
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Stratum corneum thickness however, was shown to be negatively correlated with PpIX 
ﬂ uorescence in AK as well as psoriasis. Hyperkeratosis (2) appears to be responsible for 
variations in PpIX ﬂ uorescence within lesional skin of psoriasis but also between diﬀ erent 
AK lesions. However, increased accumulation of PpIX in lesional skin compared with non-
lesional skin cannot be explained solely by diﬀ erences in stratum corneum thickness, 
since AK lesions and psoriatic plaques are both hyperkeratotic lesions. Since diﬀ erences 
in the PpIX synthetic capacity between these tissues do not play a prominent role as 
stated earlier, there must be another factor to explain this.
Disruptions in the stratum corneum integrity (1) have been reported as a possible 
explanation for the preferential accumulation of PpIX in lesional skin in NMSC (see 
paragraph 1.5.3.2 and ﬁ gure 6). Furthermore, Von Beckerath et al. showed PpIX ﬂ uorescence 
to be higher in chronically UV-exposed skin compared to UV-exposed skin which was 
shortly irradiated with UV light and hypothesized structural abnormalities in the stratum 
corneum of actinically damaged skin to enhance ALA penetration.31 However, disruptions 
in stratum corneum integrity cannot explain the higher macroscopic ﬂ uorescence found 
in lesional skin of AK, since comparable amounts of PpIX per cell were found between 
lesional and non-lesional skin in AK (chapter 2). As lesional skin in AK contains signiﬁ cantly 
more dsDNA compared with surrounding skin, preferential accumulation of PpIX in 
lesional skin from AK observed with FDAP may therefore be explained by an increased 
number of PpIX-containing cells (5), increasing the PpIX quantum yield consequently. 
This may also explain the tendency towards the higher macroscopic ﬂ uorescence 
observed in KIN III lesions compared with KIN I/II lesions described in paragraph 4.2, 
since epidermal hyperplasia is a prominent feature in BD. A slight tendency towards 
an increased stratum corneum thickness was observed in KIN III lesions compared with 
KIN I/II lesions which may possibly explain why no signiﬁ cant diﬀ erences were found in 
macroscopic ﬂ uorescence between these lesions, but this was not statistically signiﬁ cant. 
In psoriasis, an increased number of PpIX-containing cells (5) may also play a role since 
lesional psoriatic skin is also characterized by an increased number of cells (epidermal 
hyperplasia) compared with non-lesional skin. However, the relatively high ﬂ uorescence 
compared with AK observed with FDAP and increased PpIX-content per cell in lesional 
psoriatic skin suggest another mechanism. Disruptions in stratum corneum integrity 
have also been reported in psoriasis and have been correlated to psoriatic phenotype.43 
Consequently, penetration of ALA in lesional psoriatic skin may be increased resulting in 
an increased PpIX content per cell, compared with non-lesional psoriatic skin.
Once ALA has entered the epidermis, it is preferentially converted to PpIX by suprabasal 
keratinocytes in normal appearing skin (4). Whether this is caused by an increased 
activity of the enzymes in the heme-cycle and/or increased uptake of ALA into the cell 
remains unknown.  
Thus, the skin barrier (stratum corneum) has a prominent role in the explanation of 
variations in macroscopic ﬂ uorescence acquired with FDAP and the variable treatment 
success of PDT most probably. Variations in stratum corneum thickness (hyperkeratosis) 
are responsible for intra- and interlesional variations in macroscopic ﬂ uorescence. 
Disruptions in stratum corneum integrity, which are associated with pathological skin 
conditions, also play an important role and are primarily responsible for preferential 
accumulation of PpIX in lesional psoriatic skin. Also, the number of PpIX-accumulating 
cells plays an important role. Macroscopic ﬂ uorescence intensity is the net result of 
these processes. Thus can be explained why a hyperkeratotic psoriatic lesion may show 
increased PpIX ﬂ uorescence compared with its non-hyperkeratotic surrounding skin.     
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5.5.2 Photodynamic therapy in psoriasis: in search of a suitable treatment
 protocol
Although PDT has been shown to histologically as well as clinically improve psoriasis, 
currently it cannot be recommended as a ﬁ rst-line therapy because of the variable and 
partial clinical responses. As described in chapter 3, the treatment was relatively well 
tolerated but when larger body surface areas are treated, as with UV phototherapy, pain 
and side-eﬀ ects may become too severe. Since psoriatic plaques are characterized by 
hyperkeratosis, are highly susceptible to Koebnerization and because its targets for PDT 
are localized in the deeper layers of the skin, deliverance of an adequate photodynamic 
dose is challenging. Although with adequate keratolytic pre-treatment and dosimetry 
results may be expected to improve, an optimal treatment protocol has yet to be 
established. 
In a recent study by Wiegell and colleagues, the clinical eﬃ  cacy of MAL-PDT for the 
treatment of AKs on the face and scalp was studied using a non-established protocol.350 
After incubation with MAL for half an hour under an occlusive dressing, patients were 
sent outdoors for 2.5 hours after removal of the occlusive dressing but not the cream 
to receive ‘daylight’-PDT on one side of the face or scalp. The other side of the face or 
scalp was subsequently treated with 37 J/cm2 red light according to the standard 
protocol. Interestingly, clinical eﬃ  cacy of daylight-PDT was comparable to MAL-PDT 
using the standard treatment protocol. PpIX ﬂ uorescence, which was measured during 
the incubation period, remained much lower in the daylight exposed site compared to 
the site that was covered with an occlusive dressing, due to continous activation of PpIX 
during the incubation period. Daylight-PDT was also signiﬁ cantly less painful compared 
with conventional PDT. By calculating the relative eﬀ ective ﬂ uences, daylight proved to 
be more than capable of activating PpIX compared with red light, since daylight is also 
composed of the various wavelengths outside the red light range, such as blue light, 
that are relatively more eﬀ ective than red light to activate PpIX. Since pain may be an 
important limitation of PDT, daylight-PDT may be an interesting new concept in the 
photodynamic treatment of psoriasis. If continuous daylight exposure results in increased 
activation of PpIX in the superﬁ cial layers of the skin, less MAL/ALA may penetrate to the 
deeper layers resulting in inadequate treatment of the deeper lesions, which may be a 
theoretical drawback. However, considering the fact that this treatment is well tolerated 
and can be easily performed by the patient and physician, it would be interesting to 
evaluate this treatment protocol in psoriasis. It is likely that multiple treatments over 
a longer period of time may be more eﬀ ective. Since PDT is considered a safe therapy, 
without cumulative toxicity, this would be of no concern. Maybe someday ALA cream (or 
an ALA containing sunscreen) will have a role in the topical treatment of psoriasis. 
5.5.3 Fluorescence diagnosis and aneuploidy as diagnostic tools in NMSC
As already discussed in paragraph 1.5.6, according to the results from the various 
clinical studies on FDAP in the skin, FDAP can still not be regarded as a valid substitute 
for histopathology. Most studies have been performed in BCC, mostly as an additional 
tool to demarcate these lesions, but data in squamous (pre)malignancies are scarce. 
Squamous (pre)malignancies are associated with increased cumulative UV damage and 
ﬁ eld-cancerization as they preferentially occur on sun-exposed sites. In typical patients 
with widespread actinic damage, multiple biopsies may be necessary to discriminate the 
malignant lesions from the premalignancies. In paragraph 4.2, FDAP was performed in 
KINs, in order to assess its role in ﬁ eld-cancerization.
In this thesis the stratum corneum has been shown to play an important role in PpIX 
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ﬂ uorescence acquired with FDAP. This is accordance with previous reports in literature 
and apart from this, according to this thesis, no other factors have been found to explain 
the diﬀ erences in macroscopic ﬂ uorescence acquired with FDAP between diﬀ erent 
tissue types.13-25 In psoriasis, stratum corneum integrity plays an important role in 
preferential lesional ﬂ uorescence, in contrast to AK. Between diﬀ erent KIN lesions no 
diﬀ erences in ﬂ uorescence were seen with FDAP, although KIN III lesions tilted towards 
higher ﬂ uorescence, which may probably be explained by an increased number of cells 
in KIN III lesions, although this remains speculative. Therefore, the clinical application of 
FDAP as a diagnostic tool to discriminate between diﬀ erent AK lesions of diﬀ erent KIN-
grade appears to be limited. Since increased PpIX ﬂ uorescence was recorded in three 
SCCs, further studies must be performed to demonstrate whether FDAP can be used 
to discriminate between in situ AKs and invasive SCC. Again, adequate keratolytic pre-
treatment seems to be crucial for optimal results since a negative correlation was found 
between the stratum corneum thickness and macroscopic ﬂ uorescence. 
So, with the current protocol described in paragraph 4.2, FDAP has no additional value 
in the discrimination of KIN lesions. Encouraging results point at a possible role for FDAP 
to discriminate KIN lesions from SCCs but this has yet to be established. For investigative 
purposes, FDAP is an interesting tool to study PpIX accumulation in vivo and may be 
helpful in optimizing PDT and the exploration of new indications for PDT.  
Aneuploidy was found increasingly in higher KIN lesions, but in SCC it was less frequently 
found. With respect to DNA indices and aneuploidy frequencies, KIN I/II lesions have more 
in common with SCC lesions compared with KIN III lesions. Hence, serial progression 
through all KIN-stages towards SCC with the progressive accumulation of DNA damage, 
seems not to be an exclusive route towards malignancy. Although aneuploidy is a 
malignancy-speciﬁ c cell marker with several aspects correlating with malignancy-
grade, tumor stage and prognosis in various cancers, in squamous skin cancers it does 
not appear to be a good marker for early invasive disease. Growing knowledge on 
the molecular mechanisms involved in cutaneous carcinogenesis, may one day yield 
a clinically useable progression marker. For now, AKs should be regarded as early skin 
cancers which require adequate treatment.   
Figure 19: Proposed model for PpIX accumulation in psoriasis, AK and normal skin.
An explanation of the numbers in this ﬁ gure can be found in paragraph 5.5.1.
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 S AM E N VAT T I N G  E N  A LG E M E N E  D I S C U S S I E
 
 Accumulatie van protoporfyrine-IX in actinische
 keratose, psoriasis en normale huid na applicatie 
 van aminolevulinezuur en de correlatie met 
 fl uorescentie diagnostiek
Ia Het bestuderen van het PpIX-gehalte in laesionale en non-laesionale huid in AK en psoriasis in vivo na applicatie van 
ALA en dit te correleren aan de PpIX ﬂ uorescentie gemeten met FDAP. 
In paragraaf 2.1, werd PpIX accumulatie bestudeerd in patiënten met AK en psoriasis na 
applicatie van 20% ALA crème. Hierna werd FDAP uitgevoerd en werden biopten genomen 
van laesionale en non-laesionale huid. In deze biopten werd spectroﬂ uorimetrisch het 
PpIX-gehalte gemeten. Deze waarden werden vergeleken met de ﬂ uorescentie waarden 
verkregen met FDAP, om te kijken of macroscopische ﬂ uorescentie gemeten met FDAP 
gebruikt kan worden als een maat voor het PpIX-gehalte in de huid. In tabel 1 in paragraaf 
2.1 wordt een samenvatting gegeven van de resultaten. In laesionale huid van patiënten 
met AK en psoriasis werd een verhoogde PpIX ﬂ uorescentie gevonden vergeleken met 
non-laesionale (omliggende) huid. Bovendien, werd er hogere laesionale : non-laesionale 
huid ﬂ uorescentie ratio gevonden in psoriasis vergeleken met AK (1.77 versus 1.37). Het 
PpIX-gehalte was ook hoger in laesionale huid van psoriasis en AK, met laesionale : non-
laesionale huid ﬂ uorescentie ratio’s van respectievelijk 4.1 en 2.0. Wanneer het PpIX-
gehalte (per biopt) tussen de vier huidaandoeningen werd vergeleken, bleek deze hoger 
in laesionale huid van psoriasis vergeleken met de andere huidaandoeningen (ﬁ guur 
2). Laesionale huid in AK bevatte ook meer PpIX per biopt vergeleken met omliggende 
huid. Echter, na correctie voor het aantal cellen, door middel van dsDNA als epidermale 
referentie, bleek alleen laesionale huid in psoriasis signiﬁ cant meer PpIX te bevatten 
vergeleken met omliggende huid. Dit impliceert dat de verhoogde ﬂ uorescentie 
gemeten met FDAP en het PpIX-gehalte per biopt in laesionale huid van AK (vergeleken 
met omliggende huid) niet verklaard kan worden door een verhoogd PpIX-gehalte per 
cel, maar slechts door een verhoogd aantal cellen, weerspiegeld door een verhoogde 
hoeveelheid dsDNA in laesionale huid van AK (ﬁ guur 3). De verhoogde hoeveelheid PpIX 
per cel in laesionale huid van psoriasis zou het resultaat kunnen zijn van een verhoogde 
penetratie van ALA door een pathologisch stratum corneum in laesionale huid van 
psoriasis en/of verhoogde PpIX-synthese door de keratinocyten in psoriasis huid. Omdat 
in laesionale huid van psoriasis ook een verhoogd aantal cellen (hoeveelheid DNA) werd 
gevonden vergeleken met non-laesionale huid, zou dit ook kunnen bijdragen aan de 
verhoogde macroscopische ﬂ uorescentie intensiteit in laesionale huid van psoriasis 
gemeten met FDAP, net als bij AK.
Wanneer de ﬂ uorescentie waarden verkregen met FDAP werden vergeleken met 
het PpIX-gehalte in de huid, werd er een positief lineair verband gevonden (ﬁ guur 9). 
Echter, bij hogere PpIX-waarden loopt de helling van de curve horizontaler, wat mogelijk 
verklaard kan worden door de beperkte penetratie diepte van het blauwe excitatie licht 
van het digitale beeldverwerkingssysteem. Hierdoor, zou PpIX in de diepere lagen van 
de huid niet volledig geactiveerd kunnen worden. Dit is een belangrijke beperking 
van FDAP hetgeen men zich dient te beseﬀ en wanneer men deze procedure gebruikt. 
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Echter, de macroscopische ﬂ uorescentie waarden en het PpIX-gehalte in AK waren laag 
genoeg om perfect op het eerste gedeelte van de lijn te passen (r=0.79). De beperkte 
penetratie diepte van het blauwe licht zal dus geen probleem zijn wanneer FDAP wordt 
gebruikt bij AK. De vraag blijft echter of dit een probleem zal zijn bij het uitvoeren van 
FDAP bij invasieve carcinomen zoals het BCC en PCC. op Dus, FDAP zoals uitgevoerd in 
deze studie, lijkt een goede methode om het PpIX-gehalte in de huid te schatten, met 
name in het lagere ﬂ uorescentie bereik.
Ib Het bestuderen van PpIX accumulatie zonder invloeden van het stratum corneum in laesionale en non-laesionale huid 
in AK, psoriasis en normale huid na applicatie van ALA.
In paragraaf 2.2 wordt een onderzoek gepresenteerd waarin enkele overgebleven 
vraagstukken uit de vorige paragraaf worden beantwoord door middel van het 
bestuderen van PpIX accumulatie zonder invloed van het stratum corneum. In dit 
onderzoek werd PpIX accumulatie ex vivo in huid biopten van laesionale en non-laesionale 
huid van psoriasis en AK bestudeerd. Biopten van normale huid dienden als controle. 
De huidbiopten (explantaten) werden geincubeerd in een kweek medium verrijkt met 
ALA en na 16 uur werden PpIX, alsmede dsDNA, geëxtraheerd en spectroﬂ uorimetrisch 
gemeten. Omdat de penetratie route van ALA door het stratum corneum in dit model 
wordt omzeild, konden de intrinsieke aﬃ  niteit van de verschillende huidcondities om 
PpIX te accumuleren (haem-synthese) worden bestudeerd. Een verhoogde hoeveelheid 
PpIX per biopt werd gevonden in (laesionale en non-laesionale) psoriasis huid vergeleken 
met AK. Echter, een vergelijkbare hoeveelheid werd gevonden in normale huid van 
gezonde vrijwilligers (ﬁ guur 1). Na correctie door middel van dsDNA werden geen 
signiﬁ cante verschillen gevonden tussen de vijf huidcondities, hoewel non-laesionale 
huid in psoriasis en AK een tendens vertoonde naar verhoogde PpIX hoeveelheden 
vergeleken met laesionale huid. Dit wijst op het feit dat het verhoogde PpIX-gehalte en 
macroscopische ﬂ uorescentie gemeten met FDAP in laesionale huid van psoriasis en AK, 
zoals beschreven in paragraaf 2.1, niet verklaard kan worden door een verhoogd PpIX-
metabolisme. Derhalve lijken de vijf huidcondities even capabel om PpIX te produceren. 
Het verhoogde PpIX-gehalte per cel in laesionale huid in psoriasis, zoals beschreven in 
paragraaf 2.1, moet dus het gevolg zijn van verhoogde penetratie van ALA door een 
pathologisch stratum corneum. 
Ic Het bestuderen van de preferentiële accumulatie van PpIX in de epidermis, om de doelcellen voor PDT en FDAP te 
karakteriseren.
Om na te gaan of ALA penetratie en PpIX accumulatie homogeen waren door de biopten 
heen, werd ﬂ uorescentie microscopie verricht op enkele huidexplantaten. Er werd een 
homogene distributie van PpIX gezien over de gehele lengte van de epidermis, maar 
interessant genoeg werd er minder PpIX ﬂ uorescentie gezien in de basale lagen van de 
epidermis. Aangezien preferentiële accumulatie van PpIX beschreven is gediﬀ erentieerde 
cellen, werden aanvullende studies verricht om het PpIX-gehalte te kwantiﬁ ceren in 
de basale en suprabasale lagen van de epidermis. Daartoe werden huidexplantaten 
van normale huid geïncubeerd met ALA en werd het PpIX-gehalte gemeten met ﬂ ow 
cytometrie in de basale en suprabasale keratinocyten met β1-integrine als een marker 
om deze cellen te onderscheiden. In overeenstemming met de resultaten van de 
ﬂ uorescentie microscopie, werd een signiﬁ cant verhoogd PpIX-gehalte gevonden in 
suprabasale keratinocyten, wat indicatief is voor preferentiële accumulatie in terminaal 
gediﬀ erentieerde keratinocyten.
Er werden verdere onderzoeken in gekweekte keratinocyten verricht om de relatie 
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tussen terminale diﬀ erentiatie en PpIX accumulatie nader te onderzoeken. Tijdens 
verschillende groeifasen werden cellen geïncubeerd met ALA en vervolgens werd 
PpIX gemeten. Er werd signiﬁ cant meer PpIX aangemaakt in conﬂ uente celkweken, 
die een hogere mate van diﬀ erentiatie vertonen, vergeleken met subconﬂ uente 
celkweken, die een exponentiële groei vertonen en slecht gediﬀ erentieerd zijn. Deze 
gegevens ondersteunen de eerder geopperde preferentiële accumulatie van PpIX in 
terminaal gediﬀ erentieerde cellen. Echter, in een ander in vitro experiment, waarin 
dezelfde gekweekte keratinocyten werden gekweekt totdat ze geheel conﬂ uent waren, 
induceerde het weglaten van groeifactoren uit het kweek medium, wat een bekende 
manier is om diﬀ erentiatie te induceren, minder PpIX-productie per cel na incubatie met 
ALA vergeleken met cellen die doorgroeiden. Metingen van het totale PpIX-gehalte per 
celkweek toonde vervolgens vergelijkbare hoeveelheden PpIX in de twee verschillende 
celkweken. Deze bevindingen kunnen worden verklaard door een groter celvolume van 
de gediﬀ erentieerde cellen met als gevolg een verlaagd PpIX-gehalte per cel. Eventuele 
toenames in PpIX-synthese in gediﬀ erentieerde cellen zouden kunnen zijn gemaskeerd 
door een groter celvolume.
Huidexplantaten van biopten van psoriasis, AK en normale huid lijken alle even capabel 
om PpIX te accumuleren. In laesionale huid van psoriasis, lijkt de verstoorde integriteit 
van het stratum corneum een belangrijke rol te spelen, zodat er meer ALA door de 
epidermis kan doordringen en kan worden opgenomen door epidermale keratinocyten 
om vervolgens PpIX te produceren. In AK, zou dit ook een rol kunnen spelen, alleen kan 
dit de preferentiële accumulatie in laesionale huid gemeten met FDAP, welke wordt 
veroorzaakt door een verhoogd aantal PpIX-bevattende cellen, niet geheel verklaren. 
Preferentiële accumulatie van PpIX in suprabasale keratinocyten van normale huid, 
vastgesteld met ﬂ uorescentie microscopie en ﬂ ow cytometrie, zou dus kunnen wijzen 
op een terminale diﬀ erentiatie speciﬁ ek eﬀ ect.
 PDT en FDAP in psoriasis
IIa Het evalueren van de klinische en histologische eﬀ ecten van PDT en PpIX ﬂ uorescentie tijdens PDT in psoriasis. 
In paragraaf 3.1 werden de klinische en immunohistochemische eﬀ ecten van 
de fotodynamische behandeling van psoriasis bestudeerd. Na een keratolytische 
voorbehandeling met 10% salicylzuur in vaseline, werden unilaterale plaques 
behandeld met 10% ALA gedurende 4 uur gevolgd door twee belichtingen van 2 
en 8 J/cm2 (Waldmann PDT 1200 L, 40 mW/cm2) met tussentijds een donkere periode 
van 2 uur, eenmaal per week gedurende 4 weken. Contralaterale plaques werden na 
voorbehandeling behandeld met placebo-PDT. Voor en na PDT werd FDAP uitgevoerd 
om fotodegradatie van PpIX te bepalen. De ernst van de psoriasis werd klinisch bepaald 
door middel van de SUM-score. Om de histologische eﬀ ecten van ALA-PDT te bestuderen 
werden biopten genomen bij aanvang, na 1 week en na week 6 (2 weken na de laatste 
behandeling) welke immunohistochemisch werden onderzocht met markers voor 
proliferatie (Ki67), diﬀ erentiatie (K10) en inﬂ ammatie (CD4, CD8 en CD45RO).
Al één week na de eerste PDT sessie werd immunohistochemische verbetering in de 
met ALA behandelde arealen gezien met betrekking tot proliferatie en keratinisatie, 
weerspiegeld door een afname van Ki67 expressie en toename van K10 expressie, welke 
meer uitgesproken was op week 6. Deze veranderingen waren niet aanwezig in de 
gebieden die behandeld waren met placebo. Eﬀ ecten op relevante T cel subsets werden 
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echter pas gezien in week 6, te zien in een afname van het aantal CD8+ en CD45RO+, 
maar niet in het aantal CD4+ cellen, in de met ALA behandelde arealen. Alleen in het 
aantal epidermale CD8+ en dermale CD45RO+ cellen werden signiﬁ cante afnames gezien. 
In de met placebo behandelde arealen werden deze veranderingen niet gezien, maar 
werd een signiﬁ cante toename in het aantal CD4+ cellen gezien. Klinische verbetering in 
de met ALA behandelde arealen werd al na één behandeling gezien, welke aanhield tot 
week 6. In de meeste gevallen werd er een partiële klinische respons maar ook klinische 
verslechtering suggestief voor het Koebner fenomeen gezien. Enkele patiënten klaagden 
over pijn in het behandelgebied, maar het stoppen van de behandeling was niet nodig. 
Na applicatie van 10% ALA gedurende 4 uur werd er een signiﬁ cante toename in PpIX 
ﬂ uorescentie (2.57x) in laesionale huid gezien. Na 2 J/cm2 werd er echter geen signiﬁ cante 
fotodegradatie van PpIX gezien in tegenstelling tot de tweede belichting met 8 J/cm2. 
Direct na de tweede belichting bleef de PpIX ﬂ uorescentie nog steeds 2.13 keer hoger 
ten opzichte van de beginwaarde, wat wijst op voldoende PpIX intralaesionaal. Ook werd 
er in de meeste psoriasis plaques heterogene ﬂ uorescentie gezien ondanks het feit dat 
er klinisch adequaat keratolytisch voorbehandeld leek te zijn. 
Uit het bovenstaande kan worden geconcludeerd dat PDT zowel klinisch als histologisch 
in staat is om psoriasis te verbeteren. Echter met het gebruikte protocol, wordt het niet 
aanbevolen als een behandeling van eerste keuze, vanwege de partiële klinische respons 
en risico op het optreden van het Koebner fenomeen. Het heterogene ﬂ uorescentie 
patroon dat wordt gezien met FDAP zou hiervoor wel eens verantwoordelijk kunnen 
zijn. Dientengevolge wordt er een inhomogene fotodynamische dosis gegeven over 
het oppervlakte van de epidermis wat resulteert in gebieden met ernstige en minimale 
fotodynamische schade. Fluorescentiemetingen wijzen op ruim voldoende hoeveelheden 
intralaesionaal PpIX in de hoog ﬂ uorescente arealen, zelfs na de tweede belichting, wat 
wijst op het feit dat 10% ALA gedurende 4 uur voldoende lijkt om voldoende PpIX te 
induceren. De minimale fotodegradatie na de eerste belichting wijst erop dat het huidige 
protocol suboptimaal is en dat een hogere eerste licht dosis nodig is. Histologisch werden 
er na één behandeling al uitgesproken anti-psoriatische eﬀ ecten gezien in de epidermis, 
door een afname van Ki67 expressie en toename van K10 expressie. Eﬀ ecten op T cel 
subsets werden pas gezien in week 6. Men zou zich kunnen voorstellen dat door een 
verlaagde fotodynamische dosis in de diepere huidlagen, door verminderde penetratie 
van het licht alsmede van de fotosensitizer, meerdere PDT behandelingen nodig zijn om 
signiﬁ cante dermale eﬀ ecten te bewerkstelligen. 
IIb Het bestuderen van de preferentiële accumulatie van PpIX binnen psoriasis plaques door middel van FDAP om dit te 
correleren aan de histologische morfologie en immunohistochemische psoriasis-activiteitsmarkers.
In een additionele studie, beschreven in paragraaf 3.2, werd de heterogene 
ﬂ uorescentie die in de vorige paragraaf werd gezien nader onderzocht. Om de vraag 
te beantwoorden of de heterogene ﬂ uorescentie gerelateerd zou kunnen zijn aan de 
activiteit van de psoriasis of de beperkte penetratie van de fotosensitizer en/of het licht 
door de hyperkeratosen, werd FDAP verricht op psoriasis plaques na keratolytische 
voorbehandeling en applicatie van 20% ALA gedurende 3 uur. Er werden biopten 
genomen van hoog en laag ﬂ uorescerende gebieden binnen de plaques welke werden 
geanalyseerd met (immuno)histochemie om de histologische morfologie (stratum 
corneum dikte) en psoriasis activiteit, door middel van markers voor proliferatie (Ki67), 
keratinisatie (K10, ﬁ laggrine) en inﬂ ammatie (CD3), te bestuderen. 
Er werden geen verschillen gevonden in de psoriasis activiteitsmarkers tussen hoge en 
lage ﬂ uorescerende gebieden. Echter, in de biopten genomen uit de hoog ﬂ uorescerende 
gebieden werd een signiﬁ cant dunner stratum corneum gevonden vergeleken met de 
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laag ﬂ uorescerende gebieden. Wanneer de stratum corneum dikte werd gerelateerd 
aan de macroscopische ﬂ uorescentie verkregen met FDAP, werd een negatieve 
correlatie gevonden wat impliceert dat hyperkeratose een signiﬁ cante belemmerende 
factor is met betrekking tot de ALA-geïnduceerde accumulatie van PpIX. Blijkbaar was 
voorbehandeling met 10% salicylzuur in vaseline éénmaal daags gedurende één week 
niet voldoende om alle hyperkeratosen te verwijderen.
Derhalve, gebaseerd op deze gegevens, lijkt het verwijderen van hyperkeratose 
voorafgaande aan de behandeling een belangrijke manier om PDT bij psoriasis, en 
mogelijk ook andere huidaandoeningen, te optimaliseren. Zo kan er een homogene 
fotodynamische dosis worden gegeven over het gehele oppervlak van de epidermis, 
wat het risico op het Koebner fenomeen en een suboptimale behandeling door een te 
lage dosis doet verminderen. Aangezien psoriasis een T cel gemediëerde aandoening 
is en PDT hoofdzakelijk zijn eﬀ ecten in de epidermis uitoefent, vereist het aanpakken 
van dermale structuren zoals T cellen mogelijk een behandelingsprotocol bestaande uit 
meerdere sessies met een lage dosis. De klinische eﬀ ectiviteit van PDT bij psoriasis lijkt 
dus sterk afhankelijk van het afgeven van een adequate fotodynamische dosis aan de 
verschillende doelstructuren in de huid, in tegenstelling tot PDT bij NMSC, waar massale 
cytotoxiciteit wordt nagestreefd. Deze gegevens komen overeen met de algemene 
opvatting dat modulatie van het immuunsysteem door PDT, welke het belangrijkste 
doelwit is bij inﬂ ammatoire dermatosen, een behandelingsprotocol behoeft bestaande 
uit meerdere PDT sessies met een lage fotodynamische dosis.144
 
 Fluorescentie diagnostiek en DNA aneuploïdie in
 keratinocytische intraepidermale neoplasieën: 
 op zoek naar een klinisch bruikbare 
 progressiemarker
IIIa Het bestuderen van DNA aneuploïdie en proliferatie in verschillende KIN-stadia en hun mogelijke rol als progressie 
markers.
In paragraaf 4.1, werden DNA aneuploïdie en proliferatie bestudeerd in verschillende 
KIN-stadia van AK’s om hun rol als potentiële progressiemarkers te onderzoeken. Daartoe 
werden biopten van patiënten met NMSC geanalyseerd met kwantitatieve DNA ﬂ ow 
cytometrie (FCM) om hun ploïdie status en celcyclus karakteristieken te bepalen. Verder 
werd (immuno)histochemie verricht om de KIN-graad en Ki67 expressie te bepalen.
Aneuploïdie werd vaker gevonden in laesies met een hogere KIN-graad, maar niet in 
normale huid. Echter, in microinvasieve plaveiselcelcarcinomen (miSCC) werd minder 
vaak aneuploïdie gevonden dan in KIN III laesies. Het type aneuploïdie kon worden 
geclassiﬁ ceerd als hypotetraploïdie met DNA indices van KIN I/II, KIN III and miSCC 
van 1.71, 1.57 en 1.62 respectievelijk, wat duidt op een toename van de hoeveelheid 
DNA. Verder bleek aneuploïdie onafhankelijk van immuun status. Het bepalen van het 
proliferatieve compartiment met FCM (% SG2M cellen), toonde een positieve correlatie 
tussen het aantal prolifererende cellen en toenemende KIN-graad. Analoog hieraan werd 
een nog sterkere correlatie gevonden tussen de KIN-graad en de immunohistochemische 
proliferatie marker Ki67-antigen. 
Dus, aneuploïdie is een frequent voorkomend verschijnsel in (pre)maligniteiten en is 
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geassocieerd met (cutane) carcinogenese. Interessant genoeg werd er in miSCC minder 
vaak aneuploïdie gezien dan in KIN III laesies, wat in tegenspraak is met de aanname dat 
progressie van AK naar miSCC een serieel proces is waarin DNA schade in toenemende 
mate accumuleert met oplopende KIN-graad wat uiteindelijk leidt tot invasief carcinoom, 
zoals wordt gesuggereerd door de KIN-classiﬁ catie. De lagere DNA index gevonden in 
miSCC vergeleken met KIN III laesies is eveneens in overeenstemming hiermee. Vanuit 
een cytogenetisch oogpunt hebben miSCC laesies dus meer gemeen met KIN I/II dan 
met KIN III laesies. Dit zou kunnen betekenen dat in KIN I/II laesies een subkloon of 
meerdere subklonen atypische keratinocyten in staat zijn om door de basaalmembraan 
door te breken naar de papillaire dermis wat uiteindelijk leidt tot invasieve groei nog 
voordat de bovenste lagen van de epidermis de kans hebben gehad om kernatypie te 
vertonen. Verder werden lagere DNA indices gevonden in KIN III laesies dan in KIN I/II 
laesies. Als men van een seriële progressie uitgaat van KIN I naar KIN III laesies, wijst dit 
op afname van de DNA hoeveelheid (verlies van chromosomen) tijdens KIN progressie 
wat overeenkomt met de algemene hypothese dat polyploïdie/tetraploïdie gevolgd 
door aneuploïdie een frequente en vroeg optredende gebeurtenis is in tumorgenese. 
Bovendien, wordt er in twee recente artikelen gesuggereerd dat chromosomale non-
disjunctie resulteert in tetraploïdisatie en dat de tetraploïde status predisponeert voor 
tumorgenese in de afwezigheid van functioneel p53.284;349 Daar p53 vaak gemuteerd is in 
cutane (pre)maligniteiten past dit goed in het hele verhaal. 
Concluderend kan men stellen dat de huidige gegevens impliceren dat maligne 
transformatie van vroege KIN-stadia naar miSCC niet recht-toe-recht-aan is. Echter, 
aneuploïdie gemeten met onze ﬂ ow cytometrische techniek verschaft alleen 
kwantitatieve gegevens; wat dit echter zegt over de (dys)functie van tumor suppressor 
genen kan niet uit deze gegevens worden afgeleid. Bovendien, andere factoren zoals 
het immuun systeem kunnen de progressie van een (pre)maligniteit ook beïnvloeden. 
Daarom lijkt aneuploïdie geen goede marker voor invasieve ziekte. Proliferatie bleek 
sterk gecorreleerd met de KIN-graad, wat impliceert dat kernatypie gelijk op gaat met 
hyperproliferatie in epidermale keratinocyten en dientengevolge Ki67 een goede marker 
maakt voor kernatypie.
IIIb Het evalueren van de waarde van FDAP als diagnosticum om te kunnen discrimineren tussen verschillende KIN-stadia 
of proliferatie status. 
De potentiële waarde van FDAP als een non-invasieve diagnostische procedure om 
onderscheid te kunnen maken tussen verschillende KIN-stadia is beschreven in paragraaf 
4.2. In dit onderzoek werd FDAP uitgevoerd in patiënten met ﬁ eld-cancerization 
na keratolytische voorbehandeling. Vervolgens werden er biopten genomen van 
verschillende laesies. Op deze biopten werd (immuno)histochemie verricht voor nadere 
histopathologische classiﬁ catie, door middel van de KIN- alsmede de conventionele 
classiﬁ catie, het bepalen van de Ki67 expressie en de dikte van het stratum corneum.
Hoewel KIN III laesies neigden naar een verhoogde laesionale : non-laesionale 
ﬂ uorescentie ratio vergeleken met KIN I/II laesies, werden er geen signiﬁ cante verschillen 
in de macroscopische ﬂ uorescentie ratio’s gevonden tussen de verschillende KIN-stadia. 
Zes laesies welke werden geclassiﬁ ceerd als verruceuze hyperkeratosen hadden een 
signiﬁ cant lagere ﬂ uorescentie ratio, zo meestal rond de 1, vergeleken met normale huid, 
KIN I, KIN III en miSCC laesies. De drie gebiopteerde SCC’s hadden een signiﬁ cant hogere 
ﬂ uorescentie ratio vergeleken met de KIN II laesies en verruceuze hyperkeratosen. Analyse 
van de proliferatie activiteit door middel van positiviteit voor Ki67-antigen toonde ook 
geen signiﬁ cante verschillen in de ﬂ uorescentie ratio’s binnen de drie niveaus van Ki67 
expressie, wat niet vreemd is omdat Ki67 expressie en KIN-graad een sterke correlatie 
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hebben. Echter, wanneer de laesies onderverdeeld in vier diagnostische categorieën 
(terecht/fout positief/negatief ), met een ﬂ uorescentie ratio van 1.0 als afkappunt en 
KIN laesies/SCC en verruceuze hyperkeratosen/normale huid geclassiﬁ ceerd als (pre)
maligne en benigne laesies  respectievelijk, werd er een signiﬁ cant lager aantal Ki67+ 
cellen gevonden in laesies met een ﬂ uorescentie intensiteit lager dan omliggende huid 
(ﬂ uorescentie ratio < 1.0; terecht- en fout-negatieven) vergeleken met laesies met een 
ﬂ uorescentie intensiteit hoger dan omliggende huid (ﬂ uorescentie ratio > 1.0; terecht- 
en fout-positieven). Wanneer Ki67 expressie binnen de vier diagnostische categorieën 
onderling werd vergeleken, werd er een signiﬁ cant verschil gevonden tussen de fout- 
en terecht-positieve laesies en tussen de terecht-positieve en -negatieve laesies. De 
reden hiervoor zou mogelijk kunnen zijn gelegen in het relatief hoge aantal terecht-
positieve laesies die vaak hyperproliferatief zijn. Dus, proliferatie activiteit lijkt eerder een 
confounder te zijn dan de oorzaak van een hoge ﬂ uorescentie intensiteit. 
Wanneer macroscopische ﬂ uorescentie waarden werden uitgezet tegen de stratum 
corneum dikte, werd er een negatieve correlatie gevonden wat impliceert dat 
hyperkeratose een belemmerende factor is met betrekking tot PpIX accumulatie. Naar 
analogie hiervan werd er een dikker stratum corneum gevonden in laesies met een 
ﬂ uorescentie intensiteit lager dan omliggende huid (ﬂ uorescentie ratio < 1.0; terecht- 
en fout-negatieven) vergeleken met laesies met een ﬂ uorescentie ratio hoger dan 1.0 
(terecht- en fout-positieven). Bovendien werd er in de terecht- en fout-positieve laesies 
een signiﬁ cant dunner stratum corneum gevonden dan in de fout-negatieve laesies. Een 
samenvatting van deze gegevens kan men vinden in tabel II in paragraaf 4.2.
Uit het bovenstaande wordt geconcludeerd dat FDAP niet gebruikt kan worden om 
onderscheid te maken tussen verschillende KIN-stadia. Echter, er werd een tendens gezien 
naar een hogere macroscopische ﬂ uorescentie intensiteit in KIN III laesies ten opzichte 
van KIN I/II laesies. Dit kan te maken hebben met een verhoogd aantal epidermale cellen 
in KIN III laesies (epidermale hyperplasie). Hoewel er een tendens was naar een dikker 
stratum corneum in KIN III leasies vergeleken met KIN I/II laesies, konden geen statistisch 
signiﬁ cante verschillen worden aangetoond. Men kan zich voorstellen dat een dikker 
stratum corneum in KIN III leasies het ﬂ uorescentie contrast zou kunnen verminderen 
tussen de KIN I/II en KIN III laesies. Gezien de hoge ﬂ uorescentie intensiteit welke werd 
gezien in miSCC, zou het interessant zijn verdere studies te doen om te zien of FDAP 
zou kunnen worden gebruikt om KIN laesies te onderscheiden van invasief carcinoom. 
Verder lijkt de macroscopische ﬂ uorescentie onafhankelijk van proliferatie graad, maar is 
deze wel negatief gecorreleerd met de dikte van het stratum corneum. Ondanks het feit 
dat de patiënten in ons onderzoek keratolytisch werden voorbehandeld met salicylzuur 
in vaseline gedurende 1-2 weken voorafgaande aan FDAP, bleek de aanwezigheid 
van hyperkeratosen nog steeds verantwoordelijk voor variaties in macroscopische 
ﬂ uorescentie. Daar penetratie van het hydroﬁ ele ALA door het lipoﬁ ele stratum corneum 
een voorwaarde is voor PpIX vorming, is adequate keratolytische voorbehandeling 
essentieel voor optimale resultaten met FDAP en PDT. 
 Algemene conclusies
In deze paragraaf wordt een korte samenvatting gegeven van de algemene conclusies 
uit dit proefschrift.
Psoriasis en AK accumuleren preferentieel PpIX vergeleken met hun non-laesionale • 
huid na applicatie van ALA.
CHAPTER 5
149
In psoriasis wordt er een hogere laesionale : non-laesionale PpIX ﬂ uorescentie ratio • 
gezien vergeleken met AK.
De hogere macroscopische PpIX ﬂ uorescentie welke met FDAP wordt gezien in AK, • 
wordt veroorzaakt door een verhoogd aantal PpIX-bevattende cellen, terwijl bij 
psoriasis (ook) een verstoorde barriere functie van het stratum corneum een rol lijkt 
te spelen.
De positieve lineaire correlatie tussen de macroscopische PpIX ﬂ uorescentie en het • 
PpIX gehalte in de huid maakt FDAP geschikt om het PpIX gehalte in de huid te 
schatten.
Het feit dat er • ex vivo geen verschillen in PpIX accumulatie werden gevonden 
tussen verschillende huidaandoeningen impliceert dat het stratum corneum een 
prominente rol heeft bij PpIX ﬂ uorescentie verschillen in vivo.
Het suprabasale PpIX ﬂ uorescentie patroon binnen de epidermis gezien met • 
ﬂ uorescentie microscopie en welke werd bevestigd met ﬂ ow cytometrie, wijst op 
preferentiële accumulatie van PpIX in gediﬀ erentieerde cellen.
Gefractioneerde ALA-PDT is, in tegenstelling tot placebo-PDT, in staat om psoriasis • 
klinisch te verbeteren.
Gefractioneerde ALA-PDT bij psoriasis is, in tegenstelling tot placebo-PDT, • 
histologisch in staat om proliferatie en relevante T cel subsets te remmen en 
keratinisatie te normaliseren. 
Het heterogene ﬂ uorescentiepatroon, waargenomen met FDAP in psoriasis plaques, • 
kan niet verklaard worden door verschillen in psoriasis-activiteitsmarkers, maar 
slechts door verschillen in stratum corneum dikte, welke negatief gecorreleerd bleek 
met de ﬂ uorescentie intensiteit.
Aneuploïdie wordt vaker gezien in laesies van hogere KIN-graad. KIN III laesies • 
vertonen vaker aneuploïdie vergeleken met miSCC.
Vanuit cytogenetisch oogpunt, gebaseerd op hun DNA-indices, hebben KIN I/II • 
laesies meer gemeen met miSCC vergeleken met KIN III laesies, wat impliceert dat 
seriële progressie door vervolgens alle KIN-stadia naar invasief SCC niet een recht-
toe-recht-aan proces is.
FDAP is niet geschikt om verschillende KIN-stadia van elkaar te onderscheiden.• 
De negatieve correlatie tussen macroscopische ﬂ uorescentie en stratum corneum • 
dikte in AK’s, impliceert dat hyperkeratose een cruciale factor is bij interlaesionale 
verschillen in PpIX ﬂ uorescentie.
De macroscopische ﬂ uorescentie intensiteit verkregen met FDAP is onafhankelijk • 
van de met Ki67 expressie vastgestelde proliferatie activiteit.
 Algemene discussie en aanbevelingen  voor de
 toekomst
Bij het lezen van paragraaf 1.5.3 van dit proefschrift wordt al snel duidelijk dat er 
nog steeds weinig bekend is over de precieze mechanismen die betrokken zijn bij 
preferentiële accumulatie van PpIX in laesionaal weefsel. Conﬂ icterende gegevens 
tussen de diverse onderzoeken kunnen veelal worden verklaard door de verschillende 
modellen en condities die in deze studies zijn gebruikt. Bovendien zijn er vele factoren, 
zoals beschreven in paragraaf 1.5.3.3, bekend die van invloed zijn op PpIX accumulatie 
en die mogelijk de coherentie tussen deze gegevens verder negatief beinvloeden. 
Desalniettemin, hebben de uitstekende klinische resultaten PDT gemaakt tot een 
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standaard behandelingsmodaliteit voor diverse vormen van NMSC. Er is echter nog 
steeds een signiﬁ cant aantal laesies dat klinisch recidief vertoont binnen 3 jaar na PDT, 
waaronder enkele superﬁ ciële maar met name nodulaire vormen van het BCC.171 Meer 
kennis over de (preferentiële) accumulatie van PpIX in deze laesies zou niet alleen kunnen 
bijdragen aan het verder verbeteren van de klinische eﬀ ectiviteit van PDT maar ook de 
betrouwbaarheid van FDAP als een non-invasieve diagnostische procedure.
Uit de voorafgaande onderzoeken welke zijn beschreven in de hoofdstukken 2-4 kunnen 
enige algemene conclusies worden getrokken, welke hieronder worden bediscusieerd.
 Model voor PpIX accumulatie in psoriasis,
 actinische keratosen en normale huid
Het proces van PpIX accumulatie is een complex en meerstaps proces, bestaande uit 3 
fasen die de fotosensitizer moet doorlopen: (I) penetratie door het stratum corneum, 
(II) opname in de cel en (III) metabole conversie naar porfyrinen. Verschillen in deze 
fasen tussen verschillende typen weefsels zijn verantwoordelijk voor de verschillende 
farmacokinetiek en –dynamiek van PpIX accumulatie. Dit zijn intrinsieke factoren 
(weefseleigenschappen) maar ook zijn er extrinsieke factoren zoals bijvoorbeeld de 
speciﬁ eke eigenschappen van het geneesmiddel (vehiculum, concentratie, applicatietijd 
etc...). 
In dit proefschrift werden onderzoeken naar PpIX accumulatie verricht in psoriasis en 
AK, welke beide hyperproliferatieve aandoeningen zijn, maar met een belangrijk verschil 
dat AK een (pre)maligniteit is, terwijl psoriasis een benigne inﬂ ammatoire aandoening 
is. Normale huid diende steeds als controle. Uit deze onderzoeken kunnen enige 
algemene conclusies worden getrokken met betrekking tot PpIX accumulatie in deze 
huidaandoeningen. Deze worden hieronder bediscussieerd en zijn tevens samengevat 
in ﬁ guur 19. De nummers tussen haakjes in de tekst corresponderen met de nummers in 
deze ﬁ guur. De situatie van ALA penetratie door een normaal stratum corneum wordt 
weergegeven in (3). 
Proliferatie lijkt geen determinant van PpIX accumulatie, omdat er geen correlatie werd 
gevonden tussen Ki67 expressie en macroscopische ﬂ uorescentie intensiteit verkregen 
met FDAP. Dit is in overeenstemming met diverse in vitro studies, waarin geen celcyclus 
afhankelijkheid kon worden aangetoond maar slechts een volume afhankelijkheid met 
betrekking tot PpIX accumulatie.65;66 De preferentiële accumulatie van PpIX in suprabasale 
cellen (hoofdstuk 2), welke over het algemeen niet-prolifererende cellen zijn, is hier ook 
mee te rijmen. Verschillen in de PpIX-synthese capaciteit van biopten van psoriasis, AK 
en normale huid konden ook niet worden aangetoond wat impliceert dat variaties in 
de macroscopische ﬂ uorescentie intensiteit gemeten met FDAP niet verklaard kunnen 
worden door verschillen in de haem-synthese en/of opname van ALA tussen deze 
huidaandoeningen.
De stratum corneum dikte blijkt negatief gecorreleerd met de PpIX ﬂ uorescentie bij 
AK en psoriasis. Hyperkeratose (2) blijkt verantwoordelijk te zijn voor variaties in PpIX 
ﬂ uorescentie binnen laesionale huid in psoriasis maar ook tussen verschillende laesies 
in AK. Echter dit alleen kan de preferentiële accumulatie van PpIX in laesionale huid ten 
opzichte van non-laesionale huid niet verklaren, daar laesies van AK en psoriasis over het 
algemeen hyperkeratotisch zijn. Omdat de synthetische capaciteit tussen deze weefsels 
ook niet veel lijkt te verschillen moet er dus een andere factor zijn die dit kan verklaren.
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Afwijkingen in de stratum corneum integriteit (1) zijn ook geopperd als mogelijke 
verklaring voor de preferentiële accumulatie van PpIX in laesionale huid in NMSC 
(zie paragraaf 1.5.3.2 en ﬁ guur 6). Verder toonden Von Beckerath et al. aan dat PpIX 
ﬂ uorescentie hoger was in chronisch aan UV blootgestelde huid ten opzichte van huid 
welke kort was blootgesteld aan UV licht en zij stelden dat structurele veranderingen in 
het stratum corneum van actinisch beschadigde huid penetratie van ALA bevorderen. 
Echter, afwijkingen in stratum corneum integriteit kunnen de verhoogde macroscopische 
ﬂ uorescentie intensiteit in laesionale huid van AK niet verklaren omdat er vergelijkbare 
hoeveelheden PpIX per cel in laesionale en non-laesionale huid in AK werden gevonden 
(hoofdstuk 2). Daar laesionale huid van AK signiﬁ cant meer dsDNA bevat dan omliggende 
huid, kan preferentiële accumulatie van PpIX in laesionale huid van AK derhalve 
wel worden verklaard door een verhoogd aantal PpIX-bevattende cellen (5), welke 
dientengevolge de PpIX kwantum opbrengst verhogen. Dit kan ook de tendens naar een 
hogere macroscopische ﬂ uorescentie intensiteit in KIN III laesies ten opzichte van KIN I/
II laesies verklaren (paragraaf 4.2) daar epidermale hyperplasie een prominent kenmerk 
is bij M. Bowen. Een kleine tendens naar een dikker stratum corneum werd ook gezien in 
KIN III laesies ten opzichte van KIN I/II laesies wat mogelijk kan verklaren waarom er geen 
statistisch signiﬁ cante verschillen werden gevonden in macroscopische ﬂ uorescentie 
intensiteit. In psoriasis zou dit ook een rol kunnen spelen daar laesionale huid in psoriasis 
ook wordt gekenmerkt door een verhoogd aantal cellen (5) (epidermale hyperplasie) 
vergeleken met non-laesionale huid. Echter, de relatief hoge ﬂ uorescentie gemeten met 
FDAP vergeleken met AK en het verhoogde PpIX-gehalte per cel in laesionale psoriasis 
huid, impliceert een ander mechanisme. Ook in psoriasis zijn afwijkingen in de stratum 
corneum integriteit beschreven welke gecorreleerd bleken met het psoriasis fenotype.43 
Verhoogde penetratie van ALA in laesionale huid van psoriasis zou zo kunnen leiden tot 
een verhoogd PpIX-gehalte per cel ten opzichte van non-laesionale huid. 
Als ALA eenmaal de epidermis is binnen getreden wordt het preferentieel omgezet in 
PpIX door suprabasale keratinocyten in normale huid (4). Of dit het resultaat is van een 
verhoogde activiteit van enzymen in de haem-cyclus en/of verhoogde opname van ALA 
in de cel, is onbekend. 
De huidbarriere (stratum corneum) heeft een prominente rol bij variaties in de 
macroscopische ﬂ uorescentie (gemeten met FDAP) en zeer waarschijnlijk ook bij de 
wisselende klinische eﬀ ectiviteit van PDT. Variaties in de dikte van het stratum corneum 
(hyperkeratose) lijken verantwoordelijk voor intra- en interlaesionale verschillen in 
macroscopische ﬂ uorescentie. Een gestoorde integriteit van het stratum corneum, 
welke is geassocieerd met pathologische huidaandoeningen, speelt ook een grote rol 
en is primair verantwoordelijk voor de preferentiële accumulatie van PpIX in laesionale 
psoriasis huid. Ook het aantal PpIX accumulerende cellen speelt een belangrijke rol. De 
macroscopische ﬂ uorescentie intensiteit is het netto resultaat van al deze processen. 
Zo kan men bijvoorbeeld verklaren waarom een hyperkeratotische psoriasis laesie 
verhoogde PpIX ﬂ uorescentie laat zien ten opzichte van de niet-hyperkeratotische 
omliggende huid.
 Fotodynamische therapie bij psoriasis: op zoek 
 naar een geschikt behandelingsprotocol
Alhoewel klinische en histologische verbetering gezien zijn na de fotodynamische 
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behandeling van psoriasis, kan PDT niet aanbevolen worden als een behandeling van 
eerste keus vanwege de wisselende en partiële klinische respons. Zoals in hoofdstuk 3 
is beschreven werd de behandeling relatief goed verdragen maar wanneer er grotere 
huidarealen worden behandeld, net zoals bij lichttherapie met UVB/PUVA, zouden 
de pijn en overige bijwerkingen te hevig kunnen worden. Daar psoriasis plaques 
gekenmerkt worden door hyperkeratose, erg vatbaar zijn voor het Koebner fenomeen 
en de doelstructuren voor PDT gelegen zijn in de diepere lagen van de huid, is het een 
uitdaging een adequate fotodynamische dosis toe te dienen. Hoewel met een adequate 
keratolytische voorbehandeling en dosimetrie verwacht kan worden dat de resultaten 
zullen verbeteren, moet een optimaal behandelprotocol nog worden ontwikkeld.
In een recent onderzoek van Wiegell et al. werd de klinische eﬀ ectiviteit van MAL-PDT 
voor de behandeling van AK’s in het gelaat en op de scalp onderzocht met een nogal 
ongewoon protocol.350 Na incubatie met MAL onder occlusie gedurende een half uur, 
werden de patiënten naar buiten gestuurd gedurende 2.5 uur na het verwijderen van 
het occlusief verband maar niet van de crème om vervolgens halfzijdig ‘daglicht-PDT’ te 
ontvangen. De andere gelaatshelft werd vervolgens met 37 J/cm2 behandeld volgens 
het standaard protocol. Interessant genoeg bleek de klinische eﬀ ectiviteit van daglicht-
PDT vergelijkbaar met de conventionele MAL-PDT. De PpIX ﬂ uorescentie, welke werd 
gemeten tijdens de incubatie periode, bleef een stuk lager dan in de helft welke nog 
was afgedekt met het occlusief verband vanwege continue activatie van PpIX door het 
daglicht. De behandeling met daglicht-PDT werd signiﬁ cant minder pijnlijk ervaren ten 
opzicht van conventionele MAL-PDT. Door het berekenen van de ‘relatieve eﬀ ectieve 
lichtdoses’, bleek dat daglicht-PDT meer dan voldoende in staat was om alle PpIX te 
activeren, daar daglicht is opgebouwd uit verschillende golﬂ engten buiten het rode 
gebied, waaronder blauw licht, welke eﬀ ectiever zijn dan rood licht in het activeren 
van PpIX. Omdat pijn een belangrijke beperking kan zijn van PDT, zou behandeling met 
daglicht-PDT een interessant nieuw concept zijn bij de fotodynamische behandeling 
van psoriasis. Indien continue expositie aan daglicht met name resulteert in activatie 
van PpIX in de oppervlakkige lagen van de huid, zou minder ALA/MAL naar de diepere 
lagen kunnen doordringen wat resulteert in een inadequate behandeling van de diepere 
huidlagen, wat theoretisch een nadeel zou kunnen zijn. Echter, aangezien de behandeling 
goed wordt verdragen en makkelijk toepasbaar is, zou het interessant zijn dit protocol 
te evalueren bij psoriasis. Zeer waarschijnlijk zijn meerdere behandelingen over een 
groter tijdsbestek eﬀ ectiever. Daar PDT wordt gezien als een veilige behandeling, zonder 
signiﬁ cante cumulatieve toxiciteit, zou dit geen bezwaar zijn. Wellicht heeft ALA crème 
(of een ALA bevattende zonnebrandcrème) op een dag een belangrijke rol in de topicale 
behandeling van psoriasis.    
 Fluorescentie diagnostiek en aneuploïdie als
 diagnostische hulpmiddelen bij NMSC
Zoals reeds besproken in paragraaf 1.5.6 kan FDAP, naar aanleiding van de resultaten van 
de diverse klinische onderzoeken over FDAP op de huid, nog niet worden beschouwd 
als een valide alternatief voor het huidbiopt. De meeste onderzoeken zijn uitgevoerd 
bij het BCC, waar FDAP werd gebruikt als een additioneel gereedschap om deze laesies 
te demarceren, maar de gegevens over squameuze (pre)maligniteiten zijn schaars. 
Squameuze (pre)maligniteiten zijn geassocieerd met een verhoogde cumulatieve UV 
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schade en ﬁ eld-cancerization daar zij met name voorkomen op de zon blootgestelde 
huid. In patiënten met uitgebreide actinische schade, zijn vaak meerdere huidbiopten 
nodig om onderscheid te maken tussen premaligne en maligne laesies. In paragraaf 4.2 
werd FDAP toepast bij KIN laesies om diens rol bij ﬁ eld-cancerization te bestuderen.  
In dit proefschrift is aangetoond dat het stratum corneum een belangrijke rol speelt bij 
PpIX ﬂ uorescentie. Dit komt overeen met bevindingen uit andere studies en behalve dit 
zijn er geen andere factoren bekend die de verschillen in macroscopische ﬂ uorescentie 
gemeten met FDAP tussen de verschillende weefseltypen kunnen verklaren.13-25 Bij 
psoriasis speelt mogelijk de integriteit van het stratum corneum een grote rol bij de 
preferentiële laesionale ﬂ uorescentie, in tegenstelling tot AK. Er werden met FDAP geen 
verschillen gezien in ﬂ uorescentie intensiteit tussen laesies van verschillende KIN-graad, 
hoewel KIN III laesies neigden naar een hogere ﬂ uorescentie intensiteit ten opzichte 
van KIN I/II laesies, wat mogelijk verklaard kan worden door een verhoogd aantal cellen 
in KIN III laesies, maar dit blijft speculatief. Derhalve lijkt de klinische toepassing van 
FDAP beperkt om te kunnen discrimineren tussen verschillende AK van verschillende 
KIN-graad. Aanvullende studies moeten aantonen of FDAP kan worden gebruikt om 
te diﬀ erentiëren tussen in situ AK’s en invasief plaveiselcelcarcinoom. Wederom lijkt 
adequate keratolytische voorbehandeling essentieel voor optimale resultaten daar 
er een negatief verband is gevonden tussen de dikte van het stratum corneum en 
macroscopische ﬂ uorescentie. Samenvattend, lijkt FDAP niet van toegevoegde waarde 
bij het onderscheiden van laesies van verschillende KIN-graad. Bemoedigende resultaten 
wijzen erop dat FDAP een mogelijke rol heeft bij het onderscheiden van KIN-laesies en 
SCC maar dit moet nog verder worden onderzocht. Echter voor onderzoeksdoeleinden is 
FDAP een interessant hulpmiddel om PpIX accumulatie te bestuderen in vivo en kan het 
nuttig zijn bij het optimaliseren en onderzoeken van nieuwe indicaties voor PDT.
Aneuploïdie werd in toenemende mate gezien in laesies met een hogere KIN-graad, 
maar in SCC werd het minder vaak gevonden. Met betrekking tot de DNA indices en 
aneuploïdie frequentie lijken KIN I/II laesies meer op SCC laesies dan op KIN III laesies. 
Daarom lijkt seriële progressie door alle KIN-stadia naar SCC niet de enige route voor 
maligne transformatie. Hoewel aneuploïdie een kanker-speciﬁ eke cellulaire marker 
is waarvan verscheidene aspecten correleren met maligniteits-graad, tumor stadium 
en prognose in diverse vormen van kanker, lijkt het in squameuze huidkankers geen 
geschikte marker voor het vroeg detecteren van invasiviteit. Meer kennis over de 
moleculaire mechanismen welke betrokken zijn bij de cutane carcinogenese, zou kunnen 
leiden tot een klinisch bruikbare progressiemarker. Tot die tijd, zouden AK’s moeten 
worden beschouwd als vroege stadia van huidkanker welke een adequate behandeling 
behoeven.
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 Colour illustrations
 Introduction, fi gures 13, 16.
 Figure 13: Clinical appearance (A) and histopathology (B) of AK and SCC.
Figure 16: Clinical appearance (A) and histopathology (B) of psoriasis.
 Chapter 2.1, fi gure 8.
 Chapter 2.2, fi gure 3.
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uptake of ALA may also play a role, this could not be dem-
onstrated in our study. Additional studies analyzing PpIX
accumulation in cell cultured systems of AK and psoriasis
could provide further information concerning this issue.
Initially, total protein was measured as an epidermal ref-
erence value but this did not appear to be an appropriate
reference eventually: protein levels in the biopsies between
lesional and non-lesional skin in psoriasis did not differ
much from each other with a large standard deviation,
which could be explained by the fact that the amount of
dermis in the biopsies was not standardized. As lesional
skin in psoriasis is known to have higher epidermal protein
levels because of the higher proliferation rate, this suggests
the dermis to have a substantial contribution to total protein
content, thus overshadowing differences in epidermal pro-
tein content (van Erp and van de Kerkhof, 1988). DsDNA
quantification revealed evident differences in the four skin
types and appeared to be a good marker for the amount of
epidermal keratinocytes. In hyperproliferative skin condi-
tions, total DNA content is commonly increased due to in-
creased DNA synthesis, which can be a disturbing factor
when a comparison is made with normoproliferative skin. In
a study of Bauer et al (1981), the percentage of cells in the
S-phase in psoriasis appeared to be increased compared
with normal skin (9.7% vs 2.7%). In non-involved psoriatic
skin, this percentage of cells in S-phase was 3.8%. To the
best of our knowledge, in AK, these exact percentages are
not known but when proliferation indices (PI) of psoriasis
and AK were compared (using Ki-67 expression) in a study
of Caldwell et al (1997) AK appeared to have a PI that is 1.26
times the PI in psoriasis. This means that in our samples,
dsDNA values as a marker of the total number of epidermal
keratinocytes could be overestimated. When correcting our
dsDNA data accordingly, lesional psoriatic skin and AK data
had to be decreased by 7.25% and 9.14%, respectively,
and their non-lesional skin to a lesser extent. These cor-
rections, however, did not have a significant effect on our
overall data.
Our results show a positive relation between macro-
scopic fluorescence as measured with our digital imaging
system and biochemical tissue PpIX content. Although
other authors have described in vivo measuring of PpIX,
macro-, and microscopic fluorescence imaging after ALA
treatment or combinations, to the best of knowledge, no
one has linked digital macroscopic imaging directly to bi-
ochemical tissue porphyrin content (Martin et al, 1995;
Figure 8
Normal, fluorescence, and pseudo-color images from psoriatic skin in vivo. Before (A–C) and after incubation with 20% 5-aminolevulinic acid
(ALA) ointment for 3 h (D–F). Incubation with 20% ALA (3 h) ointment induced a remarkable increase in red fluorescence, which was more
pronounced in lesional skin.
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Figure 9
Correlation between protoporphyrin-IX content in the skin and
macroscopic fluorescence at the skin. r¼0.73, po0.001. Dotted
lines indicate 95% confidence intervals.
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Signiﬁcantly more protoporphyrin IX ﬂuorescence
is detected in conﬂuent compared with subconﬂuent
cell cultures
When PpIX accumulation in cell cultu es at different levels of
conﬂuence was compared, increased PpIX ﬂuorescence was
found in cell cultures with higher levels of conﬂuence. Espe-
cially between near-conﬂuent (90%) and conﬂuent (100%)
cell cultures there appeared to be a great difference in PpIX
ﬂuorescence. When the subconﬂuent cell cultures were mutu-
ally compared, there still was a tendency towards higher PpIX
ﬂuorescence in higher levels of conﬂuence, although this was
less obvious (Fig. 4a).
Induction of terminal differentiation by omission
of growth factors from the culture medium results
in decreased protoporphyrin IX (PpIX) ﬂuorescence
per cell while the total amount of PpIX does not change
Interestingly, when terminal differentiation was induced by
omission of GF from the culture medium, PpIX ﬂuorescence
per cell appeared to be lower compared with the cells that
were incubated with the addition of GF (Fig. 4b). However,
when the total amount of PpIX per cell culture corrected for
the number of cells using dsDNA was measured spectroﬂuoro-
metrically, PpIX ﬂuorescence did not signiﬁcantly differ
between the cells that were incubated with or without GF
(not shown).
Increased protoporphyrin IX ﬂuorescence is detected
in suprabasal epidermal cells compared with basal
epidermal cells
When biopsies from normal skin were incubated with ALA
and cell suspensions were labelled with antibody to CD29,
the negative population showed signiﬁcantly higher PpIX
content compared with the positive population (Fig. 5). As
(a) (b) (c) (d)
Fig 3. Fluorescence microscopy of skin explant cultures. No porphyrin-like ﬂuorescence is seen in normal skin incubated without aminolaevulinic
acid (ALA) (a). However, incubation with 1 mmol L)1 ALA (16 h) induced red ﬂuorescence conﬁned to the epidermis (b–d), typically sparing
the basal keratinocytes (d). The dotted line indicates the dermoepidermal junction.
(a)
(b)
Fig 4. Protoporphyrin IX (PpIX) accumulation in cell cultures of
different levels of conﬂuence and after induction of terminal
differentiation by omission of growth factors. (a) Human
keratinocytes from normal skin were incubated with 1 mmol L)1
aminolaevulinic acid (ALA) for 4 h and PpIX ﬂuorescence was
measured ﬂow cytometrically. Mean ± SD PpIX ﬂuorescence taken
from three separate experiments at each level of conﬂuence was
plotted. *P < 0Æ001, difference from 100% conﬂuence. (b) Cell
cultures were grown until 100% conﬂuence was reached (n = 6).
Thereafter, terminal differentiation was induced in half of the cell
cultures by omission of growth factors from the medium. After
incubation with 1 mmol L)1 ALA for 4 h, PpIX ﬂuorescence was
measured ﬂow cytometrically. Mean ± SD PpIX ﬂuorescence was
plotted (n = 3). *P < 0Æ001. a.u., arbitrary units.
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CD29-positive cells are found mainly in the basal layer of
the epidermis and CD29-negative cells are located in the
suprabasal layers (Fig. 6), CD29 can, conversely, be used as
a marker for terminal differentiation. Hence, increased accu-
mulation of PpIX in the CD29-negative population thus
points at a preferential accumulation of PpIX in differenti-
ated cells.
Discussion
In a previous study from our group it was shown that with
FDAP in psoriasis and AK signiﬁcantly more PpIX ﬂuorescence
was detected in lesional skin compared with nonlesional skin
and that generally PpIX ﬂuorescence in psoriasis was increased
compared with AK.4 When these PpIX ﬂuorescence values
were compared with the actual PpIX content in the skin sam-
ples, only in lesional psoriatic skin was more PpIX found
compared with nonlesional psoriatic skin and lesional and
nonlesional skin in AK. Basically, this could be explained by
an increased penetration of ALA through the stratum corneum
and ⁄or increased PpIX synthesis. In the present study, incuba-
tion with ALA of skin explant cultures from normal skin,
lesional and nonlesional skin of patients with psoriasis and AK
(a)
(b)
Fig 5. Protoporphyrin IX (PpIX) accumulation in normal skin in
CD29-negative and CD29-positive populations. Skin biopsies from
normal skin were incubated with 1 mmol L)1 aminolaevulinic acid
(ALA) for 4 h, except for the negative controls. After trypsinization,
cells were labelled with antibody to CD29. Subsequently, in the
CD29-positive and CD29-negative populations, PpIX ﬂuorescence was
measured with ﬂow cytometry. (a) Flow cytometric two-parameter
histogram showing the CD29-positive (green) and CD29-negative
(blue) populations and their PpIX ﬂuorescence. (b) Mean ± SD PpIX
ﬂuorescence in the CD29-positive and CD29-negative populations
taken from three separate experiments is plotted. The white bars
indicate the control CD29-positive and CD29-negative populations
which were not incubated with ALA. *P < 0Æ05, **P < 0Æ01. a.u.,
arbitrary units.
(a)
(b)
Fig 6. CD29-positive and K10-positive cells in normal skin are
complementary. Immunohistochemical staining for CD29 shows
immunoreactivity in the basal layers of the epidermis (a, green
staining), in contrast to K10 (a well-known marker for terminal
differentiation), which shows immunoreactivity in the suprabasal
layers (b, red staining). Therefore, negativity for CD29 can be used
a marker for terminal differentiation. Immunohistochemistry was
performed on frozen sections (7 lm) from normal skin using
antibodies to CD29 (anti-b1-integrin, clone K20; Dako BV, Heverlee,
Belgium) and K10 (anti-K10, clone RKSE60; Monosan, Uden, the
Netherlands). Protocols were similar to those of Korver et al.18 and
Kleinpenning et al.5
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However, fluorescence was still 2Æ13 times baseline fluores-
cence.
Immunohistochemistry
Epidermal proliferation and differentiation
Epidermal proliferation decreased during PDT as shown by a
significant reduction in the number of epidermal Ki67+ cells
()60%; P ¼ 0Æ001) (Figs 1b and 5). Epidermal K10 expression,
however, increased significantly, indicating normalization of
differentiation (+16%; P ¼ 0Æ007) (Figs 1c and 5). These chan-
ges were in parallel with the clinical improvement of the psori-
atic lesions and were absent in the placebo-treated lesions.
T-cell infiltration
CD8+ cells were mainly seen in the papillary dermis and to a
lesser extent in the epidermis (Figs 1e and 5). From baseline
to week 6 the number of epidermal CD8+ cells showed a
marked decrease ()36%; P ¼ 0Æ036) in the ALA-treated
lesions. In the dermis a decrease was also noted, but this was
not statistically significant ()31%; P ¼ 0Æ232). The number of
CD45RO+ cells, however, decreased in both epidermis
()48%; P ¼ 0Æ034) and dermis ()43%; P ¼0Æ013) (Figs 1f
and 5). CD4+ cells in the ALA-treated lesions did not show
any significant changes in either dermis ()21%; P ¼0Æ429) or
epidermis ()13%; P ¼ 0Æ112) (Fig. 1d). The placebo-treated
lesions did not show any significant changes in the studied
T-cell subsets except for a significant increase in the number
of epidermal CD4+ cells (+34%; P ¼ 0Æ029).
Fluorescence patterns
Although the studied psoriatic lesions were pretreated with a
keratolytic agent, most lesions showed inhomogenous fluores-
cence, mostly in a follicular pattern and different at the differ-
ent days the treatment took place (Fig. 4). From the clinical
appearance of the lesions the distribution of fluorescence
within the plaque was not always predictable. Fluorescence
values at some sites within the plaques were lower than nor-
mal surrounding skin fluorescence. Epidermal skin barrier also
appeared to influence PpIX formation and distribution within
the plaques as high fluorescence values were always seen
around the sites of biopsy.
Fig 2. Clinical improvement in 5-aminolaevulinic acid-photodynamic
therapy-treated psoriatic plaques. After four treatments most psoriatic
plaques clinically improved as reflected by a reduction in the plaque
severity (sum) score. This was not seen in the placebo and untreated
lesions. Note the partial response and the postinflammatory
hyperpigmentation.
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Fig 3. Photobleaching of protoporphyrin IX
during fractionated 5-aminolaevulinic acid
(ALA)-photodynamic therapy (PDT).
Macroscopic fluorescence was measured
during fractionated ALA-PDT at several time
points using the DyaDerm imaging system.
Statistically significant changes in fluorescence
were seen at 4 h incubation and after
illumination with the second light dose of
8 J cm)2, while the first light dose did not
induce statistically significant photobleaching.
Fluorescence values are depicted in relative
units (r.u.) mean +/) SEM with baseline
fluorescence set to 1Æ0. *P < 0Æ001,
**P < 0Æ01.
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Discussion
Four fractionated PDT sessions of 2 + 8 J cm)2 (2-h dark inter-
val) with 10% ALA ointment induced clinical improvement in
psoriatic plaque severity as measured by a statistically significant
lower sum score compared with the sites that were treated with
vehicle-PDT. Several authors have described clinical improve-
ment of psoriasis after multiple PDT sessions but an optimal
treatment protocol has not yet been established.1–4,7,12 Most
authors agree that the dose per treatment session required for a
clinical improvement must not be too high, as Koebnerization
and severe pain during irradiation have been reported.8 In our
study in two patients an increase in psoriatic activity was
observed in the ALA-treated sites, but not in the placebo-treated
sites. In these sites new psoriatic lesions arose, which is highly
suggestive for the Koebner phenomenon as nonlesional psoriatic
Fig 4. Clinical (a–c), fluorescence (d–f) and
pseudocolour images (g–i) from the same
patient after 5-aminolaevulinic acid
application (4 h) at baseline (a, d, g), week 1
(b, e, h) and week 2 (c, f, i). The
distribution of fluorescence varied largely at
the different time points and was generally in
a follicular pattern. Note that at the sites of
biopsy fluorescence was always present.
Fig 5. Immunohistochemistry. Ki67, keratin
10 (K10), CD8 and CD45RO stainings at
baseline, week 1 and week 6. Ki67 and K10
are displayed at · 100 magnification; T-cell
subsets are displayed at · 50 magnification.
� 2006 British Association of Dermatologists • British Journal of Dermatology 2006 155, pp429–436
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P < 0Æ05) compared with high-fluorescent skin (Fig. 2b). The
epidermis was equally broadened throughout the heterogene-
ic-fluorescent plaque (Table 2).
Immunohistochemistry
Epidermal proliferation Epidermal proliferation was increased in
both high- and low-fluorescent parts of psoriatic skin as
shown by an increased number of epidermal Ki-67+ cells.
The number of Ki-67+ cells was not significantly different in
high- or low-fluorescent lesional skin (HF ¼ 86 positive cells
per mm basement membrane, LF ¼ 69 positive cells per mm
basement membrane, P ¼ 0Æ38) (Table 2, Fig. 3).
Epidermal differentiation The epidermal K10 expression was used
to assess the extent of keratinization and appeared to be
equally decreased throughout the plaque (HF ¼ 58%, LF ¼
55%, P ¼ 0Æ51) (Table 2, Fig. 3). The aggregation of kera-
tinocytes in the psoriatic plaque was reduced as shown by the
decreased expression of filaggrin. In high- and low-fluorescent
lesional skin no statistically significant differences were
observed (HF ¼ 83%, LF ¼ 79%, P ¼ 0Æ48) (Table 2, Fig. 3).
T-cell infiltration CD3+ cells were seen mainly in the papillary
dermis and to a lesser extent in the epidermis. In the high-
fluorescent affected skin epidermal CD3+ cells were not signi-
ficantly different compared with low-fluorescent lesional skin
(a) (b) (c) 
Fig 1. Clinical and fluorescence images from one patient after 5-aminolaevulinic acid application. (a) Clinical image with marked low-fluorescent
lesional skin (1) and high-fluorescent lesional skin (2). (b) Fluorescence image of the same plaque in which heterogeneous fluorescence is seen.
(c) Pseudo-colour image of (b).
(a)
(b)
Fig 2. Morphological and immunohistochemical differences in
psoriatic plaques with heterogeneous fluorescence after 5-
aminolaevulinic acid application. (a) Normalised fluorescence. The
intensity of high-fluorescent (HF) skin was significantly higher than in
low-fluorescent (LF) skin; *P < 0Æ001. (b) The stratum corneum was
statistically significantly thicker in low-fluorescent skin compared with
high-fluorescent skin; *P < 0Æ05. Error bars denote SEM.
Fig 3. Morphological and immunohistochemical images of both low- and high-fluorescent psoriatic skin. Haematoxylin and eosin, Ki-67, keratin
10 (K10) and filaggrin stainings of heterogeneous fluorescent lesional skin are displayed at 100 · magnification. CD3 is displayed at 50 ·
magnification. Haematoxylin and eosin sections showed a significantly thicker stratum corneum in low-fluorescent psoriatic skin.
Immunohistochemically no differences in epidermal proliferation, differentiation and inflammation were found between high- and low-fluorescent
skin.
� 2006 British Association of Dermatologists • British Journal of Dermatology 2006 155, pp539–545
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P < 0Æ05) compared with high-fluorescent skin (Fig. 2b). The
epidermis was equally broadened throughout the heterogene-
ic-fluorescent plaque (Table 2).
Immunohistoch mi try
Epidermal proliferation Epidermal proliferation was increased in
both high- and low-fluorescent parts of psoriatic skin as
shown by an increased number of epidermal Ki-67+ cells.
The number of Ki-67+ cells was not significantly different in
high- or low-fluorescent lesional skin (HF ¼ 86 positive cells
per mm basement membrane, LF ¼ 69 positive cells per mm
basement membrane, P ¼ 0Æ38) (Table 2, Fig. 3).
Epidermal differentiation The epidermal K10 expression was used
to assess the extent of keratinization and appeared to be
equally decreased throughout the plaque (HF ¼ 58%, LF ¼
55%, P ¼ 0Æ51) (Table 2, Fig. 3). The aggregation of kera-
tinocytes in he psoriatic plaque was reduced as shown by the
decreased expression of filaggrin. In high- and low-fluorescent
lesional skin no statistically significant differences were
observed (HF ¼ 83%, LF ¼ 79%, P ¼ 0Æ48) (Table 2, Fig. 3).
T-cell infiltration CD3+ cells were seen mainly in the papillary
dermis and to a lesser extent in the epidermis. In the high-
fluorescent affected skin epidermal CD3+ cells were not signi-
ficantly different compared with low-fluorescent lesional skin
(a) (b) (c) 
Fig 1. Clinical and fluorescence images from one patient after 5-aminolaevulinic acid application. (a) Clinical image with marked low-fluorescent
lesional skin (1) and high-fluorescent lesional skin (2). (b) Fluorescence image of the same plaque in which heterogeneous fluorescence is seen.
(c) Pseudo-colour image of (b).
(a)
(b)
Fig 2. Morphological and immunohistochemical differences in
psoriatic plaques with heterogeneous fluorescence after 5-
aminolaevulinic acid application. (a) Normalised fluorescence. The
intensity of high-fluorescent (HF) skin was significantly higher than in
low-fluorescent (LF) skin; *P < 0Æ001. (b) The stratum corneum was
statistically significantly thicker in low-fluorescent skin compared with
high-fluorescent skin; *P < 0Æ05. Error bars denote SEM.
Fig 3. Morphological and immunohistochemical images of both low- and high-fluorescent psoriatic skin. Haematoxylin and eosin, Ki-67, keratin
10 (K10) and filaggrin stainings of heterogeneous fluorescent lesional skin are displayed at 100 · magnification. CD3 is displayed at 50 ·
magnification. Haematoxylin and eosin sections showed a significantly thicker stratum corneum in low-fluorescent psoriatic skin.
Immunohistochemically no differences in epidermal proliferation, differentiation and inflammation were found between high- and low-fluorescent
skin.
� 2006 British Association of Dermatologists • British Journal of Dermatology 2006 155, pp539–545
542 Heterogeneity of fluorescence in psoriasis after ALA, M.M. Kleinpenning et al.
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P < 0Æ05) compared with high-fluorescent skin (Fig. 2b). The
epidermis was equally broadened throughout the heterogene-
ic-fluorescent plaque (Table 2).
Immunohistochemistry
Epidermal proliferation Epidermal proliferation was increased in
both high- and low-fluorescent parts of psoriatic skin as
shown by an increased number of epidermal Ki-67+ cells.
The number of Ki-67+ cells was not significantly different in
high- or low-fluorescent lesional skin (HF ¼ 86 positive cells
per mm basement membrane, LF ¼ 69 positive cells per mm
basement membrane, P ¼ 0Æ38) (Table 2, Fig. 3).
Epidermal differentiation The epidermal K10 expression was used
to assess the extent of keratinization and appeared to be
equally decreased throughout the plaque (HF ¼ 58%, LF ¼
55%, P ¼ 0Æ51) (Table 2, Fig. 3). The aggregation of kera-
tinocytes in the psoriatic plaque was reduced as shown by the
decreased expression of filaggrin. In high- and low-fluorescent
lesional skin no statistically significant differences were
observed (HF ¼ 83%, LF ¼ 79%, P ¼ 0Æ48) (Table 2, Fig. 3).
T-cell infiltration CD3+ cells were seen mainly in the papillary
dermis and to a lesser extent in the epidermis. In the high-
fluorescent affected skin epidermal CD3+ cells were not signi-
ficantly different compared with low-fluorescent lesional skin
(a) (b) (c) 
Fig 1. Clinical and fluorescence images from one patient after 5-aminolaevulinic acid application. (a) Clinical image with marked low-fluorescent
lesional skin (1) and high-fluorescent lesional skin (2). (b) Fluorescence image of the same plaque in which heterogeneous fluorescence is seen.
(c) Pseudo-colour image of (b).
(a)
(b)
Fig 2. Morphological and immunohistochemical differences in
psoriatic plaques with heterogeneous fluorescence after 5-
aminolaevulinic acid application. (a) Normalised fluorescence. The
intensity of high-fluorescent (HF) skin was significantly higher than in
low-fluorescent (LF) skin; *P < 0Æ001. (b) The stratum corneum was
statistically significantly thicker in low-fluorescent skin compared with
high-fluorescent skin; *P < 0Æ05. Error bars denote SEM.
Fig 3. Morphological and immunohistochemical images of both low- and high-fluorescent psoriatic skin. Haematoxylin and eosin, Ki-67, keratin
10 (K10) and filaggrin stainings of heterogeneous fluorescent lesional skin are displayed at 100 · magnification. CD3 is displayed at 50 ·
magnification. Haematoxylin and eosin sections showed a significantly thicker stratum corneum in low-fluorescent psoriatic skin.
Immunohistochemically no differences in epidermal proliferation, differentiation and inflammation were found between high- and low-fluorescent
skin.
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Fig 3. Morphological and immunohistochemical images of both low- and high-fluorescent psoriatic skin. Haematoxylin and eosin, Ki-67, keratin
10 (K10) and filaggrin stainings of heterogeneous fluorescent lesional skin are displayed at 100 · magnification. CD3 is displayed at 50 ·
magnification. Haematoxylin and eosin sections showed a significantly thicker stratum corneum in low-fluorescent psoriatic skin.
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Fluorescence diagnosis and proliferation
Analysis of proliferative activity as assessed by
immunoreactivity for the Ki67 antigen did not reveal
any significant differences in fluorescence ratios
among the 3 levels of Ki67 expression (P = .46)
(Fig 4). Ki67 is a cell cycleeassociated antigen ex-
pressed in all parts of the cell cycle except G0, rep-
resenting the epidermal proliferative compartment.14
When the lesions were divided into 4 diagnostic
categories (true/false positives/negatives), with a
fluorescence ratio of 1.0 taken as a cut-off value
and KIN lesions/SCC and verrucous hyperkerato-
ses/normal-appearing skin classified as (pre)malig-
nant and benign lesions, respectively, lesions with a
fluorescence intensity lower than surrounding skin
(fluorescence ratio\ 1.0; true and false negatives)
had a significantly lower number of Ki671 cells than
lesions with a fluorescence ratio greater than 1.0
(true and false positives) (P \ .05) (Table II).
However, when Ki67 immunoreactivity from all 4
diagnostic categories was mutually compared only
a significant difference between the false-positive
and true-positive lesions (P\ .01) and true-positive
and true-negative lesions (P\ .01) was found.
Fluorescence and thickness of SC
Assessment of the thickness of the SC in relation to
the fluorescence intensity revealed a negative
correlation, which suggests SC to have a negative
effect on fluorescence intensity measured with FDAP
(Fig 5). This correlation was also assessed within
every patient if possible. Interestingly, in every
patient a negative correlation was seen, as reflected
by negative correlation coefficients (R) in Table I. In
addition, no association was found between the type
of keratin (orthokeratosis vs parakeratosis) and flu-
orescence intensity. However, the amount of
Fig 3. Images acquired with fluorescence diagnosis imaging system. Color (A), fluorescence
(B), and pseudocolor (C) images from two lesions classified as Bowen’s disease. Note that
fluorescence corresponds well with clinical picture. Color (D), fluorescence (E), and pseudo-
color (F) images from verrucous hyperkeratosis with no atypia. Lesional fluorescence is lower
than surrounding normal-appearing skin fluorescence.
Fig 4. Fluorescence ratio and Ki67 expression.
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Ki67-antigen expression was significantly increased com-
pared with normal skin but more heterogeneous compared
with the KIN lesions.
Significantly higher SG2M fractions were also found in
lesions with increasing KIN grade (P < 0.01). Assessment
of the SG2M fraction by flow cytometry also revealed a
positive correlation with KIN grade (q ¼ 0.258; P < 0.05),
although this was not as strong as for Ki67 (Fig. 5). KIN
III lesions had significantly higher SG2M fractions com-
pared with KIN I and KIN II lesions. SG2M fractions in
miSCC were significantly higher compared with KIN I
lesions but not compared with KIN II, III and normal skin.
Proliferation assessed by immunohistochemistry and flow
cytometry appeared to be weakly correlated (q ¼ 0.282;
P < 0.05)
Conclusion and discussion
In the present study aneuploidy was detected more fre-
quently in lesions with increasing KIN grade, whereas in
normal skin aneuploidy was not found, which emphasizes
the malignant potential these lesions have. Increasing
aneuploidy rates in actinic keratosis (AK) and Bowen’s dis-
ease (BD) have been reported in earlier studies (4–7) but
these studies are difficult to compare due to different tech-
niques, sample sizes and definitions of aneuploidy, that
were used. In the present study a large pool of skin biop-
sies was analysed with respect to proliferation and the pres-
ence of aneuploidy. Interestingly, aneuploidy was less
Figure 2. Immunohistochemical staining for
Ki67 antigen. In a KIN III lesion there is
transepidermal expression of the Ki67 antigen
(b) whereas in a KIN I lesion there is only Ki67
positivity of the basal one-third of the
epidermis(a).
(a) (b)
Figure 3. Flow cytometrical DNA histograms. (a) A normal DNA histogram from a diploid lesion (normal skin) shows a large peak at around 76
representing the cells in G1. At twice this distance at around 152 a small peak is seen representing the cells with a double DNA content that are in
G2. The plateau between G1 and G2 represents the cells that are in the S-phase. (b) In this lesion (KIN III) an extra peak between G1 and G2 is seen
at around 127 which represents the G1 peak from the aneuploid cells. The ratio between the G1 peak of the aneuploid and diploid cells represents
the DNA index, which is 127/76 ¼ 1.67, indicating an increased DNA content in the aneuploid cells compared with the diploid cells.
Figure 4. Ki67 antigen expression in cutaneous squamous
(pre)malignancies and normal skin. Ki67 expression is scored into four
categories (see text). *P < 0.05, ***P < 0.001, ****P < 0.0001. SE,
standard error.
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